efavirenz has been researched along with HIV Coinfection in 1884 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 96 (5.10) | 18.2507 |
| 2000's | 702 (37.26) | 29.6817 |
| 2010's | 860 (45.65) | 24.3611 |
| 2020's | 226 (12.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andries, K; Arnold, E; Bohets, H; Clark, AD; Daeyaert, F; Das, K; de Béthune, MP; De Clerck, F; de Jonge, M; De Knaep, F; Frenkel, YV; Guillemont, J; Heeres, J; Hughes, SH; Janssen, PA; Koymans, L; Kukla, M; Lampo, A; Lewi, PJ; Ludovici, D; Medaer, B; Pasquier, E; Pauwels, R; Stoffels, P; Vinkers, M; Williams, P | 1 |
| Girardet, JL; Hamatake, RK; Hong, Z; Koh, YH; Shim, JH; Xu, W; Yeh, LT; Zhang, Z | 1 |
| Colonno, R; Dicker, I; Fan, L; Gali, V; Higley, H; Krystal, M; Lin, PF; Nowicka-Sans, B; Parkin, N; Tenney, D; Terry, B; Wang, C; Zhang, S | 1 |
| Cao, Y; De Clercq, E; Liu, X; Pannecouque, C; Wang, Y; Zhan, P | 1 |
| Armanasco, N; Azijn, H; de Bethune, MP; Fletcher, P; Harman, S; Manlow, P; Nuttall, J; Perumal, D; Romano, J; Shattock, R | 1 |
| Bachmann, MH; Fessel, WJ; Kagan, RM; Mitsuya, Y; Shafer, RW; Shahriar, R; Varghese, V | 1 |
| Cabrera, SE; Domínguez-Gil, A; García, MJ; González, F; Luna, G; Santos, D; Valverde, MP | 1 |
| De Clercq, E; Fang, Z; Li, Z; Liu, X; Pannecouque, C; Zhan, P | 1 |
| Diagbouga, S; Hien, H; Hirt, D; Msellati, P; Nacro, B; Olivier, M; Peyrière, H; Rouet, F; Tréluyer, JM; Urien, S; Van De Perre, P; Zoure, E | 1 |
| Azijn, H; Boven, K; de Béthune, MP; Jochmans, D; Kraus, G; Picchio, G; Rimsky, LT; Tirry, I; Van Craenenbroeck, E; Vingerhoets, J | 1 |
| Ewart, G; Khoury, G; Luscombe, C; Miller, M; Wilkinson, J | 1 |
| Akonde, A; Calvez, V; Cisse, M; Costagliola, D; Derache, A; Descamps, D; Diarra, B; Katlama, C; Koita, V; Maïga, AI; Malet, I; Marcelin, AG; Masquelier, B; Morand-Joubert, L; Tounkara, A; Verlinden, Y; Wirden, M | 1 |
| Gatanaga, H; Hachiya, A; Hayashida, T; Ode, H; Oka, S; Sato, H | 1 |
| Fransen, S; Gupta, S; Huang, W; Paxinos, EE; Petropoulos, CJ; Stawiski, E | 1 |
| Balzarini, J; Chen, FE; De Clercq, E; Feng, XQ; He, QQ; Liang, YH; Pannecouque, C; Zeng, ZS | 1 |
| Chen, J; Chen, L; Fitch, WL; Fretland, J; Hang, JQ; Harris, SF; Heilek, G; Kertesz, DJ; Klumpp, K; Li, W; Lin, X; Mei, J; Mirzadegan, T; Qiu, Z; Tang, G; Villaseñor, AG; Wang, Z; Yang, M | 1 |
| Chen, W; Chen, X; De Clercq, E; Li, D; Li, X; Liu, X; Pannecouque, C; Tian, Y; Zhan, P | 1 |
| Chen, W; Chen, X; Clercq, ED; Li, X; Li, Z; Liu, X; Pannecouque, C; Tian, Y; Zhan, P | 1 |
| Cannizzaro, C; Chen, X; Desai, MC; Lansdon, EB; Parrish, J; Tong, L; Wang, M; Xu, L; Zheng, X | 1 |
| Balzarini, J; De Clercq, E; Li, D; Liu, H; Liu, X; Pannecouque, C; Zhan, P | 1 |
| Balzarini, J; Chen, W; Chen, X; De Clercq, E; Liu, X; Pannecouque, C; Rai, D; Tian, Y; Zhan, P | 1 |
| Chen, W; De Clercq, E; Liu, X; Liu, Z; Pannecouque, C; Zhan, P | 1 |
| Chen, W; Daelemans, D; De Clercq, E; Huang, B; Kang, D; Li, X; Liu, X; Liu, Z; Lu, X; Pannecouque, C; Yang, J; Zhan, P | 1 |
| Gu, SX; Ju, XL; Liu, GY; Lu, HH; Pannecouque, C; Xue, P; Zhang, XL; Zheng, XJ; Zhu, YY | 1 |
| Daelemans, D; De Clercq, E; Ding, X; Fang, Z; Huang, B; Huo, Z; Kang, D; Liu, X; Lu, X; Meng, Q; Pannecouque, C; Tian, Y; Wu, G; Xu, H; Yu, Z; Zhan, P; Zhang, H; Zhou, Z | 1 |
| Chen, CH; Daelemans, D; De Clercq, E; Huang, B; Kang, D; Lee, KH; Liu, J; Liu, X; Liu, Z; Pannecouque, C; Tian, Y; Zhan, P; Zhang, H | 1 |
| Gu, SX; Ju, XL; Liu, GY; Lu, HH; Zhu, YY | 1 |
| Byrareddy, SN; Kongsted, J; Kramer, VG; Kurup, S; Liu, X; Namasivayam, V; Vanangamudi, M; Zhan, P | 1 |
| Chen, F; De Clercq, E; Han, S; Pannecouque, C; Sang, Y; Zhuang, C | 1 |
| Cen, S; Dong, B; Guo, Y; Liang, C; Ma, L; Wang, J; Wang, Y; Wang, Z; Wen, J; Zhang, G; Zhou, J; Zhu, M | 1 |
| Cherukupalli, S; De Clercq, E; Jia, R; Jiang, X; Kang, D; Liu, X; Pannecouque, C; Wang, W; Wang, Z; Xie, M; Zhan, P | 1 |
| Li, ZR; Liu, YX; Lu, HZ; Meng, XM; Niu, WJ; Qiu, XY; Zheng, XY | 1 |
| Arkkila, P; Hakkarainen, A; Hanttu, A; Kivelä, P; Lehtimäki, T; Lehtinen, V; Lundbom, J; Lundbom, N; Pietiläinen, KH; Sutinen, J; Viskari, H; Vuoti, S | 1 |
| Adamson, J; Cele, S; Derache, A; Gosnell, BI; Govender, K; Gupta, RK; Harrichandparsad, R; Jeena, PM; Karim, F; Khan, K; Kløverpris, H; Lustig, G; Marais, S; Moosa, MS; Ngoepe, A; Ntshuba, N; Patel, VB; Sigal, A | 1 |
| Gao, LY; Hu, Y; Huang, XJ; Ma, P; Wu, H; Wu, Y; Xia, H; Yan, ZF | 1 |
| Benfield, T; Gerstoft, J; Graff, C; Høgh, J; Knudsen, AD; Kofoed, KF; Køber, L; Nielsen, JB; Nielsen, SD; Thomsen, MT | 1 |
| Agrati, C; Antinori, A; Antonucci, M; Avataneo, V; Calcagno, A; Cusato, J; D'Avolio, A; Di Perri, G; Notari, S; Palermiti, A; Piselli, P; Tempestilli, M; Vergori, A | 1 |
| Mungmunpuntipantip, R; Wiwanitkit, V | 1 |
| Bulimo, WD; Ngayo, MO; Okalebo, FA; Oluka, M | 1 |
| Ajok, F; Armstrong-Hough, M; Castelnuovo, B; Kajubi, P; Kalule, I; Katahoire, A; Kiragga, A; Laker, M; Lamorde, M; Mujugira, A; Odongpiny, EAL; Onen, H; Owarwo, N; Seden, K; Twimukye, A | 1 |
| Cogill, D; Decloedt, E; Gandhi, M; Jennings, L; Kellermann, T; Nkantsu, Z; Orrell, C; Spinelli, M; van Schalkwyk, M; van Zyl, G | 2 |
| Chew, GM; Chow, D; Gangcuangco, LM; Ghukasyan, H; Le, T; Limpruttidham, N; Ndhlovu, LC; Nguyen, VVC; Paul, R; Phuong, TV; Premeaux, T; Shikuma, CM; Siriwardhana, C; Vo, TL | 1 |
| Benns, A; Bolton Moore, C; Bwakura-Dangarembizi, M; Capparelli, EV; Chadwick, EG; Chakhtoura, N; Frenkel, L; Jean-Philippe, P; Libous, J; Nikanjam, M; Samson, P; Spector, SA; Tran, L; Zimmer, B | 1 |
| Albertyn, CH; Brey, N; Decloedt, EH; Esterhuizen, TM; Kellermann, TA; Nightingale, S; Sinxadi, PZ; Taljaard, JJ; van Rensburg, R | 1 |
| Badal-Faesen, S; Bryant, K; Campbell, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Fletcher, CV; Johnson, JL; Kurbatova, EV; Lalloo, U; Martinson, N; Mayanja, H; Mohapi, L; Nahid, P; Pettit, A; Pham, M; Phillips, PPJ; Podany, AT; Samaneka, W; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Whitworth, WC | 1 |
| Fichtenbaum, CJ; Guanira, JV | 1 |
| Gogela, N; Locketz, M; Maughan, D; Setshedi, M; Sonderup, M; Spearman, CW; Wainwright, H | 1 |
| Akpomiemie, G; Denti, P; Griesel, R; Kawuma, AN; Maartens, G; Sinxadi, P; Sokhela, S; Venter, WDF; Wasmann, R; Wiesner, L | 1 |
| Ahimbisibwe, GM; Ali, S; Amuge, P; Archary, M; Atwine, L; Barlow-Mosha, L; Bbuye, D; Behuhuma, O; Bernays, S; Bwakura-Dangarembizi, M; Chalermpantmetagul, S; Coelho, A; Colbers, A; Compagnucci, A; Cotton, MF; Cressey, TR; Ford, D; Giaquinto, C; Gibb, DM; Grossele, T; Kaudha, E; Kekitiinwa, AR; Kityo, CM; Klein, N; Kobbe, R; Liberty, A; Lugemwa, A; Makumbi, S; Mujuru, HA; Musiime, V; Musoke, P; Musoro, G; Ngampiyaskul, C; Puthanakit, T; Ramsagar, N; Rojo, P; Saïdi, Y; Sarfati, T; Shakeshaft, C; Turkova, A; Variava, E; Violari, A; Welch, SB; White, E; Wynne, B | 1 |
| Chen, P; Deng, L; Hong, Z; Li, C; Luo, X; Xia, J; Zheng, X; Zhou, L; Zhou, Y | 1 |
| Anugulruengkitt, S; Chantaratin, S; Chokephaibulkit, K; Jantarabenjakul, W; Kosalaraksa, P; Maleesatharn, A; Phongsamart, W; Sirikutt, P; Suntarattiwong, P | 1 |
| Adankie, BT; Aklillu, E; Amogne, W; Engidawork, E; Shibeshi, W; Tadesse, WT | 1 |
| Han, J; Li, B; Liu, Y; Xiao, J; Zhang, L; Zhao, H | 2 |
| Barboza, JJ; Castañeda-Sabogal, A; Geldres-Molina, F; Hilario-Gómez, MM | 1 |
| Ghodsi, S; Hosseini, Z; Mollazadeh, R; Sadre Bafghi, SA; Tayeb, R | 1 |
| Adimora, AA; Damron, AL; Dastgheyb, R; Fischl, MA; Fitzgerald, KC; Gustafson, DR; Konkle-Parker, D; Li, Y; Maki, PM; Milam, J; O'Halloran, JA; Ofotokun, I; Rubin, LH; Sharma, A; Spence, AB; Weber, KM; Williams, DW; Xu, Y | 1 |
| Essex, M; Gaseitsiwe, S; Kasvosve, I; Maseng, MJ; Moyo, S; Novitsky, V; Paganotti, GM; Russo, G; Tawe, L; Thami, PK | 1 |
| Barroso, PF; Bollela, VR; Elias, ABR; Lanchote, VL; Nardotto, GHB; Suarez-Kurtz, G; Ximenez, JP | 1 |
| Brun, A; de Castro, N; Hamet, G; Joly, V; Kherabi, Y; Méchaï, F; Molina, JM; Sellier, PO; Yazdanpanah, Y | 1 |
| Afonso Reis, E; Almeida-Brasil, CC; Ceccato, MDGB; de Oliveira Costa, J; Rodrigues, VA; Silveira, MR | 1 |
| Chen, T; Khoo, S; Kintu, K; Lamorde, M; Malaba, T; Myer, L; Ochanda, PN; Reynolds, H; Waitt, C; Wang, D | 1 |
| Ananworanich, J; Chan, P; Colby, D; Hsu, D; Kroon, E; Paul, R; Phanuphak, N; Pinyakorn, S; Sacdalan, C; Spudich, S; Sriplienchan, S; Valcour, V; Vasan, S; Yoon, B | 1 |
| Aklillu, E; Habtewold, A; Makonnen, E; Petros, Z | 1 |
| Amstutz, A; Belus, JM; Brown, JA; Glass, TR; Klimkait, T; Labhardt, ND; Mokhele, K; Muhairwe, J; Nsakala, BL; Rakuoane, I; Tschumi, N | 1 |
| Lugongolo, MY; Maaza, M; Manoto, SL; Mthunzi-Kufa, P; Ombinda-Lemboumba, S | 1 |
| Burkholder, GA; Heath, S; Long, DM; Moore, TJ; Muntner, P; Overton, ET; Siddiqui, M; Willig, A; Wyatt, C | 1 |
| Babalola, CP; Berzins, B; Gandhi, M; Khoo, SH; Kotila, OA; Ngene, SO; Nwogu, JN; Okochi, H; Olagunju, A; Owen, A; Taiwo, B; Tallerico, R | 1 |
| Bah, S; Dao, S; Dehbi, H; Diakite, B; Diarra, F; Diarra, Z; Dolo, G; Goita, Y; Guirou, N; Kamate, B; Kassogue, O; Kassogue, Y; Konate, I; Maiga, M; Nadifi, S; Sawadogo, MK; Sissoko, AS; Sissoko, SB; Tamboura, K; Traore, CB | 1 |
| Aarnoutse, R; Aber, F; Alinaitwe, L; Buzibye, A; Denti, P; Dooley, KE; Gausi, K; Kengo, A; Lamorde, M; Musaazi, J; Nabisere, R; Najjemba, L; Nampala, J; Omali, D; Otaalo, B; Sekaggya-Wiltshire, C; Sloan, DJ | 1 |
| Alhassan, Y; Bokako, S; Burger, D; Byamugisha, J; Byrne, K; Chen, T; Chiong, J; Colbers, A; Hodel, EM; Hu, NC; Khoo, S; Kintu, K; Lamorde, M; Malaba, TR; Mrubata, M; Myer, L; Nakatudde, I; Orrell, C; Read, J; Read, L; Reynolds, H; Seden, K; Stemmet, LA; Taegtmeyer, M; Theunissen, H; Twimukye, A; Waitt, C; Wang, D | 1 |
| Figueredo, CC; Gomes, MP; Juneau, P; Kitamura, RSA; Kubis, GC; Navarro-Silva, MA; Nogueira, KDS; Vieira, F | 1 |
| Benson, CA; Chaisson, RE; Fletcher, CV; Gupta, A; Langat, D; Mohapi, L; Mwelase, N; Omoz-Oarhe, A; Pham, MM; Podany, AT; Samaneka, W; Supparatpinyo, K; Swindells, S | 1 |
| Decloedt, EH; Esterhuizen, T; Joska, JA; Kamau, F; Kellermann, T; Khoo, S; Maartens, G; Solanke, T; Strijdom, H | 1 |
| Best, BM; Bradford, S; Capparelli, EV; Chadwick, EG; Jean-Philippe, P; Liyanage, M; McFadyen, L; Mirochnick, M; Moye, J; Nikanjam, M; Rogg, L; Vourvahis, M; Whitson, K | 1 |
| Bryant, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Johnson, JL; Kurbatova, E; Lalloo, UG; Mohapi, L; Muzanyi, G; Nahid, P; Pettit, AC; Phillips, PPJ; Podany, AT; Samaneka, W; Sanne, I; Savic, RM; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Waja, Z | 1 |
| Asawanonda, P; Boontaveeyuwat, E; Pemcharoen, J; Sriaram, A; Wongjirattikarn, R | 1 |
| Adam, GC; Anand, R; Andrews, CL; Bahnck-Teets, C; Balibar, CJ; Beshore, DC; Carroll, SS; Chi, A; Converso, A; Cornella-Taracido, I; Diamond, TL; Fang, Z; Fay, JF; Filzen, T; Goh, SL; Hollenstein, K; Howell, BJ; Klein, DJ; Lammens, A; Lan, P; Li, J; Li, Y; Lim, UM; Lu, M; Lusen, J; McHale, C; Moningka, R; Moore, KP; Park, S; Quan, S; Rodriguez, S; Rothman, DM; Schwaid, AG; Shipe, WD; Song, C; Sun, W; Tudor, M; Xu, M; Zuck, P | 1 |
| Amorim, G; Bernard, C; Bukusi, EA; Cohen, CR; Jakait, B; Mocello, AR; Musick, B; Patel, RC; Shepherd, BE; Stalter, RM; Wools-Kaloustian, K; Yiannoutsos, CT | 1 |
| Chunrong, L; Huanxia, L; Ke, Y; Lin, C; Ruifeng, Z; Shenghua, H; Tongtong, Y; Xiaojing, Y; Yin, W; Yuan, Y; Yuanhong, H | 1 |
| Cao, T; He, Y; Jia, X; Ju, B; Liu, J; Liu, X; Peng, Q; Rao, M; Song, Y; Sun, L; Wang, H; Wang, S; Xu, L; Zhang, H; Zhang, L; Zhang, Q; Zhao, F; Zhou, J; Zhou, Y | 1 |
| Abdusalaamu, K; Boulware, DR; Collins, L; Lukande, R; Meya, DB; Mishra, U; Namuju, OC; Nicol, MR; Pastick, KA; Wang, F | 1 |
| Beck, IA; Boyce, CL; Frenkel, LM; Hardy, SR; João, EC; Milne, RS; Mirochnick, MH; Morrison, RL; Shapiro, DE; Styrchak, SM; Wallner, JJ | 1 |
| Abrams, EJ; Bonner, LB; Geffner, ME; Gerschenson, M; Jao, J; Kgole, S; Kurland, IJ; Legbedze, J; Makhema, J; Masasa, G; Mmalane, M; Mmasa, KN; Mohammed, T; Moyo, S; Powis, KM; Sun, S | 1 |
| Aweeka, F; Ehrlich, H; Freeman, T; French, J; Goodwin, J; Huang, L; Kajubi, R; Kay, K; Li, F; Mwebaza, N; Ou, J; Parikh, S; Riggs, M; Ruiz-Garcia, A; Wade, M; Wang, K | 1 |
| Amanyire, G; Asiimwe, S; Chimukangara, B; De Oliveira, T; Giandhari, J; Haberer, JE; Lessells, R; Orrell, C; Pillay, S; Rabideau, DJ; Reynolds, Z; Siedner, MJ; Tong, Y; Tyagi, A | 1 |
| Chen, D; Du, Y; Huang, Z; Li, J; Wang, Y; Wen, Z; Yin, S; Zhong, H | 1 |
| Andersen, N; Beck, IA; Chung, MH; Deng, W; Frenkel, LM; Kiarie, JN; Kingoo, J; Kiptinness, C; Levine, M; Milne, RS; Panpradist, N; Sakr, SR; So, I; Yatich, N | 1 |
| Houshmand, M; Jazayeri, R; Mardi, P; Sheibani Nia, S; Tavakoli-Far, B | 1 |
| Allen, E; Banda, CG; Barnes, KI; Chirwa, M; Kapulula, M; Maartens, G; Madanitsa, M; Munharo, S; Muyaya, S; Mwapasa, V; Nkosi, D; Phiri, KS; Tarning, J; Ter Kuile, FO; Workman, L | 1 |
| Cere, MC; Chatelut, E; Fraissinet, F; Gandia, P; Lavit, M; Oumar, AA; Seraissol, P | 1 |
| Abidin, ZZ; Chidambaram, SK; Fahrni, ML; Lazzarino, AI; Misran, NFL | 1 |
| Akpomiemie, G; Bosch, B; Chandiwana, N; Hill, A; McCann, K; Mirchandani, M; Qavi, A; Sokhela, S; Venter, WDF | 1 |
| Arkkila, P; Hanttu, AM; Hartikainen, AK; Pekkala, S; Pietiläinen, KH; Satokari, R; Sutinen, JP | 1 |
| Kunene, PN; Mahlambi, PN | 1 |
| Bumpus, NN; Orsburn, BC; Wheeler, AM | 1 |
| Badal-Faesen, S; Barr, E; Belaunzaran-Zamudio, PF; Cohn, SE; Gadama, L; Gatechompol, S; Godfrey, C; Jalil, EM; Mawlana, S; Mngqibisa, R; Olefsky, M; Pham, M; Podany, AT; Scarsi, KK; Smeaton, LM; Supparatpinyo, K; Woolley, E | 1 |
| Griesel, R; Hill, A; Keene, C; Maartens, G; Meintjes, G; Omar, Z; Simmons, B; van Zyl, G; Zhao, Y | 1 |
| Aaron, L; Baltrusaitis, K; Chareka, G; Gupta, A; Jean-Philippe, P; Mandima, P; Masheto, G; Mathad, J; McCarthy, K; Montepiedra, G; Ngocho, J; Nyati, M; Onyango-Makumbi, C; Ponatshego, P; Stranix-Chibanda, L | 1 |
| Costa, B; Vale, N | 1 |
| Abba, A; Beloumou, GA; Billong, SC; Bouba, NP; Ceccherini-Silberstein, F; Chenwi, CA; Colizzi, V; Dambaya, B; Djupsa Ndjeyep, SC; Eben-Moussi, E; Etame, NK; Fokam, J; Ka'e, AC; Kengni, AMN; Kouanfack, C; Meledie, AP; Molimbou, E; Mossiang, L; Ndjolo, A; Nka, AD; Perno, CF; Santoro, MM; Semengue, ENJ; Sosso, SM; Takou, D; Teto, G; Tommo Tchouaket, MC; Yagai, B; Zoung-Kanyi Bissek, AC | 1 |
| Adams, M; Buchwald, AG; Divala, TH; Earland, DE; Laufer, MK; Laurens, MB; Mallewa, JE; Miller, J; Mungwira, RG; Nampota-Nkomba, N; Nyangulu, W; Nyirenda, OM; Parikh, S; Plowe, CV; Taylor, TE; van Oosterhout, JJ | 1 |
| Byakika-Kibwika, P; Chappell, CA; Cirrincione, LR; Cohn, SE; Fletcher, CV; Kyohairwe, I; Lamorde, M; Mackline, H; Nakalema, S; Owen, A; Pham, MM; Scarsi, KK; Siccardi, M; Winchester, L | 1 |
| Fan, X; Huang, H; Jiao, Y; Li, J; Wang, FS; Yu, XD; Zhang, D | 1 |
| Ahmed, JH; Aklillu, E; Chaka, TE; Chala, A; Kitabi, EN; Makonnen, E; Tadesse, BT | 1 |
| Ávila-Ríos, S; Brasesco, M; Cabrera, S; Chiparelli, H; Flieller, R; García-Morales, C; Girón-Callejas, A; Jordan, MR; Monreal-Flores, J; Pérez, D; Ravasi, G; Ruchansky, D; Tapia-Trejo, D | 1 |
| Braga, MDG; Mendes, JC; Reis, AMM; Silveira, MR | 1 |
| Adimora, AA; Althoff, KN; Cole, SR; Edwards, JK; Eron, JJ; Gebo, K; Gill, MJ; Horberg, MA; Hudgens, MG; Jetsupphasuk, M; Kitahata, MM; Lang, R; Lima, VD; Lu, H; Marconi, VC; Moore, RD; Rabkin, C; Rebeiro, PF; Silverberg, MJ; Sterling, TR | 1 |
| Brites, C; Chau, GD; Chazallon, C; De Castro, N; Delaugerre, C; Eholié, S; Grinsztejn, B; Khosa, C; Laureillard, D; Marcy, O; Messou, E; Molina, JM; Pilotto, JH; Wittkop, L | 1 |
| Bottomley, C; Butler, CC; Dorward, J; Garrett, N; Govender, R; Khubone, T; Lessells, RJ; Lewis, L; Maraj, M; Naidoo, K; Phakathi, S; Sookrajh, Y; van der Molen, J; Van Heerden, R | 1 |
| Banturaki, G; Buzibye, A; Castelnuovo, B; Khoo, S; Kiragga, A; Lamorde, M; Matovu, J; Neary, M; Olagunju, A; Owen, A; Twinomuhwezi, E; Waitt, C; Wools-Kaloustian, K; Yiannoutsos, C | 1 |
| Guan, W; Li, T; Li, Y; Lin, Q; Song, X; Xu, Y; Yu, W; Zhang, Y; Zhang, Z | 1 |
| Mahlambi, P; Ngwenya, N | 1 |
| Ariyaratne, KAM; Elwitigala, J; Inzaule, SC; Jayakody, C; Jayasena, S; Kale, D; Kurle, S; Patil, A; Perera, H; Rajapaksa, L; Samaraweera, G; Siriwardna, L | 1 |
| Pan, X; Rowland Yeo, K | 1 |
| Amico, KR; Boyce, C; Brummel, S; Cassim, H; Chakhtoura, N; Chinula, L; Coletti, A; Currier, JS; Fairlie, L; Frenkel, LM; Hoffman, R; Jean-Philippe, P; Johnston, B; Knowles, K; Korutaro, V; Krotje, C; Lockman, S; Masheto, G; McCarthy, K; Mmbaga, BT; Moyo, S; Patel, F; Purdue, L; Rooney, JF; Sax, PE; Shapiro, R; Stranix-Chibanda, L; Stringer, J; van Wyk, J; Ziemba, L | 1 |
| Mendicino, CCP; Pádua, CAM; Silva, GJD; Tupinambás, U | 1 |
| Cardoso, SW; Cunha, CB; Grinszteijn, B; Portela, EN; Reis, AO; Rocco Suassuna, JH; Veloso, VG | 1 |
| Agyemang, N; Badal-Faesen, S; Baker, P; Barr, E; Belaunzaran-Zamudio, PF; Cohn, SE; Gadama, L; Gatechompol, S; Godfrey, C; Haas, DW; Jalil, EM; Kayama, C; Mawlana, S; Mngqibisa, R; Olefsky, M; Pham, M; Podany, AT; Scarsi, KK; Smeaton, LM; Supparatpinyo, K; Van Schalkwyk, M; Woolley, E | 1 |
| Fang, Z; Gang, X; Guoqiang, Z; Jing, C; Min, W; Ning, W; Wei, T; Xingzhi, W | 1 |
| Chagomerana, MB; DiPrete, BL; Harrington, BJ; Hosseinipour, MC; Jumbe, A; Kumwenda, W; Maliwichi, M; Phulusa, JN; Wallie, S; Wesevich, A | 1 |
| Hachey, D; Shiluama, R; Singu, BS; van Woerden, I | 1 |
| Ahmadzia, HK; Dallmann, A; Rakhmanina, N; van den Anker, J | 1 |
| Avedissian, SN; Fletcher, CV; Mykris, TM; Podany, AT; Scarsi, KK; Weinhold, J; Winchester, LC | 1 |
| Gill, MM; Herrera, N; Maile, L; Masenyetse, L; Masitha, M; Mokone, M; Tukei, VJ | 1 |
| Castelli, F; Ferretti, S; Mignani, L; Monti, E; Quiros-Roldan, E; Tiecco, G; Zanella, I; Zizioli, D | 1 |
| Battegay, M; Berton, M; Bettonte, S; Marzolini, C; Stader, F | 1 |
| Bengtson, AM; Cu-Uvin, S; Goedecke, JH; Levitt, N; Madlala, H; Matjila, MJ; McGarvey, ST; Myer, L; Werner, EF | 1 |
| Abba, A; Adibe, MO; Alozie, FA; Chukwu, PO; Ebere, A; Ekwunife, OI; Igboeli, NU; Isah, A; Omotola, OF | 1 |
| Ballestero, JA; Castagna, VC; Elorza, SD; Gomez-Casati, ME; Gonzalez-Rodulfo, SM; Martin, MG; Paulazo, MA; Sodero, AO | 1 |
| Bula, A; Chagomerana, M; Chapola, JC; Hosseinipour, MC; Lee, F; Rosenberg, NE; Tang, JH; Tseka, J | 1 |
| Butler, CC; Dorward, J; Drain, PK; Gandhi, M; Garrett, N; Govender, K; Hayward, G; Lessells, R; Moodley, P; Samsunder, N; Sookrajh, Y; Turner, P | 1 |
| Budhathoki, C; Dooley, KE; Farley, JE; Geiger, K; Lowensen, K; Ndjeka, N; Ngozo, J; Patil, A | 1 |
| Bousmah, MA; Boyer, S; Delaporte, É; Kouanfack, C; Maradan, G; Mpoudi-Etame, M; Olinga, J; Omgba Bassega, P; Protopopescu, C; Tovar-Sanchez, T; Varloteaux, M | 1 |
| Chinula, L; Corbett, AH; Cottrell, ML; Gajer, P; Haddad, LB; Hurst, S; Kourtis, AP; Lantz, AM; Nelson, JAE; Nicol, MR; Ravel, J; Tang, JH; Tegha, G | 1 |
| Cao, X; Peng, Y; Wang, M; Wang, Y; Yu, W; Zeng, Z | 1 |
| Chandiwana, P; Duri, K; Gumbo, FZ; Marere, T; Mataramvura, H; Mazengera, LR; Mazhandu, AJ; Munjoma, PT | 1 |
| Benki-Nugent, S; Bulterys, MA; Chebet, D; Chege, M; Gomez, L; John-Stewart, G; King'e, M; Lawley, KA; Malavi, K; Moraa, H; Neary, J; Njuguna, I; Nzia, G; Onyango, A; Wagner, AD; Wamalwa, D | 1 |
| Anuradha, S; Bhrusundi, M; Dravid, AN; Kulkarni, V; Madhukarrao, KM; Morkar, DN; Nageswaramma, S; Naik, KS; Pilawan, AS; Ramapuram, JT; Raveendra, KR | 1 |
| Berrie, L; Chersich, M; Cox, MH; Diallo, K; Fairlie, L; Le Roux, J; Modi, S; Mogashoa, M; Ngeno, B; Pals, S; Sawry, S; Sherman, G; Williamson, D | 1 |
| Cao, Y; Chu, M; Huang, H; Li, M; Qin, G; Zhuang, X; Zou, M | 1 |
| Aarnoutse, R; Chabala, C; Cotton, MF; Denti, P; Galileya, LT; Gibb, D; Hesseling, A; Lee, J; McIlleron, H; Njahira Mukui, I; Rabie, H; Turkova, A; Wasmann, RE; Zar, H | 1 |
| Barrie, U; Guan, Q; Jalloh, AT; Jiba, DF; Kamara, MN; Lakoh, S; Liu, M; Song, JW; Sun, W; Tamba, FK; Wang, L; Yang, G; Yendewa, GA; Zhao, R | 1 |
| Chimbetete, C; Shamu, T; Shawarira-Bote, S | 1 |
| Chen, IT; Chen, JK; Chen, YS; Lee, SS; Sy, CL; Tsai, HC; Tseng, YT; Weng, YW; Wu, KS | 1 |
| Dretler, RH; Moye-Dickerson, PM; Nwaesei, AS | 1 |
| Akelo, V; Aweeka, F; Aziz, M; Berzins, B; Cohn, SE; Coombs, RW; Coughlin, K; Cramer, YS; Friedman, RK; Gingrich, D; Godfrey, C; Moran, LE; Rosenkranz, SL; Scarsi, KK; Swaminathan, S; Zorrilla, CD | 1 |
| Amara, A; Byakika-Kibwika, P; Byamugisha, J; Coombs, JA; Else, L; Gini, J; Heiburg, C; Hill, A; Hodel, EM; Kaboggoza, J; Khoo, S; Kintu, K; Lamorde, M; Malaba, T; Mehta, U; Myer, L; Orrell, C; Reynolds, H; Sihlangu, M; Simmons, B; Singh, Y; Waitt, C; Walimbwa, S | 1 |
| Bai, F; Bandera, A; Bernasconi, DP; Bonora, S; Castelli, F; Di Biagio, A; Focà, E; Gori, A; Lapadula, G; Migliorino, GM; Monforte, AD; Squillace, N | 1 |
| Boricic, I; Dimitrijevic, B; Dragovic, G; Jevtovic, D; Nikolic, K; Salemovic, D; Tomanovic, N | 1 |
| Cheng, L; Feng, W; Li, X; Sun, F; Wang, Y; Weng, B; Xia, P; Yuan, Q | 1 |
| Dai, L; Li, J; Liu, A; Mahajan, SD; Schwartz, SA; Scott, SR; Shao, Y; Su, B; Sun, L; Wu, H; Ye, J; Yu, H; Zhang, H; Zhang, T | 1 |
| Durán, MV; Greco, D; Lopardo, G; Sabato, S; Sánchez Thomas, D | 1 |
| Breton, G; Guilavogui, F; Karemangino, S; Laborde-Balen, G; Pizarro, L; Rouzioux, C; Temgoua, EM; Tubiana, R; Zana, DK | 1 |
| Bela, B; Ibrahim, F; Kusumaningrum, A; Yunihastuti, E | 1 |
| Abrams, EJ; le Roux, SM | 1 |
| Chadwick, EG; Correia, KF; Crowell, CS; DiPerna, A; Hazra, R; Seage, GR; Smith, R; Van Dyke, RB; Williams, PL; Yildirim, C | 1 |
| Decloedt, EH; Engelbrecht, AE; Norman, J; Rabie, H; Wiesner, L | 1 |
| Bansi-Matharu, L; Cambiano, V; Duncan, K; Maman, D; Murphy, RA; Phillips, A; Shroufi, A; Van Cutsem, G | 2 |
| Diani, E; Gibellini, D; Lanzafame, M; Lattuada, E; Luise, D; Vecchi, M; Vincenzi, M | 1 |
| Lin, KS; Nyein, PP; Win, S | 1 |
| Nabih, MF; Nur, AM; Puteh, SEW | 1 |
| Buccimazza, I; Mansoor, E; Osman, S | 1 |
| Aweeka, F; Huang, L; Hughes, E; Kajubi, R; Mwebaza, N; Mwima, MW; Nguyen, V; Nyunt, MM; Orukan, F; Parikh, S | 1 |
| Butler, LT; Hamill, MM; Law, JKC | 1 |
| Adimora, AA; Dastgheyb, R; Fischl, MA; Fitzgerald, KC; Gustafson, DR; Konkle-Parker, D; Li, Y; Maki, PM; Milam, J; Ofotokun, I; Rubin, LH; Sharma, A; Spence, AB; Weber, KM; Williams, DW; Xu, Y | 1 |
| Li, A; Li, C; Li, H; Li, W; Li, X; Xia, W | 1 |
| Atwine, D; Barrail-Tran, A; Baudin, E; Bonnet, M; Furlan, V; Gelé, T; K T Nanjebe, D; Kananura, K; Kyohairwe, R; Muyindike, W; Mworozi, K; Nyehangane, D; Orikiriza, P; Taburet, AM; Verstuyft, C | 1 |
| Äbelö, A; Ashton, M; Bienvenu, E; Birgersson, S; Janzén, D; Sundell, J | 1 |
| Bertisch, B; Estill, J | 1 |
| Apollo, T; Bansi-Matharu, L; Barnabas, R; Bertagnolio, S; Calmy, A; Cambiano, V; Cohn, J; Da Silva, J; Ford, N; Gupta, RK; Havlir, D; Jahn, A; Kuritzkes, DR; Lundgren, JD; Mellors, J; Mugurungi, O; Phillips, AN; Pillay, D; Pozniak, A; Raizes, E; Revill, P; Ripin, D; Siberry, GK; Venter, F; Wensing, A | 1 |
| Arraes, LC; Brandão, LAC; Carvalho-Silva, WHV; Coelho, AVC; Crovella, S; Guimarães, RL; Moura, RR; Valeriano, JJLS | 1 |
| Aarnoutse, R; Aber, F; Denti, P; Dooley, KE; Lamorde, M; Musaazi, J; Nabisere, R; Sekaggya-Wiltshire, C; Sloan, DJ | 1 |
| Abdullah, M; Hasan, M; Teguh H, K; Yunihastuti, E | 1 |
| Bisaso, KR; Bisaso, KS; Ette, EI; Mukonzo, JK | 1 |
| Aweeka, F; Baker, P; Berzins, B; Cohn, SE; Coombs, R; Coughlin, K; Cramer, YS; Gingrich, D; Godfrey, C; Haas, DW; Moran, LE; Rosenkranz, SL; Scarsi, KK; Zorrilla, CD | 1 |
| Bhattacharya, D; Chaktoura, N; Chipato, T; Currier, JS; Dula, D; Fowler, MG; George, K; Gnanashanmugam, D; Gupta, A; Huang, S; Klingman, KL; Martinson, F; Mohtashemi, N; Peters, MG; Tierney, C | 1 |
| Ajibola, G; Batlang, O; Bennett, K; Davey, S; Diseko, M; Hughes, MD; Isaacson, A; Kuritzkes, DR; Lichterfeld, M; Lockman, S; Makhema, J; Maswabi, K; Moyo, S; Sakoi, M; Shapiro, R; Zash, R | 1 |
| Adeagbo, BA; Adegbola, AJ; Bolaji, OO; Bolarinwa, RA; Olagunju, AE; Owen, A; Rana, A; Siccardi, M | 1 |
| Anderson, SA; Bennett, FC; Cook, K; Garifallou, JP; Gonzalez, MV; Hakonarson, H; Jordan-Sciutto, KL; Mironets, E; Ryan, SK; Sotuyo, NP; Williams, KS | 1 |
| Chen, J; Chen, R; Hu, Z; Huang, Q; Liu, L; Lu, H; Qi, T; Shen, Y; Song, W; Sun, J; Tang, Y; Wang, J; Wang, X; Wang, Z; Wei, H; Xie, R; Zhang, R | 1 |
| Azmi, M; Baber, ZU; Badlani, S; Dodani, SK; Nasim, A; Sheerani, M | 1 |
| Brouillette, MJ; Fellows, LK; Mayo, NE | 1 |
| He, J; Ma, R; Sun, S; Xu, B; Zhang, Q; Zhang, Y; Zhao, CS | 1 |
| Goddard, SL; Orkin, C | 1 |
| Kufa, T | 1 |
| Anthony, P; Best, BM; Cahn, P; Chakhtoura, N; Chokephaibulkit, K; Cressey, TR; de Lourdes B Teixeira, M; Essack, Z; Frenkel, LM; Fuller, TL; Gouvèa, MIS; Hennessy, R; João, EC; Laimon, L; Mathiba, R; Mirochnick, M; Mmbaga, BT; Moreira, LF; Morrison, RL; Ngocho, JS; Njau, BN; Pilotto, JHS; Prommas, S; Rolon, MJ; Shapiro, DE; Siberry, GK; Violari, A; Werarak, P | 1 |
| Burger, D; Byamugisha, J; Byrne, K; Chen, T; Colbers, A; Hodel, EM; Khoo, S; Kintu, K; Lamorde, M; Malaba, TR; Myer, L; Nakibuka, J; Orrell, C; Papamichael, C; Reynolds, H; Seden, K; Taegtmeyer, M; Twimukye, A; Waitt, C; Wang, D; Watson, V | 1 |
| Avihingsanon, A; Chaivichacharn, P; Manosuthi, W; Punyawudho, B; Shotelersuk, V; Tongkobpetch, S; Ubolyam, S | 1 |
| Boulle, A; Davies, MA; Eley, B; Fairlie, L; Fatti, G; Giddy, J; Kuhn, L; Nyakato, P; Rabie, H; Sawry, S; Sipambo, N; Tanser, F; Technau, KG; Wood, R | 1 |
| Alagaratnam, J; Boffito, M; Bozzali, M; Cercignani, M; Mora-Peris, B; Nelson, M; Toniolo, S; Underwood, J; Vera, JH; Winston, A | 1 |
| Arends, JE; Hakkers, CS; Hermans, AM; Hoepelman, AIM; Teunissen, CE; van Maarseveen, EM; Verberk, IMW | 1 |
| Cetindag, E; Dave, R; Fu, Y; Gandhi, T; Jablonski, J; Mediouni, S; Patel, K; Patki, M; Valente, ST; Vartak, R | 1 |
| Byakika-Kibwika, P; Kalyesubula, R; Nyende, L; Sekasanvu, E | 1 |
| Abrams, EJ; Arpadi, SM; Coovadia, A; Kuhn, L; Shen, J; Shiau, S; Strehlau, R; Yin, MT | 1 |
| Bowers, M; Grigorenko, EL; Tan, M; Thuma, P | 1 |
| Acosta, EP; Haas, DW | 1 |
| Chang, SY; Chen, YT; Chen, YW; Huang, CK; Huang, SH; Huang, WC; Hung, CC; Lin, SW; Liu, WC; Ou, ST; Sun, HY | 1 |
| Anok, A; Batte, J; Gray, R; Kisakye, A; Mayanja, R; Nakasujja, N; Nakigozi, G; Quinn, TC; Reynolds, SJ; Robertson, K; Rubin, LH; Sacktor, N; Saylor, D; Vecchio, A; Wawer, MJ | 1 |
| Avelino-Silva, VI; Fonseca, FF; Pascom, ARP; Pereira, G; Perini, FB; Pinho, RGG | 1 |
| Jianwei, L; Menghua, W; Qinwei, Y; Xin, Z; Yu, Z | 1 |
| Camacho, M; Castillo, A; Checa, A; Hernandez, I; Tapia, W; Teran, E | 1 |
| Cai, WP; Deng, XZ; Hu, FY; Lan, Y; Li, F; Li, LH; Nie, Y | 1 |
| Bonora, S; Calcagno, A; De Benedetto, I; Guastamacchia, G; Trunfio, M | 1 |
| Arpadi, SM; Burke, M; Coovadia, A; Kuhn, L; Patel, F; Shiau, S; Strehlau, R; Su, J; Yin, MT | 1 |
| Dighe, VD; Jindal, AB; Jirwankar, YB; Surve, DH | 1 |
| Baker, P; Bao, Y; Benson, CA; Chaisson, RE; Fletcher, CV; Gupta, A; Haas, DW; Mohapi, L; Mwelase, N; Podany, AT; Supparatpinyo, K; Swindells, S | 1 |
| Baker, P; Basham, R; Bourgi, K; Bradford, Y; Cindi, Z; Daar, ES; Erdem, H; Gulick, R; Haas, DW; Hulgan, T; Koethe, J; Leonard, MA; Norwood, J; Rebeiro, PF; Riddler, SA; Ritchie, MD; Sinxadi, P; Sterling, TR; Turner, M; Woodward, B | 1 |
| Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y | 1 |
| Bhende, M; Biswas, J; Kumar, KD; Selvamuthu, P; Sudharshan, S | 1 |
| Chishimba, L; Chomba, M; Mbewe, N; Saylor, D; Zimba, S | 1 |
| Aaron, L; Aurpibul, L; Bhosale, R; Bradford, S; Browning, R; Chakhtoura, N; Chanaiwa, V; Chipato, T; Costello, D; Denti, P; Gausi, K; Gupta, A; Haas, DW; Hesseling, A; Jean-Philippe, P; Kabugho, E; Masheto, GR; McCarthy, K; Mhembere, T; Mmbaga, BT; Montepiedra, G; Mutambanengwe, M; Nevrekhar, N; Norman, J; Nyati, M; Onyango-Makumbi, C; Rouzier, V; Shin, K; Sterling, TR; Stranix-Chibanda, L; Theron, G; Tongprasert, F; Vhembo, T; Violari, A; Wallis, CL; Weinberg, A; Wiesner, L; Zimmer, B | 1 |
| Banda, FM; Jao, J; Makhema, J; Masasa, G; Powis, KM; Sun, S; Yee, LM | 1 |
| Arnaiz, A; Arrúe, A; Basterreche, N; Olivas, O; Zumárraga, M | 1 |
| Abideen, G; Adeniji, H; Adeuja, O; Agbaje, EO; Akanmu, AS; Akinleye, MO; Akinyede, AA; Busari, AW; Hassan, OO; Ken-Owotor, C; Kogbe, S; Ogunfowokan, T; Onwujuobi, AG; Oreagba, IA; Owolabi, ET; Usman, SO | 1 |
| Asante-Appiah, E; Feng, M; Graham, D; Hazuda, DJ; Hwang, C; Kumar, S; Lai, MT; Martin, EA; Ngo, W; Sklar, P | 1 |
| Akpomiemie, G; Chirehwa, M; Griesel, R; Maartens, G; Moorhouse, M; Sinxadi, P; Sokhela, S; Venter, F | 1 |
| Abrams, E; Akpomiemie, G; Arulappan, N; Chandiwana, N; Chersich, M; Clayden, P; Fairlie, L; Hill, A; Lalla-Edward, S; Maartens, G; Masenya, M; Mashabane, N; McCann, K; Moorhouse, M; Norris, S; Qavi, A; Serenata, C; Simmons, B; Sokhela, S; Venter, WDF; Vos, A | 1 |
| Abong Bwenda, T; Calmy, A; Delaporte, E; Kouanfack, C; Lantche Wandji, M; LeMoing, V; Leroy, S; Mercier, N; Montoyo, A; Mpoudi-Etame, M; Mpoudi-Ngolé, E; Omgba Bassega, P; Peeters, M; Perrineau, S; Reynes, J; Tetsa Tata, D; Tongo, M; Tovar Sanchez, T; Varloteaux, M | 1 |
| Betha, TP; Dravid, A; Dravid, M; Gawali, R; Kore, S; Kulkarni, M; Mahajan, U; Rathod, N; Saraf, C; Sharma, AK | 1 |
| Bauleni, A; Corbett, A; Dube, Q; Hosseinipour, MC; Kapito-Tembo, AP; Mwale, P; Mwapasa, V; Ongubo, D; Phiri, S; Wesevich, A | 1 |
| Balboa-Barreiro, V; Castro-Iglesias, Á; Cid-Silva, P; Fernández-Bargiela, N; López-Calvo, S; Margusino-Framiñán, L; Martín-Herranz, I; Mena-De-Cea, Á; Míguez-Rey, E; Rotea-Salvo, S; Vázquez-Rodríguez, P | 1 |
| Barner, JC; Barnes, JN; Beretvas, T; Ford, KH; Lawson, KA; Nduaguba, SO; Okoh, C; Wilson, JP | 1 |
| Burkholder, GA; Collier, AC; Crane, HM; Curtis, L; Delaney, JAC; Eron, JJ; Geng, E; Harding, BN; Henegar, C; Kitahata, MM; Lindström, S; Mathews, WC; Mayer, KH; Moore, RD; Nance, RM; Rodriguez, B; Ruderman, SA; Saag, MS; Van Wyk, J; Vannappagari, V; Whitney, BM; Willig, AL; Wood, BR | 1 |
| Aklillu, E; Amogne, W; Burhenne, J; Diczfalusy, U; Habtewold, A; Makonnen, E; Yimer, G; Zumla, A | 1 |
| Hanna, GJ; Hwang, C; Kumar, S; Lin, G; Martin, E; Molina, JM; Orkin, C; Sax, PE; Squires, KE; Sussmann, O; Teppler, H | 1 |
| Chaiwarith, R; Chindamporn, A; Cressey, TR; Kaewpoowat, Q; Sirisanthana, T; Worasilchai, N; Yasri, S | 1 |
| Bousmah, MA; Boyer, S; Delaporte, E; Kouanfack, C; Lantche Wandji, M; Maradan, G; Montoyo, A; Mpoudi-Etame, M; Nishimwe, ML; Omgba Bassega, P; Tovar-Sanchez, T; Varloteaux, M | 1 |
| Eriksson, LE; Marrone, G; Mellgren, Å; Reinius, M; Svedhem, V | 1 |
| Andreini, C; Arancio, A; Banci, L; Barillari, G; Cafaro, A; Campagna, M; Ensoli, B; Falchi, M; Monini, P; Moretti, S; Palladino, C; Pavone Cossut, MR; Picconi, O; Sgadari, C; Tripiciano, A | 1 |
| Adhicari, P; Bhargava, S; Gupta, P; Pawar, M; Singh, M | 1 |
| Andersson, LM; Edén, A; Eriksen, J; Gisslén, M; Mellgren, Å; Nilsson, S; Thalme, A; Treutiger, CJ; Tyrberg, E | 1 |
| Clark, KM; Davis, K; DeSelm, CJ; Gao, H; Harlan, GH; Kutluay, SB; Mugisha, CS; Presti, RM; Shan, L; Tang, JP; Wang, Q | 1 |
| Atkinson, K; Auyeung, K; Barrios, R; Baynes, KA; Brumme, CJ; Lepik, KJ; Sereda, P; Toy, J; Watson, BE | 1 |
| Bassa, A; Hill, A; Kumar, S; Mngqibisa, R; Nelson, M; Orkin, C; Rassool, M; Rodgers, A; Teal, V; Teppler, H; Winston, A | 1 |
| Chang, SC; Chang, SY; Chiang, C; Chuang, YC; Huang, SH; Huang, WC; Hung, CC; Kuo, PH; Lin, SW; Liu, WC; Sun, HY; Wu, PY | 1 |
| Chow, NK; Harun, SN; Khan, AH; Low, LL; Sheikh Ghadzi, SM; Wong, EJ | 1 |
| Meintjes, G; Pozniak, A | 1 |
| Ambhore, JP; Chaudhari, SR; Cheke, RS; Kharkar, PS | 1 |
| Allen Reeves, A; Caballero, J; Fuentes, AV; Harrington, C; Mosley Ii, JF; Thomas, JE | 1 |
| Dong, X; Hong, L; Huang, S; Lei, S; Li, H; Li, X; Xie, R; Xin, J; Yang, C; Yang, X; Zhang, B; Zhang, R | 1 |
| Chen, Y; Deng, Y; Deng, Z; Huang, M; Qiu, C; Shi, Z; Shu, Y; Tu, X; Wang, H; Yuan, L; Zhao, X | 1 |
| Bengtson, AM; Cole, SR; Collier, AC; Crane, HM; Eaton, EF; Edwards, JK; Mathews, WC; Mollan, KR; O'Cleirigh, C; Pence, BW; Tierney, C; Weideman, AMK; Westreich, D; Xu, S | 1 |
| Abrams, EJ; Geffner, ME; Gerschenson, M; Jao, J; Kgole, S; Kurland, IJ; Legbedze, J; Makhema, J; Masasa, G; Mmalane, M; Mmasa, KN; Mohammed, T; Moyo, S; Powis, K; Sun, S | 1 |
| Fox, HS; George, JW; Lamberty, BG; Mattingly, JE; Roland, NJ; Small, CM; Stauch, KL | 1 |
| Bapat, G; Desai, D; Kulkarni, S; Mahajan, K; Rojekar, S; Vavia, P; Zinjarde, S | 1 |
| Babalola, CP; Berzins, B; Gandhi, M; Khoo, SH; Nwogu, JN; Okochi, H; Olagunju, A; Owen, A; Robertson, K; Taiwo, B; Tallerico, R | 1 |
| Cohn, SE; Denti, P; Dooley, KE; Firnhaber, C; Francis, J; Godfrey, C; Kendall, MA; McIlleron, H; Mngqibisa, R; Wu, X | 1 |
| Burger, DM; Heine, RT; Hermans, LE; Houts, T; Nijhuis, M; Schuurman, R; Tempelman, HA; Wensing, AMJ | 1 |
| Del Rio, C; Flexner, CW; Gavegnano, C; Hurwitz, SJ; Jiang, Y; Kantor, A; Kohler, JJ; Lederman, MM; Lennox, J; Marconi, VC; Moser, C; Overton, ET; Schinazi, RF; Tao, S; Tressler, RL; Tsibris, A | 1 |
| Asif, S; Baxevanidi, E; Chandiwana, N; Fairlie, L; Hill, A; Masenya, M; Serenata, C; Sokhela, S; Venter, WDF | 1 |
| Akbari, A; Dehghan-Manshadi, SA; Eslami, M; Ghodsi, S; Hosseini, Z; Mohebi, M; Mollazadeh, R; Sadre-Bafghi, SA | 1 |
| Äbelö, A; Ashton, M; Bienvenu, E; Sundell, J | 1 |
| Angira, F; Badal-Faesen, S; Baker, P; Cohn, SE; Denti, P; Francis, J; Haas, DW; Kendall, MA; Mawlana, S; McIlleron, H; Mngqibisa, R; Omoz-Oarhe, A; Robinson, JA; Samaneka, WP | 1 |
| Benamor Teixeira, ML; Chakhtoura, N; Coombs, RW; Frenkel, LM; Fuller, TL; Gouvêa, MI; Hennessey, R; João, EC; Mirochnick, M; Morrison, RL; Shapiro, DE; Whitson, K | 1 |
| Barratt, DT; Bordin Andriguetti, N; Pumuye, P; Somogyi, AA; Tucci, J; Van Schalkwyk, HK | 1 |
| Brasher, WP; Bvumbwe, M; Kazembe, PN | 1 |
| Benns, A; Bolton Moore, C; Borkowsky, W; Bwakura-Dangarembizi, M; Capparelli, EV; Chadwick, EG; Hawkins, E; Heckman, B; Jean-Philippe, P; Loftis, A; Purdue, L; Samson, P; Spector, SA; Wallis, C; Worrell, C | 1 |
| Bangsberg, DR; Cohen, K; Leisegang, R; Maartens, G; Orrell, C; Wood, R | 1 |
| Nordling, L | 1 |
| Boffito, M; Flexner, CW; Maartens, G | 1 |
| Badal-Faesen, S; Brown, TT; Campbell, TB; Cardoso, SW; Erlandson, KM; Fiorillo, SP; Hakim, J; Kumarasamy, N; Kumwenda, J; Lalloo, U; Riviere, C; Sanchez, J | 1 |
| Abrams, EJ; Coovadia, A; Hunt, G; Kuhn, L; Mbete, N; Murnane, PM; Patel, F; Shiau, S; Strehlau, R | 1 |
| Eaton, EF; Gravett, RM; Mugavero, MJ; Tamhane, AR | 1 |
| Amani-Bosse, C; Amorissani-Folquet, M; Avit, D; Blanche, S; Coulibaly, M; Dahourou, DL; Eboua, F; Kalmogho, A; Lepage, P; Leroy, V; Malateste, K; Meda, N; N'Gbeche, S; Ouédraogo, R; Ouédraogo, S; Salamon, R; Seguin-Devaux, C; Timité-Konan, M; Toni, T; Van de Perre, P; Yonaba, C | 1 |
| Abbasian, L; Ahmadi, M; Ghaeli, P; Khalili, H | 1 |
| Aplenc, R; Bellamy, SL; Bisson, GP; Gastonguay, M; Gross, R; Han, X; Moorthy, GS; Mosepele, M; Ratshaa, BR; Steenhoff, AP; Strom, BL; Vujkovic, M; Zuppa, AF | 1 |
| Arpadi, SM; Coovadia, A; Foca, M; Kuhn, L; Liberty, A; Patel, F; Pinillos, F; Ramteke, SM; Shiau, S; Strehlau, R; Violari, A | 1 |
| Ellwanger, JH; Matte, MCC; Michita, RT; Müller, TE; Renner, JDP | 1 |
| Brookhart, MA; Cole, SR; Crane, HM; Edwards, JK; Eron, JJ; Hall, HI; Kitahata, MM; Mathews, WC; Moore, RD; Mugavero, MJ; Saag, MS | 1 |
| Bakeera-Kitaka, S; Gibb, DM; Katuramu, R; Kekitiinwa, A; Mhute, T; Musiime, V; Senfuma, O; Spyer, M; Szubert, AJ; Walker, AS | 1 |
| Maartens, G; Martinson, NA; Mochan, A; Muchichwa, P; Norman, J; Rakgokong, M; Sigauke, FR; Variava, E | 1 |
| Angarano, G; Bellacosa, C; Bellazzi, LI; Celesia, BM; Chirianni, A; Cicalini, S; Corsi, P; Grilli, E; Ladisa, N; Leone, A; Maggi, P; Martinelli, C; Maserati, R; Ricci, ED; Sozio, F; Viglietti, R; Volpe, A | 1 |
| Cohen, CR; Kiarie, J; Morroni, C; Patel, RC; Scarsi, KK; Sripipatana, T | 1 |
| Li, J; Mesplède, T; Nekka, F; Sanche, S; Sheehan, N; Wainberg, MA | 1 |
| Boffito, M; Lamorde, M; Pozniak, A; Watkins, M | 1 |
| Incardona, F; Meini, G; Mloka, D; Mugusi, F; Mugusi, S; Neogi, U; Sönnerborg, A; Svärd, J; Zazzi, M | 1 |
| Aniceto, N; Antunes, F; Cruz, JP; Duarte, H; Fernandes, A; Morais, J; Paixão, P; Ribeiro, AC | 1 |
| Avihingsanon, A; Burger, DM; Gatechompol, S; Maek-A-Nantawat, W; Ruxrungtham, K; Sapsirisavat, V; Sophonphan, J; Thammajaruk, N; Thiansanguankul, W; Ubolyam, S | 1 |
| Awoke, T; Birlie, B; Braekers, R; Kasim, A; Shkedy, Z | 1 |
| Battegay, M; Bernasconi, E; Calmy, A; Cavassini, M; Fehr, J; Gayet-Ageron, A; Hirzel, C; Schmid, P; Sculier, D | 1 |
| Apostolova, N; Blas-Garcia, A; Esplugues, JV; Galindo, MJ | 1 |
| Aplenc, R; Bellamy, SL; Bisson, GP; Gross, R; Han, X; Moorthy, G; Mosepele, M; Ratshaa, B; Steenhoff, AP; Strom, BL; Vujkovic, M; Zuppa, AF | 1 |
| Achilles, SL; Chappell, CA; Chen, BA; Cohn, SE; Darin, KM; Lamorde, M; Mackline, H; Nakalema, S; Riddler, SA; Scarsi, KK | 1 |
| Cheng, Y; Liu, X; Ma, Q; Ma, Y; Mu, W; Sun, X; Zhang, F; Zhang, H; Zhao, Y | 1 |
| Agrahari, V | 1 |
| Bengtson, AM; Crane, H; Eaton, EF; Edwards, JK; Eron, JJ; Kitahata, MM; Mathews, WC; Mollan, KR; Moore, RD; Mugavero, MJ; OʼCleirigh, C; Pence, BW | 1 |
| Andolina, A; Carbone, A; Castagna, A; Franzin, M; Galizzi, N; Galli, L; Gianotti, N; Lazzarin, A; Merli, M; Muccini, C; Oltolini, C; Poli, A; Spagnuolo, V; Tadini, P | 1 |
| Bulut, N; Yılmaz, B | 1 |
| Dandara, C; Reay, R; Rheeders, M; Viljoen, M | 1 |
| Bebawy, S; Bofill, C; Haas, DW; Hulgan, T; Koethe, JR; Norwood, J; Raffanti, S; Rebeiro, P; Shepherd, B; Sterling, TR; Turner, M | 1 |
| Alemu, K; Ayele, TA; Kasim, A; Kebede, Y; Shkedy, Z; Worku, A | 1 |
| Brambilla, D; Ceffa, S; De Luca, A; Liotta, G; Luhanga, R; Magid, NA; Mancinelli, S; Marazzi, MC; Palombi, L; Sidumo, ZJ; Zanelli, G | 1 |
| Dahl, ML; Eriksen, J; Gustafsson, LL; Navér, L; Österberg, E; Rubin, J; Soeria-Atmadja, S | 1 |
| Cotarelo, M; Macías, J; Mancebo, M; Merchante, N; Merino, D; Montes-Ramírez, ML; Pérez-Pérez, M; Pineda, JA; Pulido, F; Raffo, M; Rivero-Juárez, A; Téllez, F | 1 |
| Compagnucci, A; Harrison, L; Melvin, AJ; Saidi, Y; Tudor-Williams, G; Turkova, A; Warshaw, M | 1 |
| Campbell, TB; Daar, ES; Edwards, DRV; Eron, JJ; Gulick, RM; Haas, DW; Haubrich, R; Hellwege, JN; Hudgens, MG; Ma, Q; Mollan, KR; Robertson, KR; Sax, PE; Tierney, C; Ventura, D | 1 |
| Ávila-Ríos, S; Barrera-Arellano, CA; Casillas-Rodríguez, J; García-Morales, C; Gómez-Palacio-Schjetnan, M; Murakami-Ogasawara, A; Navarro-Álvarez, S; Quiroz-Morales, VS; Reyes-Terán, G; Romero-Mora, KA; Tapia-Trejo, D | 1 |
| Asmuth, DM; Chun, TW; Garcia, JC; Kashuba, AD; Landay, A; Ma, ZM; Mann, S; Miller, CJ; Pollard, RB; Sainz, T; Serrano-Villar, S; Thompson, CG; Troia-Cancio, P; Utay, NS | 1 |
| Bolaji, O; Khoo, S; Olagunju, A; Owen, A; Schipani, A | 1 |
| Cohan, D; Conroy, AL; Dorsey, G; Gamble, JL; Havlir, DV; Kain, KC; Kamya, MR; McDonald, CR; Natureeba, P; Olwoch, P | 1 |
| Janabi, M; Kabeho, A; Mayala, H; Nicholaus, P; Nkinda, A; Pallangyo, P | 1 |
| Chen, X; Fairley, CK; He, J; Jing, J; Mao, L; Sasadeusz, J; Su, S; Wei, X; Zeng, H; Zhang, L | 1 |
| Cole, SR; Edwards, JK; Eron, JJ; Hall, HI; Mathews, WC; Moore, RD; Mugavero, MJ | 1 |
| Belcher, R; Marcangelo, M | 1 |
| Bednasz, CJ; Collier, AC; Daar, ES; Fischl, MA; Ma, Q; Morse, GD; Sax, PE; Smith, KY; Tierney, C; Venuto, CS; Wilding, GE; Yang, Y | 1 |
| Cohan, D; Conroy, AL; Dorsey, G; Gamble, JL; Hawkes, M; Kain, KC; Kamya, M; Koss, CA; McDonald, CR; Natureeba, P; Olwoch, P; Papp, E; Serghides, L; Silverman, M | 1 |
| Amberbir, A; Garone, D; Kalima, K; Kandionamaso, C; Kawalazira, G; Kwekwesa, A; Mataka, Y; Matengeni, A; Mateyu, G; Msonko, J; Singano, V; van Lettow, M; van Oosterhout, JJ | 1 |
| Chang, SC; Chang, SY; Chiang, C; Hsiao, CF; Huang, SH; Hung, CC; Lin, SW; Lin, YT; Liu, WC; Su, YC; Sun, HY | 1 |
| Foster, C; Lyall, H; Tudor-Williams, G; Williams, E; Wynberg, E | 1 |
| Alejos, B; Blanco, JR; Moreno, S | 1 |
| Balestre, E; Bärnighausen, T; Bazin, B; Boyer, S; Dabis, F; De Oliveira, T; Dreyer, J; Herbst, K; Iwuji, CC; Larmarange, J; Makowa, T; McGrath, N; Newell, ML; Okesola, N; Orne-Gliemann, J; Pillay, D; Rekacewicz, C; Tanser, F; Thiebaut, R | 1 |
| Cuong, DD; Dung, NT; Dung, NTH; Haneuse, S; Kinh, NV; Matsumoto, S; Oka, S; Tanuma, J; Thuy, PTT; Trung, NV; Vu, TV | 1 |
| Dhooria, S; Gupta, K; Pandey, RM; Ranjan, S; Sinha, S; Tripathy, S | 1 |
| Chauhan, G; Chowdhary, AS; Goyal, AK; Kesarkar, RN; Malik, T; Rath, G | 1 |
| Aweeka, F; Dorsey, G; Havlir, D; Huang, L; Jagannathan, P; Kakuru, A; Kamya, M; Muhindo, M; Nakalembe, M; Natureeba, P; Rosenthal, PJ; Savic, RM; Vucicevic, K; Wallender, E | 1 |
| Hill, AM; Hughes, S; Mitchell, N; Pozniak, AL | 1 |
| Ahmadi, NE; Ahsani-Nasab, S; Bayanolhagh, S; Esmaeilzadeh, A; Lolaie, M; Moallemi, S; Mohraz, M; Narouei, A; Sadeghi, L; SeyedAlinaghi, S; Tabatabai, RA | 1 |
| Aweeka, FT; Jagannathan, P; Kajubi, R | 1 |
| Srinivas, NR | 1 |
| Barco, A; Bonora, S; Calcagno, A; Trunfio, M | 1 |
| Babiker, A; Butler, K; Ford, D; Gibb, D; Griffin, S; Ochalek, J; Revill, P; Tierrablanca, LE; Turkova, A | 1 |
| Johnston, J; Joubert, A; Orrell, C; Smith, P; Wiesner, L | 1 |
| Awodele, O; Oshikoya, KA; Popoola, TD | 1 |
| Castelnuovo, B; Gonza, P; Kambugu, A; Kiragga, AN; Mbabazi, O; Mubiru, F; Musomba, R; Ratanshi, RP | 1 |
| Chetty, T; Coutsoudis, A; Thorne, C | 1 |
| Bourrel, R; Lapeyre-Mestre, M; Montastruc, JL; Rwagitinywa, J; Sommet, A | 1 |
| Best, BM; Burger, DM; Capparelli, E; Colbers, AC; Cressey, TR; Denti, P; Dooley, KE; Greupink, R; Huitema, ADR; Mirochnick, M; Russel, FGM; Schalkwijk, S; Ter Heine, R | 1 |
| Goldstein, DB; Kleinstein, SE; Naggie, S; Shea, PR; Stamm, LM; Sulkowski, M | 1 |
| Chatzidimitriou, D; Chatzopoulou, F; Margariti, A; Metallidis, S; Papaioannou, M; Pilalas, D; Skoura, L; Tsachouridou, O; Zebekakis, P | 1 |
| Afonso, C; Arenas-Pinto, A; Brouwers, P; Chasanov, WM; Collins, S; Cooper, DA; Cummins, N; Flynn, PM; Fox, J; Grund, B; Katlama, C; Kedem, E; Klingman, KL; Martinez, E; Sedlacek, D; Sharma, S; Sierra-Madero, J | 1 |
| Boulle, M; Buckels, NJ; Cele, S; Chen, CY; Dullabh, KJ; Ferreira, IM; Ganga, Y; Hunter, J; Jackson, L; Karim, F; Khan, K; Lustig, G; Madansein, R; Neher, RA; Sigal, A; Young, AC | 1 |
| Arpadi, SM; Coovadia, A; Kuhn, L; Mbete, N; Patel, F; Shiau, S; Strehlau, R; Yin, MT | 1 |
| Asukile, MT; Chetty, S; Cross, HM; Hussey, HS; Lee Pan, EB; Tucker, LM | 1 |
| Choonara, YE; du Toit, LC; Kondiah, PPPD; Kumar, P; Pillay, V; Siyawamwaya, M | 1 |
| Domingo, JC; Domingo, P; Gallego-Escuredo, JM; Gasa, L; Giralt, M; Maroto, AF; Mateo, GM; Morón-Ros, S; Moure, R; Quesada-López, T; Villarroya, F; Villarroya, J | 1 |
| Cofan, M; de Lazzari, E; Domingo, P; Forga, MT; Gatell, JM; González-Cordón, A; Leyes, P; Martínez, E; Negredo, E; Ros, E; Trabal, J; Vidal, F | 1 |
| Babiker, A; Bologna, R; Bunupuradah, T; Butler, K; Chalermpantmetagul, S; Compagnucci, A; Cressey, TR; Flynn, PM; Ford, D; Giaquinto, C; Gibb, DM; Harper, L; Kaudha, E; Klein, N; Montero, S; Moore, CL; Musiime, V; Nanduudu, A; Nastouli, E; Ramos Amador, JT; Riault, Y; Saïdi, Y; Scott, K; Turkova, A; Volokha, A; Welch, SB | 1 |
| Andrade-Villanueva, J; Caro-Vega, Y; Caylà, J; Crabtree-Ramírez, B; Fehr, J; Girardi, E; Kirk, O; Losso, MH; Lundgren, JD; Miller, RF; Miro, JM; Mocroft, A; Panteleev, A; Podlekareva, DN; Post, FA; Schultze, A; Sierra-Madero, J; Skrahin, A; Tetradov, S; Toibaro, J; W Efsen, AM | 1 |
| Diseko, M; Essex, M; Jacobson, DL; Lockman, S; Makhema, J; Mayondi, G; Mmalane, M; Petlo, C; Rough, K; Shapiro, RL; Zash, R | 1 |
| Diphoko, T; Essex, M; Gaseitsiwe, S; Kasvosve, I; Makhema, J; Marlink, R; Moyo, S; Musonda, R; Novitsky, V; Okatch, H; Wainberg, M | 1 |
| Bonolo, PF; Ceccato, MDGB; Costa, JO; Dos Santos, H; Mendes, JC; Reis, AMM; Silveira, MR | 1 |
| Flexner, C; Ippolito, MM; Jacobson, JM; Lederman, MM; Shapiro, TA; Tarning, J; Winterberg, M | 1 |
| Cai, W; Fan, Q; Kourtis, AP; Shepard, C; Sun, L; Tao, J; Wang, L; Zhang, F; Zhao, H; Zhao, Q | 1 |
| Acosta, EP; Bradford, Y; Daar, ES; Eron, JJ; Gulick, RM; Haas, DW; Morse, GD; Riddler, SA; Ritchie, MD; Sax, PE; Verma, A; Verma, SS | 1 |
| Aplenc, R; Bellamy, SL; Bisson, GP; Gastonguay, MR; Gross, R; Han, X; Moorthy, GS; Mosepele, M; Ratshaa, B; Steenhoff, AP; Strom, BL; Vujkovic, M; Zuppa, AF | 1 |
| Ahrens, J; Drury, A; Gilfillan, S; Gleadow-Ware, S | 1 |
| Baker, P; Cardoso, CC; da Silva, GAR; de Almeida, TB; de Azevedo, MCVM; de Castro, IJ; Ferry, FRA; Haas, DW; Pinto, JFDC; Tanuri, A | 1 |
| Diseko, M; Essex, M; Gaolethe, T; Holmes, LB; Jacobson, DL; Lockman, S; Makhema, J; Mayondi, G; Mmalane, M; Petlo, C; Shapiro, RL; Zash, R | 1 |
| Mofenson, LM | 2 |
| Chang, SC; Chang, SY; Huang, SH; Hung, CC; Lin, SW; Lin, YT; Liu, WC; Su, YC; Sun, HY | 1 |
| Antony, J; Ashoor, HM; Blondal, E; Finkelstein, Y; Ghassemi, M; Gough, K; Hemmelgarn, BR; Hutton, B; Ivory, JD; Khan, PA; Lillie, E; Straus, SE; Tricco, AC; Vafaei, A; Veroniki, AA | 1 |
| Butini, L; Costantini, A; Martini, M; Rocchi, M; Tontini, C | 1 |
| Dalwadi, DA; Harvey, BH; Ozuna, L; Schetz, JA; Viljoen, M | 1 |
| Bangsberg, DR; Boum, Y; Bwana, M; Chang, JL; Haberer, JE; Hunt, PW; Martin, JN; Musinguzi, N; Muzoora, C; Siedner, MJ; Tsai, AC | 1 |
| Alcaide, ML; Jones, DL; Peltzer, K; Rodriguez, VJ; Weiss, SM | 1 |
| Bangsberg, DR; Boum, Y; Bwana, B; Chang, JL; Haberer, JE; Hunt, PW; Kroetz, DL; Lee, SA; Martin, J; Musinguzi, N; Muzoora, C; Siedner, MJ; Tsai, AC | 1 |
| Dubrocq, G; Rakhmanina, N | 1 |
| Bagayoko-Maiga, K; Bahachimi, A; Cere, MC; Chatelut, E; Dao, S; Diarra, Z; Gandia, P; Maiga, M; Murphy, RL; Oumar, AA; Sylla, M | 1 |
| Aklillu, E; Aris, E; Bakari, M; Bertilsson, L; Burhenne, J; Janabi, M; Minzi, O; Mugusi, F; Mugusi, S; Ngaimisi, E; Sandstrom, E | 1 |
| Li, J; Mesplède, T; Nekka, F; Sanche, S; Sheehan, NL | 1 |
| Appiah, LT; Beloukas, A; Chadwick, D; Geretti, AM; Phillips, RO; Ruggiero, A; Sarfo, FS; Smith, C; Stockdale, AJ; Villa, G | 1 |
| Battegay, M; Berger, B; Donzelli, M; Duthaler, U; Erb, S; Gaugler, S; Haschke, M; Krähenbühl, S; Letang, E; Mnzava, D; Natamatungiro, A | 1 |
| Bonfanti, P; De Socio, GV; Di Biagio, A; Gulminetti, R; Madeddu, G; Maggi, P; Martinelli, C; Menzaghi, B; Orofino, G; Ricci, E; Squillace, N; Taramasso, L; Tatarelli, P; Vichi, F | 1 |
| Boffito, M; Cerrone, M; Day-Weber, I; Fedele, S; Hill, A; McClure, M; Neary, M; Owen, A; Wang, X; Weaver, C | 1 |
| Arinaitwe, WJ; Khoo, S; Kiiza, D; Laker, E; Lamorde, M; Seden, K; Waitt, C | 1 |
| Abrams, EJ; Arpadi, S; Mogashoa, M; Mutiti, A; Nxele, M; Pepeta, L; Rivadeneira, ED; Sogaula, N; Teasdale, CA; Wang, C; Yuengling, KA | 1 |
| Bisdomini, E; Boffito, M; Byakika-Kibwika, P; Khan, W; Lamorde, M; McClure, M; Mukonzo, JK; Nakalema, S; Neary, M; Owen, A; Wang, X | 1 |
| Bellamy, SL; Bisson, GP; Gross, R; Han, X; Mosepele, M; Ratshaa, B; Steenhoff, AP; Torgersen, J; Vujkovic, M; Zuppa, AF | 1 |
| Anugulruengkitt, S; Chokephaibulkit, K; Cressey, TR; Jantarabenjakul, W; Ounchanum, P; Pancharoen, C; Punnahitanon, S; Puthanakit, T; Sophonphan, J; Srirompotong, U; Suntarattiwong, P; Tawon, Y | 1 |
| Araújo, F; Barreiros, L; Bártolo, I; das Neves, J; Nunes, R; Sarmento, B; Segundo, MA; Taveira, N | 1 |
| Buzibye, A; Calcagno, A; Castelnuovo, B; Cusato, J; Fehr, J; Kambugu, A; Lamorde, M; Ledergerber, B; Sekaggya-Wiltshire, C; von Braun, A | 1 |
| Affolabi, D; Bah-Sow, O; Chirehwa, MT; Denti, P; McIlleron, H; Merle, C; Wiesner, L | 1 |
| Ding, Y; Gao, M; He, N; Li, L; Lin, H; Liu, X; Shen, W; Wang, K; Wu, Q; Zhou, S | 1 |
| Arends, JE; Ensing, MHM; Hakkers, CS; Hoepelman, AIM; Hooijenga, I; van den Berk, GE; van Zandvoort, MJE; Vink, M | 1 |
| Akakpo, AS; Bassowa, A; Dapam, AN; Kombaté, K; Laouali, AY; Mahamadou, G; Mensah, E; Mouhari-Toure, A; Pitché, P; Saka, B; Teclessou, JN | 1 |
| Bogner, JR; DeGrosky, M; Dicker, IB; Gartland, M; Joshi, SR; Lataillade, M; Llamoso, C; Lombaard, J; Min, S; Molina, JM; Morales-Ramirez, J; Pene Dumitrescu, T; Stock, DA | 1 |
| Mugusi, S; Ngaimisi, E; Sasi, P; Sungi, SS; Ulenga, N | 1 |
| Abraham, OC; Demosthenes, JP; Ghale, BC; Kannangai, R; Ramalingam, VV; Rupali, P; Varghese, GM | 1 |
| Cattaneo, D; Perno, CF; Rizzardini, G | 1 |
| Tartaglia, A | 1 |
| Aklillu, E; Bertilsson, L; Burhenne, J; Janabi, M; Kitabi, EN; Minzi, OMS; Mugusi, F; Mugusi, S; Sasi, P | 1 |
| Castro, L; Chow, DC; Duerler, T; Gangcuangco, LMA; Kallianpur, KJ; Kohorn, L; Nagamine, L; Nakamoto, BK; Paul, R; Pien, FD; Shikuma, CM; Soll, B; Souza, S; Walker, M | 1 |
| Boasso, A; Fuchs, D; Higgs, C; Keegan, MR; Nelson, M; Winston, A | 1 |
| Decloedt, EH; Haas, DW; Joska, JA; Khoo, S; Maartens, G; Sinxadi, PZ; van Zyl, GU; Wiesner, L | 1 |
| Favarato, G; Gayet-Ageron, A; Martinez de Tejada, B; Thorne, C; Winterfeld, U | 1 |
| Adamson, L; Blake, KH; Eron, JJ; Forrest, A; Joseph, SB; Kashuba, ADM; Kincer, LP; Luciw, P; Menezes, P; Price, RW; Robertson, K; Schauer, AP; Spudich, S; Srinivas, N; Swanstrom, R; Sykes, C; White, N | 1 |
| Ammassari, A; Angeletti, C; Antinori, A; Bellagamba, R; Gallo, AL; Giancola, ML; Narciso, P; Nicastri, E; Pinnetti, C; Piselli, P; Tempestilli, M; Tommasi, C; Zaccarelli, M | 1 |
| Acurcio, FA; Bonolo, PF; Ceccato, MDGB; Costa, JO; Pearson, SA; Silveira, MR | 1 |
| Garcia, LP; Hanswijk, SI; Homberg, JR; Kolk, SM; Martens, GJM; Mast, Q; Middelman, A; Rando, J; Schellekens, AFA; Ter Heine, R; van de Wijer, L; van der Ven, AJAM | 1 |
| Andreoni, M; Antinori, A; Bagnarelli, P; Borghi, V; Bruzzone, B; Callegaro, AP; De Gennaro, M; Gianotti, N; Maffongelli, G; Maggiolo, F; Saladini, F; Sterrantino, G; Vergori, A; Zaccarelli, M; Zazzi, M | 1 |
| de Mast, Q; Duinmaijer, A; Kinabo, GD; Mchaile, DN; Mmbaga, BT; Rommelse, NNJ; Schellekens, AFA; Van de Wijer, L; van der Ven, AJAM | 1 |
| Cotton, MF; Laughton, B; Rabie, H | 1 |
| do Brasil, PEAA; Hadad, DJ; Maia, IR; Rolla, V; Sant'anna, FM; Schmaltz, CAS; Trajman, A; Xavier, MS | 1 |
| Chendi, BH; Eyoh, A; Ikomey, GM; Jacobs, GB; Lyonga, E; Mesembe, M; Okomo Assoumou, MC; Yekwa, EL | 1 |
| Abrams, EJ; Brittain, K; Gomba, Y; Hu, NC; Maartens, G; Myer, L; Norman, J; Orrell, C; Phillips, TK; Sinxadi, P; Wiesner, L; Zerbe, A | 1 |
| Alfaro, J; Bogdanov, AA; Bolotin, E; Castillo, G; Gottikh, MB; Gupta, S; Leporati, A | 1 |
| Huang, JP; Huang, WH; Luo, SD; Luo, XL; Mo, LD; Ni, ZY; Su, GS; Su, HZ; Wu, JY | 1 |
| Becker, JT; Cheng, Y; Ho, K; Levine, A; Li, Y; Martin, E; Ragin, A; Rubin, LH; Sacktor, N; Wang, Z | 1 |
| Hoffman, RM; Mofenson, LM | 1 |
| Abrams, EJ; Bekker, LG; Ciaranello, AL; Dugdale, CM; Freedberg, KA; Myer, L; Sax, PE; Stern, ME; Walensky, RP; Wood, R | 1 |
| Higuchi, Y; Ishii, H; Ota, R; Tsuda, M; Yamashita, F | 1 |
| Ajibola, G; Batlang, O; Cassidy, AR; Holding, PA; Kammerer, B; Leidner, J; Lockman, S; Makhema, J; Mayondi, G; Petlo, C; Powis, KM; Shapiro, R; Williams, PL | 1 |
| Chirwa, S; Desta, Z; Gaedigk, A; Gammal, RS; Gaur, AH; Gong, L; Haas, DW; Hockings, J; Iwuchukwu, OF; Klein, TE; Lennox, J; Masimirembwa, C; Myers, A; Sukasem, C; Swart, M; Tyndale, RF; Whirl-Carrillo, M | 1 |
| Asundi, A; Bennett, M; Kinslow, J; Kuritzkes, DR; Ladner, J; Landay, A; Lin, A; Lin, NH; Melbourne, K; Pan, H; Plank, RM; Robles, Y; Starr, T; Stern, E; Weisholtz, D; White, L | 1 |
| Lanzafame, M; Lattuada, E; Luise, D; Nicolè, S; Tacconelli, E; Vecchi, M; Vento, S | 1 |
| Duarte, EC; McFarland, W; Meireles, MV; Pascom, ARP | 1 |
| Agegne, M; Amare, D; Endalamaw, D; Estifanos, F; Hussien, M; Shiferaw, MB; Temesgen, D | 1 |
| Chinula, L; Corbett, A; Cottrell, ML; Haddad, LB; Hurst, S; Kourtis, AP; Msika, A; Nelson, JAE; Tang, JH; Wiener, J | 1 |
| Borkird, T; Bouazza, N; Cressey, TR; Homkham, N; Ingsrisawang, L; Jourdain, G; Mekmullica, J; Na-Rajsima, S; Puangsombat, A; Techakunakorn, P; Treluyer, JM; Urien, S | 1 |
| Dhole, TN; Nain, S; Samani, D; Singh, H | 1 |
| Banda, CG; Chaponda, M; Hachizovu, S; Kabuya, JB; Kalilani-Phiri, L; Khoo, SH; Lalloo, DG; Mukaka, M; Mulenga, J; Mulenga, M; Mwapasa, V; Sikalima, J; Terlouw, DJ | 1 |
| Chen, J; Chen, X; Fung, AWT; He, J; Jiang, H; Lau, JTF; Li, J; Qin, P; Wang, Z; Wong, A | 1 |
| Du Plessis, S; Fouche, JP; Hoare, J; Joska, JA; Myer, L; Perez, A; Phillips, N; Stein, DJ; Vink, M; Zar, HJ | 1 |
| Anderson, J; Beilman, GJ; Calisto, SP; Chipman, JG; David, C; Douek, DC; Fletcher, CV; Haase, AT; Helgeson, E; Hoskuldsson, T; Jasurda, J; Kityo, C; Nganou-Makamdop, K; Pearson, H; Perkey, K; Reilly, C; Reimann, T; Rothenberger, M; Schacker, TW; Schmidt, TE; Southern, P; Ssali, F; Wietgrefe, S | 1 |
| Beck, IA; Birch, D; Bolton-Moore, C; Bwakura-Dangarembizi, M; Capparelli, E; Chadwick, E; Frenkel, LM; Higa, N; Pelz, A; Samson, P; Sils, T | 1 |
| Avenant, T; du Plessis, N; George, J; Goga, AE; Mazanderani, AH; Murray, TY; Pepper, MS; Sherman, GG; Snyman, T | 1 |
| Benns, A; Bwakura Dangarembizi, M; Capparelli, EV; Chadwick, EG; Chakhtoura, N; Jackson, C; Jean-Philippe, P; Libous, JL; Moore, CB; Purdue, L; Samson, P; Spector, SA; Wallis, C; Zimmer, B | 1 |
| Althoff, KN; Brown, TT; Erlandson, KM; Jacobson, LP; Kingsley, LA; Lake, JE; Margolick, JB; Ng, DK; Palella, FJ; Zhang, L | 1 |
| Alghamdi, WA; Antwi, S; Dompreh, A; Enimil, A; Kwara, A; Langaee, T; Peloquin, CA; Wiesner, L; Yang, H | 1 |
| Bukusi, EA; Cohen, CR; Jakait, B; Onono, M; Patel, RC; Thomas, K; Wools-Kaloustian, KK; Yiannoutsos, C | 1 |
| Adeniyi, OV; Ajayi, AI; Goon, DT; Iweriebor, B; Lambert, J; Obi, CL; Okoh, A | 1 |
| Bernhardt, R; Brixius-Anderko, S; Fingerhut, R; Flück, CE; Grössl, M; Malikova, J; McDougall, J; Pandey, AV; Sluka, S; Zingg, T | 1 |
| Bopitiya, S; Das, S; Dhother, J; Taha, H | 1 |
| Awoke Ayele, T; Kasim, A; Kebede, Y; Shkedy, Z; Worku, A; Zuma, K | 1 |
| Achilles, SL; Chappell, CA; Chen, BA; Lamorde, M; Matovu, J; Nakalema, S; Neary, M; Owen, A; Scarsi, KK; Siccardi, M | 1 |
| Baeten, JM; Blue, SW; Erikson, DW; Kelly, EJ; Kim, CJ; Kourtis, AP; Lingappa, JR; Mugo, N; Nanda, K; Patel, RC; Scarsi, KK; Stalter, RM; Tamraz, B; Thomas, KK | 1 |
| Boyer, S; Calmy, A; Delaporte, E; Eymard-Duvernay, S; Kouanfack, C; Leroy, S; Mpoudi-Etame, M; Omgba Bassega, P; Peeters, M | 1 |
| Brown, A; Cooper, D; Harries, J; Morroni, C | 1 |
| Asano, T; Fujiki, K; Furumoto, Y; Hayakawa, Y; Horiuchi, T; Kobayashi, K; Matsumoto, T; Matsuoka, M; Misumi, Y; Miura, N; Nozaka, T; Sakamoto, N | 1 |
| Arastéh, K; Dretler, R; Frobose, C; Gatell, JM; Hagins, DP; Harvey, C; Hoffmann, C; Hwang, C; Kumar, S; Morales-Ramirez, JO; Osiyemi, O; Plettenberg, A; Portilla, J; Raffi, F; Rodgers, A; Rugina, S; Smith, DE; Teppler, H; Thompson, M; Wan, H; Xu, X | 1 |
| Ayuso, P; Chiong, J; Neary, M; Owen, A | 1 |
| Handoko, R; Spudich, S | 1 |
| Chagomerana, MB; DiPrete, BL; Harrington, BJ; Hosseinipour, MC; Jumbe, AN; Limarzi, L; Ngongondo, M; Wallie, SD | 1 |
| Adebisi, SA; Adedeji, NO; Adedeji, TA | 1 |
| DeJesus, E; DiNubile, MJ; Leavitt, R; Lennox, JL; Miller, M; Nguyen, BY; Rockstroh, JK; Rodgers, AJ; Saag, MS; Sklar, P; Teppler, H; Walker, ML; Wan, H; Yazdanpanah, Y | 1 |
| Hermans, SM; Hoepelman, AI; Kiragga, AN; Lange, JM; Manabe, YC; van Leth, F | 1 |
| Larsen, CS; Leutscher, PD; Stecher, C; Storgaard, M | 1 |
| Frenkel, L; Ton, Q | 1 |
| Adams, JL; Corbett, AH; Dumond, JB; Forrest, A; Jennings, SH; Kashuba, AD; Kendrick, RL; Malone, S; Patterson, KB; Prince, HM; Sykes, C; Wang, R; White, N | 1 |
| Bastos, R; Baudin, E; Bhatt, N; Bonnet, M; Calmy, A; Ciaffi, L; Jani, I; Michon, C; Nunes, E; Rouzioux, C; Silva, C; Sobry, A; Taburet, AM | 1 |
| Maartens, G | 1 |
| Bayonne Kombo, ES; Gathse, A | 1 |
| Akhondzadeh, S; Alimadadi, A; Dabaghzadeh, F; Ghaeli, P; Jafari, S; Khalili, H; Khazaeipour, Z | 1 |
| Aebi-Popp, K; Gingelmaier, A; Hoesli, I; Lyons, F; Mulcahy, F; Rudin, C; Thorne, C | 1 |
| Balakrishnan, P; Iqbal, HS; Kumarasamy, N; Saravanan, S; Solomon, S; Solomon, SS; Vidya, M | 1 |
| Alobwede, SM; Kongnyuy, EJ; Shey, MS; Wiysonge, CS | 1 |
| Davidson, DC; Maggirwar, SB; Schifitto, G | 1 |
| Aweeka, F; Dooley, KE; Karlsson, MO; Marzan, F; Park, JG; Svensson, EM | 1 |
| Arnett, DK; Bagchi, S; Chi, BH; Heimburger, DC; Kabagambe, EK; Kiage, JN; Koethe, JR; Nyirenda, CK; Wellons, MF | 1 |
| Aweeka, F; Benson, CA; Grinsztejn, B; Havlir, DV; Hogg, E; Ive, P; Lu, D; Luetkemeyer, AF; Marzan, F; Rosenkranz, SL; Sanne, IM; Swindells, S | 1 |
| Ball, C; Chaowanachan, T; Krogstad, E; Woodrow, KA | 1 |
| Anabwani, G; Boiditswe, S; Ellenberg, JH; Gross, R; Lowenthal, ED; Machine, E; Rutstein, R; Sagdeo, A; Steenhoff, AP | 1 |
| Groth, J; Harrison, TS; Macallan, DC; Poulikakos, P; Wake, RM | 1 |
| Bedogni, G; Cococcioni, L; Fabiano, V; Giacomet, V; Mora, S; Stucchi, S; Viganò, A; Zuccotti, GV | 1 |
| Anagnostopoulos, A; Aouri, M; Décosterd, LA; Günthard, HF; Kuster, SP; Rotger, M; Telenti, A | 1 |
| Aguilar, A; De La Torre, J; Del Arco, A; García-Alegría, J; Olalla, J; Pombo, M; Prada, JL; Ruiz-Mateas, F; Urdiales, D | 1 |
| Dewit, S; Sersté, T; Theodorou, M; Van Gossum, M | 1 |
| Aghokeng, A; Belec, L; Bertagnolio, S; Bunupuradah, T; Burda, S; Cane, P; Cappelli, G; Charpentier, C; Dagnra, AY; de Wit, TF; Deshpande, AK; El-Katib, Z; Eshleman, SH; Fleury, HJ; Fokam, J; Ford, N; Gody, JC; Hamers, RL; Hawkins, CA; Holmes, S; Hosseinipour, MC; Jordan, MR; Kanki, PJ; Katzenstein, D; Koyalta, DD; Kumwenda, JJ; Lallemant, M; Lynen, L; Manosuthi, W; Marconi, VC; Margot, NA; Moussa, S; Ndung'u, T; Ngo-Giang-Huong, N; Nyambi, PN; Orrell, C; Peeters, M; Rhee, SY; Ruxrungtham, K; Schapiro, JM; Schuurman, R; Shafer, RW; Sigaloff, KC; Sirivichayakul, S; Smith, D; Stevens, W; Tang, MW; van Zyl, GU; Wallis, CL; Zolfo, M | 1 |
| Boven, K; Hoogstoel, A; Picchio, G; Rimsky, L; Stevens, M; Van Eygen, V; Vingerhoets, J | 1 |
| Blanche, S; Bouazza, N; Diagbouga, S; Hien, H; Hirt, D; Msellati, P; Nacro, B; Ouiminga, A; Rouet, F; Tréluyer, JM; Urien, S; Van de Perre, P; Zoure, E | 1 |
| Abgrall, S; Antinori, A; Cavassini, M; Costagliola, D; Crane, HM; Gill, MJ; Gomez Sirvent, JL; Guest, JL; Ingle, SM; Manzardo, C; May, MT; Mercie, P; Mugavero, MJ; Phillips, A; Reekie, J; Reiss, P; Saag, MS; Samji, H; Stephan, C; Sterling, TR; Sterne, JA; Tate, J; Wasmuth, JC | 1 |
| Boonsuk, S; Butchon, R; Chokephaibulkit, K; Kullert, N; Kulpeng, W; Phanuphak, N; Pilasant, S; Tantivess, S; Teerawattananon, Y; Tosanguan, K; Voramongkol, N; Werayingyong, P | 1 |
| Angel, JB; Blitz, SL; Burdge, D; Cohen, J; Conway, B; de Pokomandy, A; Gough, K; Haase, D; Klein, MB; la Porte, CJ; Loemba, H; Loutfy, MR; Pick, N; Raboud, J; Rachlis, AR; Smaill, FM; Trottier, S; Tseng, AL; Walmsley, SL | 1 |
| Aklillu, E; Gustafsson, LL; Luzze, H; Mukonzo, JK; Nakasujja, N; Ogwal-Okeng, J; Okwera, A; Sebuwufu, D; Waako, P | 1 |
| Barreiro, P; Fernández-Montero, JV; Labarga, P; Soriano, V; Vispo, E | 1 |
| Bosco, O; Cruciani, M; Malena, M; Mengoli, C; Parisi, SG; Serpelloni, G | 1 |
| DeJesus, E; Edelstein, H; Felizarta, F; Ha, B; Hao, R; Huhn, G; Kumar, P; Pappa, K; Ross, L; Sloan, L; Small, CB; Stancil, B | 1 |
| Blank, DA; Draper, HR; Dziuban, EJ; Hughey, AB; Kochelani, D; Schutze, GE; Stewart, DA | 1 |
| Burt, AD; Daly, AK; Elsharkawy, AM; Hudson, M; Masson, S; McCarron, B; Schwab, U | 1 |
| Dandara, C; Ren, Y; Skelton, M; Smith, P; Swart, M; Takuva, S | 1 |
| Acosta, EP; Andrade, A; Campbell, T; Cillo, AR; Daar, ES; Feinberg, J; Flexner, C; Jacobson, JM; Kuritzkes, DR; Lederman, M; Lu, D; Mellors, JW; Rosenkranz, SL | 1 |
| Sukasem, C; Sungkanuparph, S | 1 |
| da Silva, TP; Giacoia-Gripp, CB; Morgado, MG; Rolla, V; Sant Anna, FM; Schmaltz, CA | 1 |
| Bekker, LG; Gupta-Wright, A; Lawn, SD; Wood, R | 1 |
| Evans, D; Louwagie, G; Okello, V; Takuva, S; Zuma, K | 1 |
| Dlamini, S; Isaacs, T; Lehloenya, RJ; Ngwanya, MR | 1 |
| Cabrera Figueroa, S; Carracedo Álvarez, A; Cruz Guerrero, R; Hurlé, AD; Hurtado, LP; Sánchez Martín, A | 1 |
| Allavena, C; André-Garnier, E; Baffoin, S; Billaud, E; Ferré, V; Raffi, F; Reliquet, V; Rodallec, A; Sécher, S | 1 |
| Aderaye, G; Aklillu, E; Amogne, W; Bertilsson, L; Burhenne, J; Habtewold, A; Janabi, M; Makonnen, E; Minzi, O; Mugusi, F; Mugusi, S; Ngaimisi, E; Riedel, KD; Yimer, G | 1 |
| Baxter, J; Booth, C; Fox, Z; Geretti, AM; Johnson, JA; Lehmann, C; Lipscomb, J; Owen, A; Phillips, A; Stuyver, LJ; Tachedjian, G; Touloumi, G | 1 |
| Ferrand, RA; Ford, N; Pillay, P; Shubber, Z | 1 |
| Arribas, JR; Compston, J; Domingo, P; Gartland, M; Granier, C; Moyle, GJ; Orkin, C; Pearce, H; Sedani, S; Stellbrink, HJ | 1 |
| Beumer, JH; Christner, SM; Gramignoli, R; Parise, RA; Pillai, VC; Rudek, MA; Strom, SC; Venkataramanan, R | 1 |
| Heger, M | 1 |
| Achan, J; Ades, V; Aliba Luwedde, F; Clark, T; Cohan, D; Havlir, D; Kakuru, A; Kamya, M; Mwesigwa, J; Natureeba, P; Osterbauer, B; Plenty, A | 1 |
| Bosch, RJ; Collier, AC; Johnson, VA; Lok, JJ; Schouten, JT; Smurzynski, M; Taiwo, B; Wu, K | 1 |
| Echenique, IA; Rich, JD | 1 |
| Kekana, M; McIntyre, JA; Peters, RP; Struthers, HE; van Ramshorst, MS | 1 |
| Ahmed-Jushuf, I; Arumainayagam, J; Carlin, EM; Chandramani, S; Das, S; Ghanem, M; Kumari, B; Pammi, M; Riddell, L | 1 |
| Bertz, R; Bifano, M; Grasela, D; Hartstra, J; Hwang, C; Kandoussi, H; Oosterhuis, B; Sevinsky, H; Tiessen, R; Velinova-Donga, M | 1 |
| Bloch, E; Fink, DL | 1 |
| Chan, DP; Chan, RC; Cheung, SW; Lee, MP; Lee, SS; Li, PC; To, KW; Wong, NS | 1 |
| Ampofo, WK; Barnor, JS; Brandful, JA; Ibe, S; Ishikawa, K; Nii-Trebi, NI; Ofori, SB; Sugiura, W; Yamaoka, S | 1 |
| Clumeck, N; Molina, JM; Orkin, C; Rimsky, LT; Stevens, M; Vanveggel, S | 1 |
| Crowther, NJ; Dickens, C; Dix-Peek, T; Duarte, R; Evans, D; Menezes, CN; Prinsloo, A; Raal, F; Rassool, M; Sanne, I; Van Amsterdam, D | 1 |
| Bertrand, J; Blanc, FX; Borand, L; Chea, P; Chou, M; Mentré, F; Nay, KH; Taburet, AM; Verstuyft, C | 1 |
| de Oliveira, T; Lessells, RJ; Manasa, J; McGrath, N; Naidu, KK; Newell, ML; Skingsley, A | 1 |
| Booth, M; Chadwick, D; Kasim, A; Phillips, R; Sarfo, FS; Sarfo, MA | 1 |
| Bock, P; Fatti, G; Grimwood, A | 1 |
| Barin, B; Benet, L; Browne, M; Carlson, L; Christians, U; Floren, L; Frassetto, L; Roland, M; Stock, P; Wolfe, A | 1 |
| Achan, J; Aweeka, F; Bartelink, IH; Charlebois, E; Clark, T; Cohan, D; Gandhi, M; Havlir, D; Kamya, M; Mwesigwa, J; Plenty, A; Savic, RM; Young, SL | 1 |
| Bansi-Matharu, L; Bibby, D; Bulteel, N; Churchill, D; Dunn, D; Hill, T; Nelson, M; Sabin, C | 1 |
| Gunda, DW; Kabangila, R; Kalluvya, SE; Kasang, C; Kidenya, BR; Kidola, J; Klinker, H; Kongola, GW; Mshana, SE | 1 |
| Bedu-Addo, G; Chadwick, DR; Egan, D; Khoo, S; Owen, A; Phillips, R; Sarfo, FS; Sarfo, MA; Tetteh, LA; Zhang, Y | 1 |
| Kawalec, P; Kryst, J; Mikrut, A; Pilc, A | 1 |
| Bhavani, PK; Chandrasekar, C; Hannah, E; Kumar, H; Narendran, G; Padmapriyadarsini, C; Ponnuraja, C; Ramesh, C; Swaminathan, S; Tang, A; Wanke, C | 1 |
| Ahmad, H; Chandrashekhar, R; Dhooria, S; Ekka, M; Khan, NH; Kumar, S; Pandey, RM; Raghunandan, P; Ranjan, S; Rewari, BB; Samantaray, JC; Sharma, SK; Sinha, S; Velpandian, T; Venkatesh, S | 1 |
| Achan, J; Ades, V; Aweeka, F; Charlebois, E; Clark, T; Cohan, D; Gandhi, M; Havlir, DV; Huang, Y; Kamya, MR; Luwedde, FA; Mwesigwa, J; Natureeba, P; Plenty, A; Ruel, TD | 1 |
| Brundage, RC; Fletcher, CV; Salem, AH | 1 |
| Eley, B; Gous, H; Haas, DW; Maartens, G; McIlleron, HM; Merry, C; Moultrie, H; Nuttall, JJ; Ren, Y; Schomaker, M; Sinxadi, P; Smith, P | 1 |
| Alvarez, D; Asensi, V; García, L; Gómez-Sirvent, J; Gutiérrez, F; Masiá, M; Moreno, S; Navarro, G; Padilla, S; Vidal, F | 1 |
| Cotton, M; Edson, C; Klinker, H; Lenker, U; Pretorius, E; Rabie, H; Rosenkranz, B; von Bibra, M | 1 |
| Chappuy, H; Diagbouga, S; Drabo, A; Hien, A; Hien, H; Meda, N; Msellati, P; Nacro, B; Nicolas, J; Ouiminga, A; Rouet, F; Somé, J; Tamboura, H; Van de Perre, P; Yaméogo, S; Zoure, E | 1 |
| Domingo, P; Ribera, E | 1 |
| Casado, JL; Moreno, S | 2 |
| Ibarra-Barrueta, O; Mayo-Suarez, J; Mora-Atorrasagasti, O; Palacios-Zabalza, I | 1 |
| Liedtke, MD; Lockhart, SM; Miller, MM; Rathbun, RC | 1 |
| Bekele, D; Gudu, W | 1 |
| Conibear, T; Geretti, AM; Hill, A; Johnson, JA; Tambuyzer, L; Thys, K; Van Delft, Y; Vingerhoets, J | 1 |
| Chamnanphol, M; Jantararoungtong, T; Koomdee, N; Manosuthi, W; Prommas, S; Puangpetch, A; Santon, S; Sukasem, C; Sungkanuparph, S | 1 |
| Chan, KC; Chan, RC; Cheung, SW; Lee, SS; Naftalin, CM; Wong, KH | 1 |
| Ashton, M; Bienvenu, E; Dandara, C; Swart, M | 1 |
| Clark, M; Li, Y; Linger, M; Mast, N; Pikuleva, IA; Wiseman, J | 1 |
| Lueangniyomkul, A; Mankatitham, W; Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S | 2 |
| Alós, L; Arnaiz, JA; Benito, JM; Clotet, B; Cruceta, A; Díaz, A; Garcia, F; Gatell, JM; Leal, L; León, A; Loncá, M; Lucero, C; Martínez, E; Negredo, E; Rallón, NI; Sánchez, M; Torres, B | 1 |
| Cary, MS; Chikuse, F; Kwadiba, G; Moyo, D; Mushisha, O; Reid, MJ; Steenhoff, AP; Tanthuma, G | 1 |
| Motsa, N; Mwanyumba, A; Perry, SH; Preidis, GA; Sarero, HN; Swamy, P | 1 |
| Borghetti, A; Cauda, R; Colafigli, M; D'Avino, A; Di Giambenedetto, S; Fabbiani, M; Fanti, I; Fantoni, M; Grima, P; Mondi, A; Prosperi, M; Zaccarelli, M | 1 |
| Boven, K; Deckx, H; Doroana, M; Orkin, C; Pilotto, JH; Sungkanuparph, S; Vanveggel, S; Wohl, DA; Yeni, P | 1 |
| Clotet, B; Crespo, M; Curto, J; Ferrer, E; Imaz, A; Llibre, JM; Murillo, O; Navarro, J; Podzamczer, D; Saumoy, M; Tiraboschi, JM | 1 |
| Anderson, D; Coate, B; Dayaram, YK; Ryan, R; Schaible, D | 1 |
| Chamnanphon, M; Jantararoungtong, T; Koomdee, N; Manosuthi, W; Prommas, S; Puangpetch, A; Santon, S; Sukasem, C | 1 |
| Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S | 1 |
| Aklillu, E; Gustafsson, LL; Kuteesa, RB; Mukonzo, JK; Nanzigu, S; Ogwal-Okeng, J; Owen, JS; Ross, C; Sewankambo, N; Thabane, L | 1 |
| Mitra, AK; Pal, D; Patel, M; Paturi, DK; Vadlapatla, RK | 1 |
| Chandrasekharan, C; Kumar, AK; Ponnuraja, C; Rajesh, L; Ramachandran, G; Ramesh, K; Swaminathan, S | 1 |
| Lundgren, JD; Phillips, A | 1 |
| Choun, K; De Weggheleire, A; Lynen, L; Phirum, L; Thai, S; van Griensven, J | 1 |
| Chang, SY; Hung, CC; Kuo, CH; Lee, KY; Lin, SW; Liu, WC; Sun, HY; Tang, SY; Tsai, MS; Wu, BR | 1 |
| Alam, S; Dinello, D; Israr, M; Jia, R; Kishel, J; Meyers, C; Mitchell, D | 1 |
| Autran, B; Caby, F; Carcelain, G; Costagliola, D; Fourati, S; Guiguet, M; Guihot, A; Hattab, S; Katlama, C; Marcelin, AG | 1 |
| Pozniak, AL; Raffi, F; Wainberg, MA | 1 |
| Ahluwalia, J; Ananworanich, J; Chaithongwongwatthana, S; Cremers, S; Kerr, S; Landolt, NK; Lange, JM; Phanuphak, N; Pinyakorn, S; Thammajaruk, N; Thomas, T; Thongpaeng, P; Ubolyam, S | 1 |
| Blanc, FX; Borand, L; Chou, M; Dim, B; Fontanet, A; Goldfeld, AE; Hak, C; Kim, C; Lak, KK; Laureillard, D; Madec, Y; Marcy, O; Nerrienet, E; Pheng, P; Prak, N; Sok, T; Taburet, AM | 1 |
| Alejos, B; Antela, A; Blanco, JR; Gutiérrez, F; Hernández-Novoa, B; Jarrin, I; Lopez-Aldeguer, J; Moreno, S; Riera, M; Rubio, R; Santos, I | 1 |
| Behrens, G; Bosse, M; Chuck, SK; Cohen, C; DeMorin, J; Elion, RA; Mills, A; Nelson, M; Orkin, C; Rijnders, B; Rimsky, L; Stevens, M; Thorpe, D; Vanveggel, S; White, K; Zhong, L | 1 |
| Amin, A; Barau, C; Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; Furlan, V; Grinsztejn, B; Meggi, B; Silva, C; Taburet, AM | 1 |
| Barenbaum, S; Chimbengo, G; Gross, R; Ngoni, T; Platoff, R; Rantleru, T; Ratshaa, B; Sonenthal, PD; Steenhoff, AP | 1 |
| Hsiao, CB; Ma, Q; Sawyer, JR | 1 |
| Fitzgerald, DW; Haas, DW; Jean Juste, MA; Pape, JW; Severe, P | 1 |
| Bosch, RJ; Eron, JJ; Kuritzkes, DR; Taiwo, B; Vardhanabhuti, S | 1 |
| Chimbwandira, FM; Chirwa, Z; Crampin, AC; Dasgupta, AN; Glynn, JR; Jahn, A; Katundu, C; Kayange, M; Koole, O; Price, AJ; Saul, JL; Zaba, B | 1 |
| Crowe, SM; David, M; Gare, J; Hearps, AC; Imara, U; Kaima, P; Kelly-Hanku, A; Kombati, Z; Ryan, CE; Siba, PM; Timbi, D | 1 |
| Arnold, V; Barcellos, NT; Brites, C; Chêne, G; De Castro, N; Delaugerre, C; Fagard, C; Grinsztejn, B; Madruga, JV; Molina, JM; Morgado, M; Patey, O; Pilotto, JH; Santini-Oliveira, M; Santos, BR; Veloso, VG; Vorsatz, C | 1 |
| Arribas, J; Deckx, H; Duiculescu, D; Florence, E; Hung, CC; Sension, M; Stevens, M; Tebas, P; Vanveggel, S; Wilkin, T | 1 |
| Acosta, EP; Baker, P; Court, MH; Haas, DW; Kwara, A; Morse, GD; Papageorgiou, I; Richardson, DM | 1 |
| Arya, V; Chan-Tack, KM; Jadhav, P; Kraft, J; Liu, J; Robertson, SM; Seo, S; Singer, ME; Struble, KA | 1 |
| Cardoso, SW; Demeter, LM; Godfrey, C; Infante, R; Johnson, VA; Moran, LE; Sanchez, J; Smeaton, LM; Vogler, MA; Wright, RL | 1 |
| Brown, LA; Ferrell, D; Giunta, B; Jin, J; Obregon, D; Sadic, E; Smith, AJ; Tan, J | 1 |
| Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S | 1 |
| Amaral, E; Bahamondes, L; Bahamondes, MV; Brito, MB; de Souza, RM; Duarte, G; Ferriani, RA; Quintana, SM; Rocha Prandini, TR; Scaranari, C; Vieira, CS | 1 |
| Hull, MW; Lima, VD; Montaner, JS; Richard Harrigan, P; Sierra-Madero, J; Singer, J; Wood, E; Wu, Z | 1 |
| Domingo, JC; Domingo, P; Gallego-Escuredo, JM; Giralt, M; Gutierrez, Mdel M; Lamarca, K; Mateo, MG; Torres, F; Vidal, F; Villarroya, F; Villarroya, J | 1 |
| Amara, A; Dragovic, G; Jevtovic, D; Kusic, J; Olagunju, A; Owen, A; Siccardi, M | 1 |
| Abrams, EJ; Tsague, L | 1 |
| Andrieux-Meyer, I; Calmy, A; Ford, N; Mofenson, L; Renaud, F; Shaffer, N; Shubber, Z; Vitoria, M | 1 |
| Boucherie, C; Breton, G; Bugault, F; Chakrabarti, LA; Chêne, G; Cumont, MC; Lortholary, O; Patey, O; Richert, L; Roussillon, C | 1 |
| Antonopoulou, S; Chini, M; Demopoulos, CA; Fragopoulou, E; Gargalianos, P; Lazanas, MC; Mangafas, N; Papakonstantinou, VD; Psarra, K; Stamatakis, GM; Tsogas, N; Tsoupras, AB | 1 |
| Gui, T; Guo, W; Jia, L; Jiao, L; Li, H; Li, J; Li, L; Liu, S; Liu, Y; Zhuang, D | 1 |
| Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngasala, B; Sasi, PG | 1 |
| Boffito, M; Cressey, TR; Ford, N; Hill, A; Pozniak, A | 1 |
| Hu, Z; Kuritzkes, DR | 1 |
| Abdissa, A; Andersen, AB; Friis, H; Kaestel, P; McIlleron, H; Wiesner, L | 1 |
| Chen, HJ; Deng, M; Jiang, HY; Ruan, B; Yang, Y; Zhang, MN | 1 |
| Anutchatchaval, S; Harnlakorn, P; Kosalaraksa, P; Lumbiganon, P; Rattanamanee, S; Sopharak, C; Sringam, J; Tharnprisan, P; Udomphanit, T | 1 |
| Biasi, V; Concia, E; Costa, E; Jommi, C; Lanzafame, M; Lattuada, E; Manfre, S; Venturini, F | 1 |
| Calvo Hernández, MV; Figueroa, SC; García-Berrocal, B; Gómez, AI; Gonzalez-Buitrago, JM; Isidoro-García, M; Martín, AF; Martín, AS; Sánchez, MC; Tovar, CB; Valverde Merino, MP | 1 |
| Achan, J; Ades, V; Charlebois, ED; Clark, TD; Cohan, D; Dorsey, G; Havlir, DV; Kamya, MR; Luwedde, F; Mwesigwa, J; Natureeba, P; Nzarubara, B; Okong, P; Plenty, A | 1 |
| Back, D; Boffito, M; Else, L; Gazzard, B; Jackson, A; Nelson, M; Newell, S; Rockwood, N; Waters, L | 1 |
| Campbell, TB; Daar, ES; Eron, JJ; Gulick, RM; Mollan, KR; Na, L; O'Keefe, L; Robertson, KR; Sax, PE; Smurzynski, M; Tierney, C | 1 |
| Botes, M; Burnside, R; Clumeck, N; Cooper, DA; Dejesus, E; Heera, J; Ive, P; Lazzarin, A; Mukwaya, G; Saag, M; van Der Ryst, E; Walmsley, S | 1 |
| Crawford, KW | 1 |
| De Castro, N; Delaugerre, C; Flandre, P; Gallien, S; Molina, JM; Nguyen, N | 1 |
| Achan, J; Ades, V; Charlebois, ED; Clark, TD; Cohan, D; Havlir, DV; Kamya, MR; Koss, CA; Luwedde, F; Mwesigwa, J; Natureeba, P; Nzarubara, B; Plenty, A; Ruel, T | 1 |
| Castel, S; Chaisson, RE; Cohn, S; Denti, P; Dooley, KE; Haas, DW; Hoffmann, J; Hull, J; Martinson, N; Mashabela, F; McIlleron, H; Msandiwa, R; Wiesner, L | 1 |
| Ballow, C; Battegay, M; Elgadi, M; Feifel, U; Fuhr, R; Girlich, B; Haschke, M; Kort, J; Lang, B; Li, Y; Sabo, JP; Schobelock, M | 1 |
| Aklillu, E; Bakari, M; Bertilsson, L; Burhenne, J; Diczfalusy, U; Janabi, M; Minzi, O; Mugusi, F; Mugusi, S; Ngaimisi, E; Riedel, KD; Sasi, P; Suda, A; Ueda, N | 1 |
| de Kock, L; Derendorf, H; Diacon, AH; Donald, PR; Hernandez, KR; Prescott, K; Rosenkranz, B; Sy, SK; Yu, M | 1 |
| Amara, AB; Back, DJ; Else, LJ; Khoo, S; Olagunju, A; Puls, RL; Tjia, J | 1 |
| Coumbis, JJ; Napoli, AA; Seekins, DW; Soitkar, AM; Tilson, HH; Wood, JJ | 1 |
| Chapman, KO; Lelli, G | 1 |
| Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; da Silva, C; Furlan, V; Grinsztejn, B; Meggi, B; Taburet, AM | 1 |
| Mukonzo, JK | 1 |
| Aklillu, E; Gustafson, LL; Mukonzo, JK; Nanzigu, S; Ogwal-Okeng, J; Waako, P | 1 |
| Abdool Karim, SS; Botha, JH; Gengiah, TN; Naidoo, K; Yende-Zuma, N | 1 |
| Cheng, AK; Kulkarni, R; McColl, DJ; Miller, MD; Rhee, MS; Szwarcberg, J; White, KL | 1 |
| Aboulker, JP; Charreau, I; de Castro, N; Delaugerre, C; Gallien, S; Mahjoub, N; Molina, JM; Nere, ML; Simon, F | 1 |
| Berhanu, R; Brennan, AT; Fox, MP; Long, L; Maskew, M; Sanne, I; Shearer, K | 1 |
| Aboud, S; Kisenge, R; Mgelea, EM | 1 |
| Alessandrini, M; Čolić, A; Pepper, MS | 1 |
| Berendes, S; Campbell, TB; Cardoso, SW; Christian, P; Gupta, A; Gupte, N; Kanyama, C; Lama, JR; Mwelase, N; Pillay, S; Riviere, C; Samaneka, W; Semba, RD; Shivakoti, R; Sugandhavesa, P; Tang, AM; Yang, WT | 1 |
| Ferrada, MA; Nuermberger, E; Xie, Y | 1 |
| Manosuthi, W; Montakantikul, P; So-Ngern, A | 1 |
| Achan, J; Ades, V; Charlebois, ED; Clark, TD; Cohan, D; Gandhi, M; Havlir, DV; Kamya, MR; Koss, CA; Luwedde, F; Mwesigwa, J; Natureeba, P; Nzarubara, B; Plenty, A; Ruel, T | 1 |
| Ammassari, A; Battegay, M; Bonora, S; Burger, D; Chêne, G; Dauchy, FA; Fehr, J; Ghosn, J; Gianotti, N; Gogos, C; Grarup, J; Launay, O; Marzolini, C; Mocroft, A; Mussini, C; Obel, N; Raffi, F; Roca, B; Sabin, C; Siccardi, M; Torti, C; Zangerle, R | 1 |
| Daar, ES; de Bakker, PI; Gulick, RM; Haas, DW; Haubrich, RH; Lehmann, DS; McLaren, PJ; Ribaudo, HJ; Robbins, GK | 1 |
| Concia, E; Cucchetto, G; Lanzafame, M; Lattuada, E; Vento, S | 1 |
| Amara, A; Amin, J; Avihingsanon, A; Avinghsanon, A; Barber, T; Chetchotisakd, P; Clarke, A; Cooper, DA; Else, L; Emery, S; Jessen, H; Khoo, S; Owen, A; Puls, R; Winston, A | 1 |
| Dodderi, SK; Govindaraj, M; Pavithra, HB; Premalatha, R; Rewari, BB; Sanjeeva, GN; Shivananda, S; Sukanya, V | 1 |
| Back, DJ; Burger, D; Lamorde, M; Schapiro, JM | 1 |
| Costarelli, S; Di Giambenedetto, S; Di Pietro, M; Lorenzotti, S; Maggiolo, F; Postorino, MC; Prosperi, M; Quiros-Roldan, E; Saracino, A; Sighinolfi, L; Torti, C | 1 |
| Dave, JA; Haas, DW; Leger, PD; Levitt, NS; Maartens, G; McIlleron, HM; Sinxadi, PZ; Smith, PJ | 1 |
| Ayaya, SO; Inui, TS; Liu, H; Nyandiko, WM; Scanlon, ML; Slaven, JE; Tu, W; Vreeman, RC | 1 |
| Calvez, V; Desire, N; Girard, PM; Katlama, C; Marcelin, AG; Mercier-Darty, M; Morand-Joubert, L; Rodriguez, C; Todesco, E; Wirden, M | 1 |
| Martin-Carpenter, L; Quercia, R; Roberts, J; Zala, C | 1 |
| Anderson, J; Dhar, J; Ebrahimi, R; Ewan, J; Fisher, M; Moyle, GJ; Orkin, C; Wang, H; Wilkins, E | 1 |
| Bandera, A; Clerici, M; Gnudi, F; Gori, A; Rainone, V; Soria, A; Squillace, N; Trabattoni, D | 1 |
| Anthony, P; Kovacs, A; Louie, S; Mordwinkin, N; Neely, M; Thuvamontolrat, K; Xu, J | 1 |
| Camacho, RJ; Gomes, P; Rhee, SY; Theys, K; Vandamme, AM | 1 |
| Alonso-Villaverde, C; Ferrer, E; Martinez-Picado, J; Maso, M; Muñoz-Moreno, JA; Ouchi, D; Podzamczer, D; Prats, A; Puertas, MC; Rozas, N; Tiraboschi, JM | 1 |
| Grinsztejn, B; Haas, DW; Havlir, DV; Lu, D; Luetkemeyer, AF; McIlleron, H; Rosenkranz, SL; Sanchez, J; Sanne, I; Ssemmanda, M | 1 |
| Achan, J; Aweeka, F; Bartelink, IH; Capparelli, E; Charlebois, E; Dorsey, G; Gingrich, D; Havlir, D; Jullien, V; Kamya, M; Plenty, A; Ruel, T; Savic, RM; Scherpbier, HJ; Young, SL | 1 |
| Aurpibul, L; Chokephaibulkit, K; Cressey, TR; Phongsamart, W; Sirisanthana, V; Sricharoenchai, S; Sudjaritruk, T; Wittawatmongkol, O | 1 |
| Bader, J; Glass, TR; Klimkait, T; Labhardt, ND; Lejone, TI; Puga, D; Ringera, I | 1 |
| Grintjes-Huisman, K; Keuter, M; Koopmans, P; Mothapo, KM; Schellekens, A; van Crevel, R; van der Ven, A | 1 |
| Chin, BS; Gianella, S; Kim, G; Shin, HS; Smith, DM; Wagner, GA | 1 |
| Aderaye, G; Aklillu, E; Amogne, W; Bertilsson, L; Burhenne, J; Habtewold, A; Makonnen, E; Yimer, G | 1 |
| Clotet, B; Cruceta, A; Curran, A; Domingo, P; Ferrer, E; Gatell, JM; Guardo, AC; Loncà, M; Lozano, F; Manzardo, C; Miro, JM; Pérez, I; Plana, M; Podzamczer, D | 1 |
| Calmy, A; Doherty, M; Ford, N; Kirby, C; Pozniak, A; Shubber, Z; Vitoria, M | 1 |
| Althoff, KN; Bangsberg, DR; Bwana, MB; Davies, MA; Deeks, SG; Easterbrook, PJ; Egger, M; Fox, MP; Geng, EH; Hunt, PW; Kambugu, A; Ki Li, PC; Kiggundu, V; Lim, PL; Little, F; Martin, JN; Moore, RD; Nachega, JB; Nakanjako, D; Nakigozi, G; Nash, D; Neilands, TB; Prozesky, H; Reynolds, SJ; Thièbaut, R; Vittinghoff, EV; Wood, R; Yiannoutsos, CT; Zannou, DM | 1 |
| Calza, L; Colangeli, V; Conti, M; Danese, I; Magistrelli, E; Manfredi, R; Motta, R; Verucchi, G; Viale, P | 1 |
| Fan, P; Li, J; Li, N; Liang, Y; Ma, Y; Sun, D; Wang, Z; Yang, W; Zhu, Q | 1 |
| Amin, J; Belloso, W; Carey, D; Cooper, DA; Crabtree-Ramirez, B; Emery, S; Foulkes, S; Jessen, H; Kumar, S; Lee, MP; Losso, M; Mohapi, L; Phanupak, P; Puls, R; Winston, A | 1 |
| Chkhartishvili, N; Dvali, N; Karchava, M; Sharvadze, L; Tsertsvadze, T | 1 |
| Aris, E; Baernighausen, T; Chalamilla, G; Fawzi, W; Hertzmark, E; Jackson, E; Machumi, L; Muya, A; Mwanyika-Sando, M; Sando, D; Spiegelman, D | 1 |
| Adejuyigbe, E; Amara, A; Back, D; Bolaji, O; Else, L; Khoo, S; Olagunju, A; Owen, A; Siccardi, M; Waitt, C | 1 |
| Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E | 2 |
| Byrne, R; Nelson, M; Pavitt, CW; Rampling, T; Reid, T; Tyebally, S | 1 |
| Abecasis, AB; Theys, K; van Laethem, K | 1 |
| Amogne, W; Assefa, G; Caulk, AW; Getenet, H; Gleason, RL; Parker, I; Seifu, D; Vidakovic, B | 1 |
| Kawalec, P; Kryst, J; Pilc, A | 1 |
| Banguissa, H; Bisio, F; Boumba, JD; Bruzzi, P; Bruzzone, B; Calzi, A; Giacobbe, DR; Icardi, G; Mahoungou, P; Mboungou, FA; Mesini, A; Nicco, E; Ratto, S; Viscoli, C; Vividila, NE | 1 |
| Bisaso, KR; Ette, EI; Mukonzo, JK | 2 |
| Altman, RB; Alvarellos, ML; Klein, TE; Lau, JL; McDonagh, EM | 1 |
| Abdissa, A; Andersen, AB; Aseffa, A; Castel, S; Christiansen, M; Friis, H; Girma, T; Hagen, CM; McIlleron, H; Olsen, MF; Pedersen, C; Tesfaye, M; Wiesner, L; Yilma, D | 1 |
| Achan, J; Bacchetti, P; Charlebois, ED; Clark, TD; Cohan, D; Gandhi, M; Havlir, DV; Horng, H; Kamya, MR; Koss, CA; Mwesigwa, J; Natureeba, P; Nzarubara, B; Plenty, A; Ruel, TD | 1 |
| Bertrand, L; Toborek, M | 1 |
| Calmy, A; Cavassini, M; Ciaffi, L; Delhumeau, C; Fehr, J; Genne, D; Hill, A; Hirschel, B; Montecucco, F; Schmid, P; Spycher Elbes, R; Stoeckle, M; Wandeler, G | 1 |
| Essop, MR; Meel, R; Peters, F | 1 |
| Amin, J; Back, D; Boffito, M; Carey, D; Clarke, A; Cooper, DA; Dickinson, L; Egan, D; Else, L; Emery, S; Khoo, S; Losso, M; Orrell, C; Owen, A; Phanuphak, P; Puls, R | 2 |
| Andersen, JW; Bao, Y; Benson, CA; Chaisson, RE; Fletcher, CV; Gupta, A; Kim, P; Mohapi, L; Mwelase, T; Podany, AT; Supparatpinyo, K; Swindells, S | 1 |
| De Almeida, M; Dulioust, E; Frapsauce, C; Gayet, V; Grabar, S; Jouannet, P; Launay, O; Leruez-Ville, M; Sogni, P; Viard, JP | 1 |
| Distel, LV; Erber, S; Fiebig, N; Fietkau, R; Harrer, T; Hecht, M; Klinker, H; Parsch, H; Roth, T | 1 |
| Cai, W; Dong, P; Liu, L; Lu, H; Ma, Q; Meng, X; Shen, L; Shen, Y; Wang, J; Yin, K | 1 |
| Bañón, S; Casado, JL; Marín, A; Moreno, A; Moreno, S; Perez-Elías, MJ; Rodriguez-Sagrado, MA; Romero, V | 1 |
| Alvarez, A; Apostolova, N; Blas-Garcia, A; Esplugues, JV; Funes, HA; Galindo, MJ | 1 |
| Katamba, A; Martin, F; Mwesigire, DM; Seeley, J; Wu, AW | 1 |
| Bertelli, A; D'Erme, AM; Gola, M; Severino, M; Tchoimou, T; Testi, S; Tiradritti, L; Zuccati, G | 1 |
| Aurpibul, L; Bouazza, N; Chanta, C; Cressey, TR; Homkham, N; Ingsrisawang, L; Jourdain, G; Kamonpakorn, N; Krikajornkitti, S; Lallemant, M; Narkbunnam, T; Salvadori, N; Treluyer, JM; Urien, S | 1 |
| Currán, A; Deig, E; Guardiola, JM; Guelar, A; Llibre, JM; Martínez-Madrid, O; Pedrol, E; Ramírez, R; Tasias, M; Tikhomirova, L | 1 |
| Martinelli, A; Mayaka, GB; Muthoga, CW; Paganotti, GM; Romano, R; Russo, G; Sobze, MS; Tawe, L; Vullo, V | 1 |
| Cardoso, SW; Coelho, L; Currier, JS; Grinsztejn, B; Hoffman, RM; Lake, JE; Luz, PM; Mendonça, L; Veloso, VG | 1 |
| Avi, R; Huik, K; Jõgeda, EL; Kallas, E; Karki, T; Lutsar, I; Margus, T; Pauskar, M | 1 |
| Antony, J; Arumugam, K; D'Souza, G; De Costa, A; Kumar, DS; Kumarasamy, N; Poongulali, S; Rewari, BB; Shastri, S; Shet, A | 1 |
| Klein, MB; Mucsi, I; Rollet-Kurhajec, KC; Young, J | 1 |
| Belshan, M; Bruck, P; Date, AA; Destache, CJ; La Bruzzo, K; McMullen, E; Shibata, A; Zhou, Y | 1 |
| Flandre, P | 1 |
| Binda, K; Chen, JY; Dryden-Peterson, S; Essex, M; Lockman, S; Makhema, J; Mmalane, M; Shapiro, R; Souda, S; Zash, R | 1 |
| Biguenet, S; Bunupuradah, T; Krystal, M; Lataillade, M; Pavia-Ruz, N; Rossouw, M; Sáez-Llorens, X; Seekins, D; Sevinsky, H; Taylor, M; Yang, R | 1 |
| Antinori, A; Borchi, B; D'Ettorre, G; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Giuliani, M; Grima, P; Latini, A; Mondi, A; Rossetti, B; Sterrantino, G; Zaccarelli, M | 1 |
| Clifford, DB; Collier, AC; Croteau, D; Gelman, BB; Grant, I; Heaton, RK; Kao, YT; Letendre, SL; Ma, Q; Marra, CM; McArthur, JC; Morgello, S; Sanders, CA; Simpson, DM; Vaida, F; Wong, J | 1 |
| Avihingsanon, A; Avihingsanon, Y; Hiransuthikul, N; Kerr, SJ; Khovidhunkit, W; Praditpornsilpa, K; Ramautarsing, RA; Ruxrungtham, K; Sophonphan, J; Ubolyam, S | 1 |
| Grome, H; Jenkins, CA; Kalams, SA; Koethe, JR; Sterling, TR | 1 |
| Ances, BM; Brier, MR; Kharasch, ED; Tanenbaum, AB; Westerhaus, ET; Wu, Q | 1 |
| Abongomera, G; Asiimwe, A; Burger, D; Chabala, C; Chintu, C; Cook, AD; Gibb, DM; Kekitiinwa, A; Kenny, J; Kityo, C; Klein, N; McIlleron, H; Mirembe, G; Mulenga, V; Musiime, V; Owen-Powell, E; Thomason, MJ; Walker, AS | 1 |
| Adetokunboh, OO; Balogun, TA; Schoonees, A; Wiysonge, CS | 1 |
| Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sungkanuparph, S; Thongyen, S | 1 |
| Blat, C; Bukusi, EA; Cohen, CR; Gandhi, M; Hagey, J; Newmann, SJ; Onono, M; Patel, RC; Shade, SB; Vittinghoff, E | 1 |
| Abrams, EJ; Coovadia, A; Hunt, G; Kuhn, L; Martens, L; Patel, F; Pinillos, F; Shiau, S; Strehlau, R; Tsai, WY | 1 |
| Bon, I; Borderi, M; Calza, L; Colangeli, V; Conti, M; Danese, I; Magistrelli, E; Mancini, R; Motta, R; Re, MC; Viale, P | 1 |
| Anagnostopoulos, A; Aouri, M; Barcelo, C; Buclin, T; Cavassini, M; Decosterd, LA; Günthard, HF; Hugues, H; Rotger, M; Telenti, A; Ternon, B; Vernazza, P; Yerly, S | 1 |
| Chaula, Z; De Nardo, P; Gentilotti, E; Ippolito, G; Nguhuni, B; Nicastri, E; Vairo, F | 1 |
| Cai, W; Caughey, B; Chung, C; Dai, Z; Hu, F; Lan, Y; Li, L; Tang, X; Zhang, K | 1 |
| Freedberg, KA; Haas, DW; Li, XC; Park, SS; Schackman, BR | 1 |
| Hauptfleisch, MP; Moore, DP; Rodda, JL | 1 |
| Cohen, K; Dave, JA; Levitt, NS; Maartens, G; Micklesfield, LK | 1 |
| Cade, J; DeJesus, E; Enejosa, J; Feinberg, J; Gathe, J; Lalezari, J; Landay, AL; Lefebvre, E; Saag, M; Thompson, M | 1 |
| Back, DJ; Buzibye, A; Byakika-Kibwika, P; Cohn, SE; Darin, KM; Dilly Penchala, S; Else, LJ; Lamorde, M; Merry, C; Nakalema, S; Scarsi, KK | 1 |
| Drögemöller, BI; Grobbelaar, N; Ikediobi, O; McGregor, N; Röhrich, CR; van der Merwe, L; Warnich, L; Wright, GE | 1 |
| Andreotti, M; Floridia, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Luhanga, R; Mancinelli, S; Marazzi, MC; Marchei, E; Mwenda, R; Palombi, L; Pichini, S; Pirillo, MF; Sagno, JB; Vella, S | 1 |
| Boucherie, C; Breton, G; Caumes, E; Chaix, ML; Chêne, G; Fagard, C; Lortholary, O; May, T; Molina, JM; Padoin, C; Patey, O; Rami, A; Robert, J; Roussillon, C; Tod, M; Veziris, N | 1 |
| Shelton, JD | 1 |
| Bugnon, O; Cavassini, M; Fayet Mello, A; Locatelli, I; Parienti, JJ; Rotzinger, A; Schneider, MP | 1 |
| Bedell, R; Garone, D; Joshua, M; Kandionamaso, C; Kwekwesa, A; Mwinjiwa, E; van Oosterhout, JJ; Winata, N | 1 |
| Baldelli, S; Bini, T; Cattaneo, D; Cenderello, G; Cerea, M; Clementi, E; DʼArminio Monforte, A; Gazzaniga, A; Gervasoni, C; Iardino, R; Vimercati, S | 1 |
| Cottrell, M; Dumond, JB; Forrest, A; Francis, O; Hudgens, MG; Malone, S; Mollan, K; Patterson, KB; Prince, HM; Sharpless, NE; Sykes, C; Torrice, C; Trezza, C; Van Dam, C; Wang, R; White, N | 1 |
| Bednasz, C; DiFrancesco, R; Feng, Z; Fischl, MA; Gripshover, BM; Gu, J; Luque, AE; Ma, Q; Morse, GD; Venuto, CS; Zingman, BS | 1 |
| Anunnatsiri, S; Chetchotisakd, P; Mootsikapun, P; Thamrongwonglert, P | 1 |
| Bhakeecheep, S; Bouazza, N; Coeur, SL; Cressey, TR; Homkham, N; Hongsiriwon, S; Ingsrisawang, L; Jourdain, G; Kanjanavanit, S; Ngampiyaskul, C; Salvadori, N; Srirojana, S; Treluyer, JM; Urien, S | 1 |
| Dave, JA; Haas, DW; Levitt, NS; Maartens, G; McIlleron, HM; Sinxadi, PZ; Smith, PJ | 1 |
| Albanese, A; Asmuth, DM; Chun, TW; Deeks, SG; Kashuba, AD; Landay, A; Ma, ZM; Mann, S; Miller, CJ; Moreno, S; Pollard, RB; Sainz, T; Serrano-Villar, S; Siewe, B; Sinclair, E; Somasunderam, A; Troia-Cancio, P; Utay, NS; Wook-Chun, T; Yotter, T | 1 |
| Alfaro, RM; Calderón, MM; Kovacs, JA; Kumar, P; McManus, M; Pau, AK; Penzak, SR | 1 |
| Chu, BC; Coumbis, J; Farr, AM; Johnston, SS; Nkhoma, ET; Rosenblatt, LC; Seekins, D; Villasis-Keever, A | 1 |
| Cai, WP; He, HL; Huang, SB; Ling, XM; Liu, YF; Wang, H; Wang, M; Wang, XC; Wei, FL; Wu, H; Wu, YS; Wu, ZY; Yang, L; Zhang, FJ; Zhang, WW | 1 |
| Abrams, E; Coovadia, A; Dandara, C; Kuhn, L; Patel, F; Pinillos, F; Strehlau, R; Swart, M | 1 |
| Doherty, M; Ford, NP; Hill, AM; Khoo, SH; Pozniak, AL; Vitoria, M | 1 |
| Cluck, D; Durham, SH; Hester, EK; Lewis, P | 1 |
| Kowadisaiburana, B; Manosuthi, W; Suttha, P; Thientong, V; Wiboonchutikul, S | 1 |
| Abu-Hamdan, D; Kaatz, G; Khalil, C; Mohanty, MJ | 1 |
| Gaida, R; Godman, B; Grobler, C; Kotze, T; Truter, I | 1 |
| Berenguer, J; Blanco, JR; Estrada, V; Gómez-Garre, MD; Martínez, E; Masiá, M; Monge, S; Portilla, J; Sobrino, P; Viladés, C | 1 |
| Buclin, T; Bugnon, O; Cavassini, M; Csajka, C; Fuchs, A; Rotzinger, A; Schneider, MP | 1 |
| Cohen, K; Dave, JA; Hislop, M; Karamchand, S; Leisegang, R; Levitt, NS; Maartens, G; Schomaker, M; Walters, L | 1 |
| Gogela, N; Maughan, D; Meintjes, G; Setshedi, M; Sonderup, MW; Spearman, W; Wainwright, H | 1 |
| Bowman, VQ; Daar, ES; Diamond, C; Dube, MP; Goicoechea, M; Haubrich, RH; Jain, S; Karris, MY; Kemper, C; Kerkar, S; Morris, S; Rieg, G; Sun, X | 1 |
| Barber, X; Gutiérrez, F; Lidón, F; Masiá, M; Padilla, S; Sanchis, M; Terol, G | 1 |
| Agan, BK; Akers, K; Deiss, RG; Farmer, A; Ganesan, A; O'Bryan, TA; Okulicz, JF; Wang, X | 1 |
| Dickinson, L; Owen, A; Siccardi, M | 1 |
| Aklillu, E; Bisaso, RK; Gustafsson, LL; Mukonzo, JK; Ogwal-Okeng, J; Owen, JS | 1 |
| Bertz, R; Chapel, S; Cirincione, B; Luo, M; Roy, A; Savant, I; Sevinsky, H | 1 |
| Agaba, P; Agbaji, O; Ojeh, V; Osaigbovo, G; Shehu, NY | 1 |
| Arnedo, M; Asensi, V; Cruceta, A; del Rio, L; Domingo, P; Estrada, V; Fontdevila, J; Gatell, JM; Imaz, A; Lonca, M; Martínez, E; Miralles, C; Montero, M; Perez, I; Rojas, J | 1 |
| Bienczak, A; Burger, D; Cook, A; Denti, P; Gibb, DM; Kekitiinwa, A; Kityo, C; McIlleron, H; Mulenga, V; Walker, AS; Wiesner, L | 1 |
| Armién, B; Arteaga, G; Ávila-Ríos, S; Bautista, CT; Bello, G; Castillo Mewa, J; García-Morales, C; Martínez, AA; Mendoza, Y; Pascale, JM; Reyes-Terán, G; Sosa, N; Tapia-Trejo, D; Zaldívar, Y | 1 |
| Avihingsanon, A; Mekprasan, S; Ohata, PJ; Putcharoen, O; Ruxrungtham, K; Sirivichayakul, S; Teeranaipong, P | 1 |
| Cheng, X; Fraenkel, L; Han, Y; Hsieh, E; Insogna, KL; Li, T; Xia, W; Yin, MT; Zhu, T | 1 |
| Aderaye, G; Aklillu, E; Amogne, W; Bertilsson, L; Burhenne, J; Habtewold, A; Makonnen, E; Owen, JS; Yimer, G | 1 |
| Asboe, D; Boffito, M; Jones, R; Kabagambe, S; Lim, C; McFaul, K; Nwokolo, N; Pozniak, A; Sonecha, S | 1 |
| Amdani, SM; Chen, Z; Dalwadi, DA; Huang, RQ; Kim, S; Schetz, JA | 1 |
| Bangsberg, D; Bienczak, A; Cohen, K; Denti, P; Maartens, G; Orrell, C; Wood, R | 1 |
| Amaral, E; Bahamondes, L; Bahamondes, MV; Brito, MB; Duarte, G; Ferriani, RA; Prandini, TR; Quintana, SM; Ragazini, CS; Vieira, CS | 1 |
| Yunihastuti, E | 1 |
| Cavadas, C; Costa, S; do Céu Sousa, M; Machado, M | 1 |
| Abebe, W; Amogne, W; Caulk, AW; Eckard, AR; Gleason, RL; Rosebush, JC; Schwartz, MH; Seifu, D; Shapiro, AM | 1 |
| Hui, KH; Lam, TN; Lee, SS | 1 |
| Castelnuovo, B; Kambugu, A; Kamya, M; Kiragga, A; Mubiru, F; Reynolds, SJ | 1 |
| Belyhun, Y; Liebert, UG; Maier, M | 1 |
| Babiker, A; Bernays, S; Butler, K; Choudhury, R; Ford, D; Gibb, D; Harper, L; Inshaw, J; Kenny, J; Klein, N; Nastouli, E; Paparini, S; Rhodes, T; Scott, K; Turkova, A | 1 |
| Arpadi, SM; Coovadia, A; Kaufman, JJ; Kuhn, L; Mbete, N; McMahon, DJ; Patel, F; Shiau, S; Strehlau, R; Yin, MT | 1 |
| Amici, R; Andreotti, M; Buonomo, E; Floridia, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Mancinelli, S; Marazzi, MC; Palombi, L; Sagno, JB; Scarcella, P; Vella, S | 1 |
| Cohen, K; Maartens, G; Mouton, JP | 1 |
| Antunes, AM; Caixas, U; Correia, MJ; Diogo, LN; Grilo, NM; Harjivan, SG; Marques, MM; Monteiro, EC; Pereira, SA; Sequeira, C | 1 |
| Aklillu, E; Bertilsson, L; Burhenne, J; Diczfalusy, U; Habtewold, A; Makonnen, E; Nylén, H; Yimer, G | 1 |
| Burger, DM; de Mast, Q; Homberg, JR; Schellekens, AFA; Van de Wijer, L; van der Ven, AJAM | 1 |
| Orikiiriza, JT | 1 |
| Beanland, R; Doherty, M; Lackey, M; Li, H; Ma, Q; Ma, W; Marley, G; Renaud, F; Tucker, JD; Vitoria, M; Wei, C | 1 |
| Chen, H; Guo, W; Huang, J; Jiang, J; Liang, B; Liang, H; Liao, Y; Su, J; Xu, X; Ye, L; Zang, N | 1 |
| Dandara, C; Leutscher, PD; Masimirembwa, C | 1 |
| García-Arieta, A; Gordon, J; Gwaza, L; Leufkens, H; Potthast, H; Stahl, M; Welink, J | 1 |
| Hatz, C; Letang, E; Mapesi, H; Ramírez, A; Tanner, M | 1 |
| Felton-Coleman, A; Fletcher, CV; Owen, A; Podany, AT; Robertson, K; Sandkovsky, U; Swindells, S; Winchester, LC | 1 |
| Moreno, S; Rodgers, AJ; Serrano-Villar, S; Zhou, Y | 1 |
| Ávila-Ríos, S; Casillas-Rodríguez, J; García-Morales, C; Ji, H; León-Juárez, EA; Magis-Rodríguez, C; Matías-Florentino, M; Quiroz-Morales, VS; Reyes-Gopar, H; Reyes-Terán, G; Romero-Mora, KA; Sandstrom, P; Sierra-Madero, J; Tapia-Trejo, D; Uribe-Zuñiga, P; Valenzuela-Lara, M | 1 |
| Bansback, N; Doherty, M; Ford, N; Forrest, JI; Kanters, S; Mills, EJ; Nsanzimana, S; Popoff, E; Socias, ME; Thorlund, K; Vitoria, M | 1 |
| Cope, AB; Crooks, AM; Eron, JJ; Ferrari, G; Fiscus, SA; Gay, CL; Hicks, CB; Kuruc, JD; Margolis, DM; McGee, KS; McKellar, MS; Sebastian, J; Willis, SJ | 1 |
| Cabrera Figueroa, S; Calvo-Boyero, F; Carracedo, A; Cruz, R; Domínguez-Gil Hurlé, A; Porras-Hurtado, L; Rasool, M; Sánchez-Martín, A | 1 |
| Birbal, S; Dheda, M; Ojewole, E; Oosthuizen, F | 1 |
| Amariles, P; Galindo, J; Galindo-Orrego, X; González-Avendaño, S; Hincapié, JA; Mueses-Marín, HF | 1 |
| Dandara, C; Özdemir, V | 1 |
| Horvath, H; Rutherford, GW | 1 |
| Abrams, EJ; Cois, A; McIntyre, JA; Mellins, CA; Myer, L; Petro, G; Phillips, T; Remien, RH | 1 |
| Abach, J; Abongomera, G; Chabala, C; Colebunders, R; Cook, A; Gibb, DM; Kekitiinwa, A; Kityo, C; Lamorde, M; Mulenga, V; Musiime, V; Thomason, M; Walker, AS | 1 |
| Varghese Gupta, S; Vo, TT | 1 |
| Alioni, S; Izudi, J; Kerukadho, E; Ndungutse, D | 1 |
| Bienczak, A; Bouazza, N; Burger, D; Capparelli, EV; Cressey, TR; Denti, P; Foissac, F; Lallemant, M; McIlleron, H; Penazzato, M; Treluyer, JM; Urien, S | 1 |
| Bedimo, R; Myers, J; Rosenblatt, L | 1 |
| Brophy, JC; Chan, AK; Hawkes, MT; Mateyu, G; Mwinjiwa, E; Sodhi, SK | 1 |
| Akula, SM; Artola, RT; Barone Gibbs, B; Bielke, LR; Bironaitė, D; Bogomolovas, J; Bukelskienė, V; Burke, LE; Chen, B; Chen, D; Chen, WJ; Cook, FJ; Cook, PP; Cotutiu, P; Cui, Y; Davis, KK; Dumitras, DE; El-Sayed, MA; Grabauskienė, V; Gretz, N; Gupta, R; Hargis, BM; Heck, C; Hernandez-Velasco, X; Huang, W; Huete-Ortega, M; Jakicic, JM; Jian, J; Jiang, K; Jiang, M; Jiang, Q; Jin, T; Kiuchi, M; Kovacs, SJ; Labeit, D; Labeit, S; Lang, W; Lang, XY; Latorre, JD; Li, HF; Li, J; Li, YQ; Lin, H; Lin, X; Liu, BT; Liu, M; Longworth, J; Lu, JB; Luo, C; Mahmoud, MA; Marx, A; Menconi, A; Mihos, CG; Muresan, D; Notter, RH; Pant, B; Petrisor, FM; Podkopajev, A; Popp, RA; Portzer, LA; Pradhan, S; Qian, G; Ranjit, M; Regmi, T; Rinkūnaitė, I; Rogers, RJ; Rotar, IC; Sakurai, H; Santana, O; Schwan, AL; Shi, XM; Shkoor, MG; Šimoliūnas, E; Smalinskaitė, L; Stamatian, F; Stang, AT; Tellez, G; Vaidyanathan, S; Vicente, JL; Walker, LR; Walther, FJ; Wan, Y; Wang, H; Wang, X; Wang, Z; Weis, CA; Wen, Z; Wolfenden, AD; Wolfenden, RE; Wright, PC; Wu, D; Xing, H; Xiong, X; Yang, H; Yang, Y; Yu, Q; Yue, D; Zang, Q; Zhang, L; Zhao, B; Zheng, Y; Zhou, L; Zhou, M; Zhuge, F | 1 |
| Dudley, D; Fernandes, JC; Gonçalves, GS; Keiko Toma, H; L Machado, S; O'Connor, D; Tanuri, A | 1 |
| Asari, V; Baxter, C; Garrett, N; Grobler, A; Karim, QA; Karim, SSA; Majola, N; Naicker, N; Naidoo, A; Werner, L | 1 |
| Blockman, M; Chisholm, B; Cohen, K; Maartens, G; Njuguna, C; Stewart, A; Swart, A; Uys, A | 1 |
| Bonczkowski, P; Borch, A; De Scheerder, MA; De Spiegelaere, W; Koenig, R; Malatinkova, E; Melkova, Z; Vandekerckhove, L | 1 |
| Clumeck, N; de Oliveira, T; Gregson, J; Gupta, RK; Hamers, RL; Hoffmann, CJ; Hunt, G; Kaleebu, P; Kanki, P; Kantor, R; Kerschberger, B; Lockman, S; Marconi, VC; Ndembi, N; Pillay, D; Raizes, E; Shafer, RW; van Vuuren, C; Yang, C | 1 |
| Kondapi, AK; Kumar, P; Lakshmi, YS | 1 |
| Irlam, JH; Mbuagbaw, L; Mursleen, S; Rutherford, GW; Siegfried, N; Spaulding, AB | 1 |
| Baza, MB; Castilla, J; Del Romero, J; Hernando, V; Jerónimo, A; Río, I; Rodriguez, C; Vera, M | 1 |
| Bertrand, L; Dygert, L; Toborek, M | 1 |
| Kim, SW; Skordis-Worrall, J | 1 |
| Castelnuovo, B; Fehr, J; Kambugu, A; Magambo, B; Scherrer, AU; Sekaggya-Wiltshire, C; von Braun, A | 1 |
| Garner, W; Kulkarni, R; Miller, MD; Porter, DP; White, KL | 1 |
| Chêne, G; Gallien, S; Journot, V; Loriot, MA; Molina, JM; Morlat, P; Reliquet, V; Reynes, J; Sauvageon, H | 1 |
| Bentley, TGK; Broder, MS; Chang, E; Myers, J; Papoyan, E; Reddy, SR; Rosenblatt, L | 1 |
| Naidoo, P; Soorju, V | 1 |
| Chi, BH; Chilengi, R; Davies, MA; Egger, M; Hoffmann, CJ; Mulenga, LB; Saag, MS; Sinkala, E; Vinikoor, MJ; Wandeler, G; Zyambo, Z | 1 |
| Adamson, J; Chirehwa, M; Denti, P; Essack, S; Govender, K; Kimba-Phongi, E; McIlleron, H; Naidoo, A; Naidoo, K; Padayatchi, N; Yende-Zuma, N | 1 |
| Aweeka, FT; Chamankhah, N; Dorsey, G; Havlir, D; Huang, L; Jagannathan, P; Kajubi, R; Kakuru, A; Kamya, M; Koss, CA; Mwebaza, N; Rosenthal, PJ; Ruel, T; Were, M | 1 |
| Back, DJ; Byakika-Kibwika, P; Darin, KM; Lamorde, M; Merry, C; Neary, M; Olagunju, A; Owen, A; Scarsi, KK; Siccardi, M | 1 |
| Boulle, A; Cohen, K; Davies, MA; de Waal, R; Fortuin-de Smidt, M; Igumbor, EU; Maartens, G; Stinson, K; Technau, KG | 1 |
| Bernays, S; Gibb, D; Namukwaya Kihika, S; Paparini, S; Rhodes, T; Seeley, J | 1 |
| Burger, D; Havenith, T; Oude Lashof, A; Schippers, J; Visschers, MJ | 1 |
| Anderson, KN; Blamire, A; Chadwick, TJ; Hynes, AM; Parikh, J; Payne, B; Price, DA; Qian, J; Wilkinson, J | 1 |
| Antônio Gomes de Arruda, É; de Oliveira Rodrigues, R; Farias Ribeiro, I; Fernandes Ribeiro da Silva, S; Germano de Carvalho, P; Helena Barem Rabenhorst, S; Luri Sasahara, G; Mabel Ferreira Vasconcelos, L; Tiemi Nagao-Dias, A | 1 |
| Cao, H; Cheng, A; Crofoot, G; de Wet, J; DeJesus, E; LaMarca, A; Liu, Y; Martorell, CT; Mills, A; Molina, JM; Porter, D; Post, FA; Quirk, E; Ramgopal, M; Ruane, P; SenGupta, D; Stellbrink, HJ; Valero, IP | 1 |
| Blaylock, JM; Hartzell, JD; Morgan, MK | 1 |
| de Beaudrap, P; Delaporte, E; Etard, JF; Girard, PM; Guèye, FN; Guèye, M; Landman, R; Ndoye, I; Sow, PS | 1 |
| Basseila, GB; Bokilo, AD; Dokekias, AE; Galiba, FO; Malanda, F; Nsitou, MB; Ntsimba, P | 1 |
| Chhneang, V; Fernandez, M; Laureillard, D; Moeung, S; Ngeth, C; Piketty, C; Prak, N; Quillet, C; Riel, V; Song, S | 1 |
| de Groot-Mijnes, JD; Rothova, A; Schneider, M | 1 |
| Chearskul, P; Chearskul, S; Chokephaibulkit, K; Lapphra, K; Phongsamart, W; Prasitsuebsai, W; Vanprapar, N | 1 |
| Alpert, P; Amodio-Groton, M; Caswell, N; Saberi, P | 1 |
| Bain, AM; Bedimo, R; Busti, AJ; Eaton, SA; Nguyen, ST; Payne, KD; Rahman, AP | 1 |
| Bain, AM; Busti, AJ; Rahman, AP; Rutherford, WS; White, EA | 1 |
| Arendt, V; Gras, A; Karasi-Omes, C; Mujawamariwa, A; Ndayisaba, G; Ndimubanzi, PC; Peltier, A; Schneider, S; Wennig, R | 1 |
| Chuturgoon, AA; Dawood, H; Karamchand, L | 1 |
| Balakrishnan, P; Kumarasamy, N; Murugavel, KG; Priya, B; Saghayam, S; Shankar, EM; Solomon, S; Sundaram, M; Venkatesh, KK | 1 |
| Best, BM; Goicoechea, M | 1 |
| Breidinger, SA; Chen, J; Friedman, EJ; Gottesdiener, KM; Iwamoto, M; Kost, JT; Lasseter, KC; Stek, JE; Stone, JA; Teppler, H; Wagner, JA; Wenning, LA | 1 |
| Alfaro, RM; Busse, KH; Formentini, E; Kovacs, JA; Penzak, SR | 1 |
| Clotet, B; Llibre, JM; Moltó, J; Paredes, R; Puig, T; Ruiz, L; Santos, JR | 1 |
| Kwara, A; Nijhawan, AE; Venna, N; Zachary, KC | 1 |
| Branco, T; Caixas, U; Germano, I; Lampreia, F; Monteiro, EC; Papoila, AL; Pereira, SA | 1 |
| Bentata, M; Chêne, G; Collin, F; Garré, M; Goujard, C; Lafaurie, M; Leport, C; Levy, Y; Molina, JM | 1 |
| Casado, JL; Corral, I; Dronda, F; Hernández, B; Moreno, A; Moreno, S; Pérez-Elías, MJ; Quereda, C; Rodríguez-Sagrado, MA | 1 |
| Gibbins, S; Kon, O; O'Donoghue, M; Obiorah, I; Sathia, L; Taylor, G; Walsh, J; Winston, A | 1 |
| Abrahams, M; Boulle, A; Coetzee, D; Cohen, K; Goemaere, E; Hilderbrand, K; Maartens, G; Mathee, S; Van Cutsem, G | 1 |
| Cotter, BR; Currier, JS; Dubé, MP; Fichtenbaum, CJ; Gerschenson, M; Komarow, L; Mitchell, CK; Murphy, RL; Parker, RA; Squires, K; Stein, JH; Torriani, FJ | 1 |
| Amin, J; Avihingsanon, A; Bowden, S; Cooper, DA; Dore, GJ; Lewin, SR; Locarnini, S; Marks, P; Matthews, GV; Petcharapirat, P; Rerknimitr, R; Ruxrungtham, K; Sasadeusz, J | 1 |
| Brück, S; Brust, J; Hartmann, M; Klinker, H; Mosthaf, F; Petzold, D; Procaccianti, M; Rump, JA; Schuster, D; Witte, S | 1 |
| Boamah, I; Boima, V; Court, MH; Greenblatt, DJ; Kenu, E; Kwara, A; Lartey, M; Oliver-Commey, J; Sagoe, A; Sagoe, KW; Xexemeku, F | 1 |
| Jaen, P; Vano-Galvan, S | 1 |
| Schulz, TR; Street, AC | 1 |
| Aberg, JA; King, J | 1 |
| Ajayi, SO; Akingbola, TS; Brown, BJ; Oladokun, R; Omigbodun, OO; Osinusi, K | 1 |
| Andreoni, M; Narciso, P; Nicastri, E | 1 |
| Ainsworth, J; Anderson, J; Back, D; Bansi, L; Dunn, D; Easterbrook, P; Fisher, M; Gibbons, S; Gilson, R; Hill, T; Johnson, M; Khoo, S; Leen, C; Orkin, C; Pillay, D; Pozniak, A; Sabin, C; Stöhr, W; Winston, A | 1 |
| Angels Ribas, M; Asensi, V; Berenguer, J; Domingo, P; Gimeno, JL; González, J; Miralles, P; Pedrol, E; Pérez-Molina, JA; Ribera, E; Santamaría, JM; Santos, J; Terrón, JA | 1 |
| Angel, JB; Fätkenheuer, G; Greaves, W; Hoffmann, C; Horst, H; Landovitz, RJ; Long, J; Opravil, M | 1 |
| Amorosa, V; Cramer, YS; Gupta, SK; Hall, SD; Koletar, SL; Rosenkranz, SL; Szczech, LA | 1 |
| Blok, C; Bonora, S; Booth, C; Garcia-Diaz, A; Geretti, AM; Johnson, M; Lok, CB; Madge, S; Mahungu, T; Owen, A; Tyrer, M | 1 |
| Chaisson, RE; Dowdy, DW; Gallant, JE; Hislop, M; Maartens, G; Nachega, JB; Regensberg, L | 1 |
| Djoerban, Z; Sumantri, S | 1 |
| Beijnen, JH; Bekker, V; Crommentuyn, KM; Huitema, AD; Kuijpers, TW; Scherpbier, HJ; ter Heine, R | 1 |
| Bele, V; Dravid, A; Gupte, N; Joshi, K; Pujari, S | 1 |
| Aplenc, R; Barrett, JS; Bisson, G; Flexner, C; Foulkes, AS; Gross, R; Mosepele, M; Strom, BL; Tenhave, T; Thakur, R | 1 |
| Cosin, J; Crespo, M; Domingo, P; Galindo, MJ; García-Alcalde, ML; Garrido, M; Geijo, P; López-Aldeguer, J; Lozano, F; Muñoz, A; Pedrol, E; Ribera, E; Roca, B; Sánchez, T; Suárez-Lozano, I; Teira, R; Terrón, A; Vergara, A; Viciana, P; Vidal, F; Viladés, C | 1 |
| Cabrera, SE; Cordero, M; Domínguez-Gil, A; García, MJ; Iglesias, A; Valverde, MP | 1 |
| Guhl, C; Heinz, W; Klinker, H; Langmann, P; Leyh, M; Schirmer, D; Weissbrich, B; Winzer, R | 1 |
| Bellido, R; Clotet, B; Darwich, L; Esteve, A; Martinez-Picado, J; Ruiz, L | 1 |
| Burgisser, P; Cavassini, M; Giulieri, SG; Günthard, HF; Knoepfel, SA; Metzner, KJ; Rauch, P; Yerly, S | 1 |
| Acosta, EP; Britto, P; Carey, V; Graham, B; Jean-Philippe, P; King, JR; Kraimer, J; Moye, J; Watson, D; Wiznia, A; Yogev, R | 1 |
| Anitha, S; Gomathi, C; Hemanth Kumar, AK; Kumar, P; Menon, P; Narendran, G; Rajasekaran, S; Ramachandran, G; Ramesh, K; Swaminathan, S | 1 |
| George, C; Jayakumar, B; Lal, L; Yesoda, A | 1 |
| Delsol, E; Gutiérrez, C; Hernández, B; Moreno, S | 1 |
| Pitrak, DL | 1 |
| Ball, C; Gilmour-White, S; Mieli-Vergani, G; Rela, M; Turkova, A | 1 |
| Girard, PM; Lacombe, K; Legrand, J; Meynard, JL; Morand-Joubert, L; Poirier, JM | 1 |
| Gatanaga, H; Oka, S | 1 |
| Hemanth Kumar, AK; Jagan, I; Narendran, G; Padmapriyadarsini, C; Rajasekaran, S; Ramachandran, G; Ramesh, K; Swaminathan, S; Vasantha, M | 1 |
| Eley, BS; Maartens, G; McIlleron, HM; Meyers, TM; Nuttall, JJ; Ren, Y; Smith, PJ | 1 |
| Arab-Alameddine, M; Biollaz, J; Buclin, T; Cavassini, M; Csajka, C; Décosterd, LA; Di Iulio, J; Eap, CB; Fayet, A; Lubomirov, R; Rotger, M; Telenti, A | 1 |
| Bazerman, L; Beckwith, C; Blood, E; Cu-Uvin, S; Mitty, J | 1 |
| Moreno, V; Valencia, ME | 1 |
| Kulsomboon, V; Maleewong, U; Teerawattananon, Y | 1 |
| Kiertiburanakul, S; Malathum, K; Sathapatayavongs, B; Sungkanuparph, S; Watcharananan, S | 1 |
| Sax, PE | 6 |
| Avalos, A; Essex, M; Gaolathe, T; Hughes, MD; Mboya, JJ; Moffat, HJ; Ndwapi, N; Shapiro, RL; Shipton, LK; Stock, S; Thior, I; Wester, CW; Widenfelt, E | 1 |
| Fisac, C; Gatell, JM; Martínez, E; Podzamczer, D; Ribera, E; Virgili, N | 1 |
| Bannister, WP; Beniowski, M; Burger, DM; Castagna, A; Di Perri, G; Karlson, A; Lundgren, JD; Mocroft, A; Molto, J; Peytavin, G; Reiss, P; van Luin, M | 1 |
| Annan, NT; Bower, M; Gazzard, BG; Mandalia, S; Nelson, M; Stebbing, J | 1 |
| Dejesus, E; Ebrahimi, R; Ecker, J; Farajallah, A; Flaherty, JF; Maa, JF; McColl, D; Morales-Ramirez, JO; Reilly, K; Seekins, D; Sloan, L; Ward, DJ; Young, B | 1 |
| Court, MH; Kwara, A; Lartey, M; Rzek, NL; Sagoe, KW | 1 |
| Kanfer, I; Mills, E; Mogatle, S; Skinner, M | 1 |
| Cilliers, K; Donald, PR; Hussey, GD; Labadarios, D; Maritz, JS; McIlleron, H; Schaaf, HS; Smith, P; Willemse, M | 1 |
| Cabié, A; Chêne, G; Girard, PM; Katlama, C; Mercié, P; Michelet, C; Monchecourt, F; Morand-Joubert, L; Pétour, P; Trylesinski, A; Verdon, R | 1 |
| Anastos, K; Bacchetti, P; Benet, LZ; Cohen, M; Gandhi, M; Gange, SJ; Greenblatt, RM; Kalinowski, A; Minkoff, H; Wolfe, AR; Young, M | 1 |
| Butcher, DL; DiRienzo, AG; Garren, KW; Haas, DW; Haubrich, RH; Havlir, DV; Klingman, K; Komarow, L; Mellors, JW; Powderly, WG; Riddler, SA; Rooney, JF | 1 |
| Heckmann, JM; Parker, F; Scott, KM | 1 |
| Borroto-Esoda, K; Harris, J; Lansdon, EB; Miller, MD; O'Neal, W; Svarovskaia, ES; Wakeford, C; Waters, JM; White, KL | 1 |
| Dewar, R; Dybul, M; Kityo, C; Mbamanya, F; Mugyenyi, P; Quinn, TC; Reynolds, SJ; Ssali, F | 1 |
| Blank, A; Burhenne, J; Haefeli, WE; Hartmann, M; Hellstern, V; Matthée, AK; Mikus, G; Schuster, D | 1 |
| Lalloo, UG | 1 |
| Burapatarawong, S; Likanonsakul, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Prasithsirskul, W; Prommool, V; Ruxrungtham, K; Sungkanuparph, S; Tantanathip, P; Thawornwa, U; Thongyen, S | 1 |
| Brinkman, K; Franssen, EJ; Wiegman, DJ | 1 |
| Aurpibul, L; Cressey, TR; Puthanakit, T; Sirisanthana, V; Tanpaiboon, P | 1 |
| Back, DJ; Egan, D; Johnson, MA; Khoo, SH; Mahungu, TW; Nair, D; Owen, A; Smith, CJ; Youle, M | 1 |
| Gompels, M; Powers, V; Ward, J | 1 |
| Bernstein, BM; Brown, TT; da Silva, BA; King, MS; McComsey, GA; Qaqish, RB | 1 |
| Chan, DP; Chan, RC; Cheung, SW; Lee, SS; Liu, ST; To, KW | 1 |
| Ebrahimi, R; Ewan, J; Fisher, M; Kingston, M; Liu, H; Moyle, GJ; Orkin, C; Reilly, G; Shahmanesh, M; Wilkins, E | 1 |
| Arribas López, JR | 1 |
| Gutiérrez-Valencia, A; López-Cortés, LF; Lozano, F; Palacios, R; Rivero, A; Ruiz-Valderas, R; Terrón, A; Viciana, P | 1 |
| Kongnyuy, EJ; Shang, J; Shey, M; Wiysonge, CS | 1 |
| Burger, DM; de Wolf, F; Gras, L; Prins, JM; Richter, C; van der Ende, ME; van Luin, M; Wit, FW | 1 |
| Hanekom, WA; Maartens, G; Meintjes, G; Rangaka, MX; Seldon, R; Wilkinson, KA; Wilkinson, RJ | 1 |
| Cheng, AK; Enejosa, J; Margot, NA; McColl, DJ; Miller, MD | 1 |
| Emery, S; Winston, A | 1 |
| Barnard, RJ; Berger, DS; DeJesus, E; DiNubile, MJ; Lazzarin, A; Leavitt, R; Lennox, JL; Madruga, JV; Miller, MD; Nguyen, BY; Pollard, RB; Rodgers, AJ; Sklar, P; Williams-Diaz, A; Xu, X; Zhao, J | 1 |
| Campbell, H; Crumpacker, CS; Danovich, RM; Gotuzzo, E; Isaacs, RD; Kovacs, C; Markowitz, M; Mendo, F; Morales-Ramirez, JO; Nguyen, BY; Prada, G; Ratanasuwan, W; Strohmaier, KM; Teppler, H; Wan, H | 1 |
| Beauharnais, CA; Dillingham, R; Fitzgerald, DW; Haas, DW; Kashuba, AD; Leger, P; Pape, JW; Rezk, NL | 1 |
| Eampokarap, B; Kaewsaard, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Ruxrungtham, K; Sungkanuparph, S; Suwanvattana, P; Tantanathip, P; Thongyen, S; Uttayamakul, S | 1 |
| Charalombous, S; Churchyard, G; Cohen, K; Dandara, C; Fielding, K; Grant, A; Maartens, G; McIlleron, H; Pemba, L; Smith, P | 1 |
| Pacios, E | 1 |
| Tozzi, V | 1 |
| Maggiolo, F | 3 |
| Carey, D; Emery, S; Goodall, R; Hudson, F; Mallon, P; Mijch, A; Read, TR; Wand, H | 1 |
| Booth, CL; Fox, ZV; Geretti, AM; Heneine, W; Johnson, JA; Johnson, M; Li, JF; Phillips, AN; Smith, CJ | 1 |
| Court, MH; Kenu, E; Kwara, A; Lartey, M; Sagoe, KW | 1 |
| Battegay, M; Bernasconi, E; Bucher, HC; Cavassini, M; Fux, CA; Guenthard, HF; Hirschel, B; Rickenbach, M; Vernazza, P; Young, J | 1 |
| Boccafoglio, F; Concia, E; Gottardi, M; Lanzafame, M; Lattuada, E; Soldani, F | 1 |
| Burrell, CJ; Carr, JM; Daly, L; Green, T; Hart, W; Higgins, G; Li, P; Qiao, M; Ratcliff, R; Shaw, D | 1 |
| Bera, E; Chacko, S; Majeke, B; McCausland, K; Mgudlwa, B; Nonkwelo, R | 1 |
| Cabrera, S; Domínguez-Gil, A; Figueroa, SC; Fuertes, A; Hurléé, AD; Martín, AF; Merino, Mde L; Valverde, MP | 1 |
| Karunaianantham, R; Narayanan, PR; Rajesh, L; Swaminathan, S | 1 |
| Ainsworth, J; Anderson, J; Back, D; Bansi, L; Dunn, D; Easterbrook, P; Fisher, M; Gazzard, B; Gibbons, S; Gilson, R; Hill, T; Johnson, M; Khoo, S; Leen, C; Orkin, C; Pillay, D; Sabin, C; Stöhr, W; Winston, A | 1 |
| Louie, M; Marfatia, S; Mear, I; Meunier, J; Regnault, A; Viala-Danten, M | 1 |
| Bravo, I; Carosi, G; Clotet, B; del Arco, A; Echeverría, P; Gálvez, J; Gómez, JL; López, JC; López-Blazquez, R; Mariño, A; Moreno, A; Negredo, E; Ocampo, A; Pedrol, E; Pérez-Alvarez, N; Portilla, J; Prieto, A; Rubio, R; Viladés, C | 1 |
| Chaubal, M; Dou, H; Gendelman, HE; Graham, S; Kanmogne, G; Kanmogne, M; Ma, Z; McMillan, J; Miller, RL; Mosley, RL; Nowacek, AS; Rabinow, B; Werling, J | 1 |
| Kwara, A; Ramachandran, G; Swaminathan, S | 1 |
| Asahchop, EL; Brenner, BG; Moisi, D; Ntemgwa, M; Toni, TA; Wainberg, MA | 1 |
| Rakhmanina, NY; van den Anker, JN | 1 |
| Batuca, JR; Branco, T; Caixas, U; Delgado-Alves, J; Germano, I; Lampreia, F; Monteiro, EC; Pereira, SA | 1 |
| Belgum, T; Christensen, K; Dash, A; Destache, CJ; Sharma, A; Shibata, A | 1 |
| Chiappetta, DA; Hocht, C; Sosnik, A; Taira, C | 1 |
| Boothby, M; Gathercole, LL; McGee, KC; McTernan, PG; Nightingale, P; Shahmanesh, M; Shojaee-Moradie, F; Tomlinson, JW; Umpleby, AM | 1 |
| Burger, D; Gorowara, M; Hill, A; Ruxrungtham, K | 1 |
| Battegay, M; Bernasconi, E; Cavassini, M; Elzi, L; Furrer, H; Hirschel, B; Ledergerber, B; Marzolini, C; Vernazza, P; Weber, R | 1 |
| Cooper, V; Fisher, M; Gellaitry, G; Horne, R; Lange, AC; Vrijens, B; White, D | 1 |
| Antuna-Puente, B; Belaunzarán-Zamudio, F; Crabtree-Ramírez, B; Gutiérrez-Escolano, F; Juárez-Kasusky, I; Lima, V; Magana-Aquino, M; Méndez, P; Montaner, J; Mosqueda-Gómez, JL; Pérez-Saleme, L; Ramos-Santos, C; Rangel-Frausto, S; Sierra-Madero, J; Soto-Ramírez, LE; Torres-Escobar, I; Villasis-Keever, A | 1 |
| D'Aquila, RT; Fiscus, SA; Giguel, F; Gulick, RM; Johnson, VA; Kuritzkes, DR; Lalama, CM; Meyer, WA; Paredes, R; Ribaudo, HJ; Schackman, BR; Shikuma, C | 1 |
| Boltz, VF; Coffin, JM; Halvas, EK; Hammer, SM; Kearney, M; Mellors, JW; Nissley, D; Palmer, S; Vaida, F; Wantman, M; Wiegand, A | 1 |
| Clumeck, N; Coakley, E; Cooper, DA; Dejesus, E; Goodrich, J; Hackman, F; Heera, J; Horban, A; Ive, P; Mayer, H; Mingrone, H; Mohapi, L; Reeves, JD; Reyes-Teran, G; Saag, M; Sullivan, J; Tawadrous, M; Ting, N; Van Der Ryst, E; Walmsley, S; Westby, M | 1 |
| Dejesus, E; Ebrahimi, R; Ecker, J; Esker, S; Farajallah, A; Flaherty, JF; Grimm, K; Hodder, SL; Mounzer, K | 1 |
| Chiappetta, DA; Hocht, C; Sosnik, A | 1 |
| Airoldi, M; Cossarizza, A; De Biasi, S; Gibellini, L; Maggiolo, F; Mussini, C; Nasi, M; Pinti, M; Ravasio, V; Roat, E; Suter, F | 1 |
| de Souza, DF; Diaz, RS; Inocencio, LA; Janini, LM; Munerato, P; Oliveros, MP; Pereira, AA; Sucupira, MC | 1 |
| Gabiano, C; Giacomet, V; Manfredini, V; Marinacci, F; Mignone, F; Mora, S; Stucchi, S; Viganò, A; Zuccotti, G | 1 |
| Campo, RE; Cohen, C; Grimm, K; Maa, J; Seekins, D; Shangguan, T | 1 |
| Bartlett, JA; Crump, JA; Cunningham, CK; Emmett, SD; Kinabo, GD; Mmbaga, BT; Reddy, EA; Schimana, W; Swai, ME | 1 |
| Anderson, A; Gendelman, HE; McMillan, J; Miller, R; Nowacek, AS; Rabinow, B | 1 |
| Burger, DM; Faraj, D; Gelinck, L; Kroon, F; Kuks, PF; Richter, C; Van der Ende, ME; Van der Ven, A; van Luin, M; Van Schaik, RH; Visser, M; Wit, FW | 1 |
| Deshpande, A; Fleury, HJ; Jeannot, AC; Pinson, P; Schrive, MH; Wittkop, L | 1 |
| Chassany, O; Costagliola, D; Lavignon, M; Potard, V; Spire, B | 1 |
| Bacheler, L; Demeter, LM; Deriziotis, K; Dykes, C; Liang, H; Wang, J; Wu, H | 1 |
| Barnard, RJ; Berger, DS; Dejesus, E; Dinubile, MJ; Gilbert, CL; Lazzarin, A; Leavitt, R; Lennox, JL; Miller, MD; Nguyen, BY; Pollard, RB; Ramalho Madruga, JV; Rodgers, AJ; Sklar, P; Teppler, H; Wan, H; Zhao, J | 1 |
| Boussetta, A; Elloumi, H; Gaha, N; Ghachem, R; Ghazali, I; Zalila, H | 1 |
| Dickinson, L; Gibb, DM; Gilks, CF; Kayiwa, J; Khoo, S; Kityo, C; Lutwama, F; Munderi, P; Nalumenya, R; Reid, A; Ssali, F; Tumukunde, D; Walker, AS | 1 |
| Branco, T; Cavassini, M; Domingo, P; Fisher, M; Givens, N; Khuong-Josses, MA; Lim, ML; Moyle, GJ; Norden, AG; Pearce, HC; Podzamczer, D; Post, FA; Rieger, A; Stellbrink, HJ; Vavro, C | 1 |
| Coquerel, A; Parienti, JJ; Peytavin, G; Reliquet, V; Verdon, R | 1 |
| Cabrera Figueroa, S; Cordero Sánchez, M; de la Paz Valverde Merino, M; Domínguez-Gil Hurlé, A; Iglesias Gómez, A; Sánchez Martín, A | 1 |
| Andreotti, M; Bucciardini, R; Fragola, V; Galluzzo, C; Giuliano, M; Marchei, E; Palmisano, L; Pellegrini, M; Pichini, S; Pirillo, M; Vella, S; Weimer, L | 1 |
| Andersson, LM; Andersson, O; Edén, A; Flamholc, L; Gisslén, M; Josephson, F; Nilsson, S; Ormaasen, V; Säll, C; Sönnerborg, A; Svedhem, V; Tunbäck, P | 1 |
| Holmes, SP; Reuman, EC; Rhee, SY; Shafer, RW | 1 |
| Calmy, A; Ford, N; Frigati, L; Kranzer, K; Medu, L; Mills, EJ; Mofenson, L | 1 |
| Alonso-Villaverde, C; Aragonès, G; Beltrán-Debón, R; Camps, J; Fernández-Sender, L; Joven, J; Rodríguez-Sanabria, F; Rull, A | 1 |
| Bichet, JC; Delfraissy, JF; Ghosn, J; Sahali, S | 1 |
| Gous, H; Kruger, HS; Meyers, TM; Rheeders, M; Riddick, A; Viljoen, M | 1 |
| Butler, DM; Chantratita, W; Manosuthi, W; Richman, DD; Smith, DM; Sukasem, C | 1 |
| Behrens, G; Ho, NA; Schmidt, RE | 1 |
| Bardin, C; Blanche, S; Bouazza, N; Diagbouga, S; Hien, H; Hirt, D; Msellati, P; Nacro, B; Ouiminga, A; Rouet, F; Tréluyer, JM; Urien, S; Van De Perre, P; Zoure, E | 1 |
| Brown, TT; McComsey, GA | 1 |
| Cotich, KL; Freedberg, KA; Goldie, SJ; Hsu, HE; Losina, E; Lu, Z; Rydzak, CE; Sax, PE; Walensky, RP; Wang, B | 1 |
| Burger, DM; Gelinck, LB | 1 |
| Decha, P; Hannongbua, S; Intharathep, P; Parasuk, V; Sompornpisut, P; Udommaneethanakit, T; Wolschann, P | 1 |
| Childs, K; Ibrahim, F; Moniz, CF; Post, FA; Poulton, M; Taylor, CB; Welz, T | 1 |
| Chen, J; Li, L; Lu, H; Ma, Q; Sun, F; Sun, J; Wang, Z; Yao, Y; Zhang, L | 1 |
| Carr, DF; Cortes, CP; la Porte, CJ; Owen, A; Pirmohamed, M | 1 |
| Bosch, M; Brouwer, AM; Burger, D; Dofferhoff, T; Keuter, M; Koopmans, PP; van der Ven, A; van Luin, M | 1 |
| Acosta, EP; Clifford, D; Eichelbaum, M; Gulick, RM; Haas, DW; Liu, H; Morse, GD; Motsinger-Reif, AA; Ribaudo, HJ; Ritchie, MD; Robbins, GK; Schaeffeler, E; Schwab, M; Zanger, UM | 1 |
| Bustos Bernal, C; Cabrera Figueroa, S; Domínguez-Gil Hurlé, A; Fernández de Gatta, M; García Sánchez, MJ; Hernández García, L; Sepúlveda Correa, R | 1 |
| Gerstoft, J; Hansen, AB; Nielsen, H; Obel, N; Pedersen, C | 1 |
| Avihingsanon, A; Belloso, WH; Boesecke, C; Cooper, DA; Duncombe, C; Emery, S; Gazzard, B; Li, L; Molina, JM; Petoumenos, K; Puls, RL; Srasuebkul, P | 1 |
| Descamps, D; Descamps, V; Desnoyer, A; Kaied, FA; Le Beller, C; Peytavin, G; Yeni, P | 1 |
| Fätkenheuer, G; Gatell, J; Katlama, C; Ledergerber, B; Lundgren, JD; Mocroft, A; Parczewski, M; Reekie, J; Reiss, P; Sedlacek, D | 1 |
| Benhamou, Y; Bricaire, F; Dominguez, S; Ghosn, J; Guiguet, M; Katlama, C; Murphy, R; Peytavin, G; Tubiana, R; Valantin, MA | 1 |
| Aba, YT; Aoussi, EF; Bissagnene, E; Eholié, SP; Ehui, E; Kadio, A; Kakou, AR; Kassi, A; Ondounda, M; Ouattara, I; Tanon, A | 1 |
| Lindfelt, T; O'Brien, J; Patel, R; Song, JC; Winslow, DL | 1 |
| Elens, L; Haufroid, V; Lison, D; Vandercam, B; Wallemacq, P; Yombi, JC | 1 |
| Castelnuovo, B; Kamya, MR; Kiragga, A; Manabe, Y | 1 |
| Bastow, B; Glesby, MJ; Gulick, RM; Kuritzkes, DR; Meyer, WA; Ribaudo, HJ; Shikuma, CM; Tashima, KT; Zheng, Y | 1 |
| Cromarty, D; Rheeders, M; Theron, A; Viljoen, M | 1 |
| Aklillu, E; Burhenne, J; Haefeli, WE; Janabi, M; Minzi, OM; Mugusi, F; Mugusi, S; Ngaimisi, E; Riedel, KD; Sasi, P; Suda, A; Ueda, N | 1 |
| Bachani, D; Chan, PL; Deshpande, A; Rajasekaran, S; Rewari, BB; Srikantiah, P | 1 |
| Rutherford, GW; Siegfried, N; Spaulding, A | 1 |
| Eason, J; Funderburg, N; Goodrich, J; Heera, J; Kalinowska, M; Lederman, MM; Mayer, H; Rajicic, N; Valdez, H | 1 |
| Andrews, S; Holt, DW; Jamshidi, Y; McKeown, DA; Moreton, M; Nithiyananthan, T; Sadiq, ST; Tinworth, L | 1 |
| Chêne, G; Gallien, S; Journot, V; Leclercq, P; Molina, JM; Morlat, P; Poizot-Martin, I; Reliquet, V; Reynes, J; Rozenbaum, W; Simon, F; Yéni, P | 1 |
| Gauggel, S; Sütterlin, S; Vögele, C | 1 |
| Bangsberg, DR; Deeks, SG; Monk, A; Ragland, K | 1 |
| Kumar, AK; Ramachandran, G; Shah, I; Swaminathan, S; Vasantha, M | 1 |
| Batard, ML; Martinot, M; Roth, B; Springinsfeld, G; Tortel, MC | 1 |
| Bernasconi, E; Calmy, A; Cavassini, M; Delhumeau, C; Elzi, L; Fayet-Mello, A; Genné, D; Hirschel, B; Mercier, IK; Nguyen, A; Rauch, A | 1 |
| Hanke, CW; Tierney, EP | 1 |
| Amani-Bosse, C; Anglaret, X; Coffie, PA; Dabis, F; Danel, C; Eholié, SP; Ekouevi, DK; Messou, E; Moh, R; Ouattara, E; Sissoko, M | 1 |
| Delaporte, E; Diouf, A; Etard, JF; Girard, PM; Landman, R; Laurent, C; Molinari, N; Ndoye, I; Ngom Guèye, NF; Sow, PS; Tchatchueng Mbougua, JB | 1 |
| Best, BM; Capparelli, EV; Clifford, DB; Collier, AC; Ellis, R; Gelman, BB; Grant, I; Haubrich, R; Koopmans, PP; Letendre, SL; Mbeo, G; McCutchan, JA; Rossi, SS; Simpson, DM | 1 |
| Fisher, M; Garvey, L; Hadley, W; Higgs, C; Mandalia, S; Nelson, M; Nicola, M; Perry, N; Waters, L; Winston, A | 1 |
| DE Bakker, PI; Grady, BJ; Gulick, RM; Haas, DW; Haubrich, R; McLaren, PJ; Ribaudo, H; Ritchie, MD; Robbins, GK; Torstenson, ES | 1 |
| Giuliano, M; Marazzi, MC; Nielsen-Saines, K; Palombi, L | 1 |
| Adkison, K; Bakeera-Kitaka, S; Burger, D; Gibb, DM; Kekitiinwa, A; Kendall, L; Mugyenyi, P; Musiime, V; Musoke, P; Odongo, F; Snowden, WB; Thomason, M; Walker, AS | 1 |
| Banhegyi, D; Gazzard, B; Hill, A; Marks, S; Nelson, M; Podzamczer, D; Stark, T; Stellbrink, HJ; van Delft, Y; Vingerhoets, J | 1 |
| Irlam, JH; Mbuagbaw, LC; Rutherford, GW; Siegfried, N; Spaulding, A | 1 |
| Borroto-Esoda, K; Goodman, DD; Margot, NA; McColl, DJ; Miller, MD; Svarovskaia, ES; Zhong, L; Zhou, Y | 1 |
| Calvez, V; Flandre, P; Fourati, S; Girard, PM; Haïm-Boukobza, S; Katlama, C; Lavignon, M; Marcelin, AG; Morand-Joubert, L; Sayon, S; Simon, A; Valin, N | 1 |
| Burger, DM; de Wolf, F; Franssen, EJ; Kroon, F; Richter, C; Rigter, IM; Smit, C; van Luin, M; Wit, FW | 1 |
| Alvarez, SM; de Jesús Asencio Montiel, I; Flores, RA; Martínez, JG; Mata Marín, JA | 1 |
| Boima, V; Flanigan, TP; Kenu, E; Kwara, A; Lartey, M; Mingle, JA; Oliver-Commey, J; Sagoe, A; Sagoe, KW; Seshie, M; Wu, H; Xexemeku, F; Yang, H | 1 |
| Dewar, RL; Dlamini, JN; Follmann, DA; Highbarger, HC; Hu, Z; Pau, AK; Somaroo, H | 1 |
| Abrogoua, DP; Aulagner, G; Kablan, BJ; Petit, C | 1 |
| Chen, J; Liu, L; Lu, H; Shen, Y; Sun, J; Yao, Y; Zhang, L; Zhang, R; Zheng, Y | 1 |
| Benson, CA; Bolivar, H; Budhathoki, C; Collier, AC; Daar, ES; Farajallah, A; Fischl, MA; Godfrey, C; Jahed, NC; Katzenstein, D; Mollan, K; Myers, L; Pappa, KA; Patterson, K; Rooney, JF; Sax, PE; Tierney, C; Woodward, WC | 1 |
| León, E; Lozano de León-Naranjo, F; Pérez-Rivera, AÁ; Sáez, P | 1 |
| Brehm, JH; Haubrich, R; Hughes, MD; Lalama, CM; Mellors, JW; Riddler, SA; Sluis-Cremer, N | 1 |
| Bolhaar, MG; Karstaedt, AS | 1 |
| Ashton, M; Mukonzo, J; Rekić, D; Röshammar, D | 1 |
| Chuck, SL; Cohen, C; DeJesus, E; Elion, R; Kearney, BP; Liu, HC; Ramanathan, S; Rashbaum, B; Ruane, P; Shamblaw, D; Warren, DR; Yale, K | 1 |
| Ajana, F; Cortet, B; de la Tribonniere, X; Dubus, S; Legroux-Gérot, I; Melliez, H; Paccou, J; Pasquet, A; Viget, N; Yazdanpanah, Y | 1 |
| Childs, K; Post, FA; Welz, T | 1 |
| Baumann, S; Furrer, H; Fux, CA; Mueller, NJ | 1 |
| Buclin, T; Calmy, A; Cavassini, M; Decosterd, LA; Delhumeau, C; di Iulio, J; Fayet Mello, A; Fleurent, A; Hirschel, B; Schneider, MP; Telenti, A | 1 |
| Burger, DM; Hamers, RL; van den Berk, GE; Welzen, ME | 1 |
| Honda, M; Ishisaka, M; Ishizuka, N; Kimura, S; Oka, S | 1 |
| Cooper, V; Ewan, J; Fisher, M; Horne, R; Liu, HC; Moyle, GJ; Reilly, G | 1 |
| Goforth, HW; Kenedi, CA | 1 |
| Barry, AC; Chu, H; Eron, JJ; Ferrari, G; Fiscus, SA; Gay, CL; Hicks, CB; Kerkau, M; Kuruc, JD; Margolis, DM; Mayo, AJ; McGee, KS; Mfalila, CK; Sebastian, J | 1 |
| Baldonero, E; Bracciale, L; Cauda, R; Ciccarelli, N; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Fanti, I; Silveri, MC; Tamburrini, E | 1 |
| DiFrancesco, R; Fischl, MA; Forrest, A; Gripshover, BM; Luque, AE; Ma, Q; Morse, GD; Venuto, CS; Zingman, BS | 1 |
| Chaddha, U; Goray, A; Kumar, AK; Lala, M; Ramachandran, G; Shah, I; Swaminathan, S; Tayal, S | 1 |
| De Gruttola, V; Stitelman, OM; van der Laan, MJ; Wester, CW | 1 |
| Bernasconi, E; Calmy, A; Cavassini, M; Delhumeau, C; Elzi, L; Hirschel, B; Mello, AF; Mercier, I; Nguyen, A; Rauch, A; Schmid, P | 1 |
| Anh, DT; Bang, ND; Chau, NV; Chau, TT; Chinh, NT; de Jong, M; Dong, DT; Dung, NH; Dung, NT; Farrar, JJ; Hai, NN; Hien, NQ; Hien, TT; Lan, NN; Lan, NT; Mai, NT; Mai, PP; Minh, NH; Phu, NH; Quy, HT; Simmons, CP; Thai, PV; Thoa, NT; Tien, NA; Török, ME; Wolbers, M; Yen, NT | 1 |
| Harvey, C; Leavitt, R; Nguyen, BY; Rockstroh, J; Sklar, P; Strohmaier, K; Teppler, H; Zhao, J | 1 |
| Wepner, U | 1 |
| Warpakowski, A | 2 |
| Daar, ES; Ha, B; Jahed, NC; Kitch, D; McComsey, GA; Melbourne, K; Myers, L; Sax, PE; Tebas, P; Tierney, C | 1 |
| Avancena, P; Hubbard, T; Kitchen, CM; Marsden, MD; Zack, JA | 1 |
| Beauharnais, CA; Dillingham, R; Dupnik, K; Eyma, E; Fitzgerald, D; Guerrant, R; Jennings, S; Kashuba, A; Leger, P; Miller, E; Pape, J; Samie, A | 1 |
| Abrams, EJ; Coovadia, A; Dandara, C; Kuhn, L; Maisel, J; Martens, L; Norman, J; Strehlau, R | 1 |
| Avery, LB; Bakshi, RP; Cao, YJ; Hendrix, CW | 1 |
| Abgrall, S; Bommenel, T; Costagliola, D; Gilquin, J; Katlama, C; Lascaux, AS; Launay, O; Mahamat, A; Martinez, V; Meynard, JL; Pradier, C; Rouveix, E; Simon, A | 1 |
| Acosta, EP; Britto, P; Carey, V; Graham, B; Hazra, R; Jean-Philippe, P; King, JR; Wiznia, A; Yogev, R | 1 |
| Anderson, J; Bansi, LK; Hill, T; Huntington, SE; Newell, ML; Pillay, D; Sabin, CA; Taylor, GP; Thorne, C; Tookey, PA | 1 |
| Cohen, K; Conradie, F; Ive, P; Orrell, C; Sanne, I; Wood, R; Zeinecker, J | 1 |
| Dlamini, J; Hadigan, C; Khabo, P; Kowo, H; Ledwaba, L; Maja, P; Mokhathi, T; Mokwena, N; Orsega, S; Proschan, M; Tsoku, M | 1 |
| Bani-Sadr, F; Carrieri, P; Dabis, F; Lacombe, K; Loko, MA; Morlat, P; Neau, D; Salmon, D; Serfaty, L; Winnock, M | 1 |
| Dewar, RL; Dlamini, JN; Follmann, DA; Highbarger, HC; Hu, Z; Ledwaba, J; Maldarelli, FM; Morris, L; Pau, AK; Sangweni, P; Somaroo, H | 1 |
| Lueangniyomkul, A; Mankhatitham, W; Manosuthi, W | 1 |
| Bower, M; Gazzard, B; Mandalia, S; Nelson, M; Rockwood, N | 1 |
| Kuhn, L; Meyers, TM; Moultrie, H; Yotebieng, M | 1 |
| Aklillu, E; Ashton, M; Gustafsson, LL; Mukonzo, JK; Nanzigu, S; Ogwal-Okeng, J; Rekić, D; Röshammar, D; Waako, P | 1 |
| Alnouti, Y; Bathena, SP; Gautam, N; Gendelman, HE; Huang, J; McMillan, J; Roy, U | 1 |
| Debyser, Z; Desimmie, BA; Schrijvers, R | 1 |
| Bruzzone, B; Callegaro, AP; Di Biagio, A; Maggiolo, F; Nulvesu, L; Rosso, R; Taramasso, L; Viscoli, C | 1 |
| Aklillu, E; Bertilsson, L; Burhenne, J; Haefeli, WE; Janabi, M; Minzi, O; Mugusi, F; Mugusi, S; Ngaimisi, E; Riedel, KD; Sasi, P; Suda, A; Ueda, N | 1 |
| Bambara, RA; Demeter, LM; Dykes, C; Li, D; Liang, H; Lowe, NR; Smith, HM; Wang, J; Wu, H; Zhang, G | 1 |
| Claassen, M; Preiser, W; van der Merwe, L; van Zyl, GU; Zeier, M | 1 |
| Fox, D; Mallon, P; McMahon, G; O'Connor, R | 1 |
| Bánhegyi, D; Bannister, W; Bellido, R; Betancor, G; Bogner, J; Clotet, B; Cozzi-Lepri, A; Gargalianos, P; Kisic, M; Lundgren, J; Martinez-Picado, J; Menéndez-Arias, L; Paredes, R; Pou, C; Puertas, MC | 1 |
| Aderaye, G; Aklillu, E; Amogne, W; Burhenne, J; Habtewold, A; Haefeli, WE; Lindquist, L; Makonnen, E; Riedel, KD; Ueda, N; Worku, A; Yimer, G | 1 |
| Bogner, JR; Castagna, A; Clotet, B; Cozzi-Lepri, A; Kjaer, J; Kronborg, G; Lundgren, JD; Phillips, AN; Von Wyl, V | 1 |
| Barro, M; Diagbouga, S; Diasso, Y; Drabo, A; Foulongne, V; François, R; Hien, A; Hien, H; Michel, S; Msellati, P; Nacro, B; Ouiminga, A; Some, J; Tamboura, H; Van De Perre, P; Yaméogo, S; Zouré, E | 1 |
| Aleixo, AW; Arruda, MB; de M Brindeiro, R; Greco, DB; Martins, AN; Pires, AF; Tanuri, A | 1 |
| Aderaye, G; Aklillu, E; Amogne, W; Burhenne, J; Habtewold, A; Haefeli, WE; Lindquist, L; Makonnen, E; Suda, A; Ueda, N; Worku, A; Yimer, G | 1 |
| Calis, JC; de Wit, TF; Geelen, SP; Sigaloff, KC; van Vugt, M | 1 |
| Castagna, A; Duvivier, C; Gazzard, B; Hill, A; Marks, S; van Delft, Y; Zagler, C | 1 |
| Antunes, MV; Linden, R; Menezes, AM; Poeta, J; Real, L; Ribeiro, JP; Sprinz, E | 1 |
| Bhavani, PK; Dilip, M; Iliayas, S; Menon, PA; Narendran, G; Padmapriyadarsini, C; Ponnuraja, C; Pooranagangadevi, NP; Ramachandran, R; Ramesh Kumar, S; Selvaraju, S; Swaminathan, S; Venkatesan, P | 1 |
| Chapman, D; Dong, WW; Harrigan, PR; Heera, J; James, I; Jensen, MA; Knapp, DJ; Lewis, M; Mo, T; Portsmouth, S; Swenson, LC; Thielen, A; Valdez, H; Woods, CK; Zhong, X | 1 |
| Cabrera, S; Domínguez-Gil, A; Fuertes, A; García, MJ; Sánchez, A; Santos, D; Valverde, MP | 1 |
| Kiyotani, K; Maimbo, M; Masimirembwa, C; Mushiroda, T; Nakamura, Y | 1 |
| Camacho, A; Collado, A; de Los Santos-Gil, I; González-Serrano, M; Macías, J; Merino, D; Mira, JA; Neukam, K; Parra-García, G; Pineda, JA; Rivero, A; Ruiz-Morales, J; Torres-Cornejo, A | 1 |
| Calmy, A; Ford, N; Mofenson, L | 1 |
| Dejesus, E; Dinubile, MJ; Lazzarin, A; Leavitt, R; Lennox, JL; Nguyen, BY; Rockstroh, JK; Rodgers, AJ; Saag, MS; Sklar, P; Teppler, H; Walker, ML; Wan, H; Xu, X; Zhao, J | 1 |
| Balungi, J; Burger, DM; Bwakura-Dangarembizi, M; Ferrier, A; Fillekes, Q; Gibb, DM; Keishanyu, R; Kendall, L; Lutakome, J; Natukunda, E; Walker, AS | 1 |
| Chang, CM; Chen, HT; Chu, WL; Hsieh, LY; Ko, NY; Ko, WC; Lauderale, TL; Lee, HC; Lee, NY; Lin, CC; Lo, HJ; Tseng, FC; Wang, YL; Wu, CJ; Yang, YL | 1 |
| Butcher, DL; Direnzo, G; Garren, KW; Haubrich, RH; Havlir, DV; Klingman, KL; Mellors, JW; Ribaudo, H; Riddler, SA; Rooney, JF | 1 |
| Ashton, M; Ekvall, H; Flamholc, L; Gisslén, M; Ormaasen, V; Röshammar, D; Simonsson, US; Vesterbacka, J; Wallmark, E | 1 |
| González-Duarte, A; Pinales, R; Ramirez, C; Sierra-Madero, J | 1 |
| Albini, L; Bellagamba, R; Calabresi, A; Cesana, BM; Fezza, R; Focà, E; Gotti, D; Guaraldi, G; Izzo, I; Lapadula, G; Maggi, P; Manili, L; Motta, D; Narciso, P; Quiros-Roldan, E; Sighinolfi, L; Torti, C | 1 |
| Agarwal, R; Dubé, MP; Gupta, SK; Mather, KJ; Shen, C | 1 |
| Almond, S; Arribas, JR; Brothers, C; Maggiolo, F; Min, S; Rakhmanova, A; Rockstroh, JK; Song, I; van Lunzen, J; Yeni, P; Young, B | 1 |
| Anwikar, SR; Bandekar, MS; Kshirsagar, NA; Pazare, AP; Smrati, B; Tatke, PA | 1 |
| Ananworanich, J; Bhakeecheep, S; Bowonwattanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Kantipong, P; Klinbuayaem, V; Munsakul, W; Petoumenos, K; Prasithsirikul, W; Ruxrungtham, K; Sirivichayakul, S; Sungkanuparph, S | 1 |
| Giaquinto, C; Penazzato, M | 1 |
| Benachi, A; Karmochkine, M; Leticee, N; Viard, JP; Yamgnane, A | 1 |
| Dandara, C; Gous, H; Karlsson, MO; Meyers, TM; Rheeders, M; Viljoen, M | 1 |
| Boven, K; Clotet, B; Eron, J; Hoogstoel, A; Picchio, G; Rimsky, L; Van Eygen, V; Vingerhoets, J | 1 |
| Best, BM; Bowonwatanuwong, C; Capparelli, E; Cressey, TR; Huo, Y; Mirochnick, M; Neungton, C; Prommas, S; Sirivatanapa, P; Smith, E; Stek, A; Yuthavisuthi, P | 1 |
| Beck, O; Eriksen, J; Gustafsson, LL; Kiguba, R; Lanke, S; Ma, Q; Mahindi, M; Makumbi, F; Morse, GD; Nanzigu, S; Waako, P | 1 |
| Abdool Karim, SS; Botha, JH; Gengiah, TN; Gray, AL; Holford, NH; Naidoo, K | 1 |
| Allen, R; Aweeka, F; Cramer, Y; Dooley, KE; Flexner, C; Gupta, A; Haas, DW; Lizak, P; Park, JG; Qasba, S; Swindells, S; van Heeswijk, R; Wiggins, I | 1 |
| Amzal, B; Buranawanitchakorn, Y; Eiamsirikit, N; Jourdain, G; Lallemant, M; Lertkoonalak, R; McIntosh, K; Mekviwattanawong, S; Ngo-Giang-Huong, N; Sang-a-gad, P; Tansuphasawasdikul, S; Yutthakasemsunt, N | 1 |
| Cartón, JA; Clotet, B; Crespo, M; de Los Santos, I; Domingo, P; Iribarren, JA; Jiménez-Expósito, MJ; Knobel, H; López-Cortés, LF; Macías, J; Mallolas, J; Moreno, S; Neukam, K; Ortega, E; Pineda, JA | 1 |
| Cooper, DA; Duncombe, C; Emery, S; Gill, JM; Kerr, SJ; Li, PC; Puls, R; Taylor-Robinson, SD; Winston, A | 1 |
| Aderaye, G; Aklillu, E; Amogne, W; Burhenne, J; Habtewold, A; Lindquist, L; Makonnen, E; Riedel, KD; Suda, A; Ueda, N; Yimer, G | 1 |
| Ajassa, C; Ceccarelli, G; d'Ettorre, G; Esposito, A; Fantauzzi, A; Floridia, M; Massetti, P; Mezzaroma, I; Pastori, D; Vullo, V | 1 |
| Beck-Sagué, CM; Fernandez, AD; Leonardo-Guerrero, J; Nicholas, SW; Roman-Pouriet, J; Schmidt, NC | 1 |
| Aboulker, JP; Bocquentin, M; Charreau, I; Izopet, J; Marchou, B; Molina, JM; Taburet, AM; Tangre, P; Trancart, S | 1 |
| Durant, J; Duvivier, C; Fätkenheuer, G; Hill, A; Marks, S; Rey, D; Rieger, A; Schmidt, W; van Delft, Y | 1 |
| Manosuthi, W; Wongsawat, J | 1 |
| Bettinger, D; Bouvier-Alias, M; Calvez, V; Cottalorda, J; Delaugerre, C; Descamps, D; Flandre, P; Henquell, C; Izopet, J; Marcelin, AG; Masquelier, B; Morand-Joubert, L; Rogez, S; Ruffault, A; Signori-Schmuck, A; Tamalet, C; Trabaud, MA; Vallet, S | 1 |
| Conradie, F; Fox, M; Ive, P; McIntyre, J; Orrell, C; Papathanasopolous, MA; Sanne, I; Stevens, W; Wallis, CL; Wood, R; Zeinecker, J | 1 |
| Aklillu, E; Bakari, M; Janabi, MY; Lindquist, L; Minzi, OM; Mugusi, FM; Mugusi, SF; Ngaimisi, E; Sandstrom, EG; Sasi, PG | 1 |
| Desta, Z; Hubeny, A; Jia, J; Keiser, M; Kroemer, HK; Lütjohann, D; Marinova, M; Meyer zu Schwabedissen, HE; Modess, C; Mostertz, J; Nassif, A; Ogburn, ET; Oswald, S; Runge, D; Siegmund, W; Ulrich, A | 1 |
| Bessong, PO; Masebe, TM; Meyer, D; Ndip, RN; Nwobegahay, J | 1 |
| Al-Daghri, NM; Boothby, M; Das, S; Gathercole, LL; Harte, AL; McGee, KC; McTernan, PG; Nightingale, P; Shahmanesh, M; Shojaee-Moradie, F; Tomlinson, JW; Tripathi, G; Umpleby, AM | 1 |
| Beijnen, JH; Huitema, AD; Kromdijk, W; Mulder, JW; Rosing, H; Smit, PM | 1 |
| Brigido, LF; Collares, JK; Ferreira, JL; Fonseca, BA; Lanca, AM; Lima, DM; Rodrigues, R | 1 |
| Dudas, K; Dumont, E; Kim, J; Lou, Y; Mayers, D; Pietropaolo, K; Piscitelli, S; St Clair, M; White, S; Zala, C; Zhou, XJ | 1 |
| Duque, V; Meliço-Silvestre, A; Morais, C; Mota, V; Pereira, B; Pereira-Vaz, J; Saraiva-da-Cunha, J | 1 |
| Boven, K; Cahn, P; Clotet, B; Cohen, CJ; Crauwels, H; Fourie, J; Grinsztejn, B; Johnson, MA; Lefebvre, E; Molina, JM; Rimsky, LT; Saag, M; Supparatpinyo, K; Vanveggel, S; Williams, P; Wu, H | 1 |
| Burger, D; Heil, SG; Lindemans, J; Schenk, PW; van der Ende, ME; van der Heiden, I; van Schaik, RH | 1 |
| Kanki, PJ; Shafer, RW; Tang, MW | 1 |
| Agu, KA; Akpoigbe, KJ; Badru, T; Chabikuli, O; Eluwa, GI; Hamelmann, C | 1 |
| Bonora, S; Lanzafame, M; Lattuada, E; Vento, S | 1 |
| Anglaret, X; Chu, J; Danel, C; Eholié, S; Freedberg, KA; Gabillard, D; Hsu, HE; Moh, R; Ouattara, EN; Walensky, RP; Wong, AY | 1 |
| Mofenson, LM; Nachega, JB; Uthman, O | 1 |
| Battegay, M; Bernasconi, E; Bucher, HC; Calmy, A; Cavassini, M; Furrer, H; Fux, CA; Schäfer, J; Vernazza, P; Weber, R; Young, J | 1 |
| Luaengniyomkul, A; Mankhatitham, W; Manosuthi, W | 1 |
| Chantratita, W; Cressey, TR; Jantararoungtong, T; Lallement, M; Pasomsub, E; Prapaithong, P; Srichunrusami, C; Sukasem, C; Tawon, Y | 1 |
| Boer, KR; Burger, DM; Fillekes, Q; Geelen, SP; Kraats, Rv; Malgaz, M; Muganga, N; Mutwa, PR; Tuyishimire, D; van Schaik, RH | 1 |
| Beatty, G; Gruber, VA; Lum, PJ; McCance-Katz, EF; Peters, M; Rainey, PM | 1 |
| Cohen, K; Colebunders, R; Croxford, R; Kenyon, C; Mfolozi, S | 1 |
| Anquetil, D; Deshpande, A; Fleury, HJ; Le Bihan, L; Pinson, PR; Zongo, D | 1 |
| Amaya, G; Arns da Cunha, C; Boven, K; Buelens, A; Clumeck, N; Jayaweera, D; Junod, P; Li, T; Nelson, M; Stevens, M; Tebas, P; Vanveggel, S | 1 |
| Abdollahi, A; Dashti-Khavidaki, S; Etminani-Esfahani, M; Jafari, S; Khalili, H | 1 |
| Chan, K; Kozai, T; Lima, VD; Montaner, JS; Nosyk, B; Wood, E; Zhang, W | 1 |
| Allavena, C; Bernard, J; Billaud, E; Cuzin, L; Delpierre, C; Duvivier, C; Guillot, P; Raffi, F; Rey, D; Viget, N | 1 |
| Ang, BC; Teoh, SC | 1 |
| Edelman, EJ; Gordon, K; Justice, AC; Rodriguez-Barradas, MC | 1 |
| Buscher, A; Giordano, TP; Hartman, C; Kallen, MA | 1 |
| Balamane, M; Fessel, WJ; Katzenstein, DA; Melikian, GL; Shafer, RW; Varghese, V | 1 |
| Goliath, R; Meintjes, G; Seldon, R; Wilkinson, KA; Wilkinson, RJ | 1 |
| Back, D; Dickinson, L; Watson, V; Yilmaz, A | 1 |
| Back, D; Byakika-Kibwika, P; de Vries, PJ; Hanpithakpong, W; Katabira, E; Khoo, S; Lamorde, M; Lindegardh, N; Mayanja-Kizza, H; Mayito, J; Merry, C; Nabukeera, L; Namakula, R; Ntale, M; Pakker, N; Ryan, M; Tarning, J | 1 |
| Shah, I | 1 |
| Sun, YT; Zhang, JC | 1 |
| Dellamonica, P; Di Perri, G; Garraffo, R | 1 |
| Manning, TG | 1 |
| Cheng, AK; Cohen, C; DeJesus, E; Gallant, JE; Kearney, BP; Liu, HC; Mills, A; Quirk, E; Sax, PE; Szwarcberg, J; White, K; Wohl, D; Yale, K; Zhong, L; Zolopa, A | 1 |
| Jaye, A; Oko, F; Okomo, U; Peterson, I; Peterson, K; Togun, T; Townend, J | 1 |
| Black, V; Mehta, S; Rees, H; Schwartz, S; Taha, TE; Venter, WD | 1 |
| Almond, L; Back, D; Boffito, M; Brockmeyer, NH; Csajka, C; Marzolini, C; Owen, A; Schipani, A; Siccardi, M; Wyen, C | 1 |
| Biot, M; Chu, KM; Ford, NP; Manzi, M; Rasschaert, F; Zachariah, R; Zuniga, I | 1 |
| Aklillu, E; Bakari, M; Burhenne, J; Janabi, M; Lindquist, L; Minzi, O; Mugusi, F; Mugusi, S; Ngaimisi, E; Riedel, KD; Sandstrom, E | 1 |
| Krogstad, PA; Marsden, MD; Zack, JA | 1 |
| Bellosillo, N; Berzins, B; Calvez, V; Diallo, F; Fofana, DB; Katile, D; Maiga, AI; Maiga, MY; Marcelin, AG; Murphy, R; Penugonda, S; Sylla, A; Taiwo, B; Tounkara, A; Traore, HA | 1 |
| Akinkuotu, A; Chasela, C; Hosseinipour, MC; Jamieson, DJ; Johnson, DC; King, CC; Kourtis, AP; Maliwichi, M; Moses, A; Mwafongo, A; van der Horst, C | 1 |
| Schafer, JJ; Short, WR | 1 |
| Pommer, P | 1 |
| Back, D; Battegay, M; de Roche, M; Livio, F; Marzolini, C; Siccardi, M; Stoeckle, M | 1 |
| Coombs, RW; Dragavon, JA; Graham, SM; Holte, SE; Krieger, JN; Mandaliya, KN; McClelland, RS; Peshu, NM; Ramko, KM; Sanders, EJ | 1 |
| Borghi, V; Capetti, A; Cicconi, P; Di Biagio, A; Di Giambenedetto, S; Francisci, D; Giacometti, A; Giannarelli, D; Maggiolo, F; Monno, L; Penco, G; Prinapori, R; Sterrantino, G; Zoncada, A | 1 |
| Anastos, K; Aouizerat, B; Bacchetti, P; Cohen, M; Dehovitz, JA; Gandhi, M; Gange, SJ; Greenblatt, RM; Hanson, SC; Huang, Y; Jin, C; Liu, C; Sharp, GB | 1 |
| Aurpibul, L; Chotirosniramit, N; Kosashunhanan, N; Piyamongkol, W; Sugandhavesa, P; Supindham, T; Supparatpinyo, K; Thetket, S | 1 |
| Borderi, M; Calza, L; Colangeli, V; Di Bari, MA; Magistrelli, E; Manfredi, R; Salvadori, C; Trapani, F; Viale, P | 1 |
| Cavassini, M; Cusini, A; Decosterd, LA; Fux, CA; Gaudenz, R; Günthard, HF; Gutmann, C; Hirschel, B; Klimkait, T; Ledergerber, B; Opravil, M; Rohrbach, J; Vernazza, PL; Widmer, N; Yerly, S; Zenger, F | 1 |
| Dubé, MP; Goldman, M; Gupta, SK; Kamendulis, LM; Moe, SM; Shen, C | 1 |
| Belshan, M; Date, AA; Destache, CJ; Goede, M; La Bruzzo, K; Sanford, B; Shibata, A | 1 |
| Aarnoutse, RE; Boeree, MJ; Burger, DM; Fillekes, Q; Kibiki, GS; Kisanga, ER; Kisonga, RM; Mleoh, L; Mtabho, CM; Ndaro, A; Semvua, HH; van den Boogaard, J; van der Ven, A | 1 |
| Cohen, MS; Dumond, JB; Forrest, A; Garonzik, SM; Kashuba, AD; Kendrick, RN; Nicol, MR; Patterson, KB | 1 |
| Llibre, JM; Podzamczer, D | 1 |
| Acosta, EP; Clifford, DB; Daar, ES; Grady, B; Gulick, RM; Haas, DW; Holzinger, ER; McLaren, P; Morse, GD; Ribaudo, HJ; Ritchie, MD; Robbins, GK | 1 |
| Khusmith, S; Likanonsakul, S; Manosuthi, W; Shioda, T; Uttayamakul, S; Wichukchinda, N | 1 |
| Aderaye, G; Aklillu, E; Amogne, W; Bertilsson, L; Burhenne, J; Diczfalusy, U; Habtewold, A; Makonnen, E; Nylén, H; Riedel, KD; Yimer, G | 1 |
| Balamane, M; Bosch, RJ; Collier, AC; Daar, ES; Fischl, MA; Katzenstein, D; Lalama, CM; Mollan, K; Sax, PE; Tierney, C | 1 |
| Allavena, C; Bouquié, R; Dailly, E; Deslandes, G; Jolliet, P; Raffi, F | 1 |
| Cabie, A; Charpentier, C; Chene, G; Colin de Verdiere, N; Descamps, D; Fagard, C; Grondin, C; Joly, V; Raffi, F; Tabuteau, S; Yazdanpanah, Y; Yeni, P | 1 |
| Chersich, M; Fairlie, L; Kuhn, L; Meyers, T; Moultrie, H; Palmer, M | 1 |
| Chaikan, A; Cortes, CP; la Porte, CJ; Owen, A; Siccardi, M; Zhang, G | 1 |
| Chiappetta, DA; Hocht, C; Opezzo, JA; Sosnik, A | 1 |
| Dandara, C; Ramesar, RS; Ren, Y; Smith, P; Swart, M; Whitehorn, H | 1 |
| Ahluwalia, J; Ananworanich, J; Chaithongwongwatthana, S; Gorowara, M; Kriengsinyot, R; Landolt, NK; Lange, JM; Phanuphak, N; Pinyakorn, S; Thammajaruk, N; Thongpaeng, P; Ubolyam, S | 1 |
| Aragones, AM; Cano, SM; Castello, A; Gomez-Arbones, X; Porcel, JM; Puig, T; Schoenenberger, JA | 1 |
| Agbaji, O; Ekong, E; Graham, C; Hawkins, C; Idoko, J; Kanki, P; Meloni, S; Muazu, M; Murphy, R; Nimzing, L; Sankalé, JL; Thio, CL | 1 |
| Collier, AC; Daar, ES; Fichtenbaum, CJ; Fink, H; Gerschenson, M; Kosmiski, L; Libutti, DE; McComsey, GA; O'Riordan, M; Santana, JL; Sax, PE | 1 |
| Boven, K; Cassetti, I; Chetchotisakd, P; Cohen, CJ; Crauwels, H; Lazzarin, A; Li, T; Molina, JM; Orkin, C; Rhame, F; Rimsky, L; Stellbrink, HJ; Vanveggel, S; Williams, P | 1 |
| Blanc, FX; Borand, L; Chou, M; Goldfeld, AE; Laureillard, D; Madec, Y; Marcy, O; Pheng, P; Sok, T; Taburet, AM | 1 |
| Basse, CD; Dia, NM; Dieng, AB; Diop, BM; Diop, SA; Fortes-Déguénonvo, L; Manga, NM; Ndaw, G; Ndour, CT; Seydi, M; Soumaré, M; Sow, PS | 1 |
| Aurpibul, L; Chokephaibulkit, K; Cressey, TR; Lapphra, K; Narkbunnam, T; Oberdorfer, P; Phongsamart, W; Sirisanthana, V; Sudjaritruk, T | 1 |
| Geretti, AM; Hullsiek, KH; Jakobsen, MR; Johnson, JA; Kozal, MJ; Kuritzkes, DR; Li, JZ; Metzner, KJ; Miller, MD; Ostergaard, L; Paredes, R; Ribaudo, HJ; Svarovskaia, ES | 1 |
| Ammara, A; Back, D; Boffito, M; Gazzard, B; Jackson, A; Mohabeer, M; Moyle, G; Tjia, J; Watson, V | 1 |
| Clumeck, N; Molina, JM; Redant, K; Rimsky, L; Stevens, M; Vanveggel, S | 1 |
| Belshan, M; Date, AA; Destache, CJ; Goede, M; McMullen, E; Pham, A; Sanford, B; Shibata, A; Zhou, Y | 1 |
| Avery, LB; Hendrix, CW; McArthur, JC; Sacktor, N | 1 |
| Antinori, A; Boven, K; Clotet, B; Fourie, J; Herrera, G; Hicks, C; Madruga, JV; Mills, AM; Stevens, M; Vanveggel, S | 1 |
| Flexner, C; Lee, LS; Pham, P | 1 |
| Freedberg, KA; Nakamura, YM; Paltiel, AD; Pei, PP; Sax, PE; Schackman, BR; Walensky, RP; Weinstein, MC | 1 |
| Cooper, DA; Craig, C; Goodrich, J; Kaplan, R; Lazzarin, A; Mori, J; Pozniak, A; Pulik, P; Tawadrous, M; Valdez, H; Vernazza, P; Wang, C; Weil, E | 1 |
| Andrieux-Meyer, I; Calmy, A; Ford, N; Hargreaves, S; Mills, EJ; Renaud-Théry, F; Shaffer, N; Shubber, Z; Vitoria, M | 1 |
| Bositis, C; Hamangaba, F; Moss, WJ; Sutcliffe, CG; van Dijk, JH; Watson, DC | 1 |
| Bonafede, M; Correll, T; Hebden, T; Juday, T; Lenhart, G; Pan, K | 1 |
| Chamnanphon, M; Chantratita, W; Jantararoungtong, T; Koomdee, N; Manosuthi, W; Prommas, S; Puangpetch, A; Santon, S; Sukasem, C | 1 |
| Easterbrook, P; Jones, S; Mazhude, C; Murad, S; Taylor, C | 1 |
| Casado, JL; Dronda, F; Hertogs, K; Moreno, A; Moreno, S | 1 |
| Desch, S; Klinker, H; Langmann, P; Schirmer, D; Väth, T; Weissbrich, B; Zilly, M | 1 |
| Ammassari, A; Antinori, A; Cingolani, A; De Luca, A; Di Giambenedetto, S; Forbici, F; Girardi, E; Narciso, P; Perno, CF; Rizzo, MG; Trotta, MP; Zaccarelli, M | 1 |
| Beylot, J; Bonarek, M; Bonnet, F; De Witte, S; Morlat, P | 1 |
| Biasin, M; Clerici, M; Di Pietro, M; Lo Caputo, S; Maserati, R; Mazzotta, F; Ravasi, G; Seminari, E; Trabattoni, D | 1 |
| Cooley, TP; Modest, GA; Zacks, JF | 1 |
| Fessel, WJ; Follansbee, SE; Rego, J | 1 |
| Fuller, A; Mijch, A; Ray, J; Sabato, S; Wesselingh, S | 1 |
| Dusak, BA; Goodwin, SD; Kuritzkes, DR; Rooney, JF; Skowron, G; Squires, KE; Stevens, M; Thompson, MA; Tolson, JM; Yuen, GJ | 1 |
| Brundage, RC; Douglas, SD; Fletcher, CV; Flynn, PM; Kline, MW; Spector, SA; Starr, SE; Yong, FH | 1 |
| Back, DJ; Boffito, M; Bonora, S; Di Perri, G; Hoggard, PG; Reynolds, HE; Tija, J | 1 |
| Parienti, JJ | 1 |
| Bon, I; Borderi, M; Furlini, G; Gibellini, D; La Placa, M; Monari, P; Re, MC; Schiavone, P; Vitone, F | 1 |
| Chemlal, K; de Truchis, P; Devidas, A; Force, G; Mamet, JP; Mechali, D; Praindhui, D; Pulik, M; Rouveix, E; Welker, Y | 1 |
| Cohen, MS; Eron, JJ; Fiscus, SA; Fiske, WD; Gotzkowsky, SK; Kashuba, AD; Kim, JY; Petch, L; Reddy, YS | 1 |
| Carr, A | 2 |
| Castiel, P; Gonzalez-Canali, G; Kazatchkine, MD; Peytavin, G; Piketty, C; Trylezinski, A; Weiss, L | 1 |
| Atwine, D; Kebba, A; Kityo, C; Mwebaze, R; Nakityo, R; Peter, M | 1 |
| Carithers, GB | 1 |
| Bidault, R; Bollens, D; Choudet, N; Demarles, D; Gillotin, C; Goujard, C; Meynard, JL; Rousseau, C; Taburet, AM; Vincent, I | 1 |
| Bernstein, B; Bertz, R; Brun, S; Foit, C; Granneman, GR; Hsu, A; Isaacson, J; Kempf, DJ; King, M; Lam, W; Richards, B; Rode, R; Rynkiewicz, K; Sun, E | 1 |
| Delmas, B; Lochet, P; Lotthé, A; Mauboussin, JM; Peyrière, H; Reynes, J | 1 |
| Biollaz, J; Buclin, T; Csajka, C; Décosterd, LA; Fattinger, K; Fellay, J; Marzolini, C; Telenti, A | 1 |
| Lublin, HK; Poulsen, HD | 1 |
| Alarcón, A; Gómez-Vera, J; López-Cortés, LF; Mata, R; Pachón, J; Ruiz-Valderas, R; Viciana, P | 1 |
| Arnaud, A; Mauboussin, JM; Peyrière, H; Rouanet, I; Vincent, D | 1 |
| Antoniou, T; Park-Wyllie, LY | 1 |
| Alvarez, A; Bhumbra, N; Ma, JF; McComsey, G; Rathore, M | 1 |
| Foti, JL; Piatt, JP | 1 |
| Albrecht, MA; Bacheler, L; Bosch, RJ; Hellmann, N; Katzenstein, DA; Wang, N | 1 |
| Bakshi, KK; Chen, J; Condra, JH; Danovich, RM; DiNubile, MJ; Graham, DJ; Haas, DW; Holder, DJ; Rhodes, RR; Saah, AJ; Shivaprakash, M | 1 |
| Brun, S; Di Mascio, M; Ho, DD; Hogan, C; Hurley, A; Louie, M; Markowitz, M; Perelson, AS; Rooney, J; Ruiz, N; Simon, V; Sun, E | 1 |
| Bell, C; Matthews, GV; Nelson, MR | 1 |
| Desta, Z; Flockhart, DA; Gorski, JC; Hall, SD; Jones, DR; Ward, BA | 1 |
| Barrett, JS; Chai, M; Fiske, WD; Joshi, AS; Ludden, TM; Pieniaszek, HJ | 1 |
| Fulgaro, C; Rosticelli, E; Sabbatani, S | 1 |
| Adorni, F; Bini, T; Bongiovanni, M; Capetti, A; Castelnuovo, B; Chiesa, E; Cicconi, P; d'Arminio Monforte, A; Faggion, I; Melzi, S; Mussini, C; Rizzardini, G; Rusconi, S; Sollima, S; Tordato, F | 1 |
| Pulido, F; Torralba, M | 1 |
| Ait-Khaled, M; Falloon, J; Griffin, P; Rakik, A; Richards, N; Stone, C; Thomas, D; Tisdale, M | 1 |
| Chang, SC; Chen, MY; Deng, SC; Hsiao, CF; Hsieh, SM; Hung, CC; Sheng, WH | 1 |
| Cha, R; DiCenzo, R; Fischl, MA; Forrest, A; Hammer, SM; Morse, GD; Squires, KE; Wu, H | 1 |
| Brault, C; Chennebault, JM; Loison, J; Payan, C; Peigne, M | 1 |
| Calvez, V; Delaugerre, C; Herson, S; Katlama, C; Legrand, M; Marcelin, AG; Paris, L; Peytavin, G; Schneider, L; Simon, A; Tubiana, R; Wirden, M | 1 |
| Antela, A; Casado, JL; Dronda, F; Gutiérrez, C; Moreno, A; Moreno, S; Pérez-Elías, MJ | 1 |
| Dieterich, DT; Kontorinis, N | 1 |
| Alsina, MM; Blanco, JL; Lecha, M; López-Lerma, I | 1 |
| Balderson, K; Shah, MD | 1 |
| Labelle, C; Moreno, A; Samet, JH | 1 |
| Beijnen, JH; Huitema, AD; Kappelhoff, BS; Rosing, H | 1 |
| Pakianathan, MR; Prime, KP; Woolfson, RG | 1 |
| Collier, AC; Dehlinger, M; Demeter, LM; Erice, A; Eron, JJ; Eshleman, SH; Feinberg, JE; Fischl, MA; Giuliano, M; Hammer, SM; Morse, GD; Ribaudo, HJ; Saag, MS; Vella, S | 1 |
| Hamburger, ME; Holmberg, SD; Moorman, AC; Palella, FJ; Wood, KC | 1 |
| Moyle, GJ | 1 |
| Aranda, M; Arnaiz, JA; Cortés, C; Cruceta, A; Dalmau, D; de Lazzari, E; Domingo, P; Force, L; Gatell, JM; Javaloyas, M; Knobel, H; Llibre, JM; Martínez, E; Pedrol, E; Podzamczer, D; Ribera, E; Richart, C; Riera, M; Segura, F | 1 |
| Adonis-Koffy, L; Fassinou, P; N'dja, BB; Timité-Konan, AM | 1 |
| Bossi, P; Bricaire, F; Caumes, E; Katlama, C | 1 |
| Leen, CL | 1 |
| Becker, S; Carlson, M; DeJesus, E; Delehanty, J; DeMasi, R; Haas, FF; Haubrich, R; Henry, D; Lalezari, JP; Northfelt, DW; Powderly, W; Richmond, G; Riddler, S; Salgo, M; Sista, PR; Thompson, M; Valentine, F; Wolfe, P; Wright, D | 1 |
| Boyd, MA; Cooper, DA; Dore, GJ; Duncombe, CJ; Lange, JM; Law, WP; Mahanontharit, A; Phanuphak, P; Ruxrungtham, K | 1 |
| Boyle, BA | 2 |
| Bini, T; Bongiovanni, M; Chiesa, E; d'Arminio Monforte, A; Melzi, S | 1 |
| Back, DJ; Boffito, M; Bonora, S; Di Perri, G; Hoggard, PG; Khoo, SH; Milia, MG; Raiteri, R; Sinicco, A | 1 |
| Fowler, MG; Greenberg, AE; Holmberg, S; Moorman, A; Tong, TC | 1 |
| Arribas, JR | 1 |
| Raffi, F | 1 |
| Amador, C; Benito, C; Ena, J; Fenoll, V; Pasquau, F | 1 |
| Becker, MI; D'Aquila, RT; De Gruttola, V; Delapenha, R; Dubé, MP; Fischl, MA; Gedeon, L; Hirsch, MS; Merigan, TC; Murphy, RL; Pettinelli, C; Pollard, RB; Robbins, GK; Shafer, RW; Smeaton, LM; Snyder, SW; van der Horst, C; Vella, S | 1 |
| D'Aquila, RT; De Gruttola, V; Gripshover, BM; Haubrich, R; Hirsch, MS; Johnson, VA; Kaul, P; Martinez, AI; McCarty, SD; Merigan, TC; Morse, GD; Nokta, MA; Robbins, GK; Shafer, RW; Smeaton, LM; Snyder, SW; Swingle, M; Vella, S | 1 |
| Feinberg, J | 2 |
| Leal, M; Lissen, E; Olivera, M; Rubio, A; Sánchez-Quijano, A; Vallejo, A | 1 |
| Hirschel, B | 1 |
| de la Rosa, R; Heath, KV; Hogg, RS; Lee, N; Montaner, JS; O'Shaughnessy, MV; Wood, E; Yip, B | 1 |
| Kirkpatrick, P; Lebbos, J; Raja, A | 1 |
| Chung, C; He, T; Ho, DD; Hurley, A; Markowitz, M; Perelson, AS; Ramratnam, B; Ribeiro, R; Simon, V; Vanderhoeven, J; Zhang, L | 1 |
| Klinker, H; Langmann, P; Schubert, J; Tollmann, F; Weissbrich, B; Winzer, R; Zilly, M | 1 |
| Carroll, H; Conlon, V; Green, A; Green, DC; Green, R; Jefferson, R; Jordan, WC; Tolbert, L; Yemofio, F | 1 |
| Barreiro, P; del Río, R; Gallego, L; González de Requena, D; González-Lahoz, J; Rodríguez-Albariño, A; Soriano, V | 1 |
| Gazzard, BG; Gotch, F; Hand, J; Imami, N; Nelson, M; Pires, A; Portsmouth, S; Stebbing, J | 1 |
| Braunstein, GD | 1 |
| Holzman, R; Maslow, M; Ortiz, O; Rahim, S | 1 |
| Brundage, RC; Fenton, T; Fletcher, CV; Spector, SA; Starr, SE; Yong, FH | 1 |
| Das, S; Ghanem, M; Huengsberg, M | 1 |
| Chene, G; Lascoux-Combes, C; Molina, JM; Perusat, S; Peytavin, G; Rozenbaum, W; Sereni, D | 1 |
| Manosuthi, W; Rattanasiri, S; Sungkanuparph, S; Thakkinstian, A; Vibhagool, A | 1 |
| Arranz-Caso, JA; Estrada, V; García-Diaz, JD; Gorgolas, M | 1 |
| Calza, L; Chiodo, F; Manfredi, R | 4 |
| Cao, YZ; Feng, X; Jin, X; Li, L; Mei, S; Wei, FL; Yao, J | 1 |
| Averbuch, D; Bar Yaacov, N; Burke, M; Chowers, M; Grossman, Z; Istomin, V; Levi, I; Lorber, M; Risenberg, K; Schapiro, JM | 1 |
| Barrios, A; García-Benayas, T; González-Lahoz, J; Soriano, V | 1 |
| Clotet, B; Ferré, R; Masana, L; Negredo, E; Rey-Joly, C; Ribalta, J; Salazar, J; Sirera, G | 1 |
| Back, D; Fletcher, C; Gazzard, B; Gibbons, S; Mandalia, S; Nelson, M; Parmar, D; Pozniak, A; Smith, N; Winston, A | 1 |
| Baraldi, E; Cahn, P; Cassetti, I; Dam, JP; Gazzard, B; Hassink, E; Horban, A; Johnson, MA; Katlama, C; Lalloo, UG; Lange, JM; Levi, GC; Malan, DR; Miller, S; Mulcahy, F; Murphy, RL; Petit, D; Phanuphak, P; Raffi, F; Reboredo, G; Robinson, P; Ruxrungtham, K; Santos, BR; Squires, K; van der Westhuizen, IP; van Leeuwen, R; van Leth, F; Wit, FW; Wood, R | 1 |
| Arribas, JR; Cepeda, C; Costa, MA; Gatell, JM; González, J; Lonca, M; Lorenzo, A; Miró, JM; Peña, JM; Pulido, F; Rubio, R; Torralba, M; Vázquez, JJ | 1 |
| Acosta, EP; Gulick, RM; Klingman, KL; Kuritzkes, DR; Lustgarten, S; Maher, WE; Meyer, WA; Murphy, RL; Pilcher, CD; Reichman, RC; Ribaudo, HJ; Schackman, BR; Shikuma, CM; Snyder, S; Squires, KE; Witt, MD | 1 |
| Antinori, A; Bellagamba, R; Bonfigli, S; Boumis, E; Carvelli, C; Ceccherini-Silberstein, F; D'Arrigo, R; D'Offizi, G; De Longis, P; Forbici, F; Narciso, P; Perno, CF; Tozzi, V; Trotta, MP; Zaccarelli, M | 1 |
| Bouvet, E; Descamps, D; Larouzé, B; Massari, V; Parienti, JJ; Vabret, A; Verdon, R | 1 |
| Bergshoeff, AS; Burger, DM; de Groot, R; Fraaij, PL; Hartwig, NG; Korn, K; Neubert, J; Niehues, T; Schroten, H; van Rossum, AM | 1 |
| Baseler, M; Beck, I; Coffin, J; Daucher, M; Davey, RT; Dewar, R; Dybul, M; Ehler, L; Fauci, AS; Frenkel, L; Hallahan, CW; Maldarelli, F; Metcalf, JA; Nies-Kraske, E; Palmer, S; Piscitelli, SC; Powers, A; Rock Kress, DM; Weigand, A | 1 |
| Moberg, L; Sönnerborg, A; Ståhle, L; Svensson, JO | 1 |
| Dumoulin, FL; Fätkenheuer, G; Jütte, A; Nischalke, HD; Rockstroh, JK; Salzberger, B; Sauerbruch, T; Spengler, U; Wasmuth, JC | 1 |
| Gatanaga, H; Kikuchi, Y; Kimura, S; Kuwahara, T; Oka, S; Shirasaka, T; Tachikawa, N; Teruya, K; Tsuchiya, K; Yoshino, M | 1 |
| Bower, M; Gazzard, B; Jones, R; Mandalia, S; Michailidis, C; Nelson, M; Sawleshwarkar, S; Stebbing, J; Waters, L | 1 |
| Andrade, A; Flexner, C | 1 |
| Cassol, S; El-Sadr, W; Friedland, G; Jack, C; Karim, QA; Karim, SA; Lalloo, U | 1 |
| Carrieri, P; Garzot, MA; L'henaff, M; Obadia, Y; Spire, B | 1 |
| Meyer-Kleinmann, J | 1 |
| Bordenave, B; Claxton, S; Henry, K; Kane, E; Klebert, M; Powderly, WG; Tebas, P; Yarasheski, K | 1 |
| Delfraissy, JF; Gatell, JM; Giordano, M; Jemsek, J; Lazzarin, A; Pokrovskiy, V; Powderly, WG; Rivero, A; Rozenbaum, W; Schrader, S; Sension, M; Squires, K; Thiry, A; Vibhagool, A | 1 |
| Barry, DW; Borroto-Esoda, K; Cahn, P; Hinkle, J; Molina, JM; Mondou, E; Pearce, D; Powderly, W; Quinn, JB; Raffi, F; Rousseau, F; Saag, MS; Shaw, AL; Wolff, M | 1 |
| Cheng, AK; Coakley, DF; DeJesus, E; Gallant, JE; Lu, B; Miller, MD; Pozniak, AL; Staszewski, S; Suleiman, JM; Toole, JJ | 1 |
| Hamatake, R; Hong, Z; Zhang, Z | 1 |
| De Luca, A; Di Giambenedetto, S | 1 |
| Castillo, SA; DeJesus, E; Farthing, CF; Gough, K; Grinsztejn, B; Madison, SJ; McCarty, D; Schrader, SR; Sension, MG; Shortino, DD; Thomas, DA | 1 |
| Collazos, J; Ibarra, S; Loureiro, M | 1 |
| Maida, I; Nuñez, M; Soriano, V | 1 |
| Albrecht, MA; Bosch, RJ; Katzenstein, DA; Mellors, JW; Shulman, NS | 1 |
| Chiesi, A; Fisher, M; Horban, A; Kirk, O; Ledergerber, B; Lundgren, JD; Machala, L; Mulchany, F; Phillips, AN; Reiss, P | 1 |
| Patel, A; Patel, B; Patel, J; Patel, K; Rani, S; Shah, N | 1 |
| Furue, M | 1 |
| Konishi, M; Maeda, K; Mikasa, K; Murakawa, K; Takahashi, K; Yamashina, Y; Yoshimoto, E | 1 |
| Bresson, JL; Chaix, ML; Ghosn, J; Goujard, C; Katlama, C; Peytavin, G; Rey, E; Rouzioux, C; Tréluyer, JM; Viard, JP | 1 |
| Fernández-Palacin, A; Gómez-Mateos, J; León, EM; Lozano, F; Macías, J; Márquez, M; Mira, JA; Palacios, R; Pineda, JA; Ramayo, E; Santos, J; Terrón, A | 1 |
| Bonny, T; Brand, JD; Brothers, CH; Buendia, CB; Castillo, SA; DeJesus, E; Gerstoft, J; Hernandez, J; Herrera, G; Lanier, ER; Scott, TR; Teofilo, E | 1 |
| Alves, CR; Badaro, R; Brites, C; Netto, EM; Oliveira, AS; Pedral-Sampaio, DB | 1 |
| Fortin, C; Joly, V | 1 |
| Cruttenden, K; DiCenzo, R; Gelbard, H; Morse, G; Peterson, D; Riggs, G; Schifitto, G | 1 |
| Lee, LS; Panchalingam, A; Paton, NI; Yap, MC | 1 |
| Bloch, M; Cahn, P; Gazzard, B; Hall, DB; Horban, A; Kastelein, JJ; Katlama, C; Lange, JM; Murphy, RL; Phanuphak, P; Raffi, F; Reiss, P; Schechter, M; Stroes, E; van Leth, F; Wood, R | 1 |
| Barfod, TS | 1 |
| Conway, B; Fisher, M; Jelaska, A; Lange, JM; Laplumé, H; Martin, D; van Leth, F; Wit, FW | 1 |
| Corral, A; Gallego, O; González de Requena, D; Jiménez-Nácher, I; Soriano, V | 1 |
| Craigo, JK; Ding, M; Gupta, P; Kulka, K; Mellors, J; Montelaro, RC; Paranjpe, S; Patterson, BK | 1 |
| Bower, M; Fisher, M; Gazzard, B; Johnson, M; Jones, R; Mandalia, S; Moyle, G; Nelson, M; Orkin, C; Stebbing, J | 1 |
| Clavel, F; Hance, AJ; Joly, V; Lecossier, D; Morand-Joubert, L; Shafer, RW; Shulman, NS; Zolopa, AR | 1 |
| Gerber, JG; Wyles, DL | 1 |
| Cancio, R; Crespan, E; Hübscher, U; Locatelli, GA; Maga, G; Spadari, S | 1 |
| Boeri, E; Castagna, A; Gallotta, G; Gianotti, N; Maillard, M; Ratti, D; Serra, G; Tremolada, Y; Vacchini, D | 1 |
| Blanco, JL; Gatell, JM; Laguno, M; León, A; Mallolas, J; Martinez, E; Pumarola, T | 1 |
| Bleiber, G; Günthard, HF; Hasse, B; Krause, M | 1 |
| Delgado, J; Shulman, N | 1 |
| Antela, A; Aranzabal, L; Casado, JL; Diz, S; Dronda, F; Hernandez-Ranz, F; Marín, A; Moreno, A; Moreno, L; Moreno, S; Moya, J; Perez-Elias, MJ; Quereda, C | 1 |
| Chene, G; Collin, F; Dellamonica, P; Dupont, B; Fournier, S; Goujard, C; Journot, V; Molina, JM; Morand-Joubert, L; Morlat, P; Palmer, P; Poizot-Martin, I; Rancinan, C; Rozenbaum, W; Yéni, P | 1 |
| Alonso-Villaverde, C; Camps, J; Coll, B; Gómez, F; Joven, J; Masana, L; Parra, S | 1 |
| Brust, J; Hartmann, M; Klinker, H; Mosthaf, F; Petzoldt, D; Procaccianti, M; Rump, JA; Schuster, D | 1 |
| Badaro, R; de Wet, J; Hall, DB; Huisamen, CB; Lange, JM; Montaner, JS; van Leth, F; Vandercam, B; Wit, FW | 1 |
| Havlir, DV; Ignacio, CC; Koelsch, KK; Lu, B; Margot, N; Miller, MD; Strain, MC; Wong, JK | 1 |
| Bary, M; David, F; Gasnault, J; Kerneis, H; Linard, F; Longuet, P; Pelissolo, A; Ravaux, I | 1 |
| Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, J; MacGregor, TR; van Leth, F | 1 |
| Dalmau, D; Ferrer, E; Gatell, JM; Iniguez, D; Knobel, H; Leon, A; Niubo, J; Podzamczer, D; Polo, C; Ruiz, I | 1 |
| Andrews, S; Grinsztejn, B; Lange, JM; Lazanas, MK; Montaner, J; van Leth, F; Wilkins, E | 1 |
| Cahn, P; Castillo, SA; Craig, C; DeJesus, E; Gordon, DN; Moyle, GJ; Scott, TR; Zhao, H | 1 |
| Mallal, S; Nolan, D; Reiss, P | 1 |
| Jaillon, P; Poirier, JM; Robidou, P | 1 |
| Balakrishnan, P; Carpenter, CC; Cecelia, A; Flanigan, TP; Kumarasamy, N; Mayer, KH; Solomon, S; Vallabhaneni, S | 1 |
| Berger, DS; Cohen, CJ; Hernandez, JE; Liao, Q; Pakes, GE; Pobiner, BF; Snidow, JW; Swindells, S; Tashima, KT | 1 |
| Barreiro, P; González-Lahoz, J; Jiménez-Nacher, I; Rendón, A; Rodriguez-Novoa, S; Soriano, V | 1 |
| Lee, J | 1 |
| Corrigan, GE; Crowe, SM; Dunne, AL; Greengrass, VL; Hocking, J; Tachedjian, G; Turnbull, SP | 1 |
| Biollaz, J; Bleiber, G; Buclin, T; Colombo, S; Décosterd, L; Furrer, H; Keiser, O; Lee, BL; Rotger, M; Telenti, A | 1 |
| Heseltine, PN; Kagan, RM; Kovari, L; Merigan, TC; Winters, MA | 1 |
| Bickel, M; Carlebach, A; Dauer, B; Jacobi, V; Miller, V; Rickerts, V; Rottmann, C; Staszweski, S; Stephan, C; Thalhammer, A | 1 |
| Gazzard, BG; McCormick, K; Moyle, GJ; Osorio, J; Portsmouth, SD | 1 |
| Andreoli, A; Bandelier, C; Bianchi-Demicheli, F; Damsa, C; Lazignac, C; Maris, S; Vidailhet, P | 1 |
| Crespo, M; Ferrer, E; Fisac, C; Fumero, E; Gatell, JM; Podzamczer, D; Ribera, E; Roson, B; Virgili, N | 1 |
| Ieki, R; Iguchi, M; Kato, T; Okamura, T; Ota, T; Saito, E; Shibuya, M; Yuasa, K | 1 |
| Akarathum, N; Kanjanavanit, S; Oberdorfer, A; Puthanakit, T; Sirisanthana, T; Sirisanthana, V; Wannarit, P | 1 |
| Cui, WG; Dai, D; Diao, YY; Geng, WQ; Han, XX; Jiang, YJ; Liu, BG; Liu, J; Shang, H; Wang, Yn; Zhang, M; Zhang, ZN | 1 |
| Calza, L; Chiodo, F; Colangeli, V; Manfredi, R; Pocaterra, D; Sebastiani, T; Tampellini, L | 1 |
| Calvez, V; Deleuze, J; Dupin, N; Gorin, I; Krivine, A; Marcelin, AG; Martinez, V; Morini, JP; Perrin, L; Peytavin, G; Yerly, S | 1 |
| Brust, J; Hartmann, M; Klinker, H; Mosthaf, F; Petzoldt, D; Procaccianti, M; Rump, JA; Schuster, D; Witte, S | 1 |
| Arastèh, K; Beard, A; Cartee, L; Drauz, D; Herzmann, C; Kreckel, P; Murphy, RL; Otto, MJ; Schinazi, RF; Schulbin, H | 1 |
| Davis, EA; DeJesus, E; Hill-Zabala, C; Lang, J; Lanier, ER; Liao, Q; Markowitz, M; Shaefer, M | 1 |
| Allavena, C; Bentata, M; Brunet-François, C; Dailly, E; Delfraissy, JF; Ferré, V; Lafeuillade, A; Launay, O; Michelet, C; Poizot-Martin, I; Raffi, F; Valantin, MA | 1 |
| Aberg, JA; Alston, BL; Brobst, SW; Fichtenbaum, CJ; Gerber, JG; Rosenkranz, SL; Segal, Y; Vega, JM; Yang, A | 1 |
| Lane, J; Mican, JM; Pau, AK; Penzak, SR; Robertson, SM | 1 |
| Boffito, M; Gazzard, B; Hand, J; Maitland, D; Mandalia, S; Moyle, G; Nelson, M | 1 |
| Taéron, C | 1 |
| Angel-Moreno-Maroto, A; Hernández-Cabrera, M; Pérez-Arellano, JL; Suárez-Castellano, L | 1 |
| Bickel, M; Carlebach, A; Haberl, A; Kurowski, M; Rottmann, C; Staszewski, S; Stephan, C | 1 |
| Baird, I; Cohen, C; Elion, R; Green, L; Green, S; Schrader, S; Ward, D | 1 |
| Amel, EB; Amel, LO; Amine, SM; Asma, J; Fethi, T; Mohamed, C; Mounira, G; Taoufik, BC | 1 |
| Beijnen, JH; Huitema, AD; Kappelhoff, BS; Meenhorst, PL; Mulder, JW; Prins, JM; Yalvaç, Z | 1 |
| Baraldi, E; Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, JM; MacGregor, TR; Montella, F; Robinson, PA; Russell, DB; Thompson, MA; Uip, DE; van Leth, F | 1 |
| Barroso, PF; Boechat, LJ; Melo, MF; Schechter, M; Vettore, MV | 1 |
| López-Cortés, LF; Lucero-Muñoz, MJ; Marín-Niebla, A; Pascual-Carrasco, R; Rodríguez-Díez, M; Ruiz-Valderas, R | 1 |
| Arendt, V; Fundira, L; Lemmer, P; Omes, C; Schneider, S; Schuman, M; Tayari, JC; Wennig, R | 1 |
| Fischl, MA; Forrest, A; Hirsch, MS; Merigan, TC; Morse, GD; Park, JG; Robbins, GK; Shafer, RW; Smith, PF; Wu, H; Yu, S | 1 |
| Kolber, MA | 1 |
| Bharel, C; Koppel, BS | 1 |
| Arnedo, M; Dalmau, D; Domingo, P; Gatell, JM; González, A; Llibre, JM; Martinez, E; Ochoa de Echagüen, A; Ribera, E; Riera, M; Rosón, B; Xercavins, M | 1 |
| Antolini, D; Concia, E; Faggian, F; Lanzafame, M; Lattuada, E; Vento, S | 1 |
| Almond, LM; Back, DJ; Edirisinghe, D; Hoggard, PG; Khoo, SH | 1 |
| Kabra, SK; Lodha, R; Upadhyay, A | 1 |
| Crabtree, N; Das, S; Jackson, NC; Jefferson, W; Nightingale, P; Shahmanesh, M; Shojaee-Moradie, F; Stolinski, M; Umpleby, AM | 1 |
| Barrail, A; Goujard, C; Le Tiec, C; Taburet, AM | 1 |
| Fredericks, S; Holt, DW; Khoo, SH; Rice, P; Sadiq, ST | 1 |
| Benator, D; Burman, W; Engle, M; Khan, A; Peloquin, CA; Vernon, A; Weiner, M; Zhao, Z | 1 |
| Dubé, MP; Grinspoon, SK; Meyer, WA; Mulligan, K; Parker, RA; Robbins, GK; Roubenoff, R; Shafer, RW; Snyder, SW; Tebas, P; Wininger, DA; Zackin, RA | 1 |
| Antón, R; Borrás, J; Gutiérrez, F; Martín-Hidalgo, A; Masiá, M; Navarro, A; Padilla, S | 1 |
| Clifford, DB; D'Aquila, RT; De Gruttola, V; Donahue, JP; George, AL; Haas, DW; Hirsch, MS; Kim, RB; Labbe, L; Merigan, TC; Morse, GD; Pollard, RB; Robbins, GK; Shafer, RW; Smeaton, LM; Wilkinson, GR | 1 |
| Billaud, E; Bugnon, F; Cua, E; Cuzin, L; Dellamonica, P; Delpierre, C; Massip, P; Pugliese, P; Raffi, F | 1 |
| Boyd, MA; Cooper, DA; Duncombe, CJ; Lange, JM; Phanuphak, P; Ruxrungtham, K; Siangphoe, U; Stek, M | 1 |
| Hicks, CB | 1 |
| Bata, D; Elise, A; France, AM; François, R; Louise, WM; Philippe, M; Roger, S | 1 |
| Acosta, EP; Clifford, DB; Dorfman, D; Evans, S; Goodkin, K; Gulick, RM; Ribaudo, H; Simpson, D; Tashima, K; Yang, Y | 1 |
| Dawson, S; Woods, C | 1 |
| Asensi, V; Barrios, A; Clotet, B; Domingo, P; Estrada, V; Labarga, P; Morales, D; Negredo, E; Santos, J; Soriano, V | 1 |
| Bautista-Arredondo, S; Bertozzi, SM; Mane, A | 1 |
| Kiertiburanakul, S; Manosuthi, W; Rattanasiri, S; Ruxrungtham, K; Sungkanuparph, S; Thakkinstian, A; Vibhagool, A | 1 |
| Nolan, D | 1 |
| Burger, DM; Droste, JA; Hekster, YA; Kearney, BP | 1 |
| Baker, A; Crawford, W; Jassen, A; Jooste, JP; Van Zyl, AJ | 1 |
| Dunsch, D; Elanjkal, Z; Funk, MB; Königs, C; Kreuz, W; Linde, R; Notheis, G; Schuster, T; Stürmer, M; von Hentig, N; Wintergerst, U | 1 |
| Godfried, MH; van Santen, G; van Twillert, G | 1 |
| Mallal, S; Nolan, D; Phillips, E | 1 |
| Galegov, GA | 1 |
| Black, FT; Jørgensen, LB; Kjems, J; Mohey, R; Møller, BK; Obel, N; Tolstrup, M | 1 |
| Freedman, AR; Healy, BJ | 1 |
| Arribas, JR; Campo, RE; Cheng, AK; Chuck, S; DeJesus, E; Enejosa, J; Gallant, JE; Gazzard, B; Lu, B; McColl, D; Pozniak, AL; Toole, JJ | 1 |
| Aldrovandi, GM; Beretta, S; Giacomet, V; Luraschi, P; Martelli, L; Merlo, M; Mora, S; Rombolà, G; Viganò, A | 1 |
| Back, DJ; Khoo, SH; Owen, A | 1 |
| Bonjoch, A; Bravo, I; Clotet, B; Heilek-Sneider, GM; Martinez-Picado, J; Moltó, J; Negredo, E; Ruiz, L; Valle, M | 1 |
| Fisher, M; Gazzard, B; Higgs, C; Johnson, M; Mandalia, S; Moyle, G; Nelson, M; Teague, A | 1 |
| Beijnen, JH; Boron-Kaczmarska, A; Hall, DB; Huitema, AD; Johnson, D; Kappelhoff, BS; Lange, JM; Leith, J; Leth, FV; Livrozet, JM; Losso, MH; Saag, MS; Wit, FW | 1 |
| Beerenwinkel, N; Drton, M | 1 |
| Boyd, MA; Burger, DM; Cooper, DA; Phanuphak, P | 1 |
| Colonno, RJ; Giordano, M; Kelleher, T; Lazzarin, A; Squires, K | 1 |
| Haas, DW | 1 |
| Bloemkolk, D; Sierink, HD | 1 |
| Casteelen, G; Oudijn, MS; Vrijlandt, CM | 1 |
| Talbot, M | 2 |
| Al-Numani, D; Di Marco, M; Garg, M; Marier, JF; Monif, T; Morelli, G; Morin, I; Singla, AK; Stiles, M; Tippabhotla, SK; Vijan, T | 1 |
| Brown, H; Fletcher, C; Gazzard, B; Mandalia, S; Moyle, G | 1 |
| Antoniadou, A; Giamarellou, H; Katsarolis, I; Panagopoulos, P; Papadopoulos, A; Poulakou, G; Tsiodras, S | 1 |
| Branco, T; Caixas, U; Côrte-Real, RM; Germano, I; Lampreia, F; Monteiro, EC; Pereira, SA | 2 |
| Newman, C; Persson, A | 1 |
| Best, B; Capparelli, E; Goicoechea, M; Haubrich, R | 1 |
| Abo, Y; Anglaret, X; Anzian, A; Chenal, H; Danel, C; Eholié, S; Gabillard, D; Guehi, C; Moh, R; Rouet, F; Sorho, S | 1 |
| Boly, L; Cafaro, V; Dyner, T | 1 |
| Arvieux, C; Dailly, E; Jolliet, P; Perré, P; Raffi, F; Tattevin, P; Tribut, O | 1 |
| Demeter, LM; Dykes, C; Koval, CE; Wang, J | 1 |
| Ait-Arkoub, Z; Boutonnet, V; Calvez, V; Derache, A; Dominguez, S; Duvivier, C; Ghosn, J; Katlama, C; Marcelin, AG; Roquebert, B; Simon, A; Wirden, M | 1 |
| Guo, L; He, ML; Kung, HF; Lee, SS; Lin, CK; Sung, JJ; Tong, K | 1 |
| Hansen, AB; Justesen, US; Mathiesen, S; Von Lüttichau, HR | 1 |
| Preisig, M; Saraga, M; Zullino, DF | 1 |
| Curtin, JM; Ward, DJ | 1 |
| Hall, DB; Lange, JM; Reiss, P; van Leth, F | 1 |
| Chumpathat, N; Manosuthi, W; Muangchana, K; Sungkanuparph, S; Thongyen, S | 1 |
| Acosta, EP; Bastow, B; Carlson, M; Gulick, RM; Klingman, KL; Koletar, SL; Kuritzkes, DR; Lalama, C; Meyer, WA; Murphy, RL; Pilcher, CD; Reichman, RC; Ribaudo, HJ; Schackman, BR; Schouten, J; Shikuma, CM; Squires, KE | 1 |
| Araujo, M; Eira, M; Seguro, AC | 1 |
| Croom, KF; Frampton, JE | 1 |
| Donahue, JP; Erdem, H; George, AL; Haas, DW; Haines, JL; Kim, RB; Motsinger, AA; Raffanti, S; Rebeiro, P; Ritchie, MD; Sterling, TR | 1 |
| Breilh, D; Camou, F; Caubet, O; Djabarouti, S; Fleury, H; Lavit, M; Pellegrin, I; Pellegrin, JL; Saux, MC | 1 |
| Lange, JM; van Leth, F | 1 |
| Cheng, A; Lu, B; Margot, NA; Miller, MD | 1 |
| Burnside, AF; Jayaweera, DT; Montaner, JS; Saag, MS; Schutz, M; Schwartz, R; Walmsley, S | 1 |
| Brothers, CH; Castillo, SA; Hernandez, JE | 1 |
| Gyllensten, K; Josephson, F; Lidman, K; Sääf, M | 1 |
| de Campos, AV; Leon, E; Lopez-Cortes, LF; Lozano, F; Marin-Niebla, A; Marquez-Solero, M; Ruiz-Morales, J; Ruiz-Valderas, R; Valiente, R | 1 |
| Antinori, A; Bongiovanni, M; Cauda, R; Ciardi, M; Cicconi, P; Cozzi-Lepri, A; De Luca, A; Di Giambenedetto, S; Grisorio, B; Marconi, P; Monforte, Ad; Resta, F; Zaccarelli, M | 1 |
| Bartlett, JA; Griffith, S; Herrera, G; Irlbeck, D; Johnson, J; Liao, Q; Rodriguez, A; Shaefer, MS; Sosa, N | 1 |
| Biollaz, J; Buclin, T; Colombo, S; Décosterd, LA; Eap, CB; Furrer, H; Lee, BL; Telenti, A | 1 |
| Laurence, J | 1 |
| Friedland, G; Jack, C; Khoo, S; Lalloo, U | 1 |
| Boyd, MA; Buss, NE; Cooper, DA; Dixit, NM; Lange, JM; Perelson, AS; Phanuphak, P; Ruxrungtham, K; Salgo, MP; Siangphoe, U | 1 |
| Abgrall, S; Bouchaud, O; Costagliola, D; Yeni, PG | 2 |
| Arribas, JR; Campo, RE; Chen, SS; Cheng, AK; DeJesus, E; Enejosa, J; Gallant, JE; Gazzard, B; McColl, D; Pozniak, AL; Toole, JJ | 1 |
| Calza, L; Manfredi, R | 1 |
| Ditangco, R; Kamarulzaman, A; Kiertiburanakul, S; Phanupak, P; Pujary, S; Zhou, J | 1 |
| Kiertiburanakul, S; Manosuthi, W; Rattanasiri, S; Sungkanuparph, S; Thakkinstian, A; Vibhagool, A | 1 |
| Dunsch, D; Elanjikal, S; Funk, MB; Koenigs, C; Kreuz, W; Linde, R; von Hentig, N | 1 |
| Begley, K; Callaghan, A; Gold, J; Kelly, M; Post, JJ; Rihs, TA; Sarangapany, J; Smith, DE | 1 |
| Alonso, C; Aranda, M; Barrufet, P; Berenguer, J; Crespo, M; del Río, L; Delegido, A; Ferrer, E; Fisac, C; Gatell, JM; Lérida, A; Llibre, JM; Lonca, M; Martínez-Lacasa, J; Merino, E; Niubo, J; Pedreira, JD; Podzamczer, D; Pulido, F; Ribas, MA; Ribera, E; Rubio, R; Sanchez, P; Sanz, J; Veloso, S | 1 |
| Alvanzo, A; Baker, J; Friedland, G; Jatlow, P; McCance-Katz, EF; Moody, DE; Morse, GD; Ogundele, A; Pade, P; Rainey, PM; Smith, P | 1 |
| Anaky, MF; Blanche, S; Fassinou, P; Inwoley, A; Kouakoussui, A; Msellati, P; Rouet, F; Rouzioux, C | 1 |
| Han, N; Lan, MD; Liu, ZY; Lu, LH; Wei, HS; Yao, J; Zhang, FJ; Zhao, HX | 1 |
| Maeland, A; Skeie, L | 1 |
| Angeletti, C; Boumis, E; Chinello, P; Lisena, FP; Papetti, F; Petrosillo, N | 1 |
| Aguilar, I; Hidalgo, A; Palacios, R; Santos, J | 1 |
| Clax, PA; Cohn, SE; Hitti, J; Lertora, JJ; Park, JG; Stek, A; Watts, DH; Yu, S | 1 |
| Barbour, TD; Finlayson, RJ; Furlong, TJ | 1 |
| Blievernicht, J; Cavassini, M; Colombo, S; Décosterd, L; Eichelbaum, M; Furrer, H; Günthard, HF; Rotger, M; Saussele, T; Schwab, M; Tegude, H; Telenti, A; Zanger, UM | 1 |
| Bastow, B; Glesby, MJ; Gulick, RM; Kuritzkes, DR; Meyer, WA; Ribaudo, HJ; Shikuma, CM; Tashima, KT; Webb, N; Yang, Y | 1 |
| Dahri, K; Ensom, MH | 1 |
| Bassett, R; Brizz, B; Collier, AC; Dehlinger, M; Demeter, LM; Feinberg, JE; Fischl, MA; Garren, K; Giuliano, M; Mukherjee, AL; Tebas, P | 1 |
| Arnaiz, JA; Dalmau, D; de Lazzari, E; Domingo, P; Force, L; Gatell, JM; Knobel, H; Leyes, M; Martínez, E; Pedrol, E; Podzamczer, D; Ribera, E | 1 |
| Galli, M; Gervasoni, C; Grinelli, E; Ortu, M; Rusconi, S; Vigano, O | 1 |
| Best, B; Goicoechea, M | 1 |
| Asiimwe, F; Behumbiize, P; Brooks, JT; Forna, F; Liechty, CA; Mermin, J; Solberg, P; Tong, T; Weidle, PJ; Were, W | 1 |
| Steinbrook, R | 1 |
| Bekker, V; Jurriaans, S; Kuijpers, TW; Lange, JM; Pajkrt, D; Scherpbier, HJ | 1 |
| Baldelli, F; Bonora, S; DI Candilo, F; Lapalorcia, LM; Palladino, N; Pasticci, MB | 1 |
| Barreiro, P; Gonzalez-Lahoz, J; Jiménez-Nácher, I; Labarga, P; Martín-Carbonero, L; Rodríguez-Novoa, S; Ruiz, A; Soriano, V | 1 |
| Gupte, N; Patel, AK; Patel, B; Patel, J; Patel, K; Pujari, S; Shah, N | 1 |
| Jaruratanasirikul, S; Mahatthanatrakul, W; Ridtitid, W; Sriwiriyajan, S | 1 |
| Delaporte, E; Girard, PM; Landman, R; Ndiaye, B; Ngom Gueye, NF; Poupard, M; Sow, PS; Thiam, D | 1 |
| Alvero, C; Brundage, R; Fenton, T; Fletcher, CV; Hsia, K; Saitoh, A; Spector, SA | 1 |
| Gulick, RM; Klingman, KL; Koletar, SL; Kuritzkes, DR; Meyer, WA; Reichman, R; Ribaudo, HJ; Riddler, SA; Santana, J; Shikuma, C; Squires, KE | 1 |
| De Munter, P; Schrooten, Y; Van Laethem, K; Van Ranst, M; Van Wijngaerden, E; Vandamme, AM; Verbesselt, R | 1 |
| Bockarie, MJ; Mehlotra, RK; Zimmerman, PA | 1 |
| DiFrancesco, R; Donnelly, J; Fischl, MA; Gripshover, B; McCance-Katz, EF; Moody, DE; Morse, GD; Reichman, RC; Zingman, BS | 1 |
| Gulick, RM; Klingman, KL; Koletar, SL; Kuritzkes, DR; Lalama, CM; Pilcher, CD; Reichman, RC; Ribaudo, HJ; Schackman, BR; Schouten, J; Shikuma, CM; Squires, KE | 1 |
| Egbers, C; Eley, BS; Maartens, G; McIlleron, HM; Meyers, TM; Nuttall, JJ; Ren, Y; Smith, PJ | 1 |
| Lange, JM; van Tongeren, J; Vrouenraets, SM; Wit, FW | 1 |
| Bussmann, H; DeGruttola, SM; Essex, M; Lekoko, B; Makhema, J; Marlink, RG; Okezie, O; Thomas, AM; Wester, CN; Wester, CW | 1 |
| Anastos, K; Cohen, M; Cole, S; Hessol, NA; Justman, J; Kaplan, RC; Lu, D; Shi, Q; Tien, PC; Vigen, C; Young, M | 1 |
| Dong, QM; Guo, LP; He, ML; Kung, HF; Lee, SS; Li, LH; Lin, CK; Tan, Y; Xu, BY; Yao, H | 1 |
| Capparelli, E; Diamond, C; Goicoechea, M; Haubrich, R; Kemper, C; Rigby, A; Vidal, A; Witt, MD | 1 |
| Buclin, T; Colombo, S; Décosterd, L; Furrer, H; Rotger, M; Telenti, A | 1 |
| Caligaris, S; Capone, S; Carosi, G; Carvalho, AC; Cusato, M; De Iaco, G; Manfrin, M; Matteelli, A; Regazzi, M; Tomasoni, L; Villani, P | 1 |
| Ainsworth, JG; Haddow, LJ; Wood, CW | 1 |
| Brizz, B; Collier, AC; Evans, S; Feinberg, J; Fischl, MA; Sattler, F; Shevitz, A; Shikuma, C; Tebas, P; Yarasheski, K; Zhang, J | 1 |
| Gangakhedkar, RR; Hayatnagarkar, SS; Kurle, SN; Paranjape, RS; Sen, S; Tripathy, SP | 1 |
| Bertelsen, L; Jakobsen, MR; Laursen, A; Mohey, R; Obel, N; Ostergaard, L; Tolstrup, M | 1 |
| Klotman, PE; Rodriguez-Caprio, G; Wyatt, CM | 1 |
| Massari, V; Parienti, JJ; Poubeau, P; Rey, D; Verdon, R | 1 |
| Dubé, MP; Grinspoon, SK; Komarow, L; Mulligan, K; Parker, RA; Robbins, GK; Roubenoff, R; Tebas, P | 1 |
| Chêne, G; De Castro, N; Furco, A; Journot, V; May, T; Molina, JM; Morlat, P; Palmer, P; Raffi, F; Rancinan, C | 1 |
| Alvero, CG; Brundage, RC; Fenton, T; Fletcher, CV; Mofenson, LM; Powell, C; Spector, SA | 1 |
| Braithwaite, RS; Chang, CC; Fultz, SL; Gibert, C; Goetz, MB; Justice, AC; Kozal, MJ; Mole, L; Roberts, MS; Rodriguez-Barradas, M | 1 |
| Dia Badiane, NM; Diop, BM; Faye, MM; Manga, NM; Ndour, CT; Ngom Gueye, NF; Seydi, M; Soumare, M; Sow, AI; Sow, PS | 1 |
| Abrams, E; Blum, MR; Britto, P; Chittick, GE; Cunningham, C; Dickover, R; Draper, L; Flynn, P; Hu, C; Hughes, M; Kraimer, J; McKinney, RE; Ortiz, AA; Rathore, M; Reynolds, L; Rodman, J; Scites, M; Serchuck, LK; Smith, ME; Spector, S; Tran, P; Weinberg, A; Yogev, R | 1 |
| Amorim, AP; Campos, CP; Custódio, FL; Ferrão, SB; Fonseca, BA; Gaspar, GG; Golin, NA; Marangoni, AT; Melo, Ld; Morejón, KM; Ponzi, CC; Santana, RC; Vanni, T | 1 |
| Abad, J; Amorós-Quiles, I; Belda, A; Borrás-Blasco, J; Casterá, E; Rosique-Robles, D | 1 |
| Bhagani, S; Johnson, MA; Lampe, FC; Madge, S; Phillips, AN; Puradiredja, D; Sabin, CA; Smith, CJ; Youle, MS | 1 |
| Bernal, E; Gutiérrez, F; Martín-Hidalgo, A; Masiá, M; Padilla, S; Ramos, JM | 1 |
| Ashino, Y; Hattori, T; Hayashida, T; Irokawa, T; Komaki, Y; Tamada, T; Teruya, K; Tomaki, M; Usami, O | 1 |
| Cecelia, AJ; Devaleenal, B; Flanigan, T; Kumarasamy, N; Mayer, KH; Muthu, S; Palanivel, V; Venkatesh, KK; Yepthomi, T | 1 |
| Ansari, AW; Heiken, H; Schmidt, RE | 1 |
| Bridges, AS; Cohen, MS; Corbett, AH; Dumond, JB; Jung, BH; Kashuba, AD; Patterson, KB; Rezk, NL; Stewart, PW; Yeh, RF | 1 |
| Hamaguchi, M; Hirano, A; Ibe, S; Kaneda, T; Kudaka, Y; Mamiya, N; Okumura, N; Suzuki, T; Takahashi, M | 1 |
| Bae, AS; Borroto-Esoda, K; Harris, JL; Hinkle, JE; Quinn, JB; Rousseau, FS; Waters, JM | 1 |
| Killingley, B; Pozniak, A | 1 |
| Gulick, RM; Kuritzkes, DR; Ribaudo, HJ | 1 |
| Battegay, M; Bodmer, M; Elzi, L; Haschke, M; Krähenbühl, S; Kummer, O; Mossdorf, E | 1 |
| Alvero, C; Fenton, T; Fletcher, CV; Saitoh, A; Spector, SA | 1 |
| Barrufet, P; Crespo, M; Ferrer, E; Gatell, JM; Llibre, JM; Niubo, J; Podzamczer, D; Sanchez, P; Sanz, J; Veloso, S | 1 |
| Anitha, S; Hemanth Kumar, AK; Kumar, P; Rajasekaran, S; Ramachandran, G; Swaminathan, S | 1 |
| Banno, K; Hirano, A; Kaneda, T; Kudaka, Y; Okumura, N; Takahashi, M | 1 |
| Fujimoto, K; Gatanaga, H; Gejyo, F; Hamaguchi, M; Hayashida, T; Horiba, M; Kimura, A; Kimura, S; Koike, T; Kuwahara, T; Matsushita, S; Oka, S; Sato, I; Shirasaka, T; Takata, N; Tsuchiya, K; Tsukada, H; Ueda, M; Yamamoto, M; Yoshino, M | 1 |
| Abbara, C; Barrail, A; Boissonnas, A; Bonhomme-Faivre, L; Duclos-Vallée, JC; Samuel, D; Taburet, AM; Teicher, E; Vincent, I; Vittecoq, D | 1 |
| Barditch-Crovo, P; Carson, KA; Flexner, C; Hendrix, CW; Khan, W; Pakes, GE; Parish, M; Parsons, T; Pham, PA; Qaqish, R; Radebaugh, C | 1 |
| Frank, A; Katsounas, A; Klinker, H; Langmann, P | 1 |
| Asensi, V; Barreiro, P; de Mendoza, C; Estrada, V; González-Lahoz, J; Jiménez-Nacher, I; Palacios, R; Rivas, P; Rodríguez-Novoa, S; Sánchez-Conde, M; Santos, J; Sanz, J; Sola, J; Soriano, V | 1 |
| Maartens, G; Mehta, U | 1 |
| Lowenhaupt, EA; Matson, K; Pugatch, D; Qureishi, B; Saitoh, A | 1 |
| Arribas, JR; Campo, RE; Chen, SS; Cheng, AK; Dejesus, E; Enejosa, J; Gallant, JE; Gazzard, B; Holmes, CB; McColl, D; Pozniak, AL; Toole, JJ | 1 |
| Easley, KA; Lennox, JL; Lu, C; Ofotokun, I; Smithson, SE | 1 |
| Calmy, A; Carey, DL; Carr, A; Cooper, DA; Emery, S; Law, MG; Samaras, K; Wand, H | 1 |
| Cennimo, DJ | 1 |
| Ashton, M; Chigutsa, E; Chonzi, P; Masimirembwa, C; Nhachi, C; Nyakutira, C; Röshammar, D | 1 |
| Hanabusa, H; Hasegawa, N; Kato, S; Kinai, E; Negishi, M; Tanaka, R | 1 |
| Aweeka, F; Burchett, SK; Capparelli, E; Fenton, T; Kovacs, A; Nachman, S; Saitoh, A; Sarles, E; Spector, SA; Wiznia, A | 1 |
| Balkan, S; Delfraissy, JF; Fernandez, M; Ferradini, L; Laureillard, D; Ly, N; Ngeth, C; Pinoges, L; Prak, N; Puertas, G; Quillet, C; Rouzioux, C; Taburet, AM | 1 |
| Chen, J; Cooper, DA; Emery, S; Hazuda, DJ; Kelleher, AD; Law, M; Murray, JM; Nguyen, BY; Teppler, H | 1 |
| Chaisson, RE; Charalambous, S; Churchyard, GJ; Fielding, KL; Grant, AD; Hoffmann, CJ; Innes, C; Sulkowski, MS; Thio, CL | 1 |
| Dhanireddy, S; Kosel, BW; Spak, CW | 1 |
| Alvarez, E; Bellón, JM; Berenguer, J; Castillo, I; Cosín, J; López, JC; Miralles, P; Padilla, B; Resino, S; Sánchez Conde, M | 1 |
| Gulick, RM; Hughes, V; Krambrink, A; Kuritzkes, DR; Ribaudo, HJ; Schackman, BR | 1 |
| Bannister, WP; Clotet, B; Cozzi-Lepri, A; Karlsson, A; Kirk, O; Loveday, C; Lundgren, JD; Mocroft, A; Monforte, Ad; Ruiz, L; Staszewski, S | 1 |
| Asenjo, MA; Barrufet, P; Domingo, P; Gatell, JM; Gutiérrez, F; Knobel, H; Mallolas, J; Pedrol, E; Peñaranda, M; Peraire, J; Pich, J; Vidal, F | 1 |
| Anderson, J; Dunn, DT; Easterbrook, PJ; Fisher, M; Gazzard, B; Gilson, R; Hill, T; Johnson, M; Leen, C; Matthias, R; Orkin, C; Phillips, AN; Sabin, CA; Schwenk, A; Scullard, G | 1 |
| Clax, PA; Cohn, SE; Hitti, J; Lertora, JJ; Muderspach, L; Park, JG; Stek, A; Watts, DH; Yu, S | 1 |
| Aurpibul, L; Lee, B; Mangklabruks, A; Puthanakit, T; Sirisanthana, T; Sirisanthana, V | 1 |
| Autar, RS; Boyd, MA; Burger, DM; Cooper, DA; Lange, J; Phanuphak, P; Reiss, P; Ruxrungthams, K; Sankote, J; Wit, FW | 1 |
| Rossouw, T | 1 |
| Allavena, C; Biron, C; Dailly, E; Jolliet, P; Raffi, F | 1 |
| Acosta, EP; D'Aquila, RT; Fiscus, SA; Gulick, RM; Johnson, VA; Kuritzkes, DR; Lalama, CM; Marcial, M; Meyer, WA; Ribaudo, HJ; Schackman, BR; Shikuma, C | 1 |
| de la Torres, J; Gálvez, MC; López, M; López-Cortés, LF; Lozano, F; Palacios, R; Ríos, MJ; Rivero, A; Santos, J | 1 |
| Back, DJ; Bogner, JR; Brockmeyer, NH; Egan, D; Esser, S; Fätkenheuer, G; Groneuer, C; Harrer, T; Hendra, H; Hoffmann, C; Jaeger, H; Jetter, A; Khoo, SH; Knechten, H; Mauss, S; Owen, A; Rockstroh, J; Skoetz, N; van Lunzen, J; Vogel, M; Wyen, C | 1 |
| Carosi, G; Ceresoli, F; Cologni, G; Cossarizza, A; Costarelli, S; Gargiulo, F; Lapadula, G; Magoni, M; Manca, N; Nasi, M; Nichelatti, M; Pinti, M; Quiros-Roldan, ME; Torti, C | 1 |
| Borot, N; Hovnanian, A; Ledger, TN; Lefebvre, A; Lonjou, C; Milpied, B; Vitezica, ZG | 1 |
| Canestri, A; Delaporte, E; Girard, PM; Gueye, M; Kane, CT; Landman, R; M'boup, S; Ngom, F; Peytavin, G; Sow, PS; Vray, M | 1 |
| Herrera, L; Moreno, S; Sánchez-de la Rosa, R | 1 |
| Burger, D; Hoffmann, F; Huss, K; Jansson, A; Kurowski, M; Notheis, G; Wintergerst, U | 1 |
| Cosín, J; Domingo, P; Galindo, MJ; García Alcalde, ML; Garrido, M; Geijo, P; Gonzalez, J; Lacalle, JR; Lopez-Aldeguer, J; Lozano, F; Muñoz, A; Ribera, E; Roca, B; Sanchez, T; Suárez-Lozano, I; Teira, R; Terrón, A; Torres, F; Vergara, A; Viciana, P; Vidal, F | 1 |
| Bacchetti, P; Grunfeld, C; Heymsfield, S; Kotler, DP; Lee, G; Lewis, CE; Madden, E; Scherzer, R; Shlipak, MG; Tracy, R; Wanke, C | 1 |
| Chimsuntorn, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Sungkanuparph, S | 1 |
| Burger, DM; Compagnucci, A; Cressey, TR; Gibb, DM; Green, H; Khoo, S; Lallemant, M; Saidi, Y; Treluyer, JM | 1 |
| Acosta, EP; Gulick, RM; Kuritzkes, DR; Lalama, CM; Ribaudo, HJ; Schackman, BR; Schouten, JT | 1 |
| Lankoandé, D; Millogo, A; Sawadogo, AB; Yaméogo, AA; Yaméogo, I | 1 |
| Carolo, G; Concia, E; Gottardi, M; Lanzafame, M; Lattuada, E; Vento, S | 1 |
| Bertilsson, L; Böttiger, Y; Diczfalusy, U; Flamholc, L; Gisslén, M; Josephson, F; Ormaasen, V; Sönnerborg, A | 1 |
| Domingo, P; Martínez, E; Moreno, S; Pérez-Molina, JA | 1 |
| Brizz, B; DiRienzo, AG; Garren, KW; George, T; Haubrich, R; Havlir, D; Klingman, KL; Lalloo, UG; Mellors, JW; Murphy, RL; Peeples, L; Powderly, WG; Riddler, SA; Rooney, JF; Swindells, S | 1 |
| Calmy, A; Hirschel, B | 1 |
| Dutta, T; Garg, M; Jain, NK | 1 |
| Fletcher, CV; Saitoh, A; Torno, MS; Witt, MD | 1 |
| Khaykin, P; Postel, N; Reeb, I; Staszewski, S | 1 |
| Cordova, B; Jackson, DA; Rayner, MM | 1 |
| De Clercq, E | 1 |
| Saag, MS; Schooley, RT | 1 |
| Adkins, JC; Noble, S | 1 |
| Elliott, EB | 1 |
| Wehr, A | 1 |
| Colebunders, R; Verdonck, K | 1 |
| Lo Caputo, S; Maserati, R; Pan, A; Regazzi, MB; Seminari, E; Villani, P | 1 |
| Capoccia, K; Wolbach, J | 1 |
| Ahmad, M; Brennan, JM; Caliendo, AM; Fiske, WD; Flanigan, TP; Gormley, JM; Tashima, KT | 1 |
| Belec, L; Castiel, P; Clavel, F; Gonzalez-Canali, G; Kazatchkine, MD; Peytavin, G; Piketty, C; Race, E; Si-Mohamed, A; Weiss, L | 2 |
| Everall, I; Gonzalez, A | 1 |
| Crowe, S | 1 |
| Collier, AC; Schwartz, MA | 1 |
| Temesgen, Z; Wright, AJ | 1 |
| Castelli, F; Maserati, R; Regazzi, MB; Seminari, E; Torti, C; Viale, P; Villani, P | 1 |
| Farina, D; Johnson, P; Labriola, DF; Manion, DJ; Morales-Ramirez, J; Rachlis, A; Ruiz, NM; Skiest, D; Stanford, J; Staszewski, S; Stryker, R; Tashima, KT | 1 |
| Becker, M; Brundage, RC; Dankner, WM; Fenton, T; Fiske, W; Fletcher, CV; Flynn, PM; Gersten, M; Graham, B; Kornhauser, DM; Lischner, HW; Manion, D; McNamara, J; Mofenson, LM; Purdue, L; Ruiz, N; Siminski, S; Spector, SA; Starr, SE; Vincent, C; Yong, FH | 1 |
| Clumeck, N | 1 |
| Bossi, P; Bricaire, F; Caumes, E; Colin, D | 1 |
| Manion, D | 1 |
| Katlama, C | 1 |
| Clotet, B | 1 |
| Walters, S | 1 |
| Falloon, J; Kavlick, MF; LaFon, S; Lane, HC; Manion, DJ; Masur, H; Mitsuya, H; Piscitelli, S; Rogers, M; Sadler, B; Vogel, S; Yoshimura, K | 1 |
| Chiodo, F; Manfredi, R | 2 |
| Duval, X | 1 |
| Fiocchi, C; Gambarana, E; LoCaputo, F; Maserati, R; Pan, A; Regazzi, MB; Seminari, E; Villani, P | 1 |
| Arnó, A; Blazquez, J; Bloor, S; Bonjoch, A; Casado, JL; Clotet, B; Dronda, F; Garcia-Arata, I; Hertogs, K; Larder, B; Ruiz, L; Van Cauwenberge, A | 1 |
| Aymard, G; Deray, G; Hamani, A; Izzedine, H; Launay-Vacher, V | 1 |
| Di Perri, G; Raiteri, R; Rossati, A; Savarino, A; Sinicco, A | 1 |
| Biollaz, J; Buclin, T; Decosterd, LA; Marzolini, C; Telenti, A | 1 |
| Baird, BF; Chun, TW; Dybul, M; Engel, D; Fauci, AS; Fox, CH; Green, LG; Hertogs, K; Larder, B; Li, Y; Liu, S; Mican, JM; Orenstein, JM; Ward, DJ | 1 |
| Brosgart, CL; Israelski, DM; Katzenstein, DA; Miller, MD; Murlidharan, U; Passaro, DJ; Shafer, RW; Shulman, NS; Van Doren, S; Zolopa, AR | 1 |
| Brennan, JM; Fiske, WD; Gill, MJ; Ostrop, NJ | 1 |
| Barreiro, P; Briones, C; Dona, C; González-Lahoz, J; Soriano, V | 1 |
| Baumann, P; Decosterd, LA; Eap, CB; Marzolini, C; Telenti, A; Troillet, N | 1 |
| Chêne, G; Decazes, JM; Ferchal, F; Journot, V; Molina, JM; Morlat, P; Raffi, F; Rancinan, C; Rozenbaum, W; Sereni, D | 1 |
| Blayac, JP; Faucherre, V; Peyriere, H; Pinzani, V | 1 |
| Cheesbrough, A; Gazzard, BG; Leen, C; Moyle, GJ; Reynolds, B; Wilkins, E | 1 |
| Irlanda, IE; Kessler, HA; Narkiewicz, E; Sha, BE; Smith, KY; Tenorio, AR | 1 |
| Abremski, K; Anton, ED; Aujay, M; Bacheler, LT; Baker, D; Becker, MF; Bolling, L; Bunville, J; Ellis, D; George, HJ; Hollis, G; Krakowski, K; Kudish, P; Lasut, AL; Spalding, DR; Wang, XV | 1 |
| Avila, C; Newell, A; Rodgers, ME | 1 |
| Baldanti, F; Maggiolo, F; Maserati, R; Pan, A; Paolucci, S; Regazzi, MB; Seminari, E; Suter, F; Tinelli, C; Villani, P | 1 |
| Chang, SC; Chen, MY; Hsieh, SM; Hung, CC; Lu, PL | 1 |
| Barreiro, P; Dona, C; González-Lahoz, J; Soriano, V | 1 |
| Belohradsky, BH; Engelhorn, C; Hoffmann, F; Kurowski, M; Notheis, G; Wintergerst, U | 1 |
| Duval, X; Farinotti, R; Lamotte, C; Le Moing, V; Leport, C; Longuet, C; Peytavin, G; Vildé, JL | 1 |
| Bower, M; Gazzard, BG; Mandalia, S; Matthews, GV; Moyle, GJ; Nelson, M | 1 |
| Barry, M; Clarke, S; Harrington, P; Mulcahy, F | 1 |
| Boyle, BA; Goldenberg, D | 1 |
| Cabral, S; Fenton, T; Fletcher, CV; Hsia, K; McNamara, J; Mofenson, LM; Spector, SA; Starr, SE; Yong, FH | 1 |
| Bianchi, L; Blanco, JL; Buira, E; Casamitjana, R; Conget, I; García-Viejo, MA; Gatell, JM; Mallolas, J; Martínez, E | 1 |
| Barreiro, P; Dona, C; González-Lahoz, J; Jiménez-Náchera, I; Soriano, V | 1 |
| Burman, W; Orr, L | 1 |
| Delapenha, RA; Fessel, WJ; Haas, DW; Kaplan, M; Kessler, H; Labriola, DF; Manion, DJ; Ploughman, LM; Ruiz, NM; Seekins, D | 1 |
| Faure, I; Leng, B; Mercié, P; Pellegrin, JL; Rispal, P; Thiébaut, R; Viallard, JF | 1 |
| Biollaz, J; Buclin, T; Decosterd, LA; Greub, G; Marzolini, C; Telenti, A | 1 |
| Blanche, S; Burgard, M; Gregoire, V; Quartier, P; Teglas, JP; Treluyer, JM | 1 |
| Moyle, G | 1 |
| Caro, JJ; Migliaccio-Walle, K; O'Brien, JA; Raggio, G | 1 |
| Deeks, SG | 1 |
| Anderson, RM; Cane, PA; Ferguson, NM; Pillay, D; Taylor, S | 1 |
| Back, DJ; Barry, MG; Clarke, SM; Gibbons, SE; Mulcahy, FM; Reynolds, HE; Tjia, J | 1 |
| Darioli, R; Doser, N; Mooser, V; Nicod, P; Sudre, P; Telenti, A; Wietlisbach, V | 1 |
| Barreiro, P; González-Lahoz, J; Nuñez, M; Oller, V; Rodríguez-Rosado, R; Soriano, V | 1 |
| Ahrlund-Richter, L; Britton, S; Larsson, S; Maijgren-Steffensson, C; Sönnerborg, A; Vahlne, A | 1 |
| Bacheler, L; Baker, D; Buckery, R; Cordova, B; D'Aquila, R; Gallagher, K; Hanna, G; Hertogs, K; Jeffrey, S; Larder, B; Logue, K; Rizzo, C; Scarnati, H; Tritch, R; Wallace, L | 1 |
| Falkenberg, J; Gilden, D; Torres, G | 1 |
| James, JS | 4 |
| Highleyman, L | 3 |
| Bornhoeft, MA | 1 |
| Fakuda, D | 1 |
| Bartnof, HS | 1 |
| Baker, R | 3 |
| Cadman, J | 2 |
| Simmons, P | 1 |
| Grinberg, L | 2 |
| Gilden, D | 2 |
| Hanna, L | 1 |
| Elwell, A | 1 |
| Gallant, JE | 3 |
| Bartlett, JG | 3 |
| Fornataro, K | 2 |
| Slovick, J | 1 |
| Arroyo, HT | 1 |
| Bartnoff, H; Deeks, S; Follansbee, S | 1 |
| Goa, KL; Perry, CM; Plosker, GL | 1 |
| Beijnen, JH; Carlier, H; Gazzard, B; Harris, M; Hoetelmans, RM; Johnson, M; Kwakkelstein, MO; Lange, JM; Montaner, JS; Moyle, G; Reiss, P; van Leeuwen, R; Veldkamp, AI; Youle, M | 1 |
| Husak, R; Orfanos, CE; Raisova, M; Tebbe, B; Treudler, R | 1 |
| Cadeo, B; Carosi, G; Fiocchi, C; Marchetti, F; Regazzi, MB; Signorini, L; Viale, P; Villani, A; Villani, P | 1 |
| Hellmann, N; Huang, W; Israelski, DM; Katzenstein, D; Passaro, D; Petropoulos, C; Shafer, RW; Shulman, N; Whitcomb, J; Zolopa, AR | 1 |
| Blanch, J; Corbella, B; García, F; Gatell, JM; Parellada, E | 1 |
| Fabre, J; Hillaire-Buys, D; Mauboussin, JM; Peyriere, H; Reynes, J; Rouanet, I | 1 |
| Blanch, J; Blanco, JL; De Lazzari, E; De Pablo, J; García-Viejo , MA; Gatell, JM; Mallolas, J; Martínez, E; Peri, JM; Rousaud, A | 1 |
| Chou, TC; Giguel, F; Hirsch, MS; Kollmann, C; Tremblay, C | 1 |
| Albrecht, MA; Bosch, RJ; Dehlinger, M; Eron, J; Hammer, SM; Katzenstein, DA; Kessler, H; Liou, SH; Para, MF; Valdez, H | 1 |
| Mellors, JW; Montaner, JS | 1 |
| Casas, E; Caso, JA; Prieto, Jde M; Sanz, J | 1 |
| Harrigan, PR; Humar, A; Kelly, DV; Tseng, AL; Walmsley, SL | 1 |
| Bernard-Henry, C; Cheneau, C; de Mautort, E; Hess-Kempf, G; Krantz, V; Lang, JM; Partisani, M; Priester, M; Rey, D; Schmitt, MP | 1 |
| Chaisson, RE; Lucas, GM; Moore, RD | 1 |
| Bartlett, JG; del Rio, C | 1 |
| Bernasconi, E; Bucher, HC; Flepp, M; Friedl, AC; Furrer, H; Hirschel, B; Ledergerber, B; Telenti, A; Weber, R | 1 |
| de la Garza, CL; García-Martín, C; Gutiérrez-Casares, JR; Paoletti-Duarte, S | 1 |
| Nelson, M | 1 |
| Arribas, J | 1 |
| Lafeuillade, A | 1 |
| Stellbrink, HJ | 1 |
| Agher, R; Calvez, V; Delaugerre, C; Huraux, JM; Katlama, C; Mouroux, M; Rohban, R; Simon, A; Tricot, C | 1 |
| Back, DJ; Drake, SM; Pillay, D; Reynolds, H; Sabin, CA; Taylor, S; White, DJ | 1 |
| Baldwin, C; Burn, P; Comitis, S; Gazzard, B; Mandalia, S; Moyle, G | 1 |
| Gallego, L; González de Requena, D; González-Lahoz, J; Jiménez-Nácher, I; Núñez, M; Soriano, V | 1 |
| DiCenzo, R; Morse, GD; Smith, PF | 1 |
| Bickel, M; Jacobi, V; Rickerts, V; Staszewski, S; Tews, J | 1 |
| Clarke, SM; Mulcahy, FM | 1 |
| Bower, M; Gazzard, BG; Johnson, MA; Lampe, F; Mandalia, S; Matthews, GV; Nelson, MR; Phillips, AN; Sabin, CA | 1 |
| Belson, M; Chun, TW; Connors, M; Davey, RT; Dybul, M; Fauci, AS; Hallahan, CW; Herpin, B; Hidalgo, B; Justement, JS; Metcalf, JA; Migueles, SA; Perry, C | 1 |
| Chaisson, RE; Mehta, SH; Moore, RD; Sulkowski, MS; Thomas, DL | 1 |
| Arnó, A; Balagué, M; Bonjoch, A; Clotet, B; Cruz, L; Fumaz, CR; Gel, S; Johnston, S; Jou, A; Negredo, E; Paredes, R; Romeu, J; Ruiz, L; Sirera, G; Tuldrà, A; Tural, C | 1 |
| Henry, K; Jenny-Avital, E | 1 |
| Fundarò, C; Genovese, O; Rendeli, C; Salvaggio, E; Tamburrini, E | 1 |
| Back, DJ; Buclin, T; Chave, JP; Decosterd, LA; Eap, CB; Fellay, J; Furrer, H; Marzolini, C; Meaden, ER; Opravil, M; Pantaleo, G; Retelska, D; Ruiz, L; Schinkel, AH; Telenti, A; Vernazza, P | 1 |
| Carducci, B; Cavaliere, AF; De Santis, L; De Santis, M; Straface, G | 1 |
| Barceló, M; Domingo, P | 1 |
| Belohradsky, BH; Eberle, J; Engelhorn, C; Funk, M; Hoffmann, F; Notheis, G; Wintergerst, U | 1 |
| Bernasconi, E; Bucher, HC; Flepp, M; Hirschel, B; Ledergerber, B; Telenti, A; Wagels, T; Zellweger, C | 1 |
| Ait-Khaled, M; Brosgart, CL; Eron, JJ; Falloon, J; Feinberg, J; Flanigan, TP; Hammer, SM; Kraus, PW; Masur, H; Murphy, R; Thomas, DA; Torres, R | 1 |
| Cardella, C; Conly, J; Humar, A; Nguyen, ME; Tseng, A | 1 |
| Bettendorf, D; Bucy, RP; Chan, E; Evans, T; Gonzalez, CJ; Landay, AL; Phair, JP; Schmitz, JL; Schnizlein-Bick, CT; Spritzler, J; Squires, KE | 1 |
| Calvo, R; Carlos, MA; Lukas, JC; Rodriguez, M; Suarez, E | 1 |
| Kikuchi, Y; Oka, S; Yazaki, H | 1 |
| Olivieri, J | 1 |
| Bonjoch, A; Clotet, B; Ferrer, MJ; Fumaz, CR; Jou, T; Negredo, E; Paredes, R; Romeu, J; Sirera, G; Tuldrà, A; Tural, C | 1 |
| Maggiolo, F; Maserati, R; Migliorino, M; Pan, A; Provettoni, G; Rizzi, L; Rizzi, M; Suter, F | 1 |
| Back, DJ; Boffito, M; Di Perri, G; Hoggard, PG; Reynolds, HE; Rossati, A | 1 |
| de Groot, R; Fraaij, PL; van Rossum, AM | 1 |
| Lewis, A; Mitchell, S | 1 |
| Arendt, G; Köller, H; Theisen, A; von Giesen, HJ | 1 |
| Airoldi, M; Carosi, G; Casari, S; Castelli, F; Fausti, C; Moretti, F; Pan, A; Quiros-Roldan, E; Torti, C | 1 |
| Herhaus, C; Kaiser, R; Rockstroh, JK; Römer, K; Salzberger, B; Schliefer, K; Voigt, E; Wasmuth, JC | 1 |
| Christopherson, C; Fenton, T; Fletcher, CV; Hsia, K; Powell, CA; Saitoh, A; Spector, SA; Starr, SE | 1 |
| Edno-Mcheik, L; Lagrange, F; Molimard, M; Moore, N; Péhourcq, F; Titier, K | 1 |
| Castillo, R; El-Sherif, N; Pedalino, RP; Turitto, G | 1 |
| Kashuba, AD; Rezk, NL; Tidwell, RR | 1 |
| De Villar, NG; Estrada, V; Fernández, C; Larrad, MT; López, AG; Serrano-Rios, M | 1 |
| Aberg, JA; Bennett, KK; Bessen, LJ; Brosgart, C; DeGruttola, V; Eron, JJ; Gulick, RM; Hammer, SM; Holohan, MK; Karol, CN; Lewis, RH; Mellors, JW; Mitsuyasu, RT; Rogers, MD; Saah, AJ; Sheiner, L; Vaida, F; Valentine, FT; Wheat, LJ | 1 |
146 review(s) available for efavirenz and HIV Coinfection
| Article | Year |
|---|---|
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
Topics: Administration, Oral; Anti-HIV Agents; Biological Availability; Crystallography, X-Ray; Drug Design; Drug Evaluation, Preclinical; Genome, Viral; HIV; HIV Infections; Humans; Interdisciplinary Communication; Models, Molecular; Molecular Structure; Mutation; Nitriles; Pyrimidines; Rilpivirine | 2005 |
Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2018 |
Anti-retroviral drugs induced photosensitivity may be two culprits in mixed formulation, a case report and literature review.
Topics: Benzoxazines; Female; HIV Infections; Humans; Photochemotherapy; Tenofovir | 2022 |
Efavirenz: History, Development and Future.
Topics: Anti-HIV Agents; Benzoxazines; HIV Infections; Humans; Reverse Transcriptase Inhibitors | 2022 |
Meta-analysis of the associations of CYP2B6-516G>T polymorphisms with efavirenz-induced central nervous system side effects and virological outcome in HIV-infected adults.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; HIV Infections; Humans; Male; Polymorphism, Single Nucleotide; Prospective Studies; Retrospective Studies; Treatment Outcome; Viral Load | 2020 |
The Pharmacogenetics of Efavirenz Metabolism in Children: The Potential Genetic and Medical Contributions to Child Development in the Context of Long-Term ARV Treatment.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child Development; Child, Preschool; Cyclopropanes; Cytochrome P-450 CYP2B6; HIV Infections; Humans; Pharmacogenetics; Reverse Transcriptase Inhibitors | 2020 |
A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Astrocytes; Atazanavir Sulfate; Benzoxazines; Central Nervous System; Cognitive Dysfunction; Cyclopropanes; Dideoxynucleosides; Endothelial Cells; HIV Infections; Humans; Neurons; Nevirapine; Nitriles; Oligodendroglia; Pyrimidines | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; In Vitro Techniques; Pyridones; Rilpivirine; Triazoles | 2020 |
Efavirenz versus Protease Inhibitors in Patients with HIV: A Systematic Review and Meta-Analysis
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; HIV Protease Inhibitors; Humans; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2021 |
A Concise Analytical Profile of Efavirenz: Analytical Methodologies.
Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Pharmaceutical Preparations; Reverse Transcriptase Inhibitors; RNA; RNA-Directed DNA Polymerase | 2022 |
Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir/rilpivirine: a meta-analysis.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Depression; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Neurotoxicity Syndromes; Oxazines; Piperazines; Pyridones; Randomized Controlled Trials as Topic; Rilpivirine | 2021 |
Integrase inhibitors versus efavirenz combination antiretroviral therapies for TB/HIV coinfection: a meta-analysis of randomized controlled trials.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Coinfection; Cyclopropanes; HIV Infections; Humans; Integrase Inhibitors; Randomized Controlled Trials as Topic | 2021 |
The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir dis
Topics: Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Obesity; Oxazines; Piperazines; Pregnancy; Pregnancy Outcome; Pyridones; Tenofovir | 2021 |
Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings.
Topics: Adenine; Alanine; Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Rifampin; Tenofovir | 2017 |
Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines.
Topics: Adult; Alkynes; Benzoxazines; Contraception; Contraceptive Agents; Counseling; Cyclopropanes; Drug Implants; Family Planning Services; Female; Health Policy; HIV Infections; Humans; Kenya; Nevirapine; Pregnancy; Pregnancy Rate; Progestins; South Africa; Young Adult | 2017 |
Antiretroviral dose optimization: the future of efavirenz 400 mg dosing.
Topics: Adenine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Dose-Response Relationship, Drug; HIV Infections; Humans; Organophosphonates; Tenofovir; Treatment Outcome | 2017 |
Efavirenz: What is known about the cellular mechanisms responsible for its adverse effects.
Topics: Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans | 2017 |
Choice of initial antiretroviral drugs and treatment outcomes among HIV-infected patients in sub-Saharan Africa: systematic review and meta-analysis of observational studies.
Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; Humans; Incidence; Nevirapine; Reverse Transcriptase Inhibitors; Treatment Outcome | 2017 |
Risks of cardiovascular or central nervous system adverse events and immune reconstitution inflammatory syndrome, for dolutegravir versus other antiretrovirals: meta-analysis of randomized trials.
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Cardiovascular System; Cyclopropanes; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Nervous System; Oxazines; Piperazines; Pyridones; Randomized Controlled Trials as Topic | 2018 |
CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose.
Topics: AIDS Dementia Complex; Alkynes; Anti-HIV Agents; Benzoxazines; Brain; Central Nervous System; Cerebrospinal Fluid; Cyclopropanes; HIV Infections; HIV-1; Humans; Neopterin; Neurocognitive Disorders | 2018 |
HIV and mental illness in Malawi and the neuropsychiatric sequelae of efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Mental Disorders | 2018 |
Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs.
Topics: Abnormalities, Drug-Induced; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Congenital Abnormalities; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Infant, Low Birth Weight; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Network Meta-Analysis; Nevirapine; Perinatal Care; Pregnancy; Pregnancy Complications, Infectious; Stavudine; Stillbirth; Zidovudine | 2018 |
Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and Other HIV-1 Antiretroviral Drugs.
Topics: Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Illicit Drugs; Neurotoxicity Syndromes; Reverse Transcriptase Inhibitors | 2018 |
The pharmacokinetics, pharmacodynamics, and clinical role of fixed dose combination of tenofovir disoproxil fumarate, lamivudine and reduced dose efavirenz (TLE-400) in treating HIV-1 infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Tenofovir | 2018 |
A model-based comparative meta-analysis of the efficacy of dolutegravir-based and efavirenz-based regimens in HIV-infected patients.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Meta-Analysis as Topic; Models, Theoretical; Oxazines; Piperazines; Pyridones | 2019 |
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; HIV Infections; HIV-1; Humans; Pharmacogenetics; Pharmacogenomic Testing; Practice Guidelines as Topic | 2019 |
Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations.
Topics: Alkynes; Anti-HIV Agents; ATPases Associated with Diverse Cellular Activities; Benzoxazines; Constitutive Androstane Receptor; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Genetic Variation; Glucuronosyltransferase; HIV Infections; Humans; Metalloendopeptidases; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors | 2019 |
Treatment of Central Nervous System Manifestations of HIV in the Current Era.
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Central Nervous System Infections; Cyclopropanes; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Raltegravir Potassium | 2019 |
HIV drug resistance in mothers and infants following use of antiretrovirals to prevent mother-to-child transmission.
Topics: Alkynes; Anti-HIV Agents; Aptamers, Nucleotide; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Developing Countries; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Mothers; Nevirapine; Point Mutation; Pregnancy; Pregnancy Complications, Infectious; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Sentinel Surveillance; Sequence Analysis, DNA; Viral Load; Zidovudine | 2013 |
Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Nelfinavir; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic; Zidovudine | 2013 |
Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lipids; Maintenance Chemotherapy; Middle Aged; Nevirapine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Failure; Viral Load; Young Adult; Zidovudine | 2013 |
Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis.
Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Nevirapine; Treatment Outcome; Tuberculosis; Withholding Treatment | 2013 |
EFV/FTC/TDF-associated hepatotoxicity: a case report and review.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Liver; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2013 |
Nevirapine-based regimens in HIV-infected antiretroviral-naive patients: systematic review and meta-analysis of randomized controlled trials.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Nevirapine; Randomized Controlled Trials as Topic; Ritonavir; Treatment Outcome | 2013 |
[Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Multicenter Studies as Topic; Nitriles; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Therapeutic Equivalency; Treatment Outcome; Viral Load; Viremia | 2013 |
[Potential role of rilpivirine in simplification regimens].
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; Humans; Medication Adherence; Multicenter Studies as Topic; Nitriles; Patient Acceptance of Health Care; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Treatment Outcome | 2013 |
Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection.
Topics: Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Combinations; Drug Interactions; Half-Life; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir | 2014 |
Clinically relevant drug-drug interactions between antiretrovirals and antifungals.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-Retroviral Agents; Antifungal Agents; Benzoxazines; Carbamates; Cyclopropanes; Drug Interactions; Drug Monitoring; Echinocandins; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Itraconazole; Mycoses; Organophosphates; Pyrimidines; Ritonavir; Sulfonamides; Triazoles; Voriconazole | 2014 |
Has the time come to abandon efavirenz for first-line antiretroviral therapy?
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; Humans; Suicide | 2014 |
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis.
Topics: Abnormalities, Drug-Induced; Alkynes; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, First; Reverse Transcriptase Inhibitors; Treatment Outcome | 2014 |
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Coinfection; Cyclopropanes; HIV Infections; Humans; Nevirapine; Rifampin; Treatment Outcome; Tuberculosis; Viral Load | 2014 |
Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Black People; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Glucuronosyltransferase; HIV Infections; Humans; Metabolic Detoxication, Phase I; Metabolic Detoxication, Phase II; Nevirapine; Pharmacogenetics; Polymorphism, Single Nucleotide | 2015 |
Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Genome-Wide Association Study; HIV Infections; HIV-1; Humans; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach.
Topics: Adenine; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Cyclopropanes; Drug Resistance, Viral; Drug Therapy; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Organophosphonates; Public Health; Tenofovir | 2014 |
Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Darunavir; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lipids; Male; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Ritonavir; Time Factors; Treatment Outcome | 2015 |
Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; HIV Infections; Humans | 2015 |
Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; Humans; Randomized Controlled Trials as Topic; Receptors, CCR5; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome | 2015 |
PharmGKB summary: Efavirenz pathway, pharmacokinetics.
Topics: Alkynes; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Drug Interactions; Glucuronosyltransferase; HIV Infections; HIV-1; Humans; Metabolic Networks and Pathways; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors | 2015 |
Efavirenz and the CNS: what we already know and questions that need to be answered.
Topics: Alkynes; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Central Nervous System; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme Inhibitors; Disease Models, Animal; HIV Infections; Humans; Pharmacogenetics; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors | 2015 |
Efficacy and safety of abacavir-containing combination antiretroviral therapy as first-line treatment of HIV infected children and adolescents: a systematic review and meta-analysis.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Lopinavir; Male; Ritonavir; Stavudine | 2015 |
Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptive Agents; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Kenya; Longitudinal Studies; Nevirapine; Pregnancy; Pregnancy Rate; Retrospective Studies; Treatment Outcome | 2015 |
Efavirenz-based antiretroviral therapy versus nevirapine-including regimens for prevention of mother-to-child transmission of HIV option B plus in resource-limited settings: is there anything missing?
Topics: Adult; Africa South of the Sahara; Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Developing Countries; Female; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Nevirapine; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors | 2016 |
Breast enlargement in Malawian males on the standard first-line antiretroviral therapy regimen: Case reports and review of the literature.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Gynecomastia; HIV Infections; Humans; Male | 2015 |
A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications.
Topics: Alkynes; Anti-HIV Agents; Anxiety; Benzoxazines; Cyclopropanes; Depression; Dizziness; HIV Infections; Humans; Sleep Wake Disorders | 2016 |
Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Randomized Controlled Trials as Topic; Tenofovir; World Health Organization | 2016 |
Rethinking the risk-benefit ratio of efavirenz in HIV-infected children.
Topics: Africa; Alkynes; Benzoxazines; Central Nervous System Diseases; Child; Cognition; Cyclopropanes; HIV Infections; HIV-1; Humans; Odds Ratio; Reverse Transcriptase Inhibitors | 2016 |
The Role of ARV Associated Adverse Drug Reactions in Influencing Adherence Among HIV-Infected Individuals: A Systematic Review and Qualitative Meta-Synthesis.
Topics: Adaptation, Psychological; Alkynes; Anti-HIV Agents; Benzoxazines; Counseling; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Medication Adherence; Qualitative Research | 2017 |
Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2016 |
Rolling out Efavirenz for HIV Precision Medicine in Africa: Are We Ready for Pharmacovigilance and Tackling Neuropsychiatric Adverse Effects?
Topics: Africa South of the Sahara; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Drug Monitoring; Drug Resistance, Viral; HIV Infections; Humans; Mental Disorders; Patient Compliance; Pharmacogenomic Variants; Precision Medicine; Quality of Life | 2016 |
Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Bayes Theorem; Benzoxazines; Child; Clinical Trials as Topic; Cyclopropanes; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Male; Middle Aged; Network Meta-Analysis; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Viral Load; Young Adult | 2016 |
Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors | 2016 |
Role of Cytochrome P450 2B6 Pharmacogenomics in Determining Efavirenz-Mediated Central Nervous System Toxicity, Treatment Outcomes, and Dosage Adjustments in Patients with Human Immunodeficiency Virus Infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Dose-Response Relationship, Drug; Genotype; HIV Infections; Humans; Pharmacogenetics; Polymorphism, Genetic | 2016 |
Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Bone Diseases; Clinical Trials as Topic; Cyclopropanes; Drug Interactions; Emtricitabine; HIV Infections; Humans; Incidence; Kidney Diseases; Tenofovir; Treatment Outcome | 2016 |
Topics: Absorptiometry, Photon; Adult; Air Pollutants; Alkynes; Alleles; Animals; Anthracenes; Anthraquinones; Anti-HIV Agents; Benzoxazines; Black or African American; Bone Density; Bone Density Conservation Agents; C-Reactive Protein; Calcium, Dietary; Capsid Proteins; Cardiomyopathy, Dilated; Cardiovascular Diseases; CD4 Lymphocyte Count; Cholesterol; Collagen Type I; Cyclopropanes; Darunavir; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Emtricitabine; Epitopes; Female; Femur Neck; Gene Expression Profiling; Genetic Predisposition to Disease; Hepatitis, Viral, Animal; Hip Joint; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunization; Inflammation Mediators; Lipoproteins, LDL; Lupus Erythematosus, Systemic; Male; Mice; Mice, Inbred BALB C; Nitrates; Osteocalcin; Oxidation-Reduction; Parathyroid Hormone; Parvovirus B19, Human; Peptides; Phenotype; Pilot Projects; Polymorphism, Single Nucleotide; Raltegravir Potassium; Ritonavir; RNA, Viral; Sodium Chloride; Tenofovir; Transcriptome; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Vaccines; Vascular Endothelial Growth Factor A; Vitamin D; Young Adult | 2016 |
Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Viral Load | 2016 |
A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dyslipidemias; Fluorobenzenes; HIV Infections; Humans; Hypolipidemic Agents; Male; Middle Aged; Nevirapine; Patient Compliance; Pyrimidines; Reverse Transcriptase Inhibitors; Rosuvastatin Calcium; Sulfonamides | 2008 |
Efavirenz--still first-line king?
Topics: Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Resistance, Viral; HIV Infections; Humans; Reverse Transcriptase Inhibitors | 2008 |
Clinical impact of patient population differences and genomic variation in efavirenz therapy.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Ethnicity; HIV Infections; Humans; Liver; Oxidoreductases, N-Demethylating; Patient Compliance; Pharmacogenetics; Reverse Transcriptase Inhibitors; Treatment Outcome | 2008 |
[Maraviroc efficacy in clinical studies on the development of the molecule].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Cyclohexanes; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Design; Drug Resistance, Multiple, Viral; env Gene Products, Human Immunodeficiency Virus; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Multicenter Studies as Topic; Salvage Therapy; Treatment Outcome; Triazoles | 2008 |
[The "induction-maintenance" strategy].
Topics: Adipose Tissue; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Virus Replication; Zidovudine | 2008 |
A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Combinations; HIV Infections; Humans; Lamivudine; Nelfinavir; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic; Zidovudine | 2009 |
Pharmacogenetics of antiretrovirals.
Topics: Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Dideoxynucleosides; Glucuronosyltransferase; HIV Infections; HLA-A Antigens; HLA-B Antigens; HLA-DRB1 Chains; Humans; Nevirapine; Oligopeptides; Oxidoreductases, N-Demethylating; Pharmacogenetics; Pyridines | 2010 |
Efavirenz: a decade of clinical experience in the treatment of HIV.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; Humans; Lipodystrophy; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.
Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; Child; Cyclopropanes; Drug Interactions; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis | 2010 |
Efavirenz in the therapy of HIV infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chemistry, Pharmaceutical; Cyclopropanes; Food-Drug Interactions; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors | 2010 |
Pharmacokinetics of low-dose protease inhibitors and efavirenz in low- and middle-income countries.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Developing Countries; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Poverty; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Thailand | 2010 |
Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts.
Topics: Abnormalities, Drug-Induced; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pregnancy Trimester, First; Risk Factors | 2010 |
Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2010 |
Neuropsychiatric complications of efavirenz therapy: suggestions for a new research paradigm.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Biomedical Research; Cyclopropanes; HIV Infections; Humans; Mental Disorders; Models, Biological; Psychophysiology | 2010 |
"Bullfrog neck," a unique morphologic trait in HIV lipodystrophy: case series and review of the literature.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Middle Aged; Neck; Reverse Transcriptase Inhibitors | 2010 |
Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2010 |
A systematic review of the psychiatric side-effects of efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Mental Disorders; Sleep Initiation and Maintenance Disorders | 2011 |
HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review.
Topics: Adolescent; Africa; Alkynes; Anti-HIV Agents; Asia; Benzoxazines; Child; Child, Preschool; Cross-Sectional Studies; Cyclopropanes; Developing Countries; Drug Resistance, Viral; Female; Health Resources; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Latin America; Lopinavir; Male; Mutation; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Treatment Failure; Viral Load; Zidovudine | 2011 |
Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis.
Topics: Abnormalities, Drug-Induced; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Incidence; Neural Tube Defects; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pregnancy Trimester, First; Risk Factors; Treatment Outcome | 2011 |
Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cyclopropanes; HIV Infections; Humans; Infant; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine | 2011 |
A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Tenofovir; Treatment Failure; Viral Load; World Health Organization | 2012 |
NNRTIs: future prospects.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Forecasting; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors | 2012 |
Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Interactions; Drug Resistance, Viral; Drug Substitution; HIV Infections; HIV-1; Humans; Nitriles; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine | 2012 |
Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; HIV Infections; Humans; Nevirapine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2013 |
Non-nucleoside reverse transcriptase inhibitors--an overview.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 2003 |
Population pharmacokinetic meta-analysis with efavirenz.
Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Clinical Trials, Phase I as Topic; Cyclopropanes; Dose-Response Relationship, Drug; Drug Interactions; Female; HIV Infections; HIV Reverse Transcriptase; Humans; Male; Models, Biological; Models, Statistical; Oxazines; Reverse Transcriptase Inhibitors | 2002 |
NNRTI hepatotoxicity: efavirenz versus nevirapine.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Hepatitis B; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Liver Diseases; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 2002 |
Toxicity of non-nucleoside analogue reverse transcriptase inhibitors.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Delavirdine; HIV Infections; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 2003 |
A manic episode associated with efavirenz therapy for HIV infection.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Bipolar Disorder; Cyclopropanes; HIV Infections; Humans; Male; Oxazines; Time Factors | 2003 |
Protease inhibitor-sparing regimens: new evidence strengthens position.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Clinical Protocols; Clinical Trials as Topic; Cohort Studies; Cyclopropanes; Delavirdine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Immunosuppression Therapy; Mutation; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Viral Load | 2003 |
[Antiretroviral-induced toxiderma in HIV-infected patients].
Topics: Alkynes; Anti-HIV Agents; Anti-Inflammatory Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Hypersensitivity; Exanthema; Histamine H1 Antagonists; HIV Infections; HIV Protease Inhibitors; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Risk Factors; Steroids; Stevens-Johnson Syndrome | 2003 |
Perspectives on HAART: switch maintenance therapy.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; HIV Infections; HIV Protease Inhibitors; Humans; Lipodystrophy; Metabolic Diseases; Nevirapine; Oxazines; Patient Compliance; Reverse Transcriptase Inhibitors | 2003 |
Issues in antiretroviral toxicity.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Exanthema; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Nevirapine; Oxazines; Pregnancy; Quality of Life; Randomized Controlled Trials as Topic | 2003 |
Efavirenz: enhancing the gold standard.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Drug Administration Schedule; HIV Infections; Humans; Oxazines; Patient Compliance | 2003 |
Releasing the true power of protease inhibitors.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Oxazines; Pyridines; Randomized Controlled Trials as Topic | 2003 |
The continuing evolution of HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Delayed-Action Preparations; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Monitoring; Emtricitabine; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyridines; Randomized Controlled Trials as Topic; Stavudine; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2003 |
Editorial comment: unraveling the cause of HIV-related gynecomastia.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Diagnosis, Differential; Gynecomastia; HIV Infections; Humans; Male; Oxazines; Remission, Spontaneous; Risk Factors | 2004 |
Clinical utility of current NNRTIs and perspectives of new agents in this class under development.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 2004 |
Efavirenz for HIV-1 infection in adults: an overview.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; HIV Infections; HIV-1; Humans; Oxazines; Practice Guidelines as Topic; Reverse Transcriptase Inhibitors | 2004 |
NNRTI hypersusceptibility.
Topics: Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Hypersensitivity; Drug Resistance, Viral; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; Viral Load | 2005 |
[Neurospychiatric symptoms in HIV infected patients and the role of efavirenz].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Incidence; Mental Disorders; Oxazines | 2004 |
Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardiovascular Diseases; Cyclopropanes; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Kidney Diseases; Lopinavir; Metabolic Syndrome; Nevirapine; Organophosphonates; Oxazines; Pyrimidinones; Risk Factors; Tenofovir | 2005 |
A potentially significant interaction between efavirenz and phenytoin: a case report and review of the literature.
Topics: Adult; Alkynes; Anti-HIV Agents; Anticonvulsants; Benzoxazines; Cyclopropanes; Drug Interactions; HIV Infections; Humans; Male; Oxazines; Phenytoin; Seizures | 2005 |
Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
Topics: Adenine; Age Factors; Alkynes; Atazanavir Sulfate; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Liver; Oligopeptides; Organophosphonates; Oxazines; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Sex Factors; Tenofovir | 2005 |
Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Cardiovascular Diseases; Cyclopropanes; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Metabolic Syndrome; Nevirapine; Oxazines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Risk Factors; Stavudine; Zidovudine | 2005 |
[Non-nucleoside inhibitors of reverse transcriptase in therapy of HIV-infection].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Oxazines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase | 2005 |
Human genetic variability and HIV treatment response.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Genetic Variation; HIV Infections; HIV-1; Humans; Oxazines; Pharmacogenetics; Proteins; Reverse Transcriptase Inhibitors; Treatment Outcome | 2006 |
HIV infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Early Diagnosis; HIV Infections; HIV Protease Inhibitors; Humans; Infectious Disease Transmission, Patient-to-Professional; Nevirapine; Oxazines; Sexually Transmitted Diseases | 2005 |
[The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Treatment Outcome | 2006 |
HIV infection.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Early Diagnosis; HIV Infections; HIV Protease Inhibitors; Humans; Infectious Disease Transmission, Patient-to-Professional; Nevirapine; Sexually Transmitted Diseases | 2006 |
Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Didanosine; Drug Resistance, Viral; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Oxazines; Quality of Life; Reverse Transcriptase Inhibitors | 2006 |
Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?
Topics: Algorithms; Alkynes; Anti-HIV Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Decision Support Techniques; Drug Interactions; Drug Monitoring; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Nevirapine; Oxazines; Patient Selection; Pharmacogenetics; Practice Guidelines as Topic; Reverse Transcriptase Inhibitors | 2007 |
Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Efavirenz: a review.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors; Treatment Outcome | 2007 |
Efavirenz.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Immunocompromised Host; Mutation; Patient Compliance | 2007 |
The first once-daily single-tablet regimen for the treatment of HIV-infected patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Organophosphonates; Reverse Transcriptase Inhibitors; Tablets; Tenofovir; Therapeutic Equivalency | 2007 |
Is it safe to switch between efavirenz and nevirapine in the event of toxicity?
Topics: Alkynes; Benzoxazines; Chemical and Drug Induced Liver Injury; Cross Reactions; Cyclopropanes; Drug Eruptions; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors | 2007 |
The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2008 |
The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Virus Replication | 1998 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1998 |
Efavirenz.
Topics: Administration, Oral; Alkynes; Antiviral Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Oxazines; Reverse Transcriptase Inhibitors | 1998 |
A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Interactions; HIV Infections; HIV-1; Humans; Oxazines; Reverse Transcriptase Inhibitors | 1999 |
New reverse transcriptase inhibitors.
Topics: Adenine; Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Dideoxynucleosides; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Organophosphonates; Oxazines; Prodrugs; Reverse Transcriptase Inhibitors; Soman; Uracil | 1999 |
Strategies for second-line antiretroviral therapy in adults with HIV infection.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV; HIV Infections; Humans; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Virus Latency; Virus Replication | 1999 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
Dose-ranging studies.
Topics: Age Factors; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Oxazines | 1999 |
Review of NNRTIs: 'today and tomorrow'.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Oxazines; Reverse Transcriptase Inhibitors; Zidovudine | 1999 |
Efavirenz: resistance and cross-resistance.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Microbial; Genotype; HIV Infections; HIV-1; Humans; Mutation; Nevirapine; Oxazines; Phenotype; Reverse Transcriptase Inhibitors; Treatment Failure; Virus Replication | 1999 |
Paediatric treatment issues.
Topics: Administration, Oral; Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Oxazines | 1999 |
The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Interactions; Drug Resistance; Drug Therapy, Combination; HIV Infections; HIV Protease; HIV Reverse Transcriptase; Humans; Nevirapine; Oxazines; Protease Inhibitors; Reverse Transcriptase Inhibitors | 2001 |
International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Delavirdine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Oxazines; Phylogeny; Point Mutation; Protein Conformation; Reverse Transcriptase Inhibitors; Virus Replication | 2001 |
Efavirenz: a pharmacoeconomic review of its use in HIV infection.
Topics: Alkynes; Benzoxazines; Canada; Cyclopropanes; Economics, Pharmaceutical; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; Survival Rate; United States | 2001 |
The role of NNRTIs in antiretroviral combination therapy: an introduction.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; HIV Infections; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 2001 |
Comparison of NNRTIs in antiretroviral-naïve patients.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; HIV Infections; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Statistics as Topic; Treatment Outcome; Viral Load | 2001 |
Comparison of NNRTIs in antiretroviral-experienced patients.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Treatment Outcome | 2001 |
Factors affecting adherence and convenience in antiretroviral therapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Nevirapine; Oxazines; Patient Compliance; Problem Solving; Reverse Transcriptase Inhibitors; Treatment Refusal | 2001 |
Other issues: penetration into sanctuary sites, immune reconstitution and NNRTI sequencing.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 2001 |
Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Benzoxazines; Biological Availability; Cyclopropanes; Delavirdine; Drug Interactions; Female; Half-Life; HIV Infections; Humans; Intestinal Absorption; Male; Nevirapine; Oxazines; Pregnancy; Reverse Transcriptase Inhibitors | 2001 |
Efavirenz therapy in drug users.
Topics: Alkynes; Analgesics, Opioid; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Methadone; Oxazines; Reverse Transcriptase Inhibitors; Substance Abuse, Intravenous; Substance-Related Disorders | 2000 |
Efficacy of highly active antiretroviral therapy in HIV-1 infected children.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir | 2002 |
491 trial(s) available for efavirenz and HIV Coinfection
| Article | Year |
|---|---|
Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children?
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; Humans; Male | 2009 |
De novo electrocardiographic abnormalities in persons living with HIV.
Topics: Adult; Alkynes; Antiviral Agents; Benzoxazines; Cyclopropanes; Electrocardiography; Female; Heart; Heart Disease Risk Factors; HIV Infections; Humans; Incidence; Long QT Syndrome; Male; Middle Aged; Protease Inhibitors | 2021 |
Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam.
Topics: Alkynes; Benzoxazines; Coinfection; Cyclopropanes; Hepacivirus; Hepatitis C; HIV Infections; HLA-DR Antigens; Humans; Lipopolysaccharide Receptors; Neopterin; Raltegravir Potassium; Vietnam | 2022 |
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine.
Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Moxifloxacin; Rifampin; Tuberculosis | 2022 |
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
Topics: Administration, Oral; Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Child, Preschool; Cholesterol; Cyclopropanes; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; Viral Load | 2021 |
Efficacy and safety of Efavirenz 400 mg-based regimens switching from 600 mg-based regimens in people living with HIV with virological suppression in China: a randomized, open-label, non-inferiority study.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; HIV Infections; HIV-1; Humans; Quality of Life; Viral Load | 2022 |
A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pregnancy; Pregnancy Trimester, Third; Pyridones; Quality of Life | 2022 |
Risk Factors for Incident Hypertension Within 1 Year of Initiating Antiretroviral Therapy Among People with HIV.
Topics: Adult; Alkynes; Anti-HIV Agents; Antihypertensive Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Hypertension; Male; Middle Aged; Risk Factors; Ritonavir; Stavudine | 2022 |
Decreased Dolutegravir and Efavirenz Concentrations With Preserved Virological Suppression in Patients With Tuberculosis and Human Immunodeficiency Virus Receiving High-Dose Rifampicin.
Topics: Anti-HIV Agents; Benzoxazines; HIV; HIV Infections; Humans; Rifampin; Tuberculosis | 2023 |
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Male; Oxazines; Piperazines; Postpartum Period; Pregnancy; Pyridones; Tenofovir; Viral Load | 2022 |
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
Topics: Antitubercular Agents; Drug Therapy, Combination; HIV; HIV Infections; Humans; Isoniazid; Moxifloxacin; Rifampin; Tuberculosis; Tuberculosis, Pulmonary | 2023 |
Assessment of minority frequency pretreatment HIV drug-resistant variants in pregnant women and associations with virologic non-suppression at term.
Topics: Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Case-Control Studies; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Pharmaceutical Preparations; Pregnancy; Pregnant Women; Raltegravir Potassium; RNA; Viral Load | 2022 |
Lower Insulin Sensitivity in Newborns With In Utero HIV and Antiretroviral Exposure Who Are Uninfected in Botswana.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Botswana; Female; HIV Infections; Humans; Infant; Infant, Newborn; Insulin Resistance; Nevirapine; Pregnancy; Zidovudine | 2022 |
Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV.
Topics: Antimalarials; Female; HIV Infections; Humans; Malaria; Pregnancy; Pregnant Women; Quinolines | 2022 |
Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
Topics: Adenine; Anti-HIV Agents; Benzoxazines; Emtricitabine; HIV Infections; Humans; Lamivudine; Tenofovir | 2023 |
Gut microbiota alterations after switching from a protease inhibitor or efavirenz to raltegravir in a randomized, controlled study.
Topics: Anti-HIV Agents; Benzoxazines; Gastrointestinal Microbiome; HIV Infections; Humans; Inflammation; Protease Inhibitors; Raltegravir Potassium; RNA, Ribosomal, 16S | 2023 |
Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimens.
Topics: Adolescent; Benzoxazines; Contraception, Postcoital; Female; HIV Infections; Humans; Levonorgestrel; Rifampin; Tuberculosis | 2023 |
Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial.
Topics: Adult; Anti-Retroviral Agents; Benzoxazines; Emtricitabine; HIV Infections; Humans; Lamivudine; RNA; Tenofovir | 2023 |
Prevalence of neurotoxicity symptoms among postpartum women on isoniazid preventive therapy and efavirenz-based treatment for HIV: an exploratory objective of the IMPAACT P1078 randomized trial.
Topics: Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Postpartum Period; Pregnancy; Prevalence; Tuberculosis | 2023 |
Artemether-lumefantrine efficacy among adults on antiretroviral therapy in Malawi.
Topics: Adult; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Ethanolamines; Fluorenes; HIV Infections; Humans; Lumefantrine; Malaria; Malaria, Falciparum; Malawi; Treatment Outcome | 2023 |
Effect of double-dose levonorgestrel subdermal implant in women taking efavirenz-based antiretroviral therapy: The DoubLNG pharmacokinetic study.
Topics: Adolescent; Adult; Benzoxazines; Contraceptive Agents, Female; Female; HIV Infections; Humans; Levonorgestrel; Middle Aged; Pregnancy; Young Adult | 2023 |
Virologic response to antiretroviral therapy in people with HIV and tuberculosis in high tuberculosis burden countries.
Topics: Anti-HIV Agents; HIV Infections; Humans; Raltegravir Potassium; RNA, Viral; Tuberculosis; Viral Load | 2023 |
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial.
Topics: Adenine; Anti-HIV Agents; Benzoxazines; Child; Emtricitabine; Female; HIV Infections; Humans; Male; Pregnancy; RNA; Tenofovir; Viral Load | 2023 |
Improvements in Patient-Reported Outcomes Following Initiation of Dolutegravir-Based or Low-Dose Efavirenz-Based First-Line Antiretroviral Therapy: A Four-Year Longitudinal Analysis in Cameroon (NAMSAL ANRS 12313 Trial).
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cameroon; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Patient Reported Outcome Measures; Pyridones; Quality of Life | 2023 |
Safety of low dose efavirenz regimen in Indian adults with HIV-1 infection: Insights from a phase 4 interventional randomised trial.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Tenofovir; Treatment Outcome; Viral Load | 2023 |
More Frequent HIV Viral Load Testing With Point-Of-Care Tests Detects Elevated Viral Load Earlier in Postpartum HIV-Positive Women in a Randomized Controlled Trial in Two Clinics in Johannesburg, South Africa.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Female; HIV Infections; Humans; Point-of-Care Testing; Postpartum Period; Pregnancy; South Africa; Viral Load | 2023 |
Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Female; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; HIV Integrase Inhibitors; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Maternal-Fetal Exchange; Milk, Human; Oxazines; Piperazines; Pregnancy; Pyridones; Reverse Transcriptase Inhibitors; Risk Assessment; South Africa; Treatment Outcome; Uganda; Viral Load; Young Adult | 2019 |
Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cognition; Cyclopropanes; Drug Substitution; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Quality of Life; Rilpivirine; RNA, Viral; Sleep; Tenofovir; Viral Load | 2020 |
Effect of high-dose rifampicin on efavirenz pharmacokinetics: drug-drug interaction randomized trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; HIV Infections; Humans; Pharmaceutical Preparations; Rifampin | 2020 |
Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Topics: Adult; Alkynes; Antibiotics, Antitubercular; Antitubercular Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2B6 Inducers; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Randomized Controlled Trials as Topic; Rifampin; Treatment Outcome; Tuberculosis; Uganda | 2020 |
Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Contraceptive Agents, Female; Contraceptive Agents, Hormonal; Contraceptive Devices, Female; Cyclopropanes; Cytochrome P-450 CYP2B6; Desogestrel; Drug Interactions; Ethinyl Estradiol; Female; Genetic Association Studies; Genotype; HIV Infections; Humans; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Ritonavir; Vagina | 2020 |
Hepatotoxicity and Liver-Related Mortality in Women of Childbearing Potential Living With Human Immunodeficiency Virus and High CD4 Cell Counts Initiating Efavirenz-Containing Regimens.
Topics: Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cyclopropanes; Female; HIV; HIV Infections; Humans; Infant; Pregnancy | 2021 |
Efficacy and safety of lower dose tenofovir disoproxil fumarate and efavirenz versus standard dose in HIV-infected, antiretroviral-naive adults: a multicentre, randomized, noninferiority trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Density; China; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Male; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Outcome Assessment, Health Care; Pregnancy; Pregnancy Complications, Infectious; Raltegravir Potassium; Viral Load; Young Adult; Zidovudine | 2020 |
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Outcome Assessment, Health Care; Oxazines; Piperazines; Pregnancy; Pregnancy Outcome; Pregnancy Trimester, Third; Pyridones; Viral Load | 2020 |
Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission.
Topics: Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Male; Risk Factors | 2020 |
High efavirenz levels but not neurofilament light plasma levels are associated with poor neurocognitive functioning in asymptomatic HIV patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Asymptomatic Diseases; Attention; Benzoxazines; Biomarkers; Cognitive Dysfunction; Cyclopropanes; Executive Function; Female; HIV Infections; Humans; Male; Mental Status and Dementia Tests; Middle Aged; Neurofilament Proteins; Rilpivirine; Speech | 2020 |
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Arylamine N-Acetyltransferase; Benzoxazines; Cyclopropanes; Drug Synergism; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Nevirapine; Pharmacogenetics; Rifampin; Young Adult | 2021 |
Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens.
Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; HIV Integrase Inhibitors; Humans; Pharmacogenetics; Weight Gain | 2021 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Arylamine N-Acetyltransferase; Benzoxazines; Body Weight; Cyclopropanes; Cytochrome P-450 CYP2B6; Double-Blind Method; Drug Interactions; Equivalence Trials as Topic; Female; Genotype; HIV Infections; Humans; Isoniazid; Metabolic Clearance Rate; Middle Aged; Pregnancy; Prospective Studies; Reverse Transcriptase Inhibitors; Tuberculosis; Young Adult | 2021 |
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Oxazines; Piperazines; Pyridones; Weight Gain | 2021 |
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, n
Topics: Adenine; Adolescent; Adult; Alanine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Composition; Body Weight; Cyclopropanes; Duration of Therapy; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2020 |
Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Duration of Therapy; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Middle Aged; Oxazines; Piperazines; Pyridones; Treatment Outcome; Viral Load; Young Adult | 2020 |
Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP3A; HIV Infections; Humans; Longitudinal Studies; Rifampin; Tuberculosis | 2021 |
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Fumarates; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Tenofovir; Treatment Outcome; Triazoles | 2021 |
Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Pyridones; Tenofovir; Treatment Outcome; Triazoles | 2021 |
Outcomes of Methadone Maintenance Therapy Combined with Rilpivirine/Efavirenz in Treatment-Naive HIV-Infected Patients.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Methadone; Prospective Studies; Rilpivirine; Viral Load | 2021 |
Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agent Therapy from the ACTG A5336 Study.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Body Weight; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Drug Interactions; Female; HIV Infections; Humans; Janus Kinases; Male; Metabolic Clearance Rate; Middle Aged; Nitriles; Pyrazoles; Pyrimidines | 2021 |
Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis.
Topics: Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Drug Interactions; Female; HIV Infections; Humans; Isoniazid; Medroxyprogesterone Acetate; Pharmacogenetics; Rifampin; Tuberculosis | 2022 |
Brief Report: Vaginal Viral Shedding With Undetectable Plasma HIV Viral Load in Pregnant Women Receiving 2 Different Antiretroviral Regimens: A Randomized Clinical Trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Pregnant Women; Raltegravir Potassium; Vigna; Viral Load; Virus Shedding; Zidovudine | 2021 |
Comparison of six methods to estimate adherence in an ART-naïve cohort in a resource-poor setting: which best predicts virological and resistance outcomes?
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; RNA, Viral; South Africa; Surveys and Questionnaires; Treatment Failure; Viral Load | 2017 |
Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Composition; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Insulin-Like Growth Factor I; Lamivudine; Male; Prospective Studies; Tenofovir; Zidovudine | 2017 |
Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child, Preschool; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Infant; Lipids; Lopinavir; Male; Nevirapine; Ritonavir; RNA, Viral; Treatment Outcome | 2017 |
Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Burkina Faso; Child, Preschool; Cote d'Ivoire; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Lamivudine; Lopinavir; Male; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load | 2017 |
Effect of Valerian in Preventing Neuropsychiatric Adverse Effects of Efavirenz in HIV-Positive Patients: A Pilot Randomized, Placebo-Controlled Clinical Trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Anxiety; Benzoxazines; Cyclopropanes; Depression; Double-Blind Method; Female; HIV Infections; Humans; Hypnotics and Sedatives; Male; Patient Compliance; Pilot Projects; Valerian | 2017 |
Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Tablets; Tenofovir; Thailand | 2017 |
Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Rilpivirine; Tenofovir; Treatment Outcome; Viral Load | 2017 |
Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; Body Weight; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; Elasticity Imaging Techniques; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Raltegravir Potassium; Tenofovir; Triglycerides; Waist-Hip Ratio | 2017 |
Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Ethnicity; Female; Gene Frequency; Genotype; HIV Infections; Humans; Male; Pharmacogenetics; Polymorphism, Single Nucleotide; Proportional Hazards Models; Racial Groups; Risk Factors; Suicidal Ideation; Suicide; Treatment Outcome | 2017 |
Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution in HIV-Infected Patients Initiating Antiretroviral Therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclohexanes; Cyclopropanes; DNA, Viral; Duodenum; Female; HIV Infections; Humans; Lymphoid Tissue; Male; Maraviroc; Raltegravir Potassium; Rectum; RNA, Viral; Triazoles | 2017 |
Estradiol Levels Are Altered in Human Immunodeficiency Virus-Infected Pregnant Women Randomized to Efavirenz-Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Estradiol; Female; HIV Infections; HIV-1; Humans; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Progesterone; Ritonavir; Uganda | 2018 |
Impact of dolutegravir and efavirenz on immune recovery markers: results from a randomized clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; CD4 Lymphocyte Count; CD4-CD8 Ratio; Coinfection; Cyclopropanes; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Immunity; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Risk Factors; Treatment Outcome; Viral Load; Young Adult | 2018 |
Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Female; HIV Infections; HIV Seropositivity; Humans; Incidence; Male; Mass Screening; Middle Aged; Research Design; South Africa; Tenofovir; Treatment Outcome; Young Adult | 2018 |
Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study.
Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; Humans; India; Kaplan-Meier Estimate; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Tuberculosis; Viral Load | 2017 |
Economic evaluation of weekends-off antiretroviral therapy for young people in 11 countries.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cost-Benefit Analysis; Cyclopropanes; Drug Administration Schedule; Drugs, Generic; Follow-Up Studies; Health Care Costs; HIV Infections; Humans; Internationality; Quality-Adjusted Life Years; Regression Analysis; Treatment Outcome; Viral Load; Young Adult | 2018 |
Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial.
Topics: Alkynes; Antiviral Agents; Benzimidazoles; Benzoxazines; Black or African American; Cohort Studies; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Therapy, Combination; Female; Fluorenes; Genome-Wide Association Study; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Polymorphism, Single Nucleotide; Recurrence; Sofosbuvir | 2018 |
Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; HIV Seropositivity; Humans; Male; Middle Aged; Self-Injurious Behavior; Suicide; Viral Load | 2018 |
Decreased bone turnover in HIV-infected children on antiretroviral therapy.
Topics: Absorptiometry, Photon; Alkynes; Benzoxazines; Bone Density; Bone Remodeling; Child; Child, Preschool; Collagen Type I; Cross-Sectional Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Peptides; Ritonavir; South Africa | 2018 |
Increased cholesterol absorption rather than synthesis is involved in boosted protease inhibitor-associated hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Blood Chemical Analysis; Cholesterol; Cyclopropanes; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Young Adult | 2018 |
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial.
Topics: Adolescent; Alkynes; Benzoxazines; Child; Cyclopropanes; Drug Administration Schedule; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Young Adult | 2018 |
Effect of Antiretroviral Therapy on Plasma Concentrations of Chloroquine and Desethyl-chloroquine.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antimalarials; Antiretroviral Therapy, Highly Active; Benzoxazines; Chloroquine; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Malaria; Male; Middle Aged; Protease Inhibitors | 2018 |
Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events.
Topics: Adult; Alkynes; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Female; Genomics; Genotype; HIV; HIV Infections; Humans; Male; Middle Aged; Neurotransmitter Transport Proteins; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Receptors, Neurotransmitter; Reverse Transcriptase Inhibitors | 2018 |
Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Monitoring; Female; HIV Infections; HIV-1; Humans; Pharmacogenetics; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Uganda; United Kingdom; Viral Load | 2018 |
Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.
Topics: Adolescent; Adult; Africa, Western; Aged; Aged, 80 and over; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; Blood Chemical Analysis; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Inactivation, Metabolic; Isoniazid; Male; Middle Aged; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis; Young Adult | 2019 |
Objective and Subjective Improvement of Cognition After Discontinuing Efavirenz in Asymptomatic Patients: A Randomized Controlled Trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cognition Disorders; Cyclopropanes; Drug Substitution; HIV Infections; Humans; Male; Middle Aged; RNA, Viral; Treatment Outcome; Viral Load | 2019 |
Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Half-Life; HIV Infections; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Tenofovir; Treatment Outcome; Triterpenes | 2018 |
Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Biological Variation, Population; Child; Child, Preschool; Cyclopropanes; Drug Monitoring; Female; HIV Infections; Humans; Lamivudine; Male; Tanzania; Zidovudine | 2018 |
Predicting Efavirenz Concentrations in the Brain Tissue of HIV-Infected Individuals and Exploring their Relationship to Neurocognitive Impairment.
Topics: Adult; Alkynes; Animals; Benzoxazines; Brain; Cognition Disorders; Cyclopropanes; Female; HIV Infections; Humans; Macaca mulatta; Male; Middle Aged; Young Adult | 2019 |
Randomized clinical trial on efficacy of fixed-dose efavirenz/tenofovir/emtricitabine on alternate days versus continuous treatment.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2019 |
Daily 800 mg versus 600 mg Efavirenz for HIV Patients Treating Tuberculosis with a Rifampicin-Based Regimen: An Open Label Randomized Controlled Trial.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Middle Aged; Rifampin; Tuberculosis | 2018 |
Brief Report: HIV Shedding in the Female Genital Tract of Women on ART and Progestin Contraception: Extended Follow-up Results of a Randomized Clinical Trial.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cervix Uteri; Contraception; Contraceptive Agents, Female; Cyclopropanes; Drug Implants; Female; Follow-Up Studies; Genitalia, Female; HIV Infections; Humans; Levonorgestrel; Malawi; Medroxyprogesterone Acetate; Progestins; Treatment Outcome; Virus Shedding | 2019 |
Role of efavirenz plasma concentrations on long-term HIV suppression and immune restoration in HIV-infected children.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Child; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Immune Reconstitution; Male; Retrospective Studies; Risk Factors; Virus Replication | 2019 |
Efficacy and safety of artemether-lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz-based antiretroviral therapy in Zambia: an open label non-randomized interventional trial.
Topics: Adolescent; Adult; Aged; Alkynes; Antimalarials; Artemether, Lumefantrine Drug Combination; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Malaria, Falciparum; Male; Middle Aged; Plasmodium falciparum; Polymerase Chain Reaction; Prospective Studies; Reverse Transcriptase Inhibitors; Young Adult; Zambia | 2019 |
Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years.
Topics: Africa; Alkynes; Benzoxazines; Child, Preschool; Cohort Studies; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; Humans; India; Infant; Male; Prospective Studies; Treatment Outcome; Tuberculosis | 2019 |
Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Desogestrel; Drug Interactions; Female; Genotype; HIV Infections; Humans; Nevirapine; Polymorphism, Single Nucleotide; Young Adult | 2019 |
Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Obesity; Oxazines; Piperazines; Pregnancy; Pyridones; RNA, Viral; Tenofovir; Viral Load; Weight Gain | 2019 |
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyridones; Treatment Outcome; Triazoles; Viral Load; Young Adult | 2019 |
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Oxazines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2013 |
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Mozambique; Nevirapine; Treatment Outcome; Tuberculosis; Tuberculosis, Pulmonary | 2013 |
Cyproheptadine for prevention of neuropsychiatric adverse effects of efavirenz: a randomized clinical trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Cyproheptadine; Depression; Double-Blind Method; Female; HIV Infections; Humans; Iran; Male; Mental Disorders; Personality Inventory; Psychiatric Status Rating Scales; Serotonin Antagonists; Socioeconomic Factors; Suicidal Ideation; Surveys and Questionnaires; Treatment Outcome | 2013 |
Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Diarylquinolines; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Middle Aged; Models, Biological; Quinolines; Stochastic Processes; Treatment Outcome; Tuberculosis; Young Adult | 2013 |
Long-term body composition and metabolic changes in HIV-infected children switched from stavudine to tenofovir and from protease inhibitors to efavirenz.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; Blood Glucose; Body Composition; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Lamivudine; Linear Models; Lipids; Longitudinal Studies; Male; Organophosphonates; Stavudine; Tenofovir | 2013 |
96-Week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nitriles; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Viral Load | 2013 |
A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Cyclopropanes; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Models, Theoretical; Predictive Value of Tests; Treatment Failure; Viral Load | 2013 |
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; C-Reactive Protein; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Furans; HIV Infections; Humans; Interleukin-6; Lamivudine; Male; Middle Aged; Organophosphates; Plasminogen; Prospective Studies; Ritonavir; Sulfonamides; Vascular Cell Adhesion Molecule-1; Young Adult | 2013 |
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Organophosphonates; Pilot Projects; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; Ritonavir; RNA Stability; RNA, Viral; Tenofovir; Viral Load | 2013 |
T Cell Activation and Cytokine Profile of Tuberculosis and HIV-Positive Individuals during Antituberculous Treatment and Efavirenz-Based Regimens.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Cytokines; Female; Gene Expression Regulation; HIV Infections; HIV-1; Humans; Lymphocyte Activation; Male; Mycobacterium; Prospective Studies; Treatment Outcome; Tuberculosis; Viral Load | 2013 |
Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
Topics: Adult; Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Ethnicity; Female; Genotype; Glucuronosyltransferase; HIV Infections; Humans; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Pharmacogenetics; Prospective Studies; Treatment Outcome; Young Adult | 2013 |
96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Bone and Bones; Bone Density; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Male; Organophosphonates; Tenofovir; Time Factors; Treatment Outcome | 2013 |
WHO option B+: early experience of antiretroviral therapy sequencing after cessation of breastfeeding and risk of dermatologic toxicity.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Breast Feeding; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Drug Eruptions; Drug Substitution; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Ritonavir; Uganda; World Health Organization | 2013 |
Factors associated with remaining on initial randomized efavirenz-containing regimens.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Middle Aged; Treatment Outcome | 2013 |
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Coinfection; Cyclopropanes; Drug Interactions; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Pyrrolidines; Ritonavir; Tenofovir; Valine; Viral Nonstructural Proteins; Young Adult | 2013 |
Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Nitriles; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Viral Load | 2014 |
A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients.
Topics: Adenine; Adult; Alkynes; Analysis of Variance; Anthropometry; Anti-HIV Agents; Benzoxazines; Biomarkers; Body Composition; Cyclopropanes; DNA, Mitochondrial; Dose-Response Relationship, Drug; Drug Substitution; Female; Glucose; HIV Infections; Humans; Inflammation; Lamivudine; Lipid Metabolism; Male; Middle Aged; Phosphorous Acids; South Africa; Stavudine | 2014 |
Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.
Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydroxylases; Arylamine N-Acetyltransferase; Benzoxazines; Cambodia; Chromatography, Liquid; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; HIV Infections; Humans; Isoniazid; Lamivudine; Plasma; Polymorphism, Single Nucleotide; Rifampin; Spectrophotometry, Ultraviolet; Stavudine; Tuberculosis | 2014 |
Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Pregnancy; Proportional Hazards Models; Reverse Transcriptase Inhibitors; South Africa; Treatment Outcome; Viral Load; Young Adult | 2013 |
Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Biological Availability; Cyclopropanes; Cyclosporine; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Immunosuppressive Agents; Kidney Transplantation; Liver Transplantation; Male; Middle Aged; Nevirapine; Tacrolimus; Young Adult | 2013 |
Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Biological Availability; Breast Feeding; Cyclopropanes; Dried Blood Spot Testing; Drug Combinations; Drug Therapy, Combination; Female; Hair; HIV Infections; Humans; Lopinavir; Malnutrition; Medication Adherence; Middle Aged; Nutritional Status; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Uganda; Young Adult | 2014 |
Plasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-western Tanzania.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Monitoring; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Tanzania; Viral Load | 2013 |
Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Female; HIV Infections; Humans; Liver; Liver Function Tests; Male; Nevirapine; Rifampin; Time Factors; Treatment Outcome; Tuberculosis; Viral Load | 2013 |
Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Female; HIV Infections; Humans; India; Male; Middle Aged; Nevirapine; Pilot Projects; Rifampin; Tuberculosis | 2013 |
Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; Hair; HIV Infections; Humans; Infant; Infant, Newborn; Lopinavir; Milk, Human; Plasma; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Uganda | 2013 |
24-Month adherence, tolerance and efficacy of once-a-day antiretroviral therapy with didanosine, lamivudine, and efavirenz in African HIV-1 infected children: ANRS 12103/12167.
Topics: Adolescent; Africa; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Confidence Intervals; Cyclopropanes; Didanosine; Female; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; RNA, Viral; Surveys and Questionnaires; Viral Load | 2013 |
Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA, Viral; Drug Resistance; Europe; Female; Genotyping Techniques; HIV Infections; HIV-1; Humans; Israel; Male; Microbial Sensitivity Tests; Middle Aged; Nitriles; Pyridazines; Pyrimidines; RNA, Viral; Russia; Treatment Outcome; Young Adult | 2014 |
Immunological function restoration with lopinavir/ritonavir versus efavirenz containing regimens in HIV-infected patients: a randomized clinical trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; HIV Infections; Humans; Immune System; Lopinavir; Male; Middle Aged; Ritonavir; Time Factors; Treatment Outcome | 2014 |
Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO).
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyrimidines; Rilpivirine; Risk Factors; Vitamin D; Vitamin D Deficiency; Young Adult | 2014 |
Outcomes in older versus younger patients over 96 weeks in HIV-1- infected patients treated with rilpivirine or efavirenz in ECHO and THRIVE.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Bone Density; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyrimidines; Rilpivirine; Treatment Outcome; Vitamin D; Young Adult | 2013 |
Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Medication Adherence; Placebos; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2014 |
Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial).
Topics: Adult; Alkynes; Benzoxazines; Body Weight; Cambodia; CD4-Positive T-Lymphocytes; Coinfection; Cyclopropanes; Female; HIV Infections; Humans; Male; Reverse Transcriptase Inhibitors; Tuberculosis | 2014 |
Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Organophosphonates; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; RNA, Viral; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2014 |
Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Female; Half-Life; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Treatment Outcome; Tuberculosis; Young Adult | 2014 |
Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti.
Topics: Adult; Alkynes; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP3A; Female; Genetic Association Studies; Haiti; HIV Infections; HIV-1; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Secondary Metabolism; Treatment Outcome | 2014 |
Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Brazil; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; France; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir; Treatment Outcome; Tuberculosis; Viral Load | 2014 |
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Benzoxazines; Body Fat Distribution; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Young Adult; Zidovudine | 2014 |
Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Black People; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2B6 Inducers; Female; Gene Dosage; Glucuronosyltransferase; HIV Infections; HIV-1; Humans; Male; Polymorphism, Single Nucleotide; Prospective Studies; Reverse Transcriptase Inhibitors; Secondary Metabolism; White People | 2014 |
Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol a5227.
Topics: Adenine; Adult; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Organophosphonates; Pregnancy; Prospective Studies; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2014 |
Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Biological Availability; Contraceptive Agents, Female; Cyclopropanes; Desogestrel; Drug Combinations; Drug Implants; Drug Interactions; Female; HIV Infections; Humans; Lopinavir; Ritonavir; Young Adult | 2014 |
Comparing the efficacy of efavirenz and boosted lopinavir using viremia copy-years.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Treatment Outcome; Viral Load; Viremia | 2014 |
A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Gene Expression Regulation; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Organophosphonates; Ritonavir; Subcutaneous Fat; Tenofovir; Transcriptome | 2014 |
Lopinavir/ritonavir-based antiretroviral treatment (ART) versus efavirenz-based ART for the prevention of malaria among HIV-infected pregnant women.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antimalarials; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Infant, Newborn; Lopinavir; Malaria; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Young Adult | 2014 |
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclohexanes; Cyclopropanes; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Treatment Outcome; Triazoles; Viral Load; Young Adult | 2014 |
Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Infant, Newborn; Lopinavir; Male; Pregnancy; Premature Birth; Risk Factors; Ritonavir; Uganda; Young Adult | 2014 |
Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
Topics: Adenine; Adult; Alkynes; Aminoisobutyric Acids; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Leucine; Male; Middle Aged; Oligopeptides; Organophosphonates; Proline; Protease Inhibitors; Quinolines; Ritonavir; Sulfonamides; Tenofovir; Thiazoles; Young Adult | 2014 |
Pharmacokinetics of para-aminosalicylic acid in HIV-uninfected and HIV-coinfected tuberculosis patients receiving antiretroviral therapy, managed for multidrug-resistant and extensively drug-resistant tuberculosis.
Topics: Adult; Alkynes; Aminosalicylic Acid; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Cross-Over Studies; Cyclopropanes; Extensively Drug-Resistant Tuberculosis; Female; HIV Infections; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Tuberculosis, Multidrug-Resistant; Young Adult | 2014 |
A validated method for quantification of efavirenz in dried blood spots using high-performance liquid chromatography-mass spectrometry.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Calibration; Chromatography, High Pressure Liquid; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; HIV Infections; Humans; Mass Spectrometry; Reproducibility of Results | 2015 |
Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cobicistat; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Microbial Sensitivity Tests; Mutation; Quinolones; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2015 |
Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Retreatment; Reverse Transcriptase Inhibitors; Rilpivirine; Young Adult | 2015 |
Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Body Mass Index; C-Reactive Protein; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Didanosine; Disease Progression; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Multivariate Analysis; Oligopeptides; Prospective Studies; Pyridines; Risk Factors; Selenium; World Health Organization; Zidovudine | 2014 |
Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Breast Feeding; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lopinavir; Malaria; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Uganda; Viral Load | 2015 |
Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cerebrospinal Fluid; Cyclopropanes; Female; HIV Infections; Humans; Male | 2015 |
A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals.
Topics: Adult; Alkynes; Benzoxazines; Cholesterol; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Lamivudine; Male; Middle Aged; Tenofovir | 2015 |
Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: the IMMUNEF clinical trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Time Factors | 2015 |
Simultaneous plasma and genital pharmacokinetics and pharmacodynamics of atazanavir and efavirenz in HIV-infected women starting therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Middle Aged; RNA, Viral; Viral Load; Young Adult | 2015 |
Improvement of Depression and Anxiety After Discontinuation of Long- Term Efavirenz Treatment.
Topics: Adult; Alkynes; Anxiety; Benzoxazines; Cyclopropanes; Depression; Female; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Reverse Transcriptase Inhibitors; Surveys and Questionnaires; Withholding Treatment; Young Adult | 2015 |
Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.
Topics: Adult; Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; Humans; Male; Pharmacogenetics; Prospective Studies; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis | 2015 |
Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
Topics: Adult; Aged; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Plasma; Ritonavir; RNA, Viral; Survival Analysis; Treatment Outcome; Viral Load; Young Adult | 2015 |
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Intention to Treat Analysis; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2015 |
Lipid-based nutrient supplements do not affect efavirenz but lower plasma nevirapine concentrations in Ethiopian adult HIV patients.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Black People; Cyclopropanes; Cytochrome P-450 CYP2B6; Dietary Supplements; Ethiopia; Fatty Acids, Essential; Female; HIV Infections; Humans; Lipids; Male; Micronutrients; Nevirapine; Reverse Transcriptase Inhibitors; Urban Population | 2015 |
Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study.
Topics: Adolescent; Adult; Aged; Alkynes; Benzoxazines; Biomarkers; Cardiovascular Diseases; Cyclopropanes; Drug Substitution; Dyslipidemias; Female; HIV Infections; HIV-1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Male; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Young Adult | 2015 |
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Biomarkers; Constitutive Androstane Receptor; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Drug Administration Schedule; Female; Genotype; HIV; HIV Infections; Humans; Male; Middle Aged; Models, Biological; Nonlinear Dynamics; Pharmacogenetics; Phenotype; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2015 |
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Isoniazid; Male; Reverse Transcriptase Inhibitors; Rifampin; RNA, Viral; Tuberculosis | 2015 |
Vitamin D3 supplementation in HIV infection: effectiveness and associations with antiretroviral therapy.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Brazil; Cholecalciferol; Cyclopropanes; Dietary Supplements; Female; HIV Infections; Humans; Linear Models; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Risk Factors; Socioeconomic Factors; Vitamin D Deficiency | 2015 |
Efavirenz Capsule Sprinkle and Liquid Formulations With Didanosine and Emtricitabine in HIV-1-infected Infants and Children 3 Months to 6 Years of Age: Study AI266-922.
Topics: Alkynes; Benzoxazines; Child, Preschool; Cyclopropanes; Didanosine; Emtricitabine; Female; HIV Infections; Humans; Infant; Male; Prospective Studies | 2015 |
Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Nevirapine; Stavudine; Tablets; Uganda; Zambia; Zidovudine | 2016 |
Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial.
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Male; Nevirapine; South Africa; Viral Load | 2015 |
A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Double-Blind Method; Female; Genotype; HIV Infections; HIV-1; Humans; Imidazoles; Immunologic Factors; Male; Middle Aged; Puerto Rico; Receptors, CXCR5; Receptors, HIV; Sulfoxides; Treatment Outcome; United States; Viral Load; Viral Tropism; Young Adult | 2016 |
Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Contraceptive Agents, Female; Cyclopropanes; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Levonorgestrel; Nevirapine; Pregnancy; Pregnancy, Unplanned; Reverse Transcriptase Inhibitors; Time Factors; Uganda | 2016 |
Switching from a two-tablet regimen of tenofovir/emtricitabine and efavirenz to a one-tablet regimen may affect patients' perceptions and drug management.
Topics: Adult; Alkynes; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; Health Surveys; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Patient Satisfaction; Prospective Studies; Tablets; Tenofovir; Treatment Outcome | 2016 |
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Constitutive Androstane Receptor; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Genotype; HIV Infections; Humans; Male; Metabolic Clearance Rate; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; RNA, Viral; Young Adult | 2016 |
Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; Chromatography, High Pressure Liquid; Cyclohexanes; Cyclopropanes; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; HIV Infections; HIV Integrase Inhibitors; Humans; Immunity, Mucosal; Lymphocyte Activation; Male; Maraviroc; Pilot Projects; Raltegravir Potassium; T-Lymphocyte Subsets; Triazoles | 2016 |
Efavirenz but Not Atazanavir/Ritonavir Significantly Reduces Atovaquone Concentrations in HIV-Infected Subjects.
Topics: Administration, Oral; Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Anti-Infective Agents; Atazanavir Sulfate; Atovaquone; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Encephalitis; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Pneumonia, Pneumocystis; Reverse Transcriptase Inhibitors; Ritonavir; Toxoplasmosis, Cerebral; Young Adult | 2016 |
Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Raltegravir Potassium; Ritonavir; RNA, Viral; Surveys and Questionnaires; Tenofovir; Treatment Outcome | 2016 |
Improvement of lipoatrophy by switching from efavirenz to lopinavir/ritonavir.
Topics: Adipogenesis; Adipose Tissue; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Extremities; Female; Gene Expression Regulation; HIV Infections; Humans; Lipid Metabolism; Lipids; Lopinavir; Male; Middle Aged; Pilot Projects; Ritonavir; Treatment Outcome | 2016 |
Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Resorption; Cyclopropanes; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Plasma; Tenofovir; Vitamin D-Binding Protein; Young Adult | 2016 |
Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.
Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2B6 Inducers; Drug Therapy, Combination; Ethiopia; Female; HIV Infections; Humans; Male; Middle Aged; Rifampin; Time Factors; Treatment Outcome; Tuberculosis; Young Adult | 2016 |
Bleeding patterns of HIV-infected women using an etonogestrel-releasing contraceptive implant and efavirenz-based or lopinavir/ritonavir-based antiretroviral therapy.
Topics: Adolescent; Adult; Alkynes; Amenorrhea; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Desogestrel; Drug Combinations; Drug Implants; Drug Interactions; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Metrorrhagia; Prospective Studies; Ritonavir; Young Adult; Zidovudine | 2016 |
BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial.
Topics: Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Chronic Disease; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Medication Adherence; Viral Load; Young Adult | 2016 |
Efavirenz is associated with higher bone mass in South African children with HIV.
Topics: Absorptiometry, Photon; Alkynes; Anti-Retroviral Agents; Benzoxazines; Bone and Bones; Bone Development; CD4 Lymphocyte Count; Child; Cross-Sectional Studies; Cyclopropanes; Female; HIV Infections; Humans; Lopinavir; Male; Ritonavir; South Africa; Treatment Outcome; Viral Load | 2016 |
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Cyclopropanes; Drug Administration Schedule; Female; France; HIV Infections; HIV-1; Humans; Male; Reverse Transcriptase Inhibitors; Viral Load; Young Adult | 2016 |
Different impact of raltegravir versus efavirenz on CD4/CD8 ratio recovery in HIV-infected patients.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4-CD8 Ratio; Cyclopropanes; Female; HIV Infections; Humans; Male; Middle Aged; Raltegravir Potassium; Treatment Outcome; Young Adult | 2017 |
Effectiveness and safety of generic version of abacavir/lamivudine and efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2011-2012.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cardiovascular Diseases; Colombia; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drugs, Generic; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Treatment Outcome; Viral Load | 2016 |
Self-Reported Side Effects and Adherence to Antiretroviral Therapy in HIV-Infected Pregnant Women under Option B+: A Prospective Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Patient Compliance; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Self Report; Young Adult | 2016 |
Topics: Absorptiometry, Photon; Adult; Air Pollutants; Alkynes; Alleles; Animals; Anthracenes; Anthraquinones; Anti-HIV Agents; Benzoxazines; Black or African American; Bone Density; Bone Density Conservation Agents; C-Reactive Protein; Calcium, Dietary; Capsid Proteins; Cardiomyopathy, Dilated; Cardiovascular Diseases; CD4 Lymphocyte Count; Cholesterol; Collagen Type I; Cyclopropanes; Darunavir; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Emtricitabine; Epitopes; Female; Femur Neck; Gene Expression Profiling; Genetic Predisposition to Disease; Hepatitis, Viral, Animal; Hip Joint; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunization; Inflammation Mediators; Lipoproteins, LDL; Lupus Erythematosus, Systemic; Male; Mice; Mice, Inbred BALB C; Nitrates; Osteocalcin; Oxidation-Reduction; Parathyroid Hormone; Parvovirus B19, Human; Peptides; Phenotype; Pilot Projects; Polymorphism, Single Nucleotide; Raltegravir Potassium; Ritonavir; RNA, Viral; Sodium Chloride; Tenofovir; Transcriptome; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Vaccines; Vascular Endothelial Growth Factor A; Vitamin D; Young Adult | 2016 |
Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Patient Safety; Pregnancy; Primary Prevention; RNA, Viral; South Africa; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies; Viral Load; Zidovudine | 2017 |
Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF through 96 weeks.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Rilpivirine; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Viremia | 2017 |
Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Genetic Predisposition to Disease; HIV Infections; Humans; Male; Middle Aged; Plasma; Polymorphism, Single Nucleotide | 2017 |
Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.
Topics: Adult; Africa; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Coinfection; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Fluoroquinolones; HIV Infections; Humans; Male; Moxifloxacin; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis, Pulmonary | 2017 |
Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention.
Topics: Adolescent; Adult; Alkynes; Antimalarials; Area Under Curve; Artemisinins; Benzoxazines; Chemoprevention; Cyclopropanes; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Female; HIV Infections; Humans; Malaria; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Complications, Parasitic; Quinolines; Reverse Transcriptase Inhibitors; Uganda; Young Adult | 2017 |
The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.
Topics: Adult; Alkynes; Area Under Curve; Benzoxazines; Constitutive Androstane Receptor; Contraceptive Agents, Female; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Female; Genetic Variation; HIV Infections; Humans; Levonorgestrel; Linear Models; Multivariate Analysis; Nevirapine; Pharmacogenetics; Polymorphism, Single Nucleotide; Prospective Studies; Reverse Transcriptase Inhibitors | 2017 |
Qualitative study of the BREATHER trial (Short Cycle antiretroviral therapy): is it acceptable to young people living with HIV?
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Longitudinal Studies; Male; Medication Adherence; Patient Acceptance of Health Care; Qualitative Research; Truth Disclosure; Viral Load; Young Adult | 2017 |
Does efavirenz replacement improve neurological function in treated HIV infection?
Topics: Adult; Alkynes; Benzoxazines; Brain Chemistry; Cognition; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Neuropsychological Tests; Proton Magnetic Resonance Spectroscopy; Ritonavir; Treatment Outcome; Young Adult | 2017 |
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-i
Topics: Adenine; Adult; Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Middle Aged; Rilpivirine; Tenofovir | 2017 |
Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Male; Nevirapine; Reverse Transcriptase Inhibitors; Thailand; Treatment Outcome | 2008 |
Lymphocyte mitochondrial depolarization and apoptosis in HIV-1-infected HAART patients.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Apoptosis; Benzoxazines; CD4-Positive T-Lymphocytes; Cohort Studies; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Membrane Potential, Mitochondrial; Mitochondria; Mitochondrial Diseases; Mitochondrial Membranes; Nevirapine; Pilot Projects; Reverse Transcriptase Inhibitors; T-Lymphocyte Subsets; T-Lymphocytes, Helper-Inducer | 2008 |
Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India.
Topics: Adult; Albumins; Alkynes; Anti-HIV Agents; Antioxidants; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Drugs, Generic; Female; Glutathione Peroxidase; Glutathione Reductase; HIV Infections; Humans; India; Lamivudine; Male; Oxidative Stress; Reverse Transcriptase Inhibitors; Stavudine; Uric Acid; Young Adult; Zidovudine | 2008 |
Lack of a significant drug interaction between raltegravir and tenofovir.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2008 |
Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Bacterial Infections; Benzoxazines; Blood Platelets; Cardiovascular Diseases; Cyclopropanes; Deoxycytidine; Didanosine; Emtricitabine; Female; Hemoglobins; HIV Infections; Humans; Leukocyte Count; Male; Middle Aged; Neutrophils; Pancytopenia; Platelet Count; Prevalence; Zidovudine | 2008 |
Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV/HCV-coinfected patients.
Topics: Alkynes; Anti-HIV Agents; Anxiety Disorders; Benzoxazines; Cyclopropanes; Depression; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Mental Disorders; Mood Disorders | 2008 |
Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients.
Topics: Adult; Alkynes; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Drug Administration Schedule; Drug Monitoring; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Rifampin; Treatment Outcome; Tuberculosis | 2008 |
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Brachial Artery; CD4 Lymphocyte Count; Cyclopropanes; Endothelium, Vascular; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir; Time Factors; Zidovudine | 2008 |
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; DNA, Viral; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Thailand; Treatment Outcome; Zidovudine | 2008 |
Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.
Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Enzyme Induction; Female; Gene Frequency; Genetic Variation; Haplotypes; HIV Infections; Humans; Male; Middle Aged; Oxidoreductases, N-Demethylating; Phenotype; Prospective Studies; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis | 2008 |
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; RNA, Viral; Severity of Illness Index; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Piperazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Drugs, Generic; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Immunosuppression Therapy; India; Male; Middle Aged; Organophosphonates; Prevalence; Tenofovir; Treatment Outcome; Young Adult | 2008 |
Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Didanosine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Prospective Studies; Spain; Treatment Outcome | 2009 |
Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Lopinavir; Male; Pyrimidinones; Ritonavir | 2009 |
Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Linear Models; Male; Rifampin; Tuberculosis; Viral Load | 2009 |
Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Patient Compliance; Tenofovir | 2009 |
Effect of African potato (Hypoxis hemerocallidea) on the pharmacokinetics of efavirenz.
Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Dose-Response Relationship, Drug; Female; HIV Infections; Humans; Hypoxis; Male; Solanum tuberosum; Treatment Outcome; Young Adult | 2008 |
Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis.
Topics: Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; C-Reactive Protein; Child; Child, Preschool; Cyclopropanes; Female; HIV Infections; Humans; Male; Metabolic Clearance Rate; Rifampin; Ritonavir; Tuberculosis | 2009 |
A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; France; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.
Topics: Absorptiometry, Photon; Adult; Alkynes; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lipid Metabolism; Lopinavir; Male; Pyrimidinones; Ritonavir | 2009 |
A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Plasma; Prospective Studies; Reverse Transcriptase Inhibitors; Rifampin; RNA, Viral; Treatment Outcome; Tuberculosis; Viral Load | 2009 |
Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.
Topics: Absorptiometry, Photon; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Density; Cyclopropanes; Female; HIV Infections; Humans; Inflammation Mediators; Lamivudine; Lopinavir; Male; Middle Aged; Osteoporosis; Prospective Studies; Pyrimidinones; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Risk Factors; Ritonavir; Zidovudine | 2009 |
A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals.
Topics: Adenine; Adipose Tissue; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Extremities; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lipids; Male; Middle Aged; Organophosphonates; Tenofovir; Young Adult; Zidovudine | 2009 |
Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Mental Disorders; Middle Aged; Reverse Transcriptase Inhibitors; Sample Size; Sleep Wake Disorders; Viral Load | 2009 |
Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Monitoring; Female; HIV Infections; Humans; Male; Middle Aged; Models, Statistical; Netherlands; Plasma; Viral Load | 2009 |
Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
Topics: Adenine; Alkynes; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genome, Viral; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Mutation, Missense; Organophosphonates; Tenofovir; Treatment Failure; Zidovudine | 2009 |
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.
Topics: Adenine; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Prognosis; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Safety; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; HIV Infections; HIV-1; Humans; Pyrrolidinones; Raltegravir Potassium | 2009 |
96-Week MERIT ES analysis shows efficacy of Celsentri=Selzentry.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Cyclopropanes; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Lamivudine; Maraviroc; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome; Triazoles; Zidovudine | 2009 |
Raltegravir as effective as efavirenz in 144-week data.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome | 2009 |
Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; Rifampin; Risk Factors; South Africa; Tuberculosis | 2009 |
Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Lopinavir; Male; Prospective Studies; Pyrimidinones | 2009 |
[Efficacy and safety of TAM-sparing antiretroviral regimens in naïve HIV-positive patients].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Hyperinsulinism; Hyperlipidemias; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Prospective Studies; Tenofovir; Thymidine; Treatment Outcome; Young Adult | 2009 |
Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; India; Lamivudine; Male; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; Treatment Failure; Tuberculosis | 2009 |
Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study).
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Hypersensitivity; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load; Withholding Treatment | 2010 |
Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months.
Topics: Adenine; Adipocytes; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cell Differentiation; Cyclopropanes; Drug Therapy, Combination; Fatty Acids; Female; Gene Expression; Genes, Mitochondrial; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Up-Regulation; Zidovudine | 2009 |
The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Culture; Cyclopropanes; Didanosine; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Surveys and Questionnaires; Zidovudine | 2010 |
Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Mexico; Prospective Studies; Pyrimidinones; Ritonavir; RNA, Viral | 2010 |
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Antiviral Agents; Benzoxazines; CCR5 Receptor Antagonists; Cyclohexanes; Cyclopropanes; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Maraviroc; Middle Aged; Receptors, CCR5; Treatment Outcome; Triazoles; Viral Load; Viral Tropism; Young Adult; Zidovudine | 2010 |
Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Patient Compliance; Patient Preference; Puerto Rico; Quality of Life; Reverse Transcriptase Inhibitors; Severity of Illness Index; Tablets; Tenofovir; Treatment Outcome; United States; Young Adult | 2010 |
Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; DNA, Mitochondrial; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; RNA; RNA, Mitochondrial; Tenofovir | 2010 |
Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Patient Compliance; Patient Satisfaction; Quality of Life; Reverse Transcriptase Inhibitors; Treatment Outcome; United States; Viral Load | 2010 |
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2010 |
Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.
Topics: Adult; Aged; Alkynes; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Uganda | 2010 |
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; beta 2-Microglobulin; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Male; Middle Aged; Organophosphonates; Retinol-Binding Proteins; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Nonnucleoside reverse transcriptase inhibitor concentrations during treatment interruptions and the emergence of resistance: a substudy of the ISS-PART Trial.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Young Adult | 2010 |
Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome | 2010 |
Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children?
Topics: Adolescent; Africa, Western; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Treatment Outcome | 2010 |
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.
Topics: Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; Black People; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Female; Hispanic or Latino; HIV Infections; Humans; Male; Oxidoreductases, N-Demethylating; Pharmacogenetics; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors; Treatment Outcome; White People | 2010 |
Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial.
Topics: Absorptiometry, Photon; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Bone Density; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Pyrimidinones; Ritonavir; Zidovudine | 2011 |
Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Pyridines; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2010 |
Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; C-Reactive Protein; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; Humans; Male; Middle Aged; Sex Factors | 2011 |
Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; Biotransformation; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Drug Administration Schedule; Female; Genotype; HIV Infections; Humans; Hydroxylation; Male; Middle Aged; Oxidoreductases, N-Demethylating; Phenotype; Prospective Studies; Reverse Transcriptase Inhibitors; Sex Factors; Tanzania | 2010 |
Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients.
Topics: Alkynes; Benzoxazines; Case-Control Studies; CD4 Lymphocyte Count; Cyclohexanes; Cyclopropanes; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Receptors, CCR5; Reverse Transcriptase Inhibitors; Triazoles; Viral Load | 2010 |
Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial).
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Didanosine; Emtricitabine; Female; Follow-Up Studies; HIV Infections; Humans; Male; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
A randomized crossover study to compare efavirenz and etravirine treatment.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Anxiety Disorders; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nitriles; Practice Guidelines as Topic; Pyridazines; Pyrimidines; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires; Treatment Outcome | 2011 |
Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Treatment Outcome; Viral Load; Zidovudine | 2011 |
A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine.
Topics: Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Central Nervous System Diseases; Cyclopropanes; Feasibility Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nitriles; Pilot Projects; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Sleep Initiation and Maintenance Disorders; Treatment Outcome; Viral Load | 2011 |
Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants.
Topics: Alkynes; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 2; ATP-Binding Cassette Transporters; Benzoxazines; Computational Biology; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; Epistasis, Genetic; Genome-Wide Association Study; HIV Infections; HIV-1; Humans; Polymorphism, Single Nucleotide; Potassium Channels, Inwardly Rectifying; Receptors, Drug; Risk Factors; Software; Sulfonylurea Receptors; Treatment Failure | 2011 |
Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Confidence Intervals; Cross-Over Studies; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Uganda | 2010 |
Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy.
Topics: Adenine; Adult; Alkynes; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Tenofovir; Treatment Failure; Viral Load | 2011 |
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.
Topics: Adolescent; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Viral Load; Young Adult | 2011 |
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cobicistat; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Patient Compliance; Patient Selection; Quinolones; Tenofovir; Thiazoles; Treatment Outcome | 2011 |
Successful efavirenz dose reduction guided by therapeutic drug monitoring.
Topics: Alkynes; Anti-HIV Agents; Bayes Theorem; Benzoxazines; Cyclopropanes; Drug Monitoring; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Outcome | 2011 |
Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alanine Transaminase; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Cholesterol; Cyclopropanes; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Japan; Lamivudine; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome | 2011 |
Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Female; Health Knowledge, Attitudes, Practice; HIV Infections; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Organophosphonates; Quality of Life; Tenofovir; Treatment Outcome; Young Adult; Zidovudine | 2011 |
Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.
Topics: Alkynes; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Monitoring; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; RNA, Viral; Substance-Related Disorders | 2011 |
A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study).
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Anxiety Disorders; Benzoxazines; CD4 Lymphocyte Count; Cross-Over Studies; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Practice Guidelines as Topic; Pyrrolidinones; Raltegravir Potassium; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires; Treatment Outcome | 2011 |
Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis.
Topics: Adult; Alkynes; Anti-HIV Agents; Anti-Inflammatory Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; Cyclopropanes; Dexamethasone; Double-Blind Method; Female; HIV Infections; Humans; Lamivudine; Male; Placebos; Time Factors; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Tuberculosis, Meningeal; Zidovudine | 2011 |
Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Double-Blind Method; Female; Hepatitis B; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome | 2012 |
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG
Topics: Absorptiometry, Photon; Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Bone Density; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Fractures, Bone; HIV Infections; Humans; Intention to Treat Analysis; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Osteoporosis; Pyridines; Risk Factors; Ritonavir; Tenofovir; Viral Load | 2011 |
Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Prospective Studies; Treatment Outcome; Viral Load | 2011 |
Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Child; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2011 |
Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Reverse Transcriptase Inhibitors; Rifampin; South Africa; Treatment Outcome; Tuberculosis | 2011 |
Lactic acidosis and symptomatic hyperlactataemia in a randomized trial of first-line therapy in HIV-infected adults in South Africa.
Topics: Acidosis, Lactic; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Incidence; Lactates; Lamivudine; Male; Reverse Transcriptase Inhibitors; South Africa; Stavudine; Treatment Outcome | 2011 |
Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; Humans; Lopinavir; Male; Mutation; Ritonavir; RNA, Viral; South Africa; Treatment Failure; Viral Load | 2011 |
Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen.
Topics: Adult; Alkynes; Antibiotics, Antitubercular; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Hyperbilirubinemia; Liver Function Tests; Logistic Models; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Risk Factors; Thailand; Tuberculosis; Young Adult | 2011 |
HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Biological Availability; Body Weight; Cyclopropanes; Female; Half-Life; HIV Infections; Humans; Male; Middle Aged; Models, Biological; Nonlinear Dynamics; Pharmacogenetics; Sex Factors; Tissue Distribution; Uganda; Young Adult | 2011 |
Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis.
Topics: Alkynes; Alleles; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Induction; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Oxidoreductases, N-Demethylating; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis | 2011 |
Short-term virological efficacy, immune reconstitution, tolerance, and adherence of once-daily dosing of didanosine, lamivudine, and efavirenz in HIV-1-infected African children: ANRS 12103 Burkiname.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Child; Cyclopropanes; Didanosine; Female; HIV Infections; Humans; Lamivudine; Male; Patient Compliance; Reverse Transcriptase Inhibitors; Viral Load | 2011 |
Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results.
Topics: Adolescent; Adult; Aged; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; Humans; Male; Mental Disorders; Middle Aged; Nervous System Diseases; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2011 |
Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; Humans; India; Liver Function Tests; Male; Middle Aged; Mycobacterium tuberculosis; Nevirapine; Sputum; Treatment Outcome; Tuberculosis; Viral Load | 2011 |
Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclohexanes; Cyclopropanes; Female; High-Throughput Nucleotide Sequencing; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Retrospective Studies; Treatment Failure; Treatment Outcome; Triazoles; Viral Tropism; Young Adult | 2011 |
Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; White People; Young Adult | 2011 |
CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans.
Topics: Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; Humans; Male; Oxidoreductases, N-Demethylating; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors; Zimbabwe | 2012 |
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2011 |
Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Male; Uganda | 2011 |
Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sex Factors; Treatment Outcome; Viral Load | 2011 |
Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Limit of Detection; Lopinavir; Male; Middle Aged; Nonlinear Dynamics; Oligopeptides; Pyridines; Ritonavir; RNA, Viral; Viral Load | 2011 |
A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Creatinine; Cyclopropanes; Cystatin C; Deoxycytidine; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir | 2012 |
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.
Topics: Adult; Aged; Alkynes; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Virus Replication; Young Adult | 2012 |
Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; RNA, Viral; Stavudine | 2011 |
Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; Humans; Male; Models, Biological; Oxidoreductases, N-Demethylating; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; South Africa | 2012 |
Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; Nitriles; Phenotype; Pyrimidines; Rilpivirine; Treatment Failure; Young Adult | 2012 |
Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.
Topics: Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Cohort Studies; Cyclopropanes; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Infant, Newborn; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Prospective Studies; Statistics, Nonparametric; Young Adult | 2012 |
The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis.
Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Biotransformation; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Female; Half-Life; HIV Infections; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Reverse Transcriptase Inhibitors; Rifampin; South Africa; Tuberculosis; Young Adult | 2012 |
Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Diarylquinolines; Drug Interactions; Female; HIV Infections; Humans; Male; Middle Aged; Quinolines; Young Adult | 2012 |
Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cognition; Cognition Disorders; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Zidovudine | 2012 |
Presence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimen.
Topics: Adult; Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Half-Life; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Mutation; Reverse Transcriptase Inhibitors; Viral Load | 2012 |
Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Double-Blind Method; Female; HIV; HIV Infections; Humans; Lipids; Male; Middle Aged; Nitriles; Placebos; Pyridazines; Pyrimidines; Viral Load; Young Adult | 2012 |
Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers.
Topics: Adult; Alkynes; Animals; Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azetidines; Benzoxazines; Biological Transport; Cell Line; Cell Line, Transformed; Cyclopropanes; Cytochrome P-450 CYP3A; Dogs; Drug Interactions; Ezetimibe; Gene Expression; Glucuronosyltransferase; HEK293 Cells; HIV Infections; Humans; Hypercholesterolemia; Intestinal Absorption; Intestinal Mucosa; Intestines; Liver; Liver-Specific Organic Anion Transporter 1; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; RNA, Messenger; Young Adult | 2012 |
Evidence for a shift to anaerobic metabolism in adipose tissue in efavirenz-containing regimens for HIV with different nucleoside backbones.
Topics: Adenine; Adipose Tissue; Adult; Alkynes; Anaerobiosis; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Electron Transport Complex IV; Female; Gene Expression Regulation; HIV Infections; HIV-1; Humans; Ion Channels; Lipogenesis; Male; Middle Aged; Mitochondrial Proteins; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Uncoupling Protein 2; Zidovudine | 2012 |
HIV-1 tropism and CD4 T lymphocyte recovery in a prospective cohort of patients initiating HAART in Ribeirão Preto, Brazil.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Prospective Studies; Treatment Outcome; Viral Load; Viral Tropism | 2012 |
Safety and efficacy of GSK2248761, a next-generation nonnucleoside reverse transcriptase inhibitor, in treatment-naive HIV-1-infected subjects.
Topics: Adult; Alkynes; Anti-HIV Agents; Argentina; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Male; Mutation; Phosphinic Acids; Placebos; Reverse Transcriptase Inhibitors; Viral Load | 2012 |
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyrimidines; Rilpivirine; Treatment Outcome; Viral Load; Young Adult | 2012 |
Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy.
Topics: Adolescent; Adult; Alkynes; Benzoxazines; Cholesterol, HDL; Coinfection; Cyclopropanes; Female; HIV Infections; Humans; Lamivudine; Lipids; Male; Middle Aged; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Thailand; Triglycerides; Tuberculosis; Young Adult | 2012 |
Untreated HIV infection is associated with higher blood alcohol levels.
Topics: Adult; Alcoholism; Alkynes; Anti-HIV Agents; Benzoxazines; Cognition; Cyclopropanes; Disease Progression; Double-Blind Method; Ethanol; Female; HIV Infections; Humans; Intestinal Absorption; Male; Middle Aged; Pilot Projects; Ritonavir | 2012 |
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alkynes; Animals; Antiviral Agents; Aspartate Aminotransferases; Benzoxazines; Coinfection; Cyclopropanes; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis C; Hepatitis C Antibodies; HIV Infections; HIV-1; Humans; Liver; Liver Function Tests; Male; Middle Aged; Nitriles; Placebos; Pyrimidines; Rilpivirine; Treatment Outcome; Young Adult | 2012 |
Effects of vitamin D supplementation on the bone specific biomarkers in HIV infected individuals under treatment with efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; Bone and Bones; Bone Remodeling; Cyclopropanes; Dietary Supplements; Female; HIV Infections; Humans; Iran; Male; Metalloendopeptidases; Middle Aged; Osteocalcin; Prevalence; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Vitamin D; Vitamin D Deficiency; Vitamins | 2012 |
Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.
Topics: Adult; Alkynes; Anti-HIV Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Benzoxazines; Cross-Over Studies; Cyclopropanes; Drug Combinations; Drug Interactions; Ethanolamines; Female; Fluorenes; HIV Infections; Humans; Malaria; Male; Nevirapine; Plasma; Uganda | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Tenofovir; Thiazoles | 2012 |
Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Drug Combinations; Female; Follow-Up Studies; Gambia; HIV Infections; HIV-1; HIV-2; Humans; Infant; Kaplan-Meier Estimate; Lamivudine; Lopinavir; Male; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Zidovudine | 2012 |
Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Induced Liver Injury; Coinfection; Cyclopropanes; Demography; Haplotypes; HIV Infections; Humans; Incidence; Kaplan-Meier Estimate; Liver; Multivariate Analysis; Pharmacogenetics; Proportional Hazards Models; Risk Factors; Tanzania; Treatment Outcome; Tuberculosis | 2012 |
Tenofovir use and renal insufficiency among pregnant and general adult population of HIV-infected, ART-naïve individuals in Lilongwe, Malawi.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; CD4 Lymphocyte Count; Creatinine; Cyclopropanes; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Malawi; Male; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Renal Insufficiency; Tenofovir | 2012 |
Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Ethambutol; Female; HIV Infections; Humans; Isoniazid; Male; Organophosphonates; Oxazines; Pyrazinamide; Reverse Transcriptase Inhibitors; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary | 2013 |
Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Female; Genitalia, Female; HIV Infections; Humans; Lamivudine; Models, Biological; Oligopeptides; Organophosphonates; Premenopause; Pyridines; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Influence of ABCB-1 C3435T polymorphisms on plasma nevirapine and efavirenz levels and their effects on virologic and immunological outcomes in HIV/TB co-infected Thai adults under anti-retroviral therapy.
Topics: Adult; Alkynes; Analysis of Variance; Antiretroviral Therapy, Highly Active; Antitubercular Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Nevirapine; Polymorphism, Genetic; Real-Time Polymerase Chain Reaction; Rifampin; Thailand; Tuberculosis; Viral Load | 2012 |
HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.
Topics: Adult; Alkynes; Amino Acid Substitution; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Mutation, Missense; Oligopeptides; Pyridines; Ritonavir; Treatment Failure | 2012 |
Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Darunavir; Drug Synergism; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2013 |
Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Immune Tolerance; Lopinavir; Male; Organophosphonates; Peptide Fragments; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2013 |
Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor.
Topics: Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Chile; Cohort Studies; Constitutive Androstane Receptor; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Female; Glucuronosyltransferase; Hispanic or Latino; HIV Infections; Humans; Male; Oxidoreductases, N-Demethylating; Polymorphism, Single Nucleotide; Receptors, Cytoplasmic and Nuclear | 2013 |
Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptives, Oral, Synthetic; Cyclopropanes; Desogestrel; Drug Interactions; Ethinyl Estradiol; Female; HIV; HIV Infections; Humans; Logistic Models; Middle Aged; Nevirapine; Progesterone; Prospective Studies; Thailand; Young Adult | 2013 |
Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
Topics: Adenine; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; DNA, Mitochondrial; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Mitochondria; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2013 |
Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyrimidines; Rilpivirine; Treatment Outcome; Young Adult | 2013 |
Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies/ml or less: week 48 phase III analysis.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyrimidines; Rilpivirine; Treatment Outcome; Viral Load; Young Adult | 2013 |
Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Mental Disorders; Middle Aged; Nervous System Diseases; Nitriles; Pyrimidines; Rilpivirine; Viral Load; Young Adult | 2013 |
Unexpected drug-drug interactions in human immunodeficiency virus (HIV) therapy: induction of UGT1A1 and bile efflux transporters by Efavirenz.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Biological Transport; Confidence Intervals; Cyclopropanes; Darunavir; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Induction; Female; Glucuronosyltransferase; HIV Infections; HIV Protease Inhibitors; Humans; Incidental Findings; Male; Membrane Transport Proteins; Middle Aged; Ritonavir; Sulfonamides; Young Adult | 2012 |
Efficacy and safety of lersivirine (UK-453,061) versus efavirenz in antiretroviral treatment-naive HIV-1-infected patients: week 48 primary analysis results from an ongoing, multicenter, randomized, double-blind, phase IIb trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Intention to Treat Analysis; Male; Middle Aged; Mutation; Nitriles; Organophosphonates; Pyrazoles; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Young Adult | 2013 |
Anti-HIV agents. Efavirenz versus indinavir: who really wins?
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Oxazines; Reverse Transcriptase Inhibitors; Viral Load | 2000 |
Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Oxazines; Prognosis; Reverse Transcriptase Inhibitors; Treatment Failure | 2002 |
Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4-Positive T-Lymphocytes; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interferon-gamma; Interleukin-10; Interleukin-2; Male; Nelfinavir; Oxazines; Random Allocation; RNA, Messenger; Stavudine; Treatment Failure | 2002 |
High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: implications for pathogenesis of fat redistribution.
Topics: Adipose Tissue; Alkynes; Anti-HIV Agents; Benzoxazines; Body Composition; Cholesterol, HDL; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Hypolipidemic Agents; Niacin; Oxazines; Reverse Transcriptase Inhibitors; Surveys and Questionnaires | 2002 |
Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.
Topics: Adenine; Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Kidney Diseases; Lamivudine; Male; Organophosphonates; Oxazines; Pulse Therapy, Drug; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome | 2002 |
Efavirenz liquid formulation in human immunodeficiency virus-infected children.
Topics: Administration, Oral; Alkynes; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir; Oxazines; RNA, Viral; Sensitivity and Specificity; Severity of Illness Index; Single-Blind Method; Survival Analysis; Treatment Outcome; Viral Load | 2002 |
Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne.
Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; France; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2002 |
Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Male; Metabolic Clearance Rate; Oxazines; Semen | 2002 |
Low increase in serum lipids in patients receiving a combination of ritonavir, saquinavir and efavirenz.
Topics: Alkynes; Benzoxazines; Blood Glucose; Cholesterol; Cyclopropanes; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Triglycerides | 2002 |
Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients.
Topics: Adult; Alkynes; Area Under Curve; Benzoxazines; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Furans; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oxazines; Ritonavir; Sulfonamides | 2003 |
Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients.
Topics: Adult; Alkynes; Area Under Curve; Benzoxazines; Biological Availability; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; Humans; Logistic Models; Lopinavir; Oxazines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir | 2003 |
Once-daily saquinavir-sgc plus low-dose ritonavir (1200/100 mg) in combination with efavirenz: pharmacokinetics and efficacy in HIV-infected patients with prior antiretroviral therapy.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Viral Load | 2003 |
Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Microbial Sensitivity Tests; Oxazines; Phenotype; Proportional Hazards Models; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; RNA, Viral; Treatment Failure; Viral Load; Virus Replication | 2003 |
Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Organophosphonates; Oxazines; Treatment Failure | 2003 |
Determining the relative efficacy of highly active antiretroviral therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2003 |
HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Oxazines; Salvage Therapy; Sulfonamides | 2003 |
Response to efavirenz plus two nucleoside reverse-transcriptase inhibitors in patients with advanced stage human immunodeficiency virus-1 infection in Taiwan.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load | 2003 |
Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.
Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Indinavir; Male; Oxazines; RNA, Viral | 2003 |
A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Indinavir; Male; Nelfinavir; Oxazines; Patient Compliance; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome | 2003 |
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
Topics: Adult; Aged; Alkynes; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Disease Progression; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Failure | 2003 |
A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Enfuvirtide; Female; Furans; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Peptide Fragments; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2003 |
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Oxazines; RNA, Viral; Stavudine; Time Factors; Treatment Failure; Zidovudine | 2003 |
Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nelfinavir; Oxazines; Stavudine; Time Factors; Treatment Failure; Zidovudine | 2003 |
Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Trizivir vs. efavirenz: results from ACTG 5095.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Oxazines; Placebos; Viral Load; Zidovudine | 2003 |
Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Pilot Projects; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Virus Latency; Virus Replication | 2004 |
Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Child; Child, Preschool; Chromatography, High Pressure Liquid; Cyclopropanes; Female; HIV Infections; Humans; Male; Oxazines; Regression Analysis; RNA, Viral; Survival Analysis | 2004 |
Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial).
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Oxazines; Prospective Studies; Treatment Outcome | 2004 |
Treatment of HIV-infected patients with a combination of efavirenz, nevirapine and nucleoside reverse transcriptase inhibitors.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nevirapine; Nucleosides; Oxazines; Pilot Projects; Reverse Transcriptase Inhibitors; Treatment Outcome | 2004 |
Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Central Nervous System Diseases; Cyclopropanes; Female; Follow-Up Studies; Gynecomastia; HIV Infections; Humans; Hypersensitivity; Liver Diseases; Male; Metabolic Diseases; Nevirapine; Oxazines; Pancreatic Diseases; Prospective Studies; Reverse Transcriptase Inhibitors; Viral Load | 2004 |
Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cholesterol, HDL; Cyclopropanes; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Lipoproteins; Magnetic Resonance Spectroscopy; Male; Multivariate Analysis; Oxazines; Reverse Transcriptase Inhibitors; Stavudine | 2004 |
Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Administration Schedule; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Oxazines; Viral Load | 2004 |
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Failure | 2004 |
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
Topics: Adult; Aged; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nucleosides; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 2004 |
Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Microbial Sensitivity Tests; Mutation; Oxazines; Protease Inhibitors; Reverse Transcriptase Inhibitors; Treatment Outcome; Urban Population; Viral Load | 2004 |
Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children.
Topics: Adolescent; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lopinavir; Oxazines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome | 2004 |
A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection.
Topics: Alanine Transaminase; Alkynes; Anti-HIV Agents; Aspartate Aminotransferases; Benzoxazines; Cholesterol; Cyclopropanes; Didanosine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Polymerase Chain Reaction; RNA, Viral; Triglycerides | 2004 |
Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects.
Topics: Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Dose-Response Relationship, Drug; Female; HIV Infections; Humans; Male; Oxazines; Predictive Value of Tests; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Failure | 2004 |
Chemokine mRNA levels in mononucleated cells of HIV-infected patients before and after initiation of PI- versus NNRTI-containing HAART.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemokine CCL2; Chemokine CCL3; Chemokine CCL4; Chemokine CCL5; Chemokine CCL8; Chemokines; Cyclopropanes; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Leukocytes, Mononuclear; Macrophage Inflammatory Proteins; Male; Middle Aged; Monocyte Chemoattractant Proteins; Oxazines; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA, Messenger | 2004 |
A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nevirapine; Oxazines; Proportional Hazards Models; Prospective Studies; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction | 2004 |
A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting.
Topics: Administration, Oral; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; Costs and Cost Analysis; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Outpatient Clinics, Hospital; Oxazines; Pilot Projects; South Africa; Treatment Outcome; Tuberculosis; Urban Population | 2004 |
Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Blood Glucose; Body Composition; Bone Density; C-Peptide; Cyclopropanes; Drug Therapy, Combination; Female; Glucagon; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Insulin; Insulin Resistance; Lipids; Lipoproteins; Male; Nevirapine; Oxazines; Pilot Projects; RNA, Viral; Viral Load | 2004 |
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Oxazines; Pyridines; RNA, Viral; Zidovudine | 2004 |
Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Didanosine; Double-Blind Method; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Stavudine; Viral Load | 2004 |
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Oxazines; Prospective Studies; Stavudine; Tenofovir; Viral Load | 2004 |
Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 2004 |
Cortisol serum levels and their relationship to certain antiretroviral drugs.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Hydrocortisone; Male; Multivariate Analysis; Oxazines; Reverse Transcriptase Inhibitors | 2004 |
Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1.
Topics: Adult; Alkynes; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; India; Male; Middle Aged; Oxazines; Rifampin; Treatment Outcome; Tuberculosis | 2004 |
Gynaecomastia in HIV-infected men on highly active antiretroviral therapy: association with efavirenz and didanosine treatment.
Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Didanosine; Gynecomastia; HIV Infections; Humans; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; Testosterone; Triglycerides | 2004 |
Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; RNA, Viral; Zidovudine | 2004 |
Pharmacokinetics of indinavir at 800, 600, and 400 milligrams administered with ritonavir at 100 milligrams and efavirenz in ethnic chinese patients infected with human immunodeficiency virus.
Topics: Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; China; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Interactions; HIV Infections; Humans; Indinavir; Male; Middle Aged; Oxazines; Ritonavir | 2004 |
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cholesterol, HDL; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Oxazines | 2004 |
Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nevirapine; Oxazines; Quality of Life; Reverse Transcriptase Inhibitors; Treatment Outcome | 2004 |
New once-daily HIV combination better tolerated.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Oxazines; Tenofovir; Zidovudine | 2004 |
Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cells, Cultured; Cyclopropanes; Evolution, Molecular; HIV Infections; HIV-1; Humans; Indinavir; Leukocytes, Mononuclear; Molecular Sequence Data; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Semen; Sequence Analysis, DNA; Viral Load; Virus Latency | 2004 |
A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study).
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Viral Load; Zidovudine | 2005 |
Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine.
Topics: Adult; Alkynes; Amino Acid Substitution; Anti-HIV Agents; Base Sequence; Benzoxazines; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; Genes, pol; HIV Infections; HIV-1; Humans; Nevirapine; Oxazines; Point Mutation; Prospective Studies; Reverse Transcriptase Inhibitors; Salvage Therapy; Treatment Failure | 2005 |
Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Didanosine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome | 2005 |
[Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Comorbidity; Cyclopropanes; Exanthema; Female; Germany; HIV Infections; Humans; Male; Nevirapine; Outcome Assessment, Health Care; Oxazines; Prevalence; Prognosis; Risk Assessment; Risk Factors | 2005 |
Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Kinetics; Lamivudine; Male; Nevirapine; Oxazines; Proportional Hazards Models; RNA, Viral; Stavudine; Treatment Outcome | 2005 |
Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
Topics: Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Stavudine | 2005 |
Early virological failure with a combination of tenofovir, didanosine and efavirenz.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mutation; Organophosphonates; Oxazines; Pyrimidinones; RNA, Viral; Tenofovir; Time Factors; Treatment Failure; Viremia | 2005 |
The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Exanthema; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine; Oxazines; Sex Factors; Viral Load | 2005 |
Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Oxazines; RNA, Viral; Treatment Outcome; Viral Load | 2005 |
Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Dideoxynucleosides; Female; HIV Infections; Humans; Hydroxyurea; Male; Middle Aged; Oxazines; RNA, Viral; Time Factors; Treatment Failure | 2005 |
The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.
Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Composition; Cholesterol, HDL; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oxazines; Pilot Projects; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; Viral Load | 2005 |
Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Delayed-Action Preparations; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Patient Compliance; Quality of Life; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; Stavudine; Viral Load | 2005 |
Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine.
Topics: Adult; Alkynes; Anthropometry; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Blood Glucose; Cholesterol; Cholesterol, HDL; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Insulin Resistance; Lipodystrophy; Male; Middle Aged; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Triglycerides | 2005 |
Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Bezafibrate; Cyclopropanes; Female; HIV Infections; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Nevirapine; Oxazines; Pravastatin; Protease Inhibitors; Reverse Transcriptase Inhibitors; Treatment Outcome | 2005 |
Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort).
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine; Oxazines; Prospective Studies; Viral Load | 2005 |
Safety, pharmacokinetics, and efficacy of (+/-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine with efavirenz and stavudine in antiretroviral-naïve human immunodeficiency virus-infected patients.
Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Oxazines; Plasma; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Urine; Zalcitabine | 2005 |
Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Patient Compliance; RNA, Viral; Zidovudine | 2005 |
Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Viral; Drug Tolerance; Female; France; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oxazines; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Safety | 2005 |
Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Atorvastatin; Benzoxazines; Cholesterol, LDL; Cyclopropanes; Drug Interactions; Female; Heptanoic Acids; HIV Infections; HIV Seronegativity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Oxazines; Pravastatin; Pyrroles; Simvastatin | 2005 |
Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Oxazines; Tenofovir; Treatment Failure | 2005 |
An open-label trial of stavudine, lamivudine and efavirenz in the treatment of HIV-positive, treatment-naive patients, and implications for clinical practice.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Viral Load | 1999 |
Effects on immunological and virological outcome of patients using one protease inhibitor or one non-nucleoside reverse transcriptase inhibitor in a triple antiretroviral therapy: normal clinical practice versus clinical trial findings.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Male; Oxazines; Retrospective Studies; Treatment Outcome; Tunisia; Viremia; Zidovudine | 2005 |
Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.
Topics: Absorption; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Computer Simulation; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Models, Biological; Oxazines; Reproducibility of Results; Reverse Transcriptase Inhibitors | 2005 |
Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; HIV Infections; Humans; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Treatment Outcome | 2005 |
Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; Follow-Up Studies; Genotype; HIV Infections; HIV-1; Humans; Middle Aged; Mutation; Nevirapine; Oxazines; Phenotype; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Failure | 2005 |
Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Blood Glucose; Cyclopropanes; Drug Therapy, Combination; Dyslipidemias; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Insulin Resistance; Lipids; Male; Nelfinavir; Nucleosides; Oxazines | 2005 |
Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Drug Administration Schedule; Drug Monitoring; Female; HIV Infections; Humans; Longitudinal Studies; Male; Middle Aged; Oxazines; Risk Factors | 2005 |
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.
Topics: Adult; Alkynes; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; Cyclopropanes; Cytochrome P-450 Enzyme System; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Oxazines; Pharmacogenetics; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome | 2005 |
Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009.
Topics: Adult; Aged; Alkynes; Anthropometry; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Blood Glucose; CD4 Lymphocyte Count; Creatinine; Cyclopropanes; Disease Progression; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Lipids; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure; Treatment Outcome; Viral Load | 2005 |
Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Female; HIV Infections; Humans; Male; Middle Aged; Mood Disorders; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Sleep Wake Disorders | 2005 |
Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Male; Middle Aged; Odds Ratio; Organophosphonates; Oxazines; Prospective Studies; RNA, Viral; Tenofovir; Treatment Outcome | 2005 |
Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results.
Topics: Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Body Weight; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Oxazines; Rifampin; Treatment Outcome; Tuberculosis | 2006 |
Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.
Topics: Administration, Oral; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Exanthema; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load | 2005 |
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Oxazines; Prospective Studies; RNA, Viral; Tenofovir; Zidovudine | 2006 |
Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Cyclopropanes; Dyslipidemias; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Organophosphonates; Oxazines; Protease Inhibitors; Stavudine; Tenofovir; Treatment Outcome; Viral Load | 2005 |
Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Synergism; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; Humans; Lamivudine; Lopinavir; Organophosphonates; Oxazines; Patient Compliance; Peptide Fragments; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2006 |
An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Zidovudine | 2006 |
Comparative bioavailability of a generic capsule formulation of the reverse transcriptase inhibitor efavirenz and the innovator product.
Topics: Administration, Oral; Adolescent; Adult; Alkynes; Benzoxazines; Biological Availability; Capsules; Cross-Over Studies; Cyclopropanes; Drugs, Generic; Female; HIV Infections; Humans; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors | 2006 |
Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Contraception; Cote d'Ivoire; Cyclopropanes; Female; Follow-Up Studies; Hepatitis B; Hepatitis B Surface Antigens; HIV Infections; HIV-1; HIV-2; Humans; Male; Nervous System Diseases; Oxazines; Pregnancy; Pregnancy Complications; Transaminases; Treatment Outcome | 2006 |
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; RNA, Messenger; Viral Load; Zidovudine | 2006 |
Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903.
Topics: Adenine; Alkynes; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Treatment Outcome | 2006 |
Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Capsules; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Gelatin; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oxazines; Ritonavir; Saquinavir | 2006 |
Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.
Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Mycobacterium tuberculosis; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis | 2006 |
Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Oxazines; Ritonavir; Stavudine; Treatment Outcome | 2006 |
Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012).
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Male; Oxazines; Peptide Fragments; Ritonavir; Saquinavir; Viral Load | 2006 |
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Oxazines; RNA, Viral; Tenofovir; Time Factors; Viral Load; Zidovudine | 2006 |
Highly active antiretroviral treatment containing efavirenz or nevirapine and related toxicity in the TREAT Asia HIV Observational Database.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Drug Therapy, Combination; Exanthema; HIV Infections; HIV-1; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 2006 |
Virological and immunological responses of efavirenz-based HAART regimen initiated in HIV-infected patients at CD4 < 100 versus CD4 > or = 100 cells/mm3.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Male; Middle Aged; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral | 2006 |
Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Aged; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Extremities; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lipid Metabolism; Lipids; Male; Middle Aged; Oxazines; Stavudine; Viral Load | 2007 |
Can efavirenz be taken in the morning?
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Middle Aged; Oxazines; Patient Compliance; Reverse Transcriptase Inhibitors | 2006 |
Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Area Under Curve; Benzoxazines; CD4 Lymphocyte Count; Chromatography, Liquid; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Female; Half-Life; HIV Infections; HIV Protease Inhibitors; Humans; Injections; Medroxyprogesterone Acetate; Middle Aged; Nelfinavir; Nevirapine; Ovulation Inhibition; Oxazines; Progesterone; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors | 2007 |
Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Blood Glucose; Body Composition; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Insulin Resistance; Lactic Acid; Lamivudine; Lipids; Male; Reverse Transcriptase Inhibitors; Zidovudine | 2007 |
Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome | 2007 |
Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Disease Progression; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nevirapine; Reverse Transcriptase Inhibitors; Treatment Outcome | 2007 |
Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antifungal Agents; Area Under Curve; Benzoxazines; Candidiasis, Oral; Cyclopropanes; Drug Interactions; Female; Half-Life; HIV Infections; Humans; Ketoconazole; Lamivudine; Male; Middle Aged; Stavudine | 2007 |
Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Oxidoreductases, N-Demethylating; Polymorphism, Genetic | 2007 |
Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Prospective Studies; Regression Analysis; RNA, Viral; Time Factors; Zidovudine | 2007 |
Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Patient Compliance; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2007 |
High prevalence of subtherapeutic plasma concentrations of efavirenz in children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Female; HIV Infections; Humans; Male; Viral Load | 2007 |
Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in Botswana.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Botswana; Confounding Factors, Epidemiologic; Congenital Abnormalities; Cyclopropanes; Female; HIV Infections; Humans; Infant, Newborn; Longitudinal Studies; Male; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pregnancy Rate; Risk Factors; Treatment Outcome | 2007 |
A computer-based system to aid in the interpretation of plasma concentrations of antiretrovirals for therapeutic drug monitoring.
Topics: Adult; Algorithms; Alkynes; Anti-Retroviral Agents; Artificial Intelligence; Bayes Theorem; Benzoxazines; California; Computer Systems; Cyclopropanes; Drug Monitoring; Drug Therapy, Combination; Expert Systems; Female; Fuzzy Logic; HIV Infections; Humans; Lopinavir; Male; Models, Biological; Practice Guidelines as Topic; Prospective Studies; Pyrimidinones; Reproducibility of Results | 2007 |
Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Fat Distribution; Cyclopropanes; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Male; Pyrimidinones; Ritonavir; Time Factors | 2007 |
Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study.
Topics: Alkynes; Benzoxazines; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyslipidemias; Female; Follow-Up Studies; HIV Infections; Humans; Male; Nevirapine; Reverse Transcriptase Inhibitors; Severity of Illness Index; Single-Blind Method; Treatment Outcome | 2007 |
Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.
Topics: Absorptiometry, Photon; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Composition; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Prospective Studies; Stavudine; Time Factors; Treatment Outcome; United States; Zidovudine | 2007 |
Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial).
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cholesterol; Cyclopropanes; Deoxycytidine; Didanosine; Drug Tolerance; Emtricitabine; Female; France; HIV Infections; HIV-1; Humans; Lipids; Lipoproteins; Male; RNA, Viral; Time Factors; Treatment Outcome | 2007 |
Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial.
Topics: Administration, Oral; Adolescent; Alkynes; Area Under Curve; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Metabolic Clearance Rate; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; United States; Virus Replication | 2008 |
Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021.
Topics: Adolescent; Adult; Alkynes; Benzoxazines; Child; Child, Preschool; Clinical Protocols; Cyclopropanes; Deoxycytidine; Didanosine; Drug Administration Schedule; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Time | 2007 |
Response to efavirenz-containing regimens in previously antiretroviral-naive HIV-positive patients: the role of gender.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; Humans; Male; Sex Characteristics; Time Factors; Treatment Outcome; Viral Load | 2007 |
Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Costs and Cost Analysis; Cyclopropanes; Female; HIV; HIV Infections; Humans; India; Liver; Liver Diseases; Male; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome | 2007 |
Data shows long-term nevirapine efficacy and increases in good cholesterol.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cholesterol, HDL; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome; Viral Load | 2007 |
Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Didanosine; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Regression Analysis; Stavudine; Treatment Failure | 2007 |
A comparison of three initial antiretroviral AIDS regimens.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; HIV; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 2007 |
144-week data released on Gilead's study 934.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Time Factors; Viral Load; Zidovudine | 2007 |
Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.
Topics: Alkynes; Alleles; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Gene Frequency; Haplotypes; HIV Infections; HIV-1; Humans; Oxidoreductases, N-Demethylating; Polymorphism, Genetic | 2007 |
Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study.
Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Area Under Curve; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dose-Response Relationship, Drug; Female; Graft Rejection; Half-Life; Hepatitis C; HIV; HIV Infections; Humans; Liver Transplantation; Lopinavir; Male; Middle Aged; Nelfinavir; Pyrimidinones; Ritonavir; Tacrolimus; Viral Load | 2007 |
Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Organophosphates; Pyrimidinones; Ritonavir; Sulfonamides | 2007 |
Efavirenz-therapy in HIV-patients with underlying liver disease: importance of continuous TDM of EFV.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-HIV Agents; Aspartate Aminotransferases; Benzoxazines; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Chromatography, High Pressure Liquid; Chronic Disease; Cyclopropanes; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; HIV Infections; Humans; Liver Diseases; Male; RNA, Viral; Viral Load | 2007 |
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
Topics: Adenine; Adult; Alkynes; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2008 |
Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection.
Topics: Adult; Alkynes; Anthropometry; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Constitution; Cardiovascular Diseases; Cyclopropanes; Diabetes Mellitus, Type 2; Disease Progression; Epidemiologic Methods; Female; HIV Infections; Humans; Male; Metabolic Syndrome; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors | 2007 |
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; HIV; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Linear Models; Organic Chemicals; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Statistics, Nonparametric; Tenofovir; Time Factors; Viral Load; Virus Integration; Virus Latency; Virus Replication | 2007 |
Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events.
Topics: Adult; Alkynes; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Developing Countries; Dizziness; Drug Tolerance; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; South Africa; Treatment Outcome; Viral Load; Vomiting; Zidovudine | 2008 |
Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black People; Cyclopropanes; Double-Blind Method; Hispanic or Latino; HIV Infections; Humans; Quality of Life; Racial Groups; Risk Factors; Treatment Failure; Treatment Refusal; United States; White People | 2007 |
Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure; Treatment Outcome; Zidovudine | 2008 |
Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Contraceptive Agents, Female; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Injections, Intramuscular; Medroxyprogesterone Acetate; Nelfinavir; Nevirapine; Ovulation Inhibition; RNA, Viral; Safety; Viral Load | 2008 |
Long-term assessment of didanosine, lamivudine, and efavirenz in antiretroviral-naive patients: 3-year follow-up.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2008 |
Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; DNA, Viral; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Poor efficacy and tolerability of stavudine, didanosine, and efavirenz-based regimen in treatment-naive patients in Senegal.
Topics: Administration, Oral; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Developing Countries; Didanosine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; HIV Infections; Humans; Male; Maximum Tolerated Dose; Patient Compliance; Risk Assessment; RNA, Viral; Senegal; Severity of Illness Index; Stavudine; Survival Rate; Treatment Outcome; Viral Load | 2007 |
First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Hypertriglyceridemia; Kaplan-Meier Estimate; Longitudinal Studies; Lopinavir; Male; Pyrimidinones; Retrospective Studies; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load; Withholding Treatment | 2008 |
Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.
Topics: Adolescent; Alkynes; Benzoxazines; CD4 Lymphocyte Count; CD4-CD8 Ratio; Child; Child, Preschool; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Mutation; Nevirapine; Plasma; Reverse Transcriptase Inhibitors; Time Factors; Viral Load; Withholding Treatment | 2008 |
Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load | 2008 |
CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Enzyme Induction; Enzyme Inhibitors; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxycholesterols; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Young Adult | 2008 |
Class-sparing regimens for initial treatment of HIV-1 infection.
Topics: Adolescent; Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Kaplan-Meier Estimate; Lopinavir; Male; Middle Aged; Mutation; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Failure | 2008 |
Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Oxazines; Viral Load; Zidovudine | 1999 |
Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Mutation; Oxazines; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Saquinavir; Treatment Outcome | 1999 |
Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Nelfinavir; Oxazines; Spectrophotometry, Ultraviolet | 1999 |
Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 1999 |
Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.
Topics: Adolescent; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral | 1999 |
Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity.
Topics: Adult; Alkynes; Antiviral Agents; Area Under Curve; Base Sequence; Benzoxazines; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Furans; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation; Oxazines; Phenotype; Pilot Projects; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2000 |
Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Chromatography, High Pressure Liquid; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Nelfinavir; Oxazines; Stavudine | 2000 |
Evaluation of lymph node virus burden in human immunodeficiency virus-infected patients receiving efavirenz-based protease inhibitor--sparing highly active antiretroviral therapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Coculture Techniques; Cross-Sectional Studies; Cyclopropanes; Genotype; HIV; HIV Infections; Humans; In Situ Hybridization; Lymph Nodes; Oxazines; Protease Inhibitors; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Virus Replication | 2000 |
Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Didanosine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Oxazines; Pilot Projects; RNA, Viral | 2000 |
Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitors.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nelfinavir; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Stavudine | 1999 |
Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy.
Topics: Adipose Tissue; Adult; Alkynes; Benzoxazines; Blood Glucose; Body Constitution; Body Mass Index; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lipids; Lipodystrophy; Male; Middle Aged; Oxazines; Protease Inhibitors; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2000 |
Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Indinavir; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome | 2001 |
The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz.
Topics: Adult; Alkynes; Analgesics, Opioid; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Male; Methadone; Oxazines; Reverse Transcriptase Inhibitors; Substance Withdrawal Syndrome | 2001 |
Performance of a quadruple combination including nelfinavir plus efavirenz in naive subjects with high baseline viral load and in patients failing protease inhibitor-containing regimens.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Spain; Treatment Failure; Viral Load; Virus Replication | 2001 |
Efavirenz shows promising results.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Oxazines; Reverse Transcriptase Inhibitors; Zidovudine | 1998 |
CSF replication reduced with Sustiva.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cerebrospinal Fluid; Cyclopropanes; HIV Infections; HIV-1; Humans; Oxazines; RNA, Viral | 1998 |
Sustiva added to three-drug combination.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zidovudine | 1998 |
Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Nelfinavir; Nevirapine; Oxazines; Prospective Studies; Salvage Therapy | 2001 |
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Half-Life; HIV Infections; HIV-1; Humans; Male; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Viral Load | 2001 |
Pharmacokinetic evaluation of oral levofloxacin in human immunodeficiency virus-infected subjects receiving concomitant antiretroviral therapy.
Topics: Administration, Oral; Alkynes; Anti-HIV Agents; Anti-Infective Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Interactions; HIV Infections; Humans; Levofloxacin; Nelfinavir; Ofloxacin; Oxazines; Prospective Studies | 2001 |
Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
Topics: Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Male; Mutation; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral; Treatment Failure; Viral Load | 2001 |
Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Viremia | 2001 |
Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load | 2001 |
Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Indinavir; Male; Middle Aged; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load | 2002 |
Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Coculture Techniques; Cyclopropanes; Drug Synergism; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Interferon-gamma; Interleukin-2; Lamivudine; Lymphocyte Activation; Lymphocyte Subsets; Oxazines; Pilot Projects; Reverse Transcriptase Inhibitors; Stavudine | 2002 |
Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nevirapine; Oxazines; Prospective Studies; Treatment Outcome | 2002 |
HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Female; Furans; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Phenotype; Retrospective Studies; RNA, Viral; Safety; Sulfonamides; Treatment Failure | 2002 |
Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antigens, CD; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Cyclopropanes; Didanosine; Dideoxynucleosides; Double-Blind Method; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2002 |
Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Drug Therapy, Combination; Emotions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Patient Compliance; Prospective Studies; Quality of Life; Reverse Transcriptase Inhibitors; Surveys and Questionnaires; Treatment Outcome | 2002 |
Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous system in HIV-1-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Viral Diseases; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Oxazines; Psychomotor Performance; Reverse Transcriptase Inhibitors; Treatment Outcome | 2002 |
Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Child; Child, Preschool; Cyclopropanes; DNA, Viral; Drug Therapy, Combination; Female; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Leukocytes, Mononuclear; Male; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load | 2002 |
A prospective comparison of the two main indications of efavirenz in 2001 highly active antiretroviral therapy (HAART) regimens: first-line versus salvage use.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; DNA, Viral; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Salvage Therapy; Treatment Outcome | 2002 |
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Disease Progression; Double-Blind Method; Drug Resistance, Viral; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Nelfinavir; Organophosphonates; Oxazines; Proportional Hazards Models; Reverse Transcriptase Inhibitors; Saquinavir; Sulfonamides; Treatment Failure; Viral Load | 2002 |
1249 other study(ies) available for efavirenz and HIV Coinfection
| Article | Year |
|---|---|
A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
Topics: Administration, Oral; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Dogs; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Mutation; Reverse Transcriptase Inhibitors; Triazoles | 2007 |
Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
Topics: Antiviral Agents; Cell Line; Guanine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans | 2008 |
1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Biological Assay; Cell Line; Chemistry, Pharmaceutical; Drug Design; Drug Evaluation, Preclinical; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Chemical; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thiadiazoles; Virus Replication | 2008 |
Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
Topics: Anti-HIV Agents; Cells, Cultured; Cervix Uteri; Dose-Response Relationship, Drug; Female; HIV Infections; HIV-1; Humans; Luciferases; Macrophages; Organ Culture Techniques; Pyrimidines; Reverse Transcriptase Inhibitors; T-Lymphocytes | 2009 |
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
Topics: Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Nucleosides; Phenotype; Reverse Transcriptase Inhibitors | 2009 |
Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Age Factors; Alkynes; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; Humans; Male; Middle Aged; Oxidoreductases, N-Demethylating; Polymorphism, Genetic; Sex Factors | 2009 |
Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
Topics: Acetamides; Anti-HIV Agents; Cell Line; HIV Infections; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Models, Molecular; Protein Binding; Structure-Activity Relationship | 2009 |
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cell Line; Cells, Cultured; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Molecular Structure; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Rilpivirine | 2010 |
Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages.
Topics: Anti-HIV Agents; Blotting, Western; Cell Line; Cell Survival; Cells, Cultured; Drug Resistance, Viral; HIV Infections; HIV-1; HIV-2; Human Immunodeficiency Virus Proteins; Humans; Macrophages; Microscopy, Electron, Transmission; Molecular Structure; Polymerase Chain Reaction; Viral Regulatory and Accessory Proteins; Virion; Virus Release; Virus Replication | 2010 |
Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; Mutation; Nitriles; Phylogeny; Pyridazines; Pyrimidines | 2010 |
Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
Topics: Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Genes, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; In Vitro Techniques; Models, Molecular; Mutation, Missense; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Recombination, Genetic; Virus Replication | 2010 |
Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutagenesis, Site-Directed; Mutation; Nucleosides; Phenotype; pol Gene Products, Human Immunodeficiency Virus; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Virus Replication | 2010 |
Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
Topics: Anti-HIV Agents; Cell Line; Cell Survival; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Nitriles; Protein Binding; Pyridazines; Pyrimidines; Quinazolines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2010 |
Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Mutation; Piperidines; Pyrimidines; Structure-Activity Relationship | 2010 |
Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
Topics: Acetamides; Anti-HIV Agents; Cell Line; HIV Infections; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Triazoles; Virus Replication | 2011 |
Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Structure-Activity Relationship; Thioacetamide | 2012 |
Synthesis and biological evaluation of phosphonate analogues of nevirapine.
Topics: HIV Infections; HIV-1; Humans; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2013 |
Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.
Topics: Cell Line; Delavirdine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Pyridazines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2013 |
Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.
Topics: Anti-HIV Agents; Cell Line; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2013 |
Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
Topics: Anti-HIV Agents; Catalytic Domain; Dose-Response Relationship, Drug; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Molecular Structure; Niacinamide; Protein Conformation; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured | 2014 |
Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
Topics: Anti-HIV Agents; Binding Sites; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Point Mutation; Pyridines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2016 |
Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
Topics: Anti-HIV Agents; Cell Line; Drug Design; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Keto Acids; Molecular Docking Simulation; Pyrimidines; Reverse Transcriptase Inhibitors | 2017 |
Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
Topics: Animals; Anti-HIV Agents; Drug Resistance, Viral; HEK293 Cells; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Pyrimidines; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thiophenes | 2017 |
Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Niacinamide; Point Mutation; Structure-Activity Relationship; Triazoles | 2018 |
The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Drug Discovery; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors | 2019 |
Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.
Topics: Administration, Oral; Animals; Anti-HIV Agents; Apoptosis; Drug Design; Female; HIV Infections; HIV-1; Humans; Ligands; Male; Mice; Microsomes, Liver; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Rats; Reverse Transcriptase Inhibitors; Tissue Distribution; Tumor Cells, Cultured; Virus Replication | 2019 |
Rational design and Structure-Activity relationship of coumarin derivatives effective on HIV-1 protease and partially on HIV-1 reverse transcriptase.
Topics: Anti-HIV Agents; Cell Line; Coumarins; Dose-Response Relationship, Drug; Drug Design; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Molecular Structure; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2020 |
Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
Topics: Anti-HIV Agents; Chemistry, Pharmaceutical; Heterocyclic Compounds, 1-Ring; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Reverse Transcriptase Inhibitors | 2022 |
Effect of albumin and CYP2B6 polymorphisms on exposure of efavirenz: A population pharmacokinetic analysis in Chinese HIV-infected adults.
Topics: Adult; Albumins; Alkynes; Anti-HIV Agents; Benzoxazines; China; Cyclopropanes; Cytochrome P-450 CYP2B6; HIV Infections; Humans; Polymorphism, Genetic | 2021 |
Liver Fat, Adipose Tissue, and Body Composition Changes After Switching from a Protease Inhibitor or Efavirenz to Raltegravir.
Topics: Adipose Tissue; Alkynes; Benzoxazines; Body Composition; Cyclopropanes; HIV Infections; Humans; Liver; Protease Inhibitors; Raltegravir Potassium | 2021 |
T cell derived HIV-1 is present in the CSF in the face of suppressive antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; T-Lymphocytes; Tenofovir | 2021 |
Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV.
Topics: Adenine; Adult; Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cobicistat; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Prospective Studies; Quality of Life; Quinolones; Sleep Quality; Tenofovir | 2021 |
Vitamin D as Modulator of Drug Concentrations: A Study on Two Italian Cohorts of People Living with HIV Administered with Efavirenz.
Topics: Adult; Alkynes; Benzoxazines; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Italy; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Seasons; Treatment Outcome; Vitamin D; Vitamins | 2021 |
Efavirenz, dysrhythmia and HIV.
Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; Humans | 2021 |
Association between social psychological status and efavirenz and nevirapine plasma concentration among HIV patients in Kenya.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Female; HIV Infections; Humans; Kenya; Male; Middle Aged; Nevirapine; Socioeconomic Factors; Young Adult | 2021 |
Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Patient Outcome Assessment; Piperazines; Pyridones; Uganda | 2021 |
Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Resistance; Emtricitabine; HIV Infections; Humans; South Africa; Tenofovir; Viral Load; Viremia | 2022 |
Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Cytochrome P-450 CYP2B6; Genotype; HIV Infections; Humans; Infant; Tuberculosis | 2022 |
Pharmacogenetics of the Late-Onset Efavirenz Neurotoxicity Syndrome (LENS).
Topics: Adult; Alkynes; Anti-HIV Agents; Arylamine N-Acetyltransferase; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; HIV Infections; Humans; Isoniazid; Male; Neurotoxicity Syndromes; Pharmacogenetics; Polymorphism, Single Nucleotide | 2022 |
Is it time to retire efavirenz as a first-line option worldwide?
Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; Humans | 2022 |
A natural history of efavirenz drug-induced liver injury.
Topics: Adult; Alkynes; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Female; HIV Infections; Humans; Male; Prospective Studies; Reverse Transcriptase Inhibitors; South Africa | 2021 |
Concentration-response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Randomized Controlled Trials as Topic; Weight Gain | 2022 |
Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; Tenofovir | 2022 |
Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi-centre 48-week efficacy and safety study in Thailand.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Quality of Life; Rilpivirine; Thailand; Treatment Outcome; Viral Load | 2022 |
Prevalence and predictors of glucose metabolism disorders among People Living with HIV on combination antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Blood Glucose; Cross-Sectional Studies; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Ethiopia; Female; Glucose; Glucose Metabolism Disorders; HIV; HIV Infections; Humans; Insulin; Male; Prevalence; Ritonavir | 2022 |
Lipid profile levels in HIV-AIDS patients on treatment with efavirenz and atazanavir. Cohort study.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cholesterol, LDL; Cohort Studies; Cyclopropanes; HIV Infections; Humans; Retrospective Studies | 2021 |
An overview of genetic variants regarding efavirenz-related dysthymias in HIV-infected patients: Response to a letter to the editor.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans | 2022 |
Integrase Inhibitors are Associated with Neuropsychiatric Symptoms in Women with HIV.
Topics: Anti-HIV Agents; Benzoxazines; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Oxazines; Raltegravir Potassium | 2023 |
The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Botswana; Cyclopropanes; Cytochrome P-450 CYP2B6; Genotype; HIV Infections; Humans; Leukocytes, Mononuclear; Nevirapine; Polymorphism, Single Nucleotide; Retrospective Studies; Reverse Transcriptase Inhibitors | 2022 |
Pharmacogenetic predictors of variability in efavirenz pharmacokinetics in an admixed Brazilian HIV cohort.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Brazil; Cyclopropanes; Cytochrome P-450 CYP2B6; Genotype; HIV Infections; Humans; Pharmacogenetics; Polymorphism, Single Nucleotide | 2022 |
Brief Report: Efficacy and Safety of Efavirenz, Raltegravir, and Dolutegravir in HIV-1/TB Coinfection. A Multicenter Retrospective Cohort Study in France.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Coinfection; Cyclopropanes; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Retrospective Studies; Treatment Outcome; Tuberculosis; Viral Load | 2022 |
Levels of adherence to contemporary antiretroviral regimens and the likelihood of viral suppression: a cohort study in a Brazilian metropolis.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Brazil; Cohort Studies; HIV Infections; Humans; Lamivudine; Prospective Studies; Tenofovir | 2023 |
Immunological, Cognitive, and Psychiatric Outcomes After Initiating Efavirenz- and Dolutegravir-based Antiretroviral Therapy During Acute Human Immunodeficiency Virus Infection.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Cognition; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Retrospective Studies | 2023 |
Constitutive androstane receptor and pregnane X receptor genotype influence efavirenz plasma concentration and CYP2B6 enzyme activity.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Constitutive Androstane Receptor; Cyclopropanes; Cytochrome P-450 CYP2B6; Genotype; HIV Infections; Humans; Pregnane X Receptor; Tandem Mass Spectrometry | 2022 |
Dolutegravir in real life: Self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Lesotho; Male; Middle Aged; Outcome Assessment, Health Care; Oxazines; Prospective Studies; Self Report; Tenofovir | 2023 |
The combination of low level laser therapy and efavirenz drastically reduces HIV infection in TZM-bl cells.
Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Low-Level Light Therapy; Necrosis | 2021 |
Comparison of efavirenz levels in blood and hair with pharmacy refills as measures of adherence and predictors of viral suppression among people living with HIV in Nigeria.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Hair; HIV Infections; Humans; Nigeria; Pharmacy | 2022 |
Influence of CYP2B6 and CYP3A4 polymorphisms on the virologic and immunologic responses of patients treated with efavirenz-containing regimen.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP3A; Genotype; HIV Infections; Humans; Polymorphism, Single Nucleotide | 2022 |
Do anti-HIV drugs pose a threat to photosynthetic microorganisms?
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Lamivudine; Photosynthesis; Tenofovir; Water | 2022 |
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.
Topics: Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Isoniazid; Nevirapine; Rifampin | 2022 |
Concentrations of Efavirenz, Tenofovir, and Emtricitabine in Obesity: A Cross-Sectional Study.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Emtricitabine; HIV Infections; Humans; Obesity, Abdominal; Tenofovir | 2022 |
Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Infant; Infant, Newborn; Maraviroc; Nevirapine | 2022 |
A Phenotypic Screen Identifies Potent DPP9 Inhibitors Capable of Killing HIV-1 Infected Cells.
Topics: Alkynes; Benzoxazines; CARD Signaling Adaptor Proteins; Cyclopropanes; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; HIV Infections; HIV-1; Humans; Inflammasomes; Leukocytes, Mononuclear; Neoplasm Proteins | 2022 |
Contraceptive implant use duration is not associated with breakthrough pregnancy among women living with HIV and using efavirenz: a retrospective, longitudinal analysis.
Topics: Adolescent; Adult; Alkynes; Benzoxazines; Contraceptive Agents; Cyclopropanes; Female; HIV Infections; Humans; Levonorgestrel; Middle Aged; Nevirapine; Pregnancy; Retrospective Studies; Young Adult | 2022 |
Effectiveness and Safety of Dolutegravir Versus Efavirenz-Based Antiviral Regimen in People Living With HIV-1 in Sichuan Province of China: A Real-World Study.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Male; Oxazines; Piperazines; Pyridones; Retrospective Studies | 2022 |
Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
Topics: Adenine; Alanine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cholesterol, LDL; Cobicistat; Cyclopropanes; Emtricitabine; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lamivudine; Lipoproteins, HDL; Quinolones; Retrospective Studies; Tenofovir | 2022 |
A post-mortem analysis of tenofovir, lamivudine, efavirenz and fluconazole penetration in female genital tissues.
Topics: Anti-HIV Agents; Autopsy; Benzoxazines; Chromatography, Liquid; Female; Fluconazole; Genitalia, Female; HIV Infections; Humans; Lamivudine; Tandem Mass Spectrometry; Tenofovir | 2022 |
Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Drug Combinations; Fluorenes; HIV Infections; Humans; Lopinavir; Lumefantrine; Malaria; Malaria, Falciparum; Nevirapine; Ritonavir; Uganda | 2023 |
Antiretroviral therapy adherence patterns, virological suppression, and emergence of drug resistance: A nested case-control study from Uganda and South Africa.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Case-Control Studies; Drug Resistance; HIV Infections; HIV Integrase Inhibitors; Humans; Longitudinal Studies; South Africa; Treatment Failure; Uganda; Viral Load | 2022 |
Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Creatinine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Lamivudine; Prospective Studies; Pyridones; RNA; Tenofovir; Triglycerides | 2022 |
Low-frequency pre-treatment HIV drug resistance: effects on 2-year outcome of first-line efavirenz-based antiretroviral therapy.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Treatment Failure | 2022 |
Urine tenofovir-monitoring predicts HIV viremia in patients treated with high genetic-barrier regimens.
Topics: Anti-HIV Agents; Cross-Sectional Studies; HIV Infections; Humans; Protease Inhibitors; Ritonavir; Tenofovir; Viral Load; Viremia | 2022 |
Frequency of CYP2B6 Alleles in Major Iranian Ethnicities, Affecting Response to Efavirenz.
Topics: Alleles; Cytochrome P-450 CYP2B6; Gene Frequency; HIV Infections; Humans; Iran; Polymorphism, Single Nucleotide | 2022 |
Anxiety, depression, and sleep disturbances among people on long-term efavirenz-based treatment for HIV: a cross-sectional study in Beijing, China.
Topics: Anxiety; Beijing; Cross-Sectional Studies; Depression; HIV Infections; Humans; Sleep; Sleep Wake Disorders | 2022 |
Method validation and clinical application for the quantification of lopinavir, efavirenz, and ritonavir in breast milk using liquid chromatography tandem mass spectrometry.
Topics: Anti-Retroviral Agents; Chromatography, Liquid; Female; HIV Infections; Humans; Lopinavir; Milk, Human; Ritonavir; Tandem Mass Spectrometry | 2022 |
Clinical predictors of efavirenz-based regimen treatment durability: A two-year case-control study of antiretroviral-naïve patients.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Case-Control Studies; CD4 Lymphocyte Count; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Opportunistic Infections; Retrospective Studies; Substance Abuse, Intravenous; Treatment Outcome; Viral Load | 2023 |
Case study on antiretroviral drugs uptake from soil irrigated with contaminated water: Bio-accumulation and bio-translocation to roots, stem, leaves, and fruits.
Topics: Bioaccumulation; Fruit; HIV Infections; Humans; Nevirapine; Soil; Soil Pollutants; Vegetables; Water; Water Pollution | 2023 |
Biotransformation of Efavirenz and Proteomic Analysis of Cytochrome P450s and UDP-Glucuronosyltransferases in Mouse, Macaque, and Human Brain-Derived In Vitro Systems.
Topics: Animals; Biotransformation; Brain; Cytochrome P-450 Enzyme System; Glucuronosyltransferase; HIV Infections; Humans; Macaca; Mice; Mice, Inbred C57BL; Microsomes, Liver; Proteomics; Uridine Diphosphate | 2023 |
Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Cameroon; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Tenofovir; Viral Load | 2022 |
Incidence and risk factors of hypertriglyceridemia in males with human immunodeficiency virus who are treated with combination antiretroviral therapy: a retrospective cohort study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; HIV Infections; HIV-1; Humans; Hypertriglyceridemia; Incidence; Lamivudine; Male; Retrospective Studies; Risk Factors; Tenofovir; Triglycerides | 2023 |
Genetic and non-genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus-1-infected children in Ethiopia.
Topics: Anti-HIV Agents; Benzoxazines; Body Weight; Child; Cyclopropanes; Cytochrome P-450 CYP2B6; Ethiopia; Genotype; HIV Infections; HIV-1; Humans | 2023 |
HIV Drug Resistance in Adults Initiating or Reinitiating Antiretroviral Therapy in Uruguay-Results of a Nationally Representative Survey, 2018-2019.
Topics: Adult; Anti-Retroviral Agents; Cross-Sectional Studies; Female; HIV Infections; HIV-1; Humans; Male; Ritonavir; Uruguay | 2023 |
Neuropsychiatric adverse drug reactions and associated factors in a cohort of individuals starting dolutegravir-based or efavirenz-based antiretroviral therapy in Belo Horizonte, Brazil.
Topics: Benzoxazines; Brazil; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Prospective Studies | 2023 |
Optimizing Treatment for Human Immunodeficiency Virus to Improve Clinical Outcomes Using Precision Medicine.
Topics: Acquired Immunodeficiency Syndrome; HIV; HIV Infections; Humans; Precision Medicine; Reverse Transcriptase Inhibitors | 2023 |
Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Female; HIV Infections; Humans; Male; Pregnancy; Retrospective Studies; South Africa; Tuberculosis; Viral Load | 2023 |
Relating CYP2B6 genotype and efavirenz resistance among post-partum women living with HIV with high viremia in Uganda: a nested cross-sectional study.
Topics: Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; Humans; Polymorphism, Single Nucleotide; Postpartum Period; Pregnancy; Uganda; Viremia | 2023 |
Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular bone score in Chinese HIV-infected males.
Topics: Adult; Anti-HIV Agents; Bone Density; Cancellous Bone; East Asian People; HIV Infections; Humans; Lamivudine; Male; Muscles; Osteoporosis; Retrospective Studies; Sarcopenia; Stavudine; Tenofovir; Young Adult | 2023 |
Methods optimization and application: Solid phase extraction, ultrasonic extraction and Soxhlet extraction for the determination of antiretroviral drugs in river water, wastewater, sludge, soil and sediment.
Topics: Ecosystem; HIV Infections; Humans; Nevirapine; Rivers; Sewage; Soil; Solid Phase Extraction; Ultrasonics; Wastewater; Water; Water Pollutants, Chemical | 2023 |
Prevalence of pretreatment drug resistance in persons initiating and reinitiating antiretroviral therapy in Sri Lanka: results from a national representative survey.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Cross-Sectional Studies; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Homosexuality, Male; Humans; Male; Mutation; Nevirapine; Prevalence; Sexual and Gender Minorities; Sri Lanka | 2023 |
Physiologically Based Pharmacokinetic Modeling to Determine the Impact of CYP2B6 Genotype on Efavirenz Exposure in Children, Mothers and Breastfeeding Infants.
Topics: Anti-HIV Agents; Benzoxazines; Breast Feeding; Child; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; Humans; Infant; Mothers | 2023 |
Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Female; HIV; HIV Infections; Humans; Male; Viral Load | 2023 |
Evaluation of Glomerular Filtration Rate Trends in People Living With HIV Corrected by the Baseline Glomerular Filtration Rate.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Glomerular Filtration Rate; HIV Infections; Humans; Hypertension; Renal Insufficiency | 2023 |
Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis.
Topics: Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Contraception, Postcoital; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Female; Genotype; HIV Infections; Humans; Isoniazid; Levonorgestrel; Pharmacogenetics; Rifampin; Tuberculosis | 2023 |
Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China.
Topics: China; Drug Combinations; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Retrospective Studies; Tenofovir | 2023 |
Three-year outcomes for women newly initiated on lifelong antiretroviral therapy during pregnancy - Malawi option B.
Topics: Female; HIV Infections; Humans; Infant; Infant, Newborn; Malawi; Male; Pregnancy; Premature Birth; Prospective Studies; Tenofovir | 2023 |
Weight gain in Namibians with HIV switching from efavirenz to dolutegravir.
Topics: Anti-HIV Agents; Benzoxazines; Emtricitabine; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Retrospective Studies; Tenofovir; Weight Gain | 2023 |
Mechanistic Modeling of the Drug-Drug Interaction Between Efavirenz and Dolutegravir: Is This Interaction Clinically Relevant When Switching From Efavirenz to Dolutegravir During Pregnancy?
Topics: Benzoxazines; Drug Interactions; Female; Glucuronosyltransferase; HIV Infections; Humans; Pregnancy | 2023 |
Quantification of nine antiretroviral drugs in cerebrospinal fluid: An approach to overcome sample collection tube adsorption.
Topics: Adsorption; Ammonium Hydroxide; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Chromatography, Liquid; Emtricitabine; HIV Infections; Humans; Lamivudine; Methanol; Ritonavir; Tandem Mass Spectrometry; Tenofovir; Water | 2023 |
Optimizing antiretroviral therapy for children living with HIV: Experience from an observational cohort in Lesotho.
Topics: Anti-HIV Agents; Child; Child, Preschool; Female; HIV Infections; Humans; Infant; Lesotho; Lopinavir; Male; Nevirapine; Retrospective Studies; Ritonavir; Viral Load | 2023 |
Comparison of Efavirenz and Doravirine Developmental Toxicity in an Embryo Animal Model.
Topics: Animals; Anti-HIV Agents; Child; Embryo, Nonmammalian; HIV Infections; Humans; Lipids; Rats; Reverse Transcriptase Inhibitors; Zebrafish | 2023 |
Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz-containing regimen.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Female; HIV Infections; Humans; Male; Rilpivirine | 2023 |
Associations of HIV and antiretroviral therapy with gestational diabetes in South Africa.
Topics: Adult; Benzoxazines; Diabetes, Gestational; Female; Glucose; HIV Infections; Humans; Infant; Postpartum Period; Pregnancy; Prospective Studies; South Africa | 2023 |
Cost-effectiveness of dolutegravir vs. efavirenz-based combined antiretroviral therapies in HIV-infected treatment-naive patients in a Nigerian treatment centre.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Case-Control Studies; Cost-Benefit Analysis; HIV Infections; Humans; Nigeria; Retrospective Studies | 2023 |
Phytosterols reverse antiretroviral-induced hearing loss, with potential implications for cochlear aging.
Topics: Animals; Cholesterol 24-Hydroxylase; Hearing Loss; HIV Infections; Mice; Phytosterols | 2023 |
Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV.
Topics: Anti-Retroviral Agents; Benzoxazines; Counseling; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans | 2023 |
Diagnostic accuracy of a point-of-care urine tenofovir assay, and associations with HIV viraemia and drug resistance among people receiving dolutegravir and efavirenz-based antiretroviral therapy.
Topics: Adult; Benzoxazines; Chromatography, Liquid; Cross-Sectional Studies; Female; HIV Infections; Humans; Male; Point-of-Care Systems; Tandem Mass Spectrometry; Tenofovir; Viremia | 2023 |
Successful Multidrug-Resistant Tuberculosis Treatment Without HIV Viral Suppression: A Missed Opportunity.
Topics: Adult; Antitubercular Agents; Antiviral Agents; Female; HIV Infections; Humans; Male; Protease Inhibitors; Retrospective Studies; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2023 |
Vaginal microbiome, antiretroviral concentrations, and HIV genital shedding in the setting of hormonal contraception initiation in Malawi.
Topics: Anti-Retroviral Agents; Female; HIV Infections; Hormonal Contraception; Humans; Lamivudine; Levonorgestrel; Malawi; Medroxyprogesterone Acetate; Microbiota; Tenofovir; Vagina | 2023 |
Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessment.
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Tenofovir | 2023 |
Antenatal hepatitis B virus sero-prevalence, risk factors, pregnancy outcomes and vertical transmission rate within 24 months after birth in a high HIV prevalence setting.
Topics: Child; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Mothers; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prevalence; Risk Factors; Seroepidemiologic Studies; Tenofovir | 2023 |
Neurodevelopment of children who are HIV-exposed and uninfected in Kenya.
Topics: Child; Child Development; Female; HIV Infections; Humans; Infant; Infant, Newborn; Kenya; Male; Mothers; Pregnancy; Pregnancy Complications, Infectious; Premature Birth | 2023 |
Cost-effectiveness analysis of antiretroviral drugs for treatment-naive HIV infection in China.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cost-Effectiveness Analysis; Dideoxynucleosides; Emtricitabine; HIV Infections; Humans; Lamivudine | 2023 |
Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Female; HIV; HIV Infections; Humans; Infant; Infant, Newborn; Isoniazid; Lopinavir; Male; Pyrazinamide; Rifampin; Ritonavir; Tuberculosis | 2023 |
HIV viral suppression at different thresholds and duration of treatment in the dolutegravir treatment era in Sierra Leone: a nationwide survey.
Topics: Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Duration of Therapy; Female; HIV Infections; Humans; Male; Oxazines; RNA; Sierra Leone; Viral Load | 2023 |
Gynecomastia in HIV-positive adult men receiving efavirenz-based antiretroviral therapy at Newlands clinic, Harare, Zimbabwe.
Topics: Adult; Alkynes; Amlodipine; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Female; Gynecomastia; HIV Infections; Humans; Incidence; Isoniazid; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Zimbabwe | 2019 |
Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Prevalence; Reverse Transcriptase Inhibitors; Taiwan; Zidovudine | 2019 |
Efavirenz-Induced Vanishing Bile Duct Syndrome: A Case Report.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Bile Ducts; Cholestasis; Cyclopropanes; Emtricitabine; HIV Infections; Humans; Male; Middle Aged | 2021 |
Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Contraceptive Agents; Contraceptive Devices, Female; Cyclopropanes; Desogestrel; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Lynestrenol; Middle Aged; Progesterone; Ritonavir; Viral Load; Young Adult | 2019 |
Severe hepatotoxicity induced by efavirenz in a treatment-naïve, low body mass index HIV-infected, female patient with no hepatitis and other virus co-infections.
Topics: Adult; Alkynes; Benzoxazines; Body Mass Index; Chemical and Drug Induced Liver Injury; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 2019 |
Impact of Lopinavir/Ritonavir and Efavirenz-Based Antiretroviral Therapy on the Lipid Profile of Chinese HIV/AIDS Treatment-Naïve Patients in Beijing: A Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Asian People; Beijing; Benzoxazines; Case-Control Studies; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Dyslipidemias; Female; HIV Infections; Hospitals, University; Humans; Lipids; Lopinavir; Male; Middle Aged; Retrospective Studies; Ritonavir; Treatment Outcome | 2019 |
[High prevalence of hypovitaminosis D in HIV-infected persons attending an outpatient clinic, Buenos Aires city].
Topics: Adult; Aged; Aged, 80 and over; Alkynes; Ambulatory Care Facilities; Antirheumatic Agents; Argentina; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; Humans; Male; Middle Aged; Prevalence; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Viral Load; Vitamin D Deficiency; Young Adult | 2019 |
HIV viral load algorithm: what are the needs in the field?
Topics: Africa South of the Sahara; Algorithms; Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Viral Load | 2020 |
HIV Drug Resistance after Failure of 6 Month First-line Therapy in a Hospital: A Case Series.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2019 |
Efavirenz in pregnancy.
Topics: Alkynes; Benzoxazines; Child; Cyclopropanes; Female; HIV Infections; Humans; Microcephaly; Pregnancy; Prospective Studies | 2020 |
Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Combinations; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Male; Microcephaly; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Puerto Rico; Tenofovir; Young Adult; Zidovudine | 2020 |
Pediatric Antiretroviral Therapeutic Drug Monitoring: A Five and a Half Year Experience from a South African Tertiary Hospital.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; Humans; Lopinavir; Male; Medication Adherence; Nevirapine; Pregnancy; Retrospective Studies; South Africa; Tertiary Care Centers; Treatment Outcome | 2020 |
HIV viral load algorithm: what are the needs in the field?: authors' response.
Topics: Africa South of the Sahara; Algorithms; Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Viral Load | 2020 |
'High' antiretroviral deintensification strategy and cellular HIV DNA levels.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; DNA, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Nevirapine; Pilot Projects | 2020 |
Drug-induced immune hemolytic anemia because of efavirenz: a case report.
Topics: Alkynes; Anemia, Hemolytic; Benzoxazines; Cyclopropanes; Female; Hemoglobins; HIV Infections; Humans; Middle Aged | 2020 |
Evaluation of Selected Outcomes of Combination Antiretroviral Therapy: Yemen Cohort Retrospective Descriptive Studies.
Topics: Adult; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Retrospective Studies; Tenofovir; Treatment Outcome; Yemen; Young Adult | 2019 |
Gynaecomastia in the Durban Breast Unit: A Comparison of HIV- and Non-HIV-Infected Individuals.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Breast Neoplasms; Cyclopropanes; Gynecomastia; HIV Infections; Humans; Incidence; Male; Middle Aged; Puberty; Retrospective Studies; Reverse Transcriptase Inhibitors; South Africa; Young Adult | 2020 |
Efavirenz-Based Antiretroviral Therapy Reduces Artemether-Lumefantrine Exposure for Malaria Treatment in HIV-Infected Pregnant Women.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Benzoxazines; Cyclopropanes; Drug Combinations; Drug Interactions; Female; HIV Infections; Humans; Lumefantrine; Malaria; Malaria, Falciparum; Pregnancy; Prospective Studies; Uganda; Young Adult | 2020 |
Predictors of Discontinuation of Efavirenz as Treatment for HIV, Due to Neuropsychiatric Side Effects, in a Multi-Ethnic Sample in the United Kingdom.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Ethnicity; Female; HIV Infections; Humans; Male; Mental Disorders; Middle Aged; Retrospective Studies; Treatment Adherence and Compliance; United Kingdom; Withholding Treatment; Young Adult | 2020 |
Associations between Antiretroviral Drugs on Depressive Symptomatology in Homogenous Subgroups of Women with HIV.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Depression; Depressive Disorder, Major; Diagnostic Self Evaluation; Female; Follow-Up Studies; HIV Infections; Humans; Middle Aged; Occupations; Patients; Prospective Studies; Psychology; Socioeconomic Factors; Surveys and Questionnaires; Symptom Assessment | 2021 |
Traditional Chinese Medicine Can Improve the Immune Reconstruction of HIV/AIDS Patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Drugs, Chinese Herbal; HIV Infections; Humans; Immune Reconstitution; Lamivudine; Medicine, Chinese Traditional; Middle Aged; Pilot Projects; Prospective Studies; T-Lymphocytes; Tenofovir; Treatment Outcome; Young Adult | 2020 |
Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing Strategy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Biological Availability; CD4 Lymphocyte Count; Chromatography, Liquid; Coinfection; Cyclopropanes; Dose-Response Relationship, Drug; Female; Genotype; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Sex Factors; Tandem Mass Spectrometry; Tuberculosis; Young Adult | 2020 |
More evidence for dolutegravir as first-line ART for all.
Topics: Africa South of the Sahara; Alkynes; Benzoxazines; Cyclopropanes; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Risk Assessment | 2020 |
Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
Topics: Adolescent; Adult; Africa South of the Sahara; Alkynes; Anti-HIV Agents; Benzoxazines; Cost-Benefit Analysis; Cyclopropanes; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Male; Middle Aged; Oxazines; Piperazines; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications; Pyridones; Randomized Controlled Trials as Topic; Young Adult | 2020 |
Increased risk of dizziness in human immunodeficiency virus-infected patients taking zidovudine and efavirenz combination: a Brazilian cohort study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Brazil; Cyclopropanes; Depression; Dizziness; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Sleep Initiation and Maintenance Disorders; Survival Analysis; Time Factors; Zidovudine | 2020 |
Incidence and predictors of nevirapine and efavirenz-associated rash among Indonesian HIV patients.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Exanthema; Female; Hepatitis C; HIV Infections; Humans; Incidence; Indonesia; Male; Nevirapine; Retrospective Studies | 2022 |
Maximizing Knowledge Extraction From Patient-Reported Outcome Data Using Exposure-Outcome Item Response Modeling Approach: Understanding Efavirenz-Induced Central Nervous System Toxicity.
Topics: Alkynes; Benzoxazines; Central Nervous System; Cognitive Dysfunction; Computer Simulation; Cyclopropanes; Disease Progression; Drug Administration Schedule; Hallucinations; HIV Infections; Humans; Models, Psychological; Patient Reported Outcome Measures; Patient-Specific Modeling; Reverse Transcriptase Inhibitors; Severity of Illness Index; Sleep Wake Disorders; Symptom Assessment; Time Factors | 2020 |
Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.
Topics: Adult; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Botswana; Cyclopropanes; Cytochrome P-450 CYP2B6 Inducers; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP3A Inducers; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Mothers; Oxazines; Piperazines; Pregnancy; Pyridones; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir; Young Adult | 2020 |
Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz.
Topics: Adult; Alkynes; Artemether, Lumefantrine Drug Combination; Benzoxazines; Case-Control Studies; Constitutive Androstane Receptor; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Genotyping Techniques; HIV Infections; Humans; Malaria; Polymorphism, Single Nucleotide; Pregnancy; Receptors, Cytoplasmic and Nuclear; Treatment Outcome | 2020 |
Neuroinflammation and EIF2 Signaling Persist despite Antiretroviral Treatment in an hiPSC Tri-culture Model of HIV Infection.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Astrocytes; Benzoxazines; CD40 Antigens; Cell Differentiation; Cells, Cultured; Cyclopropanes; Cytokines; Eukaryotic Initiation Factor-2; HIV Infections; Humans; Induced Pluripotent Stem Cells; Inflammation; Microglia; Models, Biological; Neurons; rho-Specific Guanine Nucleotide Dissociation Inhibitors; Signal Transduction; Single-Cell Analysis; Transforming Growth Factor alpha | 2020 |
Movement disorder in a patient with Human Immunodeficiency Virus on an anti-retroviral therapy: A Case Report.
Topics: AIDS Dementia Complex; Alkynes; Anti-HIV Agents; Benzoxazines; Blood-Brain Barrier; Brain Stem; Cerebellar Ataxia; Cerebellum; Cyclopropanes; Drug Substitution; Female; Gait Ataxia; HIV Infections; Humans; Lamivudine; Magnetic Resonance Imaging; Mesencephalon; Middle Aged; Neurodegenerative Diseases; Nystagmus, Pathologic; Panic Disorder; Pons; Postural Balance; Sensation Disorders; Tenofovir; Zidovudine | 2020 |
Efavirenz and cognition that matters.
Topics: Alkynes; Benzoxazines; Cognition; Cyclopropanes; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Rilpivirine; Sleep | 2020 |
The Early Results of Vertebral Pathological Compression Fracture of Extra- nodal Lymphoma with HIV-positive Patients Treated by Percutaneous Kyphoplasty.
Topics: Adult; Alkynes; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Benzoxazines; Burkitt Lymphoma; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cementoplasty; Cyclophosphamide; Cyclopropanes; Doxorubicin; Female; Fractures, Compression; HIV Infections; Humans; Kyphoplasty; Lamivudine; Lumbar Vertebrae; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Retrospective Studies; Rituximab; Spinal Fractures; Tenofovir; Tomography, X-Ray Computed; Vincristine; Viral Load | 2020 |
Enrolling pregnant women with HIV into clinical trials.
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; National Institute of Child Health and Human Development (U.S.); Pregnancy; Raltegravir Potassium; United States | 2020 |
Opportunities and limits for dolutegravir in late pregnancy.
Topics: Alkynes; Animals; Benzoxazines; Cyclopropanes; Dolphins; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pregnancy; Pyridones | 2020 |
Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; Humans; Male; Middle Aged; Models, Biological; Pharmacogenetics; Thailand; Young Adult | 2020 |
Changes in functional connectivity in people with HIV switching antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asymptomatic Diseases; Benzoxazines; Cognitive Dysfunction; Connectome; Cyclopropanes; Drug Substitution; Emtricitabine; Executive Function; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Magnetic Resonance Imaging; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Oxazines; Piperazines; Prospective Studies; Pyridones; Raltegravir Potassium; Rilpivirine; Tenofovir | 2020 |
Efavirenz nanomicelles loaded vaginal film (EZ film) for preexposure prophylaxis (PrEP) of HIV.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HeLa Cells; HIV Infections; HIV-1; Humans | 2020 |
Prevalence of renal dysfunction among HIV infected patients receiving Tenofovir at Mulago: a cross-sectional study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glycosuria; HIV Infections; Humans; Hypercalcemia; Hyperkalemia; Hyperphosphatemia; Hypocalcemia; Hypokalemia; Hypophosphatemia; Lamivudine; Male; Middle Aged; Prevalence; Proteinuria; Renal Insufficiency; Tenofovir; Uganda | 2020 |
Bone turnover markers in children living with HIV remaining on ritonavir-boosted lopinavir or switching to efavirenz.
Topics: Alkynes; Benzoxazines; Bone Remodeling; Child; Cyclopropanes; HIV Infections; Humans; Lopinavir; Ritonavir | 2020 |
Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral Regimens.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Pharmacogenetics; Piperazines; Pyridones | 2021 |
Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral sup
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Drug Monitoring; Drug Substitution; Emtricitabine; HIV Infections; Humans; Lamivudine; Male; Prospective Studies; Taiwan; Tenofovir; Treatment Outcome; Viral Load | 2021 |
Neurocognitive Effects of Antiretroviral Initiation Among People Living With HIV in Rural Uganda.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cognition; Cohort Studies; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Longitudinal Studies; Male; Middle Aged; Neurocognitive Disorders; Neuropsychological Tests; Rural Population; Uganda | 2020 |
Impact of antiretroviral regimen on viral suppression among pregnant women living with HIV in Brazil.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Brazil; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Middle Aged; Pregnancy; Pregnancy Complications, Infectious; Raltegravir Potassium; Treatment Outcome; Viral Load | 2020 |
Case report: one case of coronavirus disease 2019 (COVID-19) in a patient co-infected by HIV with a normal CD4
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Betacoronavirus; C-Reactive Protein; CD4 Lymphocyte Count; Chills; Coronavirus Infections; COVID-19; Cyclopropanes; Fatigue; Female; Fever; HIV; HIV Infections; Humans; Immunocompromised Host; Immunoglobulin M; Lamivudine; Middle Aged; Pandemics; Pharyngitis; Pneumonia, Viral; Real-Time Polymerase Chain Reaction; SARS-CoV-2; Sputum; Time Factors; Tomography, X-Ray Computed; Virus Shedding; Zidovudine | 2020 |
Depression is associated with efavirenz-containing treatments in newly antiretroviral therapy initiated HIV patients in Ecuador.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Depression; Ecuador; Female; HIV Infections; Humans; Male; Prospective Studies; Reverse Transcriptase Inhibitors; Young Adult | 2020 |
Assessing the association between platelets and immune recovery in HIV/HBV co-infected patients: A long-term cohort in Asia.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Blood Platelets; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Cohort Studies; Cyclopropanes; Female; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Immune Reconstitution; Lamivudine; Longitudinal Studies; Male; Platelet Count; Retrospective Studies; Tenofovir | 2020 |
Switch to Efavirenz Attenuates Lipoatrophy in Girls With Perinatal HIV.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cross-Sectional Studies; Cyclopropanes; Female; HIV Infections; Humans; Male; South Africa | 2021 |
Long-Acting Efavirenz and HIV-1 Fusion Inhibitor Peptide Co-loaded Polymer-Lipid Hybrid Nanoparticles: Statistical Optimization, Cellular Uptake, and
Topics: Alkynes; Animals; Benzoxazines; Cyclopropanes; Drug Carriers; Drug Compounding; Drug Liberation; Female; HIV Infections; HIV-1; Humans; Jurkat Cells; Lipids; Mice; Models, Animal; Nanoparticles; Peptides; Polymers; Rats; Reverse Transcriptase Inhibitors; Tissue Distribution; Virus Internalization | 2020 |
Efavirenz-Associated Retinal Toxicity Presenting with Night Vision Defects in Patients with Human Immunodeficiency Virus.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Color Vision; Cyclopropanes; Electroretinography; Evoked Potentials, Visual; Female; HIV Infections; Humans; Male; Middle Aged; Night Blindness; Ophthalmoscopy; Retina; Retinal Diseases; Reverse Transcriptase Inhibitors; Slit Lamp Microscopy; Tomography, Optical Coherence; Visual Acuity | 2020 |
Immune reconstitution inflammatory syndrome: a report of TB-IRIS after switching from efavirenz to dolutegravir.
Topics: Adult; Alkynes; Benzoxazines; Coinfection; Cyclopropanes; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Hospitals, Teaching; Humans; Immune Reconstitution Inflammatory Syndrome; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tuberculosis; Zambia | 2021 |
Fetal biometry following in-utero exposure to dolutegravir-based or efavirenz-based antiretroviral therapy.
Topics: Alkynes; Benzoxazines; Biometry; Cyclopropanes; Female; Fetus; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Oxazines; Piperazines; Pregnancy; Pregnancy Complications, Infectious; Pyridones; Reverse Transcriptase Inhibitors; Ultrasonography, Prenatal | 2020 |
Repeat episode of late-onset psychosis associated with efavirenz.
Topics: Age of Onset; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delusions; HIV Infections; Humans; Male; Middle Aged; Psychotic Disorders | 2020 |
Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Benzoxazines; Cyclopropanes; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Lopinavir; Malaria; Male; Middle Aged; Nevirapine; Nigeria; Ritonavir; Treatment Outcome; Young Adult | 2020 |
Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhibito
Topics: Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Female; HIV Infections; HIV-1; Humans; India; Lamivudine; Male; Middle Aged; Private Sector; Retrospective Studies; Reverse Transcriptase Inhibitors; Tablets; Tenofovir; Tertiary Care Centers; Treatment Outcome; Viral Load | 2020 |
Growth and Neurodevelopment Outcomes in HIV-, Tenofovir-, and Efavirenz-Exposed Breastfed Infants in the PMTCT Option B+ Program in Malawi.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Breast Feeding; Cyclopropanes; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Malawi; Male; Pregnancy; Prospective Studies; Tenofovir | 2021 |
Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pyridones | 2022 |
Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
Topics: Adult; Alanine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain | 2021 |
Drug-drug interaction between itraconazole capsule and efavirenz in adults with HIV for talaromycosis treatment.
Topics: Adolescent; Adult; Alkynes; Antifungal Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Itraconazole; Male; Middle Aged; Mycoses; Pharmaceutical Preparations; Young Adult | 2021 |
Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial).
Topics: Adult; Alkynes; Benzoxazines; Cameroon; Cost-Benefit Analysis; Cyclopropanes; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pyridones | 2021 |
Longitudinal trends and determinants of patient-reported side effects on ART-a Swedish national registry study.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Arthralgia; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Erectile Dysfunction; Female; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Longitudinal Studies; Male; Middle Aged; Nausea; Oxazines; Patient Reported Outcome Measures; Piperazines; Pyridones; Quality of Life; Registries; Sweden | 2020 |
HIV-1 Tat Protein Enters Dysfunctional Endothelial Cells via Integrins and Renders Them Permissive to Virus Replication.
Topics: Alkynes; Benzoxazines; Biomarkers; Cell Adhesion; Cell-Penetrating Peptides; Cyclopropanes; Cytokines; Endothelial Cells; Fibronectins; HIV Infections; HIV-1; Host-Pathogen Interactions; Humans; Inflammation Mediators; Integrins; Models, Molecular; Oxidation-Reduction; Protein Binding; Protein Conformation; Protein Interaction Domains and Motifs; Structure-Activity Relationship; tat Gene Products, Human Immunodeficiency Virus; Temperature; Virus Replication; Vitronectin | 2020 |
A novel association of efavirenz induced severe cutaneous adverse reactions with HLA- DRB1*03:01: A case-control study from North-East India.
Topics: Alkynes; Benzoxazines; Case-Control Studies; Cyclopropanes; Gene Frequency; HIV Infections; HLA-DRB1 Chains; Humans; India | 2021 |
Higher plasma drug levels in elderly people living with HIV treated with darunavir.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Case-Control Studies; Cross-Sectional Studies; Cyclopropanes; Darunavir; Drug Interactions; HIV Infections; Humans; Male; Middle Aged; Plasma; Sweden | 2021 |
CARD8 is an inflammasome sensor for HIV-1 protease activity.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CARD Signaling Adaptor Proteins; Caspase 1; CD4-Positive T-Lymphocytes; Cyclopropanes; Enzyme Activation; HIV Infections; HIV Protease; HIV-1; Humans; Inflammasomes; Macrophages; Neoplasm Proteins; Pyroptosis; Reverse Transcriptase Inhibitors; Rilpivirine; THP-1 Cells; Virus Latency | 2021 |
Untimed Efavirenz Drug Levels After Switching From Brand to Generic Formulations: A Short Communication.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drugs, Generic; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Treatment Outcome | 2021 |
Impact of Efavirenz Mid-dose Plasma Concentration on Long-Term Weight Change Among Virologically Suppressed People Living With HIV.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; HIV Infections; HIV-1; Humans; Male; Prospective Studies; Retrospective Studies; Weight Gain | 2021 |
The association between cigarette smoking and efavirenz plasma concentration using the population pharmacokinetic approach.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cigarette Smoking; Cyclopropanes; HIV Infections; Humans; Prospective Studies; Smoking | 2021 |
Raltegravir in patients with tuberculosis.
Topics: Alkynes; Benzoxazines; Coinfection; Cyclopropanes; HIV Infections; Humans; Raltegravir Potassium; Tuberculosis | 2021 |
Transportability From Randomized Trials to Clinical Care: On Initial HIV Treatment With Efavirenz and Suicidal Thoughts or Behaviors.
Topics: Adult; Alkynes; Anti-HIV Agents; Antidepressive Agents; Benzoxazines; Cyclopropanes; Depression; Drug Prescriptions; Female; HIV; HIV Infections; Humans; Incidence; Male; Observational Studies as Topic; Proportional Hazards Models; Randomized Controlled Trials as Topic; Suicidal Ideation; Translational Research, Biomedical; United States | 2021 |
Gestational diabetes in women living with HIV in Botswana: lower rates with dolutegravir- than with efavirenz-based antiretroviral therapy.
Topics: Adolescent; Adult; Alkynes; Benzoxazines; Botswana; Cyclopropanes; Diabetes, Gestational; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pregnancy; Pyridones | 2021 |
Physiologically Relevant Concentrations of Dolutegravir, Emtricitabine, and Efavirenz Induce Distinct Metabolic Alterations in HeLa Epithelial and BV2 Microglial Cells.
Topics: Adenosine Triphosphate; Alkynes; Anti-HIV Agents; Benzoxazines; Cell Line, Tumor; Cyclopropanes; Emtricitabine; Epithelial Cells; HeLa Cells; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Membrane Potential, Mitochondrial; Microglia; Mitochondria; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Virus Latency; Xanthenes | 2021 |
Layer-by-Layer Assembled Nanostructured Lipid Carriers for CD-44 Receptor-Based Targeting in HIV-Infected Macrophages for Efficient HIV-1 Inhibition.
Topics: Alkynes; Benzoxazines; Cell Survival; Cyclopropanes; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; HEK293 Cells; HIV Infections; HIV-1; Humans; Hyaluronan Receptors; Lipids; Macrophages; Nanostructures; Reverse Transcriptase Inhibitors; THP-1 Cells | 2021 |
Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; Humans; Male; Nigeria; Pharmacogenetics; Polymorphism, Single Nucleotide | 2021 |
A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment.
Topics: Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Contraceptive Agents, Hormonal; Contraceptive Effectiveness; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; HIV Infections; Humans; Isoniazid; Lopinavir; Medroxyprogesterone Acetate; Nelfinavir; Rifampin; Ritonavir; Tuberculosis | 2021 |
Point-of-Care Detection of Nonadherence to Antiretroviral Treatment for HIV-1 in Resource-Limited Settings Using Drug Level Testing for Efavirenz, Lopinavir, and Dolutegravir: A Validation and Pharmacokinetic Simulation Study.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Immunoenzyme Techniques; Limit of Detection; Lopinavir; Medication Adherence; Oxazines; Piperazines; Point-of-Care Testing; Pyridones; Reproducibility of Results; Rural Population; South Africa | 2021 |
Association between exposure to Efavirenz and substrates of dysrhythmia in HIV-infected young adults.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Electrocardiography; Female; HIV Infections; Humans; Male; Retrospective Studies; Ventricular Premature Complexes; Young Adult | 2021 |
Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIV.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chromatography, Liquid; Coinfection; Cyclopropanes; HIV Infections; Humans; Liver-Specific Organic Anion Transporter 1; Rifampin; Tandem Mass Spectrometry; Tuberculosis | 2021 |
Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele.
Topics: Adolescent; Adult; Aged; Alkynes; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2B6 Inducers; Female; Gene Frequency; Genotype; HIV Infections; Humans; Male; Middle Aged; Papua New Guinea; Young Adult | 2021 |
Infection or drug toxicity? Acute ataxia and encephalopathy after uncomplicated falciparum malaria and efavirenz dose adjustment.
Topics: Adolescent; Alkynes; Antiretroviral Therapy, Highly Active; Ataxia; Benzoxazines; Brain Diseases; Cyclopropanes; Diplopia; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Malaria, Falciparum; Plasmodium falciparum; Reverse Transcriptase Inhibitors | 2020 |
CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection.
Topics: Alkynes; Benzoxazines; Child, Preschool; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; Humans; Infant; Male; Prospective Studies; Reverse Transcriptase Inhibitors | 2017 |
How the genomics revolution could finally help Africa.
Topics: Africa; Alkynes; Anti-HIV Agents; Apolipoprotein L1; Apolipoproteins; Benzoxazines; Black People; Charities; Cyclopropanes; Diabetes Mellitus, Type 2; Genetic Predisposition to Disease; Genetics, Medical; Genome-Wide Association Study; Genomics; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kidney Diseases; Lipoproteins, HDL; National Institutes of Health (U.S.); Neoplasms; Oxazines; Piperazines; Polymorphism, Single Nucleotide; Precision Medicine; Public Health; Pyridones; Reverse Transcriptase Inhibitors; Stroke; Trypanosomiasis, African; United States; White People | 2017 |
Antiretroviral Therapy Initiation and Changes in Self-Reported Depression.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Depression; Follow-Up Studies; HIV Infections; Humans; Insurance, Health; Logistic Models; Male; Middle Aged; Retrospective Studies; Self Report; Young Adult | 2017 |
Brief Report: CYP2B6 516G>T Minor Allele Protective of Late Virologic Failure in Efavirenz-Treated HIV-Infected Patients in Botswana.
Topics: Adult; Alkynes; Alleles; Anti-HIV Agents; Benzoxazines; Black People; Botswana; Case-Control Studies; CD4 Lymphocyte Count; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2B6 Inducers; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Polymorphism, Single Nucleotide; Treatment Failure | 2017 |
Patterns of Growth, Body Composition, and Lipid Profiles in a South African Cohort of Human Immunodeficiency Virus-Infected and Uninfected Children: A Cross-Sectional Study.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Blood Pressure; Body Composition; Child; Child, Preschool; Cross-Sectional Studies; Cyclopropanes; Drug Therapy, Combination; Dyslipidemias; Female; Growth; Growth Disorders; HIV Infections; Humans; Lipids; Longitudinal Studies; Male; Reverse Transcriptase Inhibitors; South Africa | 2018 |
CYP2B6 516 G>T polymorphism and side effects of the central nervous system in HIV-positive individuals under Efavirenz treatment: Study of a sample from southern Brazil.
Topics: Adult; Alkynes; Benzoxazines; CD4-CD8 Ratio; Central Nervous System; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; Humans; Male; Middle Aged; Polymorphism, Genetic; Prospective Studies; Reverse Transcriptase Inhibitors; Viral Load | 2017 |
Incident AIDS or Death After Initiation of Human Immunodeficiency Virus Treatment Regimens Including Raltegravir or Efavirenz Among Adults in the United States.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Male; Middle Aged; Raltegravir Potassium; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; United States; Viral Load; Young Adult | 2017 |
Virologic Response to First-line Efavirenz- or Nevirapine-based Antiretroviral Therapy in HIV-infected African Children.
Topics: Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Male; Nevirapine; Retrospective Studies; Uganda; Viral Load; Zimbabwe | 2017 |
Brief Report: Late Efavirenz-Induced Ataxia and Encephalopathy: A Case Series.
Topics: Adult; Alkynes; Anti-HIV Agents; Ataxia; Benzoxazines; Brain Diseases; CD4 Lymphocyte Count; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; South Africa; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2017 |
Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Biomarkers; Brachial Artery; Cardiovascular Diseases; Carotid Intima-Media Thickness; CD4 Lymphocyte Count; Chi-Square Distribution; Cyclopropanes; Darunavir; Endothelium, Vascular; Female; HIV Infections; Humans; Inflammation Mediators; Italy; Lipids; Longitudinal Studies; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Risk Factors; Ritonavir; Time Factors; Treatment Outcome; Vasodilation | 2017 |
A Mathematical Model to Predict HIV Virological Failure and Elucidate the Role of Lymph Node Drug Penetration.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lymph Nodes; Medication Adherence; Models, Biological; Mutation; Ritonavir; Tenofovir; Viral Load | 2017 |
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Clinical Decision-Making; Computational Biology; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Monitoring, Physiologic; Nevirapine; pol Gene Products, Human Immunodeficiency Virus; Stavudine; Tanzania; Tenofovir; Treatment Failure; Viral Load | 2017 |
Population Approach to Efavirenz Therapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Female; Hepacivirus; Hepatitis C; HIV; HIV Infections; Humans; Male; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors | 2017 |
Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Ethiopia; Female; HIV Infections; Humans; Lamivudine; Male; Models, Theoretical; Nevirapine; Pregnancy; Retrospective Studies; Stavudine; Tenofovir; Time-to-Treatment; Treatment Failure; Zidovudine | 2017 |
CYP2B6 genotypes and early efavirenz-based HIV treatment outcomes in Botswana.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Botswana; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Genotyping Techniques; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; RNA, Viral; Surveys and Questionnaires; Survival Analysis; Treatment Outcome; Viral Load; Young Adult | 2017 |
Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy.
Topics: Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Contraception; Contraceptive Agents, Female; Cyclopropanes; Desogestrel; Drug Antagonism; Female; HIV Infections; Humans; Middle Aged; Nevirapine; Uganda; Young Adult | 2017 |
Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus.
Topics: Adolescent; Alkynes; Asian People; Benzoxazines; Child; Cohort Studies; Cross-Sectional Studies; Cyclopropanes; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Polymorphism, Single Nucleotide; Retrospective Studies; Ritonavir | 2017 |
Nanomicrobicides for HIV vaginal transmission prevention: where do we stand?
Topics: Administration, Intravaginal; Alkynes; Anti-HIV Agents; Benzoxazines; Cellulose; Cyclopropanes; Female; HIV Infections; Humans; Nanomedicine; Nanoparticles; Virus Internalization | 2017 |
The Relationship Between Efavirenz as Initial Antiretroviral Therapy and Suicidal Thoughts Among HIV-Infected Adults in Routine Care.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Factors; Suicidal Ideation; Suicide, Attempted; Viral Load | 2017 |
Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Drugs, Generic; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Patient Safety; Poisson Distribution; RNA, Viral; Treatment Outcome; Zidovudine | 2017 |
Misleading
Topics: Adenocarcinoma; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Fluorodeoxyglucose F18; Gastrectomy; HIV Infections; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Stomach Neoplasms; Tenofovir; Treatment Outcome | 2018 |
CYP2B6 Haplotype Predicts Efavirenz Plasma Concentration in Black South African HIV-1-Infected Children: A Longitudinal Pediatric Pharmacogenomic Study.
Topics: Adolescent; Alkynes; Alleles; Anti-HIV Agents; Benzoxazines; Black People; Child; Child, Preschool; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Dosage Calculations; Female; Gene Expression; Gene Frequency; Haplotypes; HIV Infections; HIV-1; Humans; Male; Pharmacogenetics; Polymorphism, Single Nucleotide; Prospective Studies; South Africa | 2017 |
Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.
Topics: Adult; Alkynes; Benzoxazines; Cohort Studies; Cyclopropanes; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Weight Gain | 2017 |
Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Longitudinal Studies; Male; Mozambique; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2017 |
Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.
Topics: Age Factors; Alkynes; Alleles; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Ethnicity; Female; Gene Frequency; Genotype; HIV; HIV Infections; Humans; Male; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Sex Factors; Sweden; Viral Load | 2017 |
Hepatic, Renal, Hematologic, and Inflammatory Markers in HIV-Infected Children on Long-term Suppressive Antiretroviral Therapy.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; C-Reactive Protein; Child; Child, Preschool; Cholesterol; Creatinine; Cyclopropanes; Cystatin C; Drug Monitoring; Europe; Female; Fibrin Fibrinogen Degradation Products; HIV Infections; Humans; Inflammation; Interleukin-6; Kidney; Lipopolysaccharide Receptors; Liver; Lopinavir; Male; North America; Reverse Transcriptase Inhibitors; Ritonavir; Time Factors; Treatment Outcome | 2017 |
HIV pretreatment drug resistance trends in three geographic areas of Mexico.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Multiple, Viral; Epidemiological Monitoring; Female; Genotype; Geography; HIV Infections; HIV-1; Humans; Male; Mexico; Mutation; Prevalence; Retrospective Studies; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Young Adult | 2017 |
Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Black People; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2B6 Inducers; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nigeria; Pregnancy; Young Adult | 2018 |
Altered angiogenesis as a common mechanism underlying preterm birth, small for gestational age, and stillbirth in women living with HIV.
Topics: Adult; Alkynes; Angiopoietin-1; Angiopoietin-2; Anti-HIV Agents; Benzoxazines; Biomarkers; Cyclopropanes; Drug Combinations; Endoglin; Female; HIV Infections; Humans; Infant, Newborn; Infant, Small for Gestational Age; Lopinavir; Neovascularization, Physiologic; Placenta Growth Factor; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Premature Birth; Ritonavir; Stillbirth; Uganda; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2017 |
Human immunodeficiency virus infection acquired through a traditional healer's ritual: a case report.
Topics: Adult; Alkynes; Antiviral Agents; Benzoxazines; Ceremonial Behavior; Cyclopropanes; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; Humans; Lamivudine; Medicine, Traditional; Tanzania; Tenofovir | 2017 |
HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cohort Studies; Coinfection; Cyclopropanes; Female; Hepatitis B; Hepatitis C; HIV; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Retrospective Studies; Treatment Outcome; Viral Load; Zidovudine | 2018 |
Virologic suppression and CD4+ cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Male; Middle Aged; Raltegravir Potassium; Survival Analysis; Time Factors; Treatment Outcome; United States; Viral Load; Young Adult | 2018 |
Efavirenz precipitating hallucinations in a patient with an undetected psychotic prodrome: a call for better screening at the point of care.
Topics: Adult; Alkynes; Antipsychotic Agents; Benzoxazines; Cyclopropanes; Hallucinations; HIV Infections; Humans; Male; Mental Disorders; Point-of-Care Systems | 2017 |
Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Treatment Failure; Viral Load | 2017 |
The burden of gynecomastia among men on antiretroviral therapy in Zomba, Malawi.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Gynecomastia; HIV Infections; Humans; Malawi; Male; Middle Aged; Nipples; Obesity; Prevalence; Quality of Life; Severity of Illness Index | 2017 |
Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; HIV Seropositivity; Humans; Male; Polymorphism, Single Nucleotide; Young Adult | 2017 |
Discontinuation of Efavirenz in Paediatric Patients: Why do Children Switch?
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Body Weight; CD4 Lymphocyte Count; Child; Cyclopropanes; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Male; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Failure; Viral Load | 2018 |
Long-term viral suppression and immune recovery during first-line antiretroviral therapy: a study of an HIV-infected adult cohort in Hanoi, Vietnam.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Longitudinal Studies; Male; Middle Aged; Nevirapine; Stavudine; Time Factors; Vietnam; Viral Load; Young Adult; Zidovudine | 2017 |
Efaverinz and nano-gold-loaded mannosylated niosomes: a host cell-targeted topical HIV-1 prophylaxis via thermogel system.
Topics: Administration, Topical; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cell Survival; Cyclopropanes; Epithelium; Female; Gels; Gold; HeLa Cells; Hemolysis; HIV Infections; HIV-1; Humans; Liposomes; Mannose; Metal Nanoparticles; Rats; Temperature; Vagina | 2018 |
Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Antimalarials; Artemisinins; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Infections; Humans; Malaria, Falciparum; Pregnancy; Pregnancy Complications, Parasitic; Quinolines; Young Adult | 2018 |
Different Degrees of Immune Recovery Using Antiretroviral Regimens with Vonavir or Zidovudine/Lamivudine/Efavirenz in HIVPositive Patients Receiving First Line Treatment in Iran.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Immunity, Cellular; Iran; Lamivudine; Male; Retrospective Studies; Reverse Transcriptase Inhibitors; Sex Factors; Time Factors; Zidovudine | 2018 |
Response to "Antiretroviral Therapy With Efavirenz in HIV-Infected Pregnant Women: Understanding the Possible Mechanisms for Drug-Drug Interaction".
Topics: Alkynes; Artemisinins; Benzoxazines; Chemoprevention; Cyclopropanes; Drug Interactions; Female; HIV; HIV Infections; Humans; Malaria; Pregnancy; Quinolines | 2018 |
Antiretroviral Therapy With Efavirenz in HIV-Infected Pregnant Women: Understanding the Possible Mechanisms for Drug-Drug Interaction.
Topics: Alkynes; Artemisinins; Benzoxazines; Chemoprevention; Cyclopropanes; Drug Interactions; Female; HIV; HIV Infections; Humans; Malaria; Pregnancy; Quinolines | 2018 |
A validated liquid chromatography/tandem mass spectrometry method for the analysis of efavirenz in 0.2 mg hair samples from human immunodeficiency virus infected patients.
Topics: Alkynes; Benzoxazines; Chromatography, Liquid; Cyclopropanes; Drug Monitoring; Female; Hair; HIV; HIV Infections; Humans; Limit of Detection; Male; Reverse Transcriptase Inhibitors; Tandem Mass Spectrometry | 2018 |
A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria.
Topics: Abdominal Pain; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; Humans; Incidence; Lamivudine; Male; Middle Aged; Nausea; Nevirapine; Nigeria; Prospective Studies; Sleep Initiation and Maintenance Disorders; Tenofovir; Young Adult; Zidovudine | 2016 |
Antiretroviral treatment Long-Term (ALT) cohort: a prospective cohort of 10 years of ART-experienced patients in Uganda.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nevirapine; Prospective Studies; RNA, Viral; Time; Uganda; Viral Load; Zidovudine | 2018 |
Preterm delivery and small-for-gestation outcomes in HIV-infected pregnant women on antiretroviral therapy in rural South Africa: Results from a cohort study, 2010-2015.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Infant, Newborn; Infant, Premature; Infant, Small for Gestational Age; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Retrospective Studies; Rural Population; South Africa; Tenofovir; Young Adult | 2018 |
Comparison of adherence to generic multi-tablet regimens vs. brand multi-tablet and brand single-tablet regimens likely to incorporate generic antiretroviral drugs by breaking or not fixed-dose combinations in HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Drugs, Generic; Female; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Tablets; Viral Load; Zidovudine | 2018 |
A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Case-Control Studies; Cyclopropanes; Feasibility Studies; Female; HIV Infections; Humans; Meta-Analysis as Topic; Models, Biological; Pregnancy | 2018 |
Prevalence and correlates of persistent intracellular HIV transcription in individuals on efavirenz versus atazanavir-based regimens: A prospective cohort study.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Prospective Studies; Reverse Transcription; RNA, Messenger; RNA, Viral; Viral Load; Virus Latency; Virus Replication | 2018 |
Incomplete inhibition of HIV infection results in more HIV infected lymph node cells by reducing cell death.
Topics: Algorithms; Alkynes; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cell Death; Cell Line, Tumor; Cells, Cultured; Cyclopropanes; HIV Infections; HIV-1; Host-Pathogen Interactions; Humans; Lymph Nodes; Models, Theoretical; Reverse Transcriptase Inhibitors; Virus Replication | 2018 |
A proposed management algorithm for late-onset efavirenz neurotoxicity.
Topics: Adult; Algorithms; Alkynes; Antitubercular Agents; Benzoxazines; Brain Diseases; Cerebellar Ataxia; Cyclopropanes; Electroencephalography; Female; HIV Infections; Humans; Isoniazid; Neurotoxins; Retrospective Studies; Reverse Transcriptase Inhibitors; South Africa; Toxicity Tests | 2018 |
3D printed, controlled release, tritherapeutic tablet matrix for advanced anti-HIV-1 drug delivery.
Topics: Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delayed-Action Preparations; Drug Liberation; Emtricitabine; HIV Infections; HIV-1; Humans; Printing, Three-Dimensional; Swine; Tablets; Tenofovir | 2019 |
Reciprocal Effects of Antiretroviral Drugs Used To Treat HIV Infection on the Fibroblast Growth Factor 21/β-Klotho System.
Topics: Adipose Tissue; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Diabetes Mellitus, Type 2; Drug Combinations; Endoplasmic Reticulum Stress; Fibroblast Growth Factors; Hep G2 Cells; HIV Infections; HIV Integrase Inhibitors; Humans; Klotho Proteins; Liver; Lopinavir; Maraviroc; Membrane Proteins; Muscle, Skeletal; Obesity; Oxidative Stress; Protease Inhibitors; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Thapsigargin; Tunicamycin | 2018 |
Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Europe; Europe, Eastern; Female; HIV Infections; Humans; Latin America; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Risk Factors; Survival Rate; Treatment Outcome; Tuberculosis | 2018 |
Effect of Gestational Age at Tenofovir-Emtricitabine-Efavirenz Initiation on Adverse Birth Outcomes in Botswana.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Botswana; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; Fetal Death; Gestational Age; HIV Infections; Humans; Infant, Low Birth Weight; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Stillbirth; Tenofovir | 2018 |
Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Botswana; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; Genotyping Techniques; HIV Infections; HIV-1; Humans; Male; Microbial Sensitivity Tests; Mutation; Nevirapine; Nitriles; pol Gene Products, Human Immunodeficiency Virus; Prevalence; Pyridazines; Pyrimidines; Rilpivirine; Treatment Failure; Young Adult | 2018 |
Adverse reactions associated with first-line regimens in patient initiating antiretroviral therapy.
Topics: Adolescent; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Brazil; Cross-Sectional Studies; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; Quality of Life; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2018 |
Risk factors associated with preterm delivery and low delivery weight among HIV-exposed neonates in China.
Topics: Adult; Alkynes; Benzoxazines; China; Cross-Sectional Studies; Cyclopropanes; Female; HIV Infections; Humans; Infant, Newborn; Pregnancy; Pregnancy Complications, Infectious; Premature Birth; Retrospective Studies; Risk Factors | 2018 |
Polymorphisms in cytochrome P450 are associated with extensive efavirenz pharmacokinetics and CNS toxicities in an HIV cohort in Botswana.
Topics: Adult; Alkynes; Alleles; Benzoxazines; Botswana; Central Nervous System; Cohort Studies; Cyclopropanes; Cytochrome P-450 Enzyme System; Female; Genotype; HIV Infections; Humans; Male; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors | 2018 |
Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals.
Topics: Adult; Aged; Alkynes; Benzoxazines; Brazil; Constitutive Androstane Receptor; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; Genetic Association Studies; HIV Infections; Humans; Inactivation, Metabolic; Male; Middle Aged; Polymorphism, Genetic; Reverse Transcriptase Inhibitors | 2018 |
Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Botswana; Cyclopropanes; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pyridones; Young Adult | 2018 |
In-utero ART exposure and the need for pharmacovigilance.
Topics: Alkynes; Benzoxazines; Botswana; Cyclopropanes; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Pharmacovigilance; Piperazines; Pregnancy; Pyridones | 2018 |
Effectiveness of half-a-tablet efavirenz plus 2 nucleos(t)ide reverse-transcriptase inhibitors as maintenance therapy with the guidance of therapeutic drug monitoring among virologically suppressed HIV-positive patients: A prospective study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Sustained Virologic Response; Tablets; Viral Load | 2020 |
Day-On, Day-Off emtricitabine, tenofovir disoproxil fumarate and efavirenz single tablet regimen (DODO) as maintenance therapy in HIV-infected patients.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; Humans; Maintenance Chemotherapy; Male; Middle Aged; Reverse Transcriptase Inhibitors; Tablets; Tenofovir | 2018 |
Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Depression; Female; HIV Infections; Humans; Male; Nevirapine; Prospective Studies; Suicidal Ideation; Uganda | 2018 |
The Use of Efavirenz During Pregnancy is Associated with Suicidal Ideation in Postpartum Women in Rural South Africa.
Topics: Adult; Alkynes; Benzoxazines; Contraindications, Drug; Cross-Sectional Studies; Cyclopropanes; Depression; Depression, Postpartum; Female; HIV Infections; Humans; Intimate Partner Violence; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Risk Factors; Rural Population; Social Stigma; South Africa; Suicidal Ideation; Surveys and Questionnaires; Young Adult | 2019 |
CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2B6 Inducers; Depression; Female; Genotype; HIV; HIV Infections; Humans; Male; Odds Ratio; Polymorphism, Single Nucleotide; Prospective Studies; Uganda; Viral Load | 2018 |
Efavirenz and Lopinavir Levels in HIV-Infected Women and Their Nursing Infants, in Mali.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Breast Feeding; Cyclopropanes; Female; HIV Infections; Humans; Infant; Lopinavir; Male; Mali; Mothers; Safety; Tissue Distribution; Young Adult | 2018 |
Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.
Topics: Adult; Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Mental Disorders; Pharmacogenetics; Prospective Studies; Rifampin; Tuberculosis | 2018 |
Exploring an alternative explanation for the second phase of viral decay: Infection of short-lived cells in a drug-limited compartment during HAART.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4-Positive T-Lymphocytes; Cyclopropanes; Emtricitabine; HIV Infections; HIV-1; Host-Pathogen Interactions; Humans; Models, Statistical; Monocytes; RNA, Viral; Tenofovir; Viral Load; Virus Replication | 2018 |
Drug resistance outcomes of long-term ART with tenofovir disoproxil fumarate in the absence of virological monitoring.
Topics: Adult; Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Viremia | 2018 |
Using dried blood spots to facilitate therapeutic drug monitoring of antiretroviral drugs in resource-poor regions.
Topics: Adult; Aged; Aged, 80 and over; Alkynes; Anti-Retroviral Agents; Benzoxazines; Biological Transport; Cohort Studies; Cyclopropanes; Dried Blood Spot Testing; Drug Monitoring; Female; Health Resources; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Nevirapine; Rural Population; Switzerland; Tanzania | 2018 |
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA).
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Integrase Inhibitors; Lipid Metabolism; Lipids; Male; Middle Aged; Oxazines; Piperazines; Protease Inhibitors; Pyridones; Rilpivirine; Ritonavir; Treatment Outcome | 2018 |
Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Rifampin; Viral Load; Young Adult | 2019 |
High prevalence and long duration of nervous system and psychiatric adverse drug reactions in Ugandan patients taking efavirenz 600 mg daily.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dizziness; Drug Administration Schedule; Female; HIV Infections; Humans; Longitudinal Studies; Male; Mental Disorders; Nervous System Diseases; Outpatients; Prevalence; Prospective Studies; Risk Factors; Uganda | 2018 |
HIV viral suppression and longevity among a cohort of children initiating antiretroviral therapy in Eastern Cape, South Africa.
Topics: Adult; Alkynes; Ambulatory Care Facilities; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Female; Health Resources; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Medication Adherence; Ritonavir; South Africa; Viral Load | 2018 |
Impact of Efavirenz Metabolism on Loss to Care in Older HIV+ Africans.
Topics: Adult; Age Factors; Alkynes; Anti-HIV Agents; Benzoxazines; Black People; Botswana; Cohort Studies; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Young Adult | 2019 |
Nevirapine Concentrations During the First Month of Life and Maternal Efavirenz Washout in High-Risk HIV-Exposed Infants Receiving Triple Antiretroviral Prophylaxis.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chemoprevention; Cyclopropanes; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Longitudinal Studies; Male; Nevirapine; Plasma; Prospective Studies; Thailand | 2019 |
Noncovalent PEG Coating of Nanoparticle Drug Carriers Improves the Local Pharmacokinetics of Rectal Anti-HIV Microbicides.
Topics: Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Caco-2 Cells; Cyclopropanes; Drug Carriers; HIV Infections; HIV-1; Humans; Male; Mice; Nanoparticles; Polyesters; Polyethylene Glycols | 2018 |
High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Female; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Serum; Tuberculosis; Uganda; Young Adult | 2019 |
Low body mass index and efavirenz use are independently associated with self-reported fatigue in HIV-infected patients.
Topics: Adult; Age Factors; Alkynes; Anti-Retroviral Agents; Benzoxazines; Body Mass Index; CD4 Lymphocyte Count; China; Cyclopropanes; Fatigue; Female; HIV Infections; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Self Report; Time Factors | 2019 |
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)-induced Stevens-Johnson syndrome and gynecomastia in an HIV-infected child: A case report.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Gynecomastia; HIV Infections; Humans; Lamivudine; Male; Mucositis; Nevirapine; Reverse Transcriptase Inhibitors; Stevens-Johnson Syndrome | 2018 |
Frequency of cross-resistance to rilpivirine and etravirine among HIV-1 subtype C infected individuals failing nevirapine/efavirenz based ART regimen.
Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Rilpivirine; Sweden | 2019 |
A three-in-one, long-acting, nanosuspension reformulation of off-patent antiretrovirals for low-income and middle-income countries.
Topics: Alkynes; Animals; Benzoxazines; Cyclopropanes; HIV Infections; Lopinavir; Primates; Tenofovir | 2018 |
Multidrug nanosuspensions: future perspectives on drug delivery system for HIV combination antiretroviral therapy.
Topics: Alkynes; Animals; Benzoxazines; Cyclopropanes; Drug Delivery Systems; HIV; HIV Infections; Lopinavir; Primates; Tenofovir | 2018 |
Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype.
Topics: Adult; Alkynes; Benzoxazines; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Female; Genotype; HIV Infections; Humans; Male; Middle Aged; Rifampin; Tanzania; Tissue Distribution; Tuberculosis | 2018 |
Sleep and neuropsychological performance in HIV+ subjects on efavirenz-based therapy and response to switch in therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cobicistat; Cyclopropanes; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Sleep Wake Disorders; Tenofovir | 2018 |
Tryptophan metabolism and its relationship with central nervous system toxicity in people living with HIV switching from efavirenz to dolutegravir.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Central Nervous System; Cyclopropanes; Drug Substitution; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kynurenine; Male; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; Tryptophan | 2019 |
Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Blood-Brain Barrier; Central Nervous System; Cognition; Cyclopropanes; Female; HIV Infections; Humans; Male; Middle Aged; Pharmacogenetics; Pharmacogenomic Variants; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; Viral Load; Young Adult | 2019 |
Birth Defects After Exposure to Efavirenz-Based Antiretroviral Therapy at Conception/First Trimester of Pregnancy: A Multicohort Analysis.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Female; Fertilization; HIV Infections; Humans; Infant, Newborn; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, First; Stillbirth | 2019 |
Symfi, Symfi Lo, and Cimduo for HIV.
Topics: Adenine; Administration, Oral; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Interactions; HIV Infections; HIV-1; Humans; Lamivudine; Phosphorous Acids; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2019 |
Health-related quality of life among HIV-infected patients initiating treatment in Brazil in the single-tablet regimen era.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Anxiety; Benzoxazines; Brazil; Cyclopropanes; Depression; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Oxazines; Piperazines; Pyridones; Quality of Life; Surveys and Questionnaires; Tablets | 2019 |
Neurodevelopmental and behavioral consequences of perinatal exposure to the HIV drug efavirenz in a rodent model.
Topics: Alkynes; Animals; Benzoxazines; Body Weight; Cyclopropanes; Developmental Disabilities; Female; HIV Infections; Male; Motor Activity; Motor Cortex; Neurons; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Reflex, Startle; Serotonin | 2019 |
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Treatment Outcome; Triazoles | 2019 |
Neuropsychiatric symptoms in Tanzanian HIV-infected children receiving long-term efavirenz treatment: a multicentre, cross-sectional, observational study.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Cross-Sectional Studies; Cyclopropanes; Female; HIV Infections; Humans; Interviews as Topic; Male; Neurodevelopmental Disorders; Neuropsychological Tests; Reverse Transcriptase Inhibitors; Tanzania; Viral Load | 2019 |
Should efavirenz be used in children and, if so, how?
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cross-Sectional Studies; Cyclopropanes; HIV Infections; Humans | 2019 |
Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cameroon; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Nevirapine; Patient Compliance; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2019 |
Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Emtricitabine; Europe; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Sustained Virologic Response; Tenofovir; Treatment Failure; Viral Load; Young Adult | 2019 |
A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Emtricitabine; Female; HIV Infections; Humans; Logistic Models; Organophosphates; Plasma; Self Report; South Africa; Tenofovir | 2019 |
Antiretroviral Hydrophobic Core Graft-Copolymer Nanoparticles: The Effectiveness against Mutant HIV-1 Strains and in Vivo Distribution after Topical Application.
Topics: Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Drug Carriers; Drug Combinations; Drug Liberation; Drug Resistance, Viral; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Hydrophobic and Hydrophilic Interactions; Molecular Dynamics Simulation; Mutation; Nanoparticles; Polyethylene Glycols; Polylysine; Quinolones; Rats; Reverse Transcriptase Inhibitors; Tissue Distribution | 2019 |
Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Incidence; Lamivudine; Male; Middle Aged; Mutation; Nevirapine; Stavudine; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2019 |
Neuropsychological changes in efavirenz switch regimens.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Depression; Drug Substitution; Female; HIV Infections; Humans; Male; Middle Aged; Neuropsychological Tests; Severity of Illness Index | 2019 |
Decision Making in a Time of Uncertainty: Dolutegravir for Reproductive-Age Women.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Decision Making; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Pyridones; Risk Assessment; Uncertainty | 2019 |
Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
Topics: Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Long-Acting Reversible Contraception; Middle Aged; Models, Theoretical; Neural Tube Defects; Oxazines; Piperazines; Pyridones; South Africa; Young Adult | 2019 |
In Utero Efavirenz Exposure and Neurodevelopmental Outcomes in HIV-exposed Uninfected Children in Botswana.
Topics: Alkynes; Benzoxazines; Botswana; Child; Child Development; Child, Preschool; Cyclopropanes; Female; HIV Infections; Humans; Male; Outcome Assessment, Health Care; Paternal Exposure; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Reverse Transcriptase Inhibitors | 2019 |
Immunological and Neurometabolite Changes Associated With Switch From Efavirenz to an Integrase Inhibitor.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; Boston; Central Nervous System; Cyclopropanes; Female; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Glutathione; HIV Infections; HIV Integrase Inhibitors; Humans; Inflammation; Male; Middle Aged; Neurons; Neuropsychology; Oxidative Stress; Pilot Projects; Receptors, Tumor Necrosis Factor, Type I | 2019 |
Efavirenz dose reduction is associated with improved lipid profile in HIV-1 infected patients.
Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Lipids; Sweden | 2019 |
Comparative effectiveness of first-line antiretroviral therapy: results from a large real-world cohort after the implementation of dolutegravir.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Brazil; Cyclopropanes; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Sustained Virologic Response; Treatment Outcome; Viral Load; Young Adult | 2019 |
Viral suppression rate among children tested for HIV viral load at the Amhara Public Health Institute, Bahir Dar, Ethiopia.
Topics: Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Child, Preschool; Cross-Sectional Studies; Cyclopropanes; Ethiopia; Female; HIV Infections; Humans; Infant; Male; Nevirapine; Odds Ratio; Treatment Adherence and Compliance; Viral Load | 2019 |
Interleukin-10 polymorphisms and susceptibility to ARV associated hepatotoxicity.
Topics: Adult; Alcohol Drinking; Alkynes; Anti-Retroviral Agents; Benzoxazines; Case-Control Studies; Chemical and Drug Induced Liver Injury; Cyclopropanes; Cytokines; Disease Susceptibility; Epistasis, Genetic; Female; Gene-Environment Interaction; Genetic Predisposition to Disease; Genotype; HIV Infections; Humans; Interleukin-10; Male; Multivariate Analysis; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Regression Analysis; Risk Factors; Severity of Illness Index; Tobacco Use | 2019 |
Efavirenz use and neurocognitive performance among older people living with HIV who were on antiretroviral therapy.
Topics: Aged; Aged, 80 and over; Alkynes; Benzoxazines; China; Cross-Sectional Studies; Cyclopropanes; Female; HIV Infections; Humans; Longitudinal Studies; Male; Middle Aged; Neuropsychological Tests; Reverse Transcriptase Inhibitors | 2020 |
Efavirenz is associated with altered fronto-striatal function in HIV+ adolescents.
Topics: Alkynes; Benzoxazines; Brain; Child; Cyclopropanes; Female; HIV Infections; Humans; Magnetic Resonance Imaging; Male; Reverse Transcriptase Inhibitors | 2019 |
Impact of Integrase Inhibition Compared With Nonnucleoside Inhibition on HIV Reservoirs in Lymphoid Tissues.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dendritic Cells, Follicular; Female; HIV Infections; HIV Integrase Inhibitors; Humans; In Situ Hybridization; Lymph Nodes; Lymphoid Tissue; Male; Raltegravir Potassium; Viral Load; Viremia; Young Adult | 2019 |
Association of Virologic Failure and Nonnucleoside Reverse Transcriptase Inhibitor Resistance Found in Antiretroviral-Naive Children Infected With Human Immunodeficiency Virus and Given Efavirenz-Based Treatment.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-Retroviral Agents; Benzoxazines; Child, Preschool; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Infant; Male; Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Failure; Tuberculosis | 2020 |
Non-nucleoside reverse transcriptase inhibitor levels among HIV-exposed uninfected infants at the time of HIV PCR testing - findings from a tertiary healthcare facility in Pretoria, South Africa.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Breast Feeding; Cohort Studies; Cyclopropanes; Female; HIV; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Nevirapine; Polymerase Chain Reaction; Prospective Studies; Reverse Transcriptase Inhibitors; South Africa; Tertiary Healthcare | 2019 |
Risk Factors for Falls, Falls With Injury, and Falls With Fracture Among Older Men With or at Risk of HIV Infection.
Topics: Accidental Falls; Aged; Alkynes; Benzoxazines; Cohort Studies; Cyclopropanes; Exercise; Female; Fractures, Bone; HIV Infections; Humans; Logistic Models; Male; Middle Aged; Risk Factors; Substance-Related Disorders | 2019 |
Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Biological Variation, Individual; Child; Child, Preschool; Coinfection; Cyclopropanes; Drug Interactions; Drug Monitoring; Female; Genotype; HIV Infections; Humans; Male; Models, Theoretical; Pharmacogenomic Testing; Pharmacogenomic Variants; Reverse Transcriptase Inhibitors; Tuberculosis | 2019 |
Increasing body mass index or weight does not appear to influence the association between efavirenz-based antiretroviral therapy and implant effectiveness among HIV-positive women in western Kenya.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; Body Weight; Cohort Studies; Contraceptive Agents; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Kenya; Male; Middle Aged; Nevirapine; Obesity; Overweight; Pregnancy; Pregnancy Rate; Treatment Outcome; Young Adult | 2019 |
HIV-1 drug resistance surveillance among parturient women on anti-retroviral therapy in the Eastern Cape, South Africa: Implications for elimination of mother-to-child transmission.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Maternal Age; Mutation; Parturition; pol Gene Products, Human Immunodeficiency Virus; Population Surveillance; Pregnancy; Prevalence; South Africa; Young Adult | 2019 |
HIV Drug Efavirenz Inhibits CYP21A2 Activity with Possible Clinical Implications.
Topics: Adrenal Hyperplasia, Congenital; Adult; Alkynes; Benzoxazines; Cell Line; Cyclopropanes; Female; HIV Infections; Humans; Infant, Newborn; Pregnancy; Pregnancy Complications, Infectious; Premature Birth; Prenatal Exposure Delayed Effects; Reverse Transcriptase Inhibitors; Steroid 21-Hydroxylase | 2019 |
The Effect of Low Dose Oral Vitamin D on Bone Mineral Density Changes in HIV Patients: 36 Months Follow Up.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Density; Cyclopropanes; Female; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Parathyroid Hormone; Prospective Studies; Tenofovir; Vitamin D; Vitamin D Deficiency | 2020 |
Model-based prediction of CD4 cells counts in HIV-infected adults on antiretroviral therapy in Northwest Ethiopia: A flexible mixed effects approach.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Disease Progression; Ethiopia; HIV Infections; Humans; Models, Biological; Retrospective Studies | 2019 |
Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure.
Topics: Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Drug Substitution; Female; HIV Infections; Humans; Male; Middle Aged; Models, Theoretical; South Africa; Treatment Failure; Viral Load; Young Adult | 2019 |
A pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptive Agents, Female; Cyclopropanes; Desogestrel; Drug Antagonism; Female; HIV Infections; Humans; Kenya; Levonorgestrel; Linear Models; Nevirapine; Pharmacogenomic Testing; Uganda | 2019 |
Perspectives on contraceptive implant use in women living with HIV in Cape Town, South Africa: a qualitative study among primary healthcare providers and stakeholders.
Topics: Alkynes; Attitude of Health Personnel; Benzoxazines; Contraceptive Agents, Female; Cyclopropanes; Drug Implants; Female; HIV Infections; Humans; Male; Physicians, Primary Care; Qualitative Research; South Africa; Stakeholder Participation | 2019 |
A case of esophageal cancer with human immunodeficiency virus infection that progressed rapidly after neoadjuvant chemoradiotherapy.
Topics: Aged; Alkynes; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoxazines; Chemoradiotherapy; Cisplatin; Cyclopropanes; Deglutition Disorders; Disease Progression; Drug Interactions; Emtricitabine; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fatal Outcome; Female; Fluorouracil; Gastrostomy; HIV Infections; Humans; Neoadjuvant Therapy; Neoplasm Staging; Renal Insufficiency; RNA, Viral; Tenofovir; Viral Load | 2020 |
Safety and efficacy of Option B+ ART in Malawi: few severe maternal toxicity events or infant HIV infections among pregnant women initiating tenofovir/lamivudine/efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Malawi; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Young Adult | 2019 |
Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
Topics: Adolescent; Adult; Age Factors; Albuminuria; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Sex Factors; Tenofovir; Young Adult; Zidovudine | 2020 |
Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; Comorbidity; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mycobacterium tuberculosis; Nevirapine; Proportional Hazards Models; Risk Factors; Survival Analysis; Tuberculosis, Pulmonary; Uganda; Viral Load | 2013 |
Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Mental Disorders; Withholding Treatment | 2013 |
Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
Topics: Adenine; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Black or African American; Cyclopropanes; Data Interpretation, Statistical; Deoxycytidine; Emtricitabine; Female; Frail Elderly; HIV; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir; White People | 2013 |
ART and tuberculosis: the final nail in nevirapine's coffin?
Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Nevirapine; Tuberculosis | 2013 |
[Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asthenia; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Eruptions; Drug Hypersensitivity; Drug Substitution; Emtricitabine; Female; Fever; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Syndrome; Tenofovir | 2013 |
National Guidelines for the prevention of mother-to-child transmission of HIV across Europe - how do countries differ?
Topics: AIDS Serodiagnosis; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Data Collection; Delivery, Obstetric; Europe; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious; Prenatal Care; Surveys and Questionnaires; Zidovudine | 2013 |
HIV-1 drug resistance among newly HIV-1 infected individuals attending tertiary referral center in Chennai, India.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; India; Nevirapine; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; Tertiary Care Centers | 2011 |
Valproic acid inhibits the release of soluble CD40L induced by non-nucleoside reverse transcriptase inhibitors in human immunodeficiency virus infected individuals.
Topics: Alkynes; Benzoxazines; Blood Platelets; Blood-Brain Barrier; CD40 Ligand; Cyclopropanes; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; HIV Infections; Humans; Male; MAP Kinase Kinase 4; Permeability; Phosphorylation; Reverse Transcriptase Inhibitors; Valproic Acid | 2013 |
Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cyclopropanes; Female; HIV; HIV Infections; Humans; Insulin Resistance; Lamivudine; Male; Middle Aged; Nevirapine; Organophosphonates; Risk Factors; Stavudine; Tenofovir; Triglycerides; Zambia; Zidovudine | 2013 |
Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Body Weight; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Male; Rifampin; Treatment Outcome; Tuberculosis; Viral Load | 2013 |
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis.
Topics: Adenine; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cell Line; Cervix Uteri; Chemistry, Pharmaceutical; Cyclopropanes; Delayed-Action Preparations; Drug Carriers; Drug Synergism; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Lactic Acid; Macaca; Models, Biological; Nanoparticles; Organophosphonates; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Saquinavir; Spectroscopy, Fourier Transform Infrared; Tenofovir; Tissue Culture Techniques | 2013 |
Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children.
Topics: Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; Botswana; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nevirapine; Regression Analysis; Retrospective Studies; RNA, Viral; Treatment Failure; Viral Load | 2013 |
Evaluation of a pro-active strategy for managing tuberculosis-HIV co-infection in a UK tertiary care setting.
Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Coinfection; Cyclopropanes; Drug Monitoring; HIV Infections; Humans; Middle Aged; Mycobacterium; Prospective Studies; Rifampin; Time Factors; Treatment Outcome; Tuberculosis; United Kingdom; Viral Load | 2013 |
Efavirenz intoxication due to a new CYP2B6 constellation.
Topics: Adult; Alkynes; Alleles; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Genotype; HIV Infections; HIV-1; Humans; Male; Pharmacogenetics; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors | 2013 |
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Comorbidity; Cross-Sectional Studies; Cyclopropanes; Diabetes Mellitus; Drug Combinations; Dyslipidemias; Echocardiography; Female; Furans; HIV Infections; Humans; Hypertension; Hypertrophy, Left Ventricular; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphates; Organophosphonates; Risk Factors; Ritonavir; Smoking; Spain; Sulfonamides; Tenofovir; Zidovudine | 2013 |
Factors associated with vitamin D deficiency in a population of 2044 HIV-infected patients.
Topics: Adult; Aged; Aged, 80 and over; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; Humans; Male; Middle Aged; Prevalence; Retrospective Studies; Risk Factors; Viral Load; Vitamin D; Vitamin D Deficiency; Young Adult | 2014 |
Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Databases, Factual; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV-1; Humans; Mutation, Missense; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Tenofovir; Zidovudine | 2013 |
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Europe; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Lamivudine; Lopinavir; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir; Time Factors; United States | 2013 |
Economic evaluation of 3-drug antiretroviral regimens for the prevention of mother-to-child HIV transmission in Thailand.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Health Services; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Models, Econometric; Mothers; Nevirapine; Pregnancy; Thailand; Zidovudine | 2015 |
Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Linear Models; Middle Aged; Nevirapine; Oligopeptides; Pyridines; Risk Factors; Viral Load | 2013 |
Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.
Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cognitive Dysfunction; Constitutive Androstane Receptor; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Female; Gene Frequency; Hallucinations; HIV Infections; Humans; Kaplan-Meier Estimate; Male; Memory Disorders; Mental Disorders; Prospective Studies; Rifampin; Sleep Arousal Disorders; Tuberculosis; Uganda | 2013 |
Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Coinfection; Cyclopropanes; Darunavir; Female; Follow-Up Studies; Hepatitis C; HIV Infections; Humans; Liver; Male; Nevirapine; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2013 |
Stevens-Johnson syndrome and HIV in children in Swaziland.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Eswatini; Female; HIV Infections; Hospitalization; Humans; Infant; Male; Nevirapine; Retrospective Studies; Stevens-Johnson Syndrome; Trimethoprim, Sulfamethoxazole Drug Combination; Young Adult | 2013 |
Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser.
Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genetic Predisposition to Disease; HIV Infections; Humans; Liver Failure, Acute; Liver Transplantation | 2013 |
High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Asian People; Benzoxazines; Black People; Case-Control Studies; Constitutive Androstane Receptor; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Gene Frequency; Haplotypes; HIV Infections; Humans; Multivariate Analysis; Pharmacogenetics; Polymorphism, Single Nucleotide; South Africa; White People | 2013 |
Would a CYP2B6 test help HIV patients being treated with efavirenz?
Topics: Alkynes; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Central Nervous System; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug-Related Side Effects and Adverse Reactions; Genotype; HIV; HIV Infections; Humans; Polymorphism, Single Nucleotide; Treatment Outcome | 2013 |
Temporal association between incident tuberculosis and poor virological outcomes in a South African antiretroviral treatment service.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Incidence; Lamivudine; Male; Medication Adherence; Nevirapine; Risk Factors; South Africa; Stavudine; Time Factors; Tuberculosis; Viral Load | 2013 |
Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Eswatini; Female; Follow-Up Studies; HIV Infections; Humans; Incidence; Male; Multivariate Analysis; Nevirapine; Proportional Hazards Models; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Tuberculosis | 2013 |
Annular erythema and photosensitivity as manifestations of efavirenz-induced cutaneous reactions: a review of five consecutive cases.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Erythema; Female; HIV Infections; Humans; Male; Photosensitivity Disorders; Retrospective Studies; Skin Diseases, Genetic; South Africa | 2013 |
Treatment. Least virological failure in children taking efavirenz.
Topics: Alkynes; Benzoxazines; Botswana; Cyclopropanes; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Viral Load | 2013 |
Impact of pharmacogenetics on CNS side effects related to efavirenz.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Biomarkers, Pharmacological; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide | 2013 |
Evaluation of residual viremia and quantitation of soluble CD14 in a large cohort of HIV-infected adults on a long-term non-nucleoside reverse transcriptase inhibitor-based regimen.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cross-Sectional Studies; Cyclopropanes; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; HIV-1; Humans; Lipopolysaccharide Receptors; Male; Middle Aged; Monocytes; Nevirapine; Reverse Transcriptase Inhibitors; Viral Load; Viremia | 2013 |
Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; DNA Mutational Analysis; Drug Resistance, Viral; Female; High-Throughput Nucleotide Sequencing; HIV Infections; HIV-1; Humans; Logistic Models; Male; Middle Aged; Nevirapine; Odds Ratio; Reverse Transcriptase Inhibitors | 2013 |
Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.
Topics: 14-alpha Demethylase Inhibitors; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Erlotinib Hydrochloride; Female; Half-Life; Hepatocytes; HIV Infections; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Nucleic Acid Synthesis Inhibitors; Quinazolines; Rifampin; Ritonavir | 2013 |
Trials challenging HIV drug doses could usher in huge cost cuts.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Costs and Cost Analysis; Cyclopropanes; Dose-Response Relationship, Drug; HIV; HIV Infections; Humans | 2013 |
Efavirenz-induced gynecomastia in a prepubertal girl with human immunodeficiency virus infection: a case report.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Breast Diseases; Child; Cyclopropanes; Female; HIV Infections; Humans | 2013 |
Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study).
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cardiovascular Diseases; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Kidney Diseases; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Viral Load | 2013 |
[Raltegravir - long lasting effectiveness, well tolerated and well combined].
Topics: Adolescent; Adult; Alkynes; Benzoxazines; Child; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Long-Term Care; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Viral Load; Virus Replication | 2013 |
Liver transplantation for acute liver failure due to efavirenz hepatotoxicity: the importance of routine monitoring.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Female; HIV Infections; Humans; Liver; Liver Function Tests; Liver Transplantation; Reverse Transcriptase Inhibitors; Treatment Outcome | 2013 |
Sleep quality in efavirenz-treated Chinese HIV patients - comparing between GT and GG genotype of CYP2B6-516 G/T polymorphisms.
Topics: Adult; Alkynes; Alleles; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Asian People; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; Humans; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Prospective Studies; Quality of Life; Reverse Transcriptase Inhibitors; Sleep; Surveys and Questionnaires; Treatment Outcome | 2014 |
HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Resistance, Viral; Epidemiological Monitoring; Female; Ghana; HIV Infections; HIV Protease; HIV-1; Humans; Infant; Lamivudine; Male; Middle Aged; Molecular Epidemiology; Molecular Typing; Mutation, Missense; Nevirapine; Prevalence; Sequence Analysis, DNA; Stavudine; Zidovudine | 2013 |
High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa.
Topics: Adolescent; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Nevirapine; Outcome Assessment, Health Care; Prevalence; South Africa; Stavudine; Young Adult; Zidovudine | 2013 |
Long-term effectiveness of first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in Ghana.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; Ghana; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Retrospective Studies; Reverse Transcriptase Inhibitors; Survival Analysis; Treatment Outcome; Viral Load; Withholding Treatment | 2014 |
The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Failure | 2014 |
Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cohort Studies; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Female; Ghana; Glucuronosyltransferase; HIV Infections; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Retrospective Studies; Young Adult | 2014 |
Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Body Weight; Child; Child, Preschool; Cyclopropanes; HIV Infections; Humans; Infant; Pharmacogenetics | 2014 |
Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.
Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Female; Genotype; HIV Infections; Humans; Male; Plasma; Rifampin; Tuberculosis | 2013 |
Risk of clinically significant depression in HIV-infected patients: effect of antiretroviral drugs.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Depression; Female; HIV Infections; Humans; Male; Middle Aged; Poisson Distribution; Prospective Studies; Reverse Transcriptase Inhibitors | 2014 |
Are lopinavir and efavirenz serum concentrations in HIV-infected children in the therapeutic range in clinical practice?
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Chromatography, Liquid; Cyclopropanes; Drug Monitoring; Female; HIV Infections; Hospitals; Humans; Infant; Lopinavir; Male; Prospective Studies; Serum; South Africa | 2014 |
Effect of concomitant use of montelukast and efavirenz on neuropsychiatric adverse events.
Topics: Acetates; Adult; Alkynes; Anti-Asthmatic Agents; Anti-HIV Agents; Asthma; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Neurotoxicity Syndromes; Quinolines; Sulfides | 2014 |
Encephalocele following a periconceptional exposure to efavirenz: a case report.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Encephalocele; Female; Fetal Death; HIV Infections; Humans; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors | 2013 |
Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Chromatography, High Pressure Liquid; Cohort Studies; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Gene Frequency; HIV Infections; Humans; Male; Plasma; Polymorphism, Single Nucleotide; Thailand; Young Adult | 2014 |
CYP2B6-G516T genotype influences plasma efavirenz concentration in a Hong Kong population, allowing potential individualization of therapy.
Topics: Adult; Alkynes; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; HIV-1; Hong Kong; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors | 2014 |
The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 Enzyme System; Female; HIV Infections; Humans; Male; Middle Aged; Plasma; Polymorphism, Single Nucleotide; Rwanda; Tuberculosis; Young Adult | 2014 |
Pharmacologic stimulation of cytochrome P450 46A1 and cerebral cholesterol turnover in mice.
Topics: Alkynes; Alzheimer Disease; Animals; Benzoxazines; Brain; Brain Chemistry; Cattle; Cholesterol; Cholesterol 24-Hydroxylase; Cyclopropanes; Enzyme Activation; Female; HIV Infections; Male; Mice; Models, Biological; Reverse Transcriptase Inhibitors; Steroid Hydroxylases | 2014 |
CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Biological Factors; Chemical and Drug Induced Liver Injury; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Gene Frequency; Genotyping Techniques; Haplotypes; HIV Infections; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Real-Time Polymerase Chain Reaction; Thailand | 2014 |
Diabetes mellitus in HIV-infected patients receiving antiretroviral therapy.
Topics: Adult; Alkynes; Benzoxazines; Case-Control Studies; CD4 Lymphocyte Count; Cyclopropanes; Diabetes Mellitus; Female; HIV Infections; Humans; Logistic Models; Male; Middle Aged; Retrospective Studies | 2013 |
Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies.
Topics: Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Contraceptive Agents, Female; Cyclopropanes; Drug Interactions; Eswatini; Female; HIV Infections; Humans; Lopinavir; Middle Aged; Nevirapine; Pregnancy; Pregnancy, Unplanned; Ritonavir; Young Adult | 2014 |
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Retrospective Studies; Tablets | 2014 |
Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; Time Factors; Treatment Failure; Treatment Outcome; Viral Load | 2014 |
Pharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adults.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Asian People; Benzoxazines; Biomarkers; Cyclopropanes; Cytochrome P-450 Enzyme System; Female; Gene Frequency; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Polymorphism, Single Nucleotide; Prospective Studies; Tenofovir; Young Adult | 2014 |
CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1.
Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Haplotypes; HIV Infections; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors; Tuberculosis | 2014 |
Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.
Topics: Adult; Alkynes; Area Under Curve; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Pharmacogenetics; Reverse Transcriptase Inhibitors; Treatment Outcome; Uganda; Zidovudine | 2014 |
Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genetic Association Studies; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis | 2013 |
Antiretroviral dose reduction: good for patients and rollout.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Reverse Transcriptase Inhibitors | 2014 |
Hepatitis B and C co-infection among HIV-infected adults while on antiretroviral treatment: long-term survival, CD4 cell count recovery and antiretroviral toxicity in Cambodia.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cambodia; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Female; Hepatitis B; Hepatitis C; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Liver; Logistic Models; Male; Middle Aged; Nevirapine; Proportional Hazards Models; Retrospective Studies; Stavudine; Treatment Outcome; Zidovudine | 2014 |
Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy.
Topics: Adult; Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydroxylases; Asian People; Benzoxazines; Body Weight; China; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Monitoring; Drug Therapy, Combination; Ethnicity; Female; HIV Infections; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polymorphism, Single Nucleotide; Rifampin; Tuberculosis; Young Adult | 2014 |
HIV nucleoside reverse transcriptase inhibitors efavirenz and tenofovir change the growth and differentiation of primary gingival epithelium.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cyclopropanes; Dose-Response Relationship, Drug; Gene Expression Regulation; Gingiva; HIV Infections; Humans; Keratin-6; Keratinocytes; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2014 |
Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; C-Reactive Protein; CD4 Lymphocyte Count; Chemokine CXCL10; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Immune System; Inflammation; Interferon-gamma; Interleukin-6; Lipopolysaccharide Receptors; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome | 2014 |
Significant decrease of ethinylestradiol with nevirapine, and of etonogestrel with efavirenz in HIV-positive women.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptive Agents, Female; Cyclopropanes; Desogestrel; Dose-Response Relationship, Drug; Drug Interactions; Ethinyl Estradiol; Female; HIV Infections; Humans; Nevirapine; Prospective Studies | 2014 |
Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir-boosted protease inhibitor-based versus a nonnucleoside reverse transcriptase inhibitor-based first-line regimen.
Topics: Adult; Age Factors; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Prospective Studies; Ritonavir; RNA, Viral; Spain; Treatment Outcome; Viral Load | 2014 |
Baseline predictors of efavirenz-containing antiretroviral regimen adverse experiences.
Topics: Adult; Alcohol Drinking; Alkynes; Anti-HIV Agents; Benzoxazines; Body Weight; Botswana; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Depression; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors | 2014 |
Single-tablet, once-daily treatment regimens for HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; HIV Reverse Transcriptase; Humans; Nitriles; Organophosphonates; Pyrimidines; Quinolones; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Thiazoles | 2014 |
Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Evolution, Molecular; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mutation; Phylogeny; pol Gene Products, Human Immunodeficiency Virus; Retrospective Studies; Ritonavir; RNA, Viral; Viral Load; Viremia | 2015 |
Uptake of prevention of mother-to-child-transmission using Option B+ in northern rural Malawi: a retrospective cohort study.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemoprevention; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Malawi; Nevirapine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Prenatal Care; Retrospective Studies; Rural Population; Tenofovir; Young Adult | 2014 |
Presence of HIV drug resistance in antiretroviral therapy-naive and -experienced patients from Papua New Guinea.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dried Blood Spot Testing; Drug Resistance, Viral; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Papua New Guinea; Reverse Transcriptase Inhibitors; Stavudine; Treatment Failure; Viral Load; Young Adult; Zidovudine | 2014 |
Why did the FDA approve efavirenz 800 mg when co-administered with rifampin?
Topics: Alkynes; Antibiotics, Antitubercular; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Coinfection; Computer Simulation; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Administration Schedule; Drug Approval; Drug Dosage Calculations; Drug Interactions; Genotype; HIV Infections; Humans; Models, Biological; Phenotype; Polypharmacy; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis; United States; United States Food and Drug Administration | 2014 |
Efavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND).
Topics: Alkynes; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Benzoxazines; Cell Line; Cognition Disorders; Cyclopropanes; Female; HIV Infections; Humans; Lamivudine; Mice; Oxidative Stress; Phagocytosis; Reverse Transcriptase Inhibitors; Zidovudine | 2014 |
ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Creatinine; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organophosphonates; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors; Tenofovir | 2014 |
CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients.
Topics: Adult; Alkynes; Benzoxazines; Cohort Studies; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2B6 Inducers; Female; HIV Infections; Humans; Male; Middle Aged; Serbia; Smoking | 2014 |
Commentary: Antiretroviral treatment for pregnant and breastfeeding women--the shifting paradigm.
Topics: Abnormalities, Drug-Induced; Alkynes; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Female; HIV Infections; Humans; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors | 2014 |
Biomarkers of CD4+ T-cell activation as risk factors for tuberculosis-associated immune reconstitution inflammatory syndrome.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; CD4-Positive T-Lymphocytes; Cyclopropanes; Deoxycytidine; Emtricitabine; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Lymphocyte Activation; Male; Middle Aged; Mycobacterium tuberculosis; Organophosphonates; Risk Factors; Tenofovir; Tuberculosis | 2014 |
In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients.
Topics: Adenine; Adult; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Interleukin-10; Interleukin-6; Interleukin-8; Lamivudine; Male; Middle Aged; Organophosphonates; Platelet Activating Factor; Tenofovir; Tumor Necrosis Factor-alpha | 2014 |
Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.
Topics: Alkynes; Benzoxazines; China; Cyclopropanes; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Nevirapine; Phenotype; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2014 |
Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy.
Topics: Adult; Africa South of the Sahara; Aged; Alkynes; Anti-Retroviral Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Benzoxazines; Cyclopropanes; Drug Combinations; Drug Interactions; Ethanolamines; Female; Fluorenes; HIV Infections; Humans; Malaria; Male; Middle Aged; Nevirapine; Prospective Studies; Treatment Outcome; Young Adult | 2014 |
Does pregnancy affect the pharmacokinetics of efavirenz?
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Pregnancy; Pregnancy Complications, Infectious | 2014 |
Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HEK293 Cells; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Inhibitory Concentration 50; Mutation; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Virion; Virus Replication | 2014 |
Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource-limited settings.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chromatography, Liquid; Cyclopropanes; HIV Infections; Humans; Immunoenzyme Techniques; Tandem Mass Spectrometry | 2014 |
Switching from efavirenz to nevirapine in children: 1-week dose escalation strategy.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Female; HIV Infections; Humans; Male; Nevirapine; Retrospective Studies | 2014 |
[Budget impact analysis of efavirenz daily dose reduction at the Verona University Hospital].
Topics: Adult; Alkynes; Benzoxazines; Budgets; Cyclopropanes; Dose-Response Relationship, Drug; Female; HIV Infections; HIV-1; Hospitals, University; Humans; Italy; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2014 |
Dose reduction of efavirenz: an observational study describing cost-effectiveness, pharmacokinetics and pharmacogenetics.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cost-Benefit Analysis; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Monitoring; Female; Genotype; HIV; HIV Infections; Humans; Male; Middle Aged; Pharmacogenetics | 2014 |
Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy.
Topics: Adult; Alkynes; Area Under Curve; Benzoxazines; Cyclohexanes; Cyclopropanes; Drug Administration Schedule; Drug Substitution; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Outcome; Triazoles; Viral Load | 2015 |
Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cause of Death; Cyclopropanes; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Randomized Controlled Trials as Topic; RNA, Viral; Suicidal Ideation; Suicide; Suicide, Attempted; Viral Load | 2014 |
Summaries for patients. Efavirenz and the risk for suicidal behaviors.
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Suicide | 2014 |
Etravirine and rilpivirine-specific mutations selected by efavirenz and nevirapine exposure in patients infected with HIV-1 non-B subtypes.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation, Missense; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Rilpivirine; Treatment Outcome; Viral Load | 2014 |
Safety and efficacy of coformulated efavirenz/emtricitabine/tenofovir single-tablet regimen in treatment-naive patients infected with HIV-1.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Europe; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Plasma; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Coinfection; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Plasma; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; South Africa; Tuberculosis; Viral Load; Young Adult | 2015 |
Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Female; Genotype; HIV Infections; Humans; Hydroxycholesterols; Male; Middle Aged; Rifampin; Tuberculosis | 2014 |
No evident association between efavirenz use and suicidality was identified from a disproportionality analysis using the FAERS database.
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Product Surveillance, Postmarketing; Suicide; United States | 2014 |
Blepharoptosis and HAART related mitochondrial myopathy.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Blepharoptosis; Cyclopropanes; Didanosine; Dideoxynucleosides; DNA, Mitochondrial; HIV Infections; Humans; Male; Middle Aged; Mitochondria, Muscle; Mitochondrial Myopathies; Oculomotor Muscles | 2014 |
Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; Cyclopropanes; Drug Tolerance; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Treatment Outcome; Tuberculosis | 2015 |
The challenge of paediatric efavirenz dosing: implications and way forward for the sub-Saharan Africa.
Topics: Adolescent; Africa South of the Sahara; Age Factors; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Female; HIV Infections; Humans; Infant; Male | 2014 |
CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.
Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genetic Variation; Genotype; HIV Infections; Humans; Male; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis | 2014 |
Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment.
Topics: Adult; Alkynes; Alleles; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Female; Gene Frequency; Genotype; Haplotypes; HIV Infections; Humans; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Treatment Outcome; Tuberculosis; Young Adult | 2015 |
The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; Follow-Up Studies; HIV; HIV Infections; Humans; Male; Middle Aged; Nevirapine; South Africa; Treatment Failure; Viremia; Young Adult | 2014 |
Detecting virological failure in HIV-infected Tanzanian children.
Topics: Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Cross-Sectional Studies; Cyclopropanes; Drug Monitoring; Drug Resistance, Multiple, Viral; False Negative Reactions; False Positive Reactions; Female; HIV Infections; Humans; Male; Monitoring, Immunologic; Nevirapine; Predictive Value of Tests; Tanzania; Treatment Failure; Viral Load | 2014 |
Primary HIV infection presenting as limbic encephalitis and rhabdomyolysis.
Topics: Acute Kidney Injury; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Diagnosis, Differential; Diffusion Magnetic Resonance Imaging; Emtricitabine; HIV Infections; Humans; Limbic Encephalitis; Magnetic Resonance Imaging; Male; Rhabdomyolysis; Tenofovir | 2015 |
Clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy.
Topics: Adult; Age Factors; Alkynes; Ambulatory Care Facilities; Anti-Retroviral Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Polypharmacy; Prevalence; Protease Inhibitors; Risk Factors; Sex Factors; Thailand | 2014 |
Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Weight; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Male; Middle Aged; Obesity; Regression Analysis; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2015 |
Efavirenz dose reduction in HIV-infected patients: a long-term follow-up.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Monitoring; Female; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; RNA, Viral; Treatment Outcome; Viral Load | 2014 |
Nevirapine-related adverse events among children switched from efavirenz to nevirapine as compared to children who were started on nevirapine-based antiretroviral therapy directly.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Drug Administration Schedule; Drug Hypersensitivity; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Incidence; India; Male; Nevirapine; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome | 2015 |
Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Italy; Male; Middle Aged; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2015 |
Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Black People; Child; Child, Preschool; Constitutive Androstane Receptor; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; South Africa; Young Adult | 2015 |
Comprehensive evaluation of caregiver-reported antiretroviral therapy adherence for HIV-infected children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Caregivers; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Infant; Infant, Newborn; Kenya; Logistic Models; Male; Medication Adherence; Nevirapine; Parents; Prospective Studies; Surveys and Questionnaires | 2015 |
Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Genotyping Techniques; High-Throughput Nucleotide Sequencing; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Plasma; Tenofovir; Treatment Failure | 2015 |
Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; Mutation, Missense; Nevirapine; Rilpivirine; Treatment Failure | 2015 |
Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Cognition Disorders; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Substitution; Emtricitabine; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Pilot Projects; Prospective Studies; Tenofovir; Tumor Necrosis Factor-alpha; Viral Load | 2015 |
Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.
Topics: Alkynes; Antitubercular Agents; Arylamine N-Acetyltransferase; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; Humans; Male; Peru; Pharmacogenetics; Rifampin; South Africa; Tuberculosis; Uganda | 2015 |
Ginkgo biloba: reduced efficacy of efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Biotransformation; Cyclopropanes; Ginkgo biloba; Herb-Drug Interactions; HIV Infections; Humans; Middle Aged; Patient Safety; Plant Extracts; Reverse Transcriptase Inhibitors; Risk Assessment; Risk Factors; Viral Load | 2015 |
The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda.
Topics: Adolescent; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Cyclopropanes; HIV Infections; Humans; Lopinavir; Malnutrition; Models, Theoretical; Nevirapine; Poverty; Randomized Controlled Trials as Topic; Treatment Failure; Treatment Outcome; Uganda; Viral Load; Young Adult | 2015 |
Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Density; Calcium; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Prospective Studies; RNA, Viral; Tenofovir; Treatment Outcome; Urinalysis; Viral Load | 2015 |
Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Female; Health Resources; HIV; HIV Infections; Humans; Lamivudine; Lesotho; Logistic Models; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load; Zidovudine | 2015 |
Short Communication: Increase of HIV-1 K103N Transmitted Drug Resistance and Its Association with Efavirenz Use in South Korea.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cluster Analysis; Cyclopropanes; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Incidence; Male; Molecular Sequence Data; Mutation, Missense; Phylogeny; Republic of Korea; Sequence Analysis, DNA | 2015 |
CD41 T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa.
Topics: Adult; Africa; Alkynes; Anti-HIV Agents; Asia; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nevirapine; North America; RNA, Viral; Virus Replication | 2015 |
Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.
Topics: Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Female; Hepatitis C; HIV Infections; Humans; Liver Function Tests; Male; Middle Aged; Raltegravir Potassium; Ritonavir | 2015 |
[Analysis on HIV suppression effect after initiating antiretroviral treatment and related factors among AIDS patients in Henan province during 2008 and 2013].
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; Health Facilities; HIV Infections; Humans; Lamivudine; Male; Nevirapine; Stavudine; Time-to-Treatment; Treatment Outcome; Zidovudine | 2015 |
Distinct drug resistance profile of HIV-1 subtype A strain circulating in Georgia.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Mutation; pol Gene Products, Human Immunodeficiency Virus; Reverse Transcriptase Inhibitors | 2015 |
Time trends of baseline demographics and clinical characteristics of HIV infected children enrolled in care and treatment service in Dar es Salaam, Tanzania.
Topics: Adolescent; Age Distribution; Alkynes; Ambulatory Care Facilities; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Comorbidity; Cyclopropanes; Female; HIV Infections; Humans; Infant; Lamivudine; Linear Models; Male; Nevirapine; Severity of Illness Index; Tanzania; Tuberculosis; Zidovudine | 2015 |
Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Breast Feeding; Constitutive Androstane Receptor; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; HIV Infections; Humans; Infant; Infant, Newborn; Linear Models; Milk, Human; Pharmacogenetics; Polymorphism, Single Nucleotide; Young Adult | 2015 |
The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
Topics: Adult; Aged; Alkynes; Anti-Retroviral Agents; Antimalarials; Benzoxazines; Cyclopropanes; Drug Interactions; Ethanolamines; Female; Fluorenes; HIV Infections; Humans; Lumefantrine; Malaria; Male; Middle Aged; Nevirapine; Prospective Studies; Tanzania; Young Adult | 2015 |
Acute porphyria precipitated by efavirenz.
Topics: Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; HIV Infections; Humans; Male; Porphyria, Acute Intermittent; Reverse Transcriptase Inhibitors; Viral Load | 2015 |
Lack of evidence for the selection of E138 mutations by first-generation non-nucleoside reverse transcriptase inhibitors in patients infected with HIV-1 non-B subtypes.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nevirapine; Reverse Transcriptase Inhibitors | 2015 |
Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.
Topics: Adult; Alkynes; Anti-HIV Agents; Atherosclerosis; Benzoxazines; Biomarkers; Blood Pressure; C-Reactive Protein; Carotid Intima-Media Thickness; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; Cyclopropanes; Ethiopia; Female; Heart Rate; HIV Infections; HIV-1; Humans; Lipodystrophy; Lopinavir; Male; Middle Aged; Nevirapine; Pulse Wave Analysis; Ritonavir; Triglycerides | 2015 |
Pregnancy outcomes following exposure to efavirenz-based antiretroviral therapy in the Republic of Congo.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Congo; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Retrospective Studies | 2015 |
Markov model for characterizing neuropsychologic impairment and Monte Carlo simulation for optimizing efavirenz therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Female; HIV Infections; Humans; Male; Markov Chains; Models, Biological; Monte Carlo Method; Neuropsychological Tests; Neurotoxicity Syndromes; Reverse Transcriptase Inhibitors | 2015 |
CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
Topics: Alkynes; Anti-HIV Agents; Antimalarials; Artemether; Artemisinins; ATP Binding Cassette Transporter, Subfamily B; Benzoxazines; Case-Control Studies; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Drug Antagonism; Drug Therapy, Combination; Ethanolamines; Fluorenes; Genotype; HIV Infections; Humans; Lumefantrine; Malaria; Nevirapine; Prospective Studies | 2016 |
Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Breast Feeding; Chromatography, Liquid; Cohort Studies; Cyclopropanes; Drug Monitoring; Female; Hair; HIV Infections; Humans; Infant; Infant, Newborn; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Randomized Controlled Trials as Topic; Tandem Mass Spectrometry; Treatment Outcome; Uganda; Viral Load | 2015 |
Dysregulation of Endoplasmic Reticulum Stress and Autophagic Responses by the Antiretroviral Drug Efavirenz.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Autophagy; Benzoxazines; Blood-Brain Barrier; Brain; Cell Line; Cyclopropanes; Disease Models, Animal; DNA-Binding Proteins; Endoplasmic Reticulum Stress; Endoribonucleases; Gene Expression Regulation; HIV Infections; Humans; Mice; Mice, Transgenic; Regulatory Factor X Transcription Factors; Transcription Factors | 2015 |
Tricuspid valve endocarditis associated with intravenous nyoape use: a report of 3 cases.
Topics: Adult; Alkynes; Anti-Bacterial Agents; Benzoxazines; Cannabis; Cyclopropanes; Endocarditis; Heroin; HIV Infections; Humans; Illicit Drugs; Male; Methamphetamine; Pulmonary Embolism; Ritonavir; South Africa; Substance-Related Disorders; Tricuspid Valve; Tricuspid Valve Insufficiency; Young Adult | 2014 |
Impaired sperm motility in HIV-infected men: an unexpected adverse effect of efavirenz?
Topics: Adult; Alkynes; Benzoxazines; Case-Control Studies; Cyclopropanes; HIV Infections; Humans; Infertility, Male; Male; Reverse Transcriptase Inhibitors; Semen Analysis; Sperm Motility | 2015 |
Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells.
Topics: Alkynes; Antineoplastic Agents; Benzoxazines; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclopropanes; Drug Screening Assays, Antitumor; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Pancreatic Neoplasms; Reverse Transcriptase Inhibitors | 2015 |
Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection.
Topics: Adolescent; Adult; Aged; Alkynes; Alleles; Anti-HIV Agents; Asian People; Benzoxazines; China; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2B6 Inducers; Drug Monitoring; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Haplotypes; HIV Infections; Humans; Inactivation, Metabolic; Male; Middle Aged; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors; Young Adult | 2015 |
The influence of patient beliefs and treatment satisfaction on the discontinuation of current first-line antiretroviral regimens.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Male; Middle Aged; Patient Satisfaction; Personal Satisfaction; Proportional Hazards Models; Treatment Outcome | 2016 |
Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Depression; Female; HIV Infections; Humans; Interviews as Topic; Male; Mental Health; Nevirapine; Prospective Studies; Quality of Life; Reverse Transcriptase Inhibitors; Treatment Outcome; Uganda; World Health Organization | 2015 |
Two cases of successful efavirenz desensitization in patients with several anti-HIV drugs hypersensitivities.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Desensitization, Immunologic; Drug Eruptions; Drug Hypersensitivity; Female; HIV Infections; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors | 2015 |
Efavirenz Concentrations and Probability of HIV Replication in Children.
Topics: Alkynes; Benzoxazines; Child; Cohort Studies; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Reverse Transcriptase Inhibitors; Viral Load | 2015 |
Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Central Nervous System Diseases; Cyclopropanes; Drug Substitution; Female; HIV Infections; Humans; Male; Medication Adherence; Mental Disorders; Middle Aged; Nevirapine; Prospective Studies; Quality of Life; Reverse Transcriptase Inhibitors | 2015 |
CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon.
Topics: Adolescent; Adult; Alkynes; Benzoxazines; Black People; Cameroon; Child; Child, Preschool; Cross-Sectional Studies; Cyclopropanes; Cytochrome P-450 CYP2B6; Gene Frequency; HIV Infections; Humans; Infant; Nevirapine; Polymorphism, Single Nucleotide; Precision Medicine; Young Adult | 2015 |
Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Estonia; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Prevalence; Reverse Transcriptase Inhibitors; Zidovudine | 2016 |
Longitudinal Analysis of Adherence to First-Line Antiretroviral Therapy: Evidence of Treatment Sustainability from an Indian HIV Cohort.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; Humans; India; Lamivudine; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2016 |
Fibroblast growth factor 23: associations with antiretroviral therapy in patients co-infected with HIV and hepatitis C.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Bayes Theorem; Benzoxazines; Canada; Coinfection; Cyclopropanes; Dideoxynucleosides; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Hepatitis C; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Prospective Studies; Risk Factors; Tenofovir | 2016 |
Thermosensitive Gel Containing Cellulose Acetate Phthalate-Efavirenz Combination Nanoparticles for Prevention of HIV-1 Infection.
Topics: Alkynes; Antiviral Agents; Benzoxazines; Cell Proliferation; Cellulose; Cyclopropanes; Delayed-Action Preparations; Diffusion; Gels; HeLa Cells; HIV Infections; HIV-1; Humans; Nanocapsules; Particle Size; Temperature | 2015 |
Choice of effect measure in HIV randomized trials.
Topics: Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Endpoint Determination; HIV Infections; HIV-1; Humans; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Time; Treatment Outcome; Viral Load | 2015 |
Reassuring Birth Outcomes With Tenofovir/Emtricitabine/Efavirenz Used for Prevention of Mother-to-Child Transmission of HIV in Botswana.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Botswana; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Pregnancy; Tenofovir | 2016 |
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Medication Adherence; Retrospective Studies; Risk Assessment; Tablets | 2016 |
Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cognitive Dysfunction; Coinfection; Cyclopropanes; Drug Therapy, Combination; Executive Function; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Lopinavir; Male; Memory; Middle Aged; Neuropsychological Tests; Ritonavir; Verbal Learning | 2016 |
The Association of Gender, Age, Efavirenz Use, and Hypovitaminosis D Among HIV-Infected Adults Living in the Tropics.
Topics: Adult; Age Factors; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Female; HIV Infections; Humans; Male; Middle Aged; Prevalence; Sex Factors; Thailand; Tropical Climate; Vitamin D Deficiency | 2016 |
The metabolic and cardiovascular consequences of obesity in persons with HIV on long-term antiretroviral therapy.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cardiovascular Diseases; Cohort Studies; Cyclopropanes; Emtricitabine; Female; HIV Infections; Humans; Male; Metabolic Diseases; Middle Aged; Obesity; Risk Assessment; Tenofovir | 2016 |
Effect of HAART on Brain Organization and Function in HIV-Negative Subjects.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Brain; Cerebrovascular Circulation; Connectome; Cyclopropanes; Female; Healthy Volunteers; HIV Infections; Humans; Magnetic Resonance Imaging; Male; Ritonavir | 2015 |
COMPARISON OF THAI GOVERNMENT MANUFACTURED TENOFOVIR (TENOFOVIR GPO300) WITH PRIVATELY MANUFACTURED TENOFOVIR (VIREAD) USED ALONG WITH LAMIVUDINE AND EFAVIRENZ TO TREAT THAI HIV PATIENTS.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Government; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2015 |
Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; Cyclopropanes; Dideoxynucleosides; Drug Combinations; E-Selectin; Emtricitabine; Female; HIV Infections; Humans; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-6; Lamivudine; Male; Middle Aged; P-Selectin; Tenofovir; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2016 |
In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Genotype; Glucuronides; HIV Infections; Humans; Hydroxylation; Metabolic Detoxication, Phase I; Metabolic Detoxication, Phase II; Metabolomics; Neurotoxicity Syndromes; Phenotype; Reverse Transcriptase Inhibitors; Risk Assessment; Sulfates; Tandem Mass Spectrometry | 2016 |
Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART).
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Case-Control Studies; Cyclopropanes; DNA, Mitochondrial; Drug Combinations; Female; HIV; HIV Infections; Humans; Lamivudine; Lipodystrophy; Lopinavir; Male; Middle Aged; Mitochondria; Nelfinavir; Predictive Value of Tests; Ritonavir; ROC Curve; Stavudine; Zidovudine | 2015 |
Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cost-Benefit Analysis; Cyclopropanes; Cytochrome P-450 CYP2B6; Genotype; Genotyping Techniques; HIV Infections; Humans; Models, Theoretical; Quality-Adjusted Life Years | 2015 |
Efavirenz as a cause of ataxia in children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Ataxia; Benzoxazines; Child; Cyclopropanes; Female; HIV Infections; HIV Seropositivity; Humans | 2015 |
Antiretroviral Therapy, Especially Efavirenz, Is Associated with Low Bone Mineral Density in HIV-Infected South Africans.
Topics: Adult; Age Factors; Alkynes; Anti-Retroviral Agents; Benzoxazines; Bone Density; Cross-Sectional Studies; Cyclopropanes; Female; Femur; HIV Infections; Humans; Lopinavir; Lumbar Vertebrae; Male; Radiography; Reverse Transcriptase Inhibitors; South Africa | 2015 |
CYP2B6*6 and CYP2B6*18 Predict Long-Term Efavirenz Exposure Measured in Hair Samples in HIV-Positive South African Women.
Topics: Adult; Aged; Alkynes; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Ethnicity; Female; Hair; HIV Infections; Humans; Middle Aged; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; South Africa; Young Adult | 2016 |
Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Chromatography, Liquid; Cyclopropanes; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Malawi; Pregnancy; Pregnancy Complications, Infectious; Tandem Mass Spectrometry; Tenofovir; Viral Load; Young Adult | 2016 |
Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; France; HIV Infections; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Tuberculosis; Viral Load | 2016 |
Reduced Effectiveness of Contraceptive Implants for Women Taking the Antiretroviral Efavirenz (EFV): Still Good Enough and for How Long?
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptive Agents, Female; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Pregnancy; Reverse Transcriptase Inhibitors | 2015 |
Comparison of the In Vivo Pharmacokinetics and In Vitro Dissolution of Branded Versus Generic Efavirenz Formulation in HIV-Infected Patients.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drugs, Generic; HIV Infections; Humans; Solubility | 2016 |
Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapy.
Topics: Adult; Aged; Aging; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclin-Dependent Kinase Inhibitor p16; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; Gene Expression; HIV Infections; Humans; Male; Middle Aged; Nucleotides; Ritonavir; Tenofovir; Young Adult | 2016 |
Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Dyslipidemias; Female; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Lipids; Lipodystrophy; Male; Middle Aged; Retrospective Studies; Substance-Related Disorders | 2016 |
Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia.
Topics: Alkynes; Benzoxazines; Cohort Studies; Cyclopropanes; Dyslipidemias; HIV Infections; HIV-1; Humans; Lipids; Rilpivirine; RNA, Viral | 2016 |
A Population Pharmacokinetic/Pharmacodynamic Model Predicts Favorable HDL Cholesterol Changes Over the First 5 Years in Children Treated With Current Efavirenz-Based Regimens.
Topics: Alkynes; Benzoxazines; Child; Child, Preschool; Cholesterol, HDL; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Male; Models, Biological; Population Surveillance; Predictive Value of Tests; Thailand; Treatment Outcome | 2016 |
Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations.
Topics: Adult; Alkynes; Benzoxazines; Blood Glucose; Cross-Sectional Studies; Cyclopropanes; Female; HIV Infections; Humans; Lipid Metabolism; Lipids; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors | 2016 |
No Evidence of an Association Between Efavirenz Exposure and Suicidality Among HIV Patients Initiating Antiretroviral Therapy in a Retrospective Cohort Study of Real World Data.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Retrospective Studies; Risk Factors; Suicidal Ideation; Suicide, Attempted | 2016 |
Efficacy and Safety of Tenofovir and Lamivudine in Combination with Efavirenz in Patients Co-infected with Human Immunodeficiency Virus and Hepatitis B Virus in China.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-HIV Agents; Aspartate Aminotransferases; Benzoxazines; CD4-Positive T-Lymphocytes; Coinfection; Cyclopropanes; Female; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Tenofovir | 2016 |
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study.
Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Global Health; HIV Infections; HIV-1; Humans; Lamivudine; Pre-Exposure Prophylaxis; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2016 |
Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Child; Child, Preschool; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Haplotypes; HIV Infections; Humans; Male; Polymorphism, Single Nucleotide | 2016 |
Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Phosphorous Acids; Piperazines; Public Health; Pyridones; Ritonavir | 2016 |
The Rise and Fall of Efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Practice Guidelines as Topic; Reverse Transcriptase Inhibitors | 2016 |
Significant intolerability of efavirenz in HIV occupational postexposure prophylaxis.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; Health Personnel; HIV Infections; Humans; Male; Medication Adherence; Occupational Exposure; Post-Exposure Prophylaxis; Retrospective Studies; Thailand | 2016 |
Efavirenz-Associated Urinary Matrix Stone-A Rare Presentation.
Topics: Aged; Alkynes; Benzoxazines; Cyclopropanes; Escherichia coli Infections; HIV Infections; Humans; Kidney Calculi; Male; Reverse Transcriptase Inhibitors; United States; Urinary Tract Infections | 2016 |
Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapy.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Biomarkers; Cyclopropanes; Female; HIV Infections; Humans; Lipoproteins, LDL; Male; Oxidative Stress; Peroxidase; Phospholipases A2; Plasma; Prospective Studies | 2016 |
Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Monitoring; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Medication Adherence; Nitriles; Pyridazines; Pyrimidines; Retrospective Studies; Reverse Transcriptase Inhibitors | 2016 |
Risk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Diabetes Mellitus; Female; HIV Infections; Humans; Incidence; Male; Reverse Transcriptase Inhibitors; Risk Factors; South Africa; Statistics as Topic | 2016 |
Identification of a novel and severe pattern of efavirenz drug-induced liver injury in South Africa.
Topics: Adult; Alkynes; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Female; HIV Infections; Humans; Male; Pregnancy; Prospective Studies; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; South Africa; Survival Analysis | 2016 |
Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study.
Topics: Adult; Age Factors; Alkynes; Atazanavir Sulfate; Benzoxazines; CD4-CD8 Ratio; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Interferon Type I; Male; Middle Aged; Oligopeptides; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ribavirin; Ritonavir | 2016 |
Factors associated with HIV viral load "blips" and the relationship between self-reported adherence and efavirenz blood levels on blip occurrence: a case-control study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Case-Control Studies; Cyclopropanes; Female; HIV Infections; Humans; Male; Medication Adherence; Prospective Studies; Self Report; Viral Load | 2016 |
Validation of Computational Approaches for Antiretroviral Dose Optimization.
Topics: Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Administration Schedule; Drug Dosage Calculations; Gene Expression; HIV; HIV Infections; Humans; Microbial Sensitivity Tests; Models, Statistical; Mutation Rate | 2016 |
CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.
Topics: Adult; Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis; Viral Load; Zidovudine | 2016 |
Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Biological Availability; Body Weight; Child, Preschool; Clinical Trials as Topic; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Administration Schedule; Drug Dosage Calculations; Female; Gene Expression; Genotype; HIV Infections; HIV-1; Humans; Infant; Male; Models, Statistical; Polymorphism, Genetic; Reverse Transcriptase Inhibitors | 2016 |
A 33-year-old patient with human immunodeficiency virus on antiretroviral therapy with efavirenz-induced complex partial seizures: a case report.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Male; Reverse Transcriptase Inhibitors; Seizures | 2016 |
Transition modeling of neuropsychiatric impairment in HIV.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Mental Disorders; Models, Psychological; Time Factors | 2016 |
Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children.
Topics: Adolescent; Age Factors; Alkynes; Benzoxazines; Child; Cyclopropanes; Female; HIV Infections; Humans; Male; Multivariate Analysis; Reverse Transcriptase Inhibitors; Sex Factors | 2016 |
HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Middle Aged; Mutation; Nevirapine; Panama; Prevalence; Retrospective Studies; Young Adult | 2016 |
Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Thailand; Viral Load; Young Adult | 2016 |
Comparison of efavirenz and protease inhibitor based combination antiretroviral therapy regimens in treatment-naïve people living with HIV with baseline resistance.
Topics: Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Retrospective Studies; Reverse Transcriptase Inhibitors; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load | 2016 |
Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz.
Topics: Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Binding, Competitive; Brain; Calcium Signaling; CHO Cells; Cricetulus; Cyclopropanes; Dose-Response Relationship, Drug; Drug Partial Agonism; Guinea Pigs; HEK293 Cells; HeLa Cells; HIV Infections; HIV-1; Humans; Membrane Potentials; Monoamine Oxidase Inhibitors; Protein Binding; Radioligand Assay; Receptors, Muscarinic; Receptors, Serotonin; Reverse Transcriptase Inhibitors; Serotonin Antagonists; Time Factors; Transfection | 2016 |
Effect of mid-dose efavirenz concentrations and CYP2B6 genotype on viral suppression in patients on first-line antiretroviral therapy.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; HIV; HIV Infections; Humans; Male; Plasma; Polymorphism, Genetic; RNA, Viral; Treatment Outcome; Viral Load | 2016 |
Are We Giving Optimal Dose of Efavirenz?
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cyclopropanes; HIV Infections; Humans | 2016 |
Antileishmanial activity of antiretroviral drugs combined with miltefosine.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antiprotozoal Agents; Atazanavir Sulfate; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Delavirdine; Drug Therapy, Combination; HIV Infections; Humans; Leishmania infantum; Leishmaniasis, Visceral; Macrophages; Male; Mice, Inbred BALB C; Nevirapine; Phosphorylcholine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Tenofovir | 2016 |
Efavirenz and ritonavir-boosted lopinavir use exhibited elevated markers of atherosclerosis across age groups in people living with HIV in Ethiopia.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atherosclerosis; Benzoxazines; Biomarkers; Carotid Intima-Media Thickness; Child; Cyclopropanes; Ethiopia; Female; HIV Infections; Humans; Lipids; Lopinavir; Male; Middle Aged; Pulse Wave Analysis; Ritonavir; Young Adult | 2016 |
Dose Optimization of Efavirenz Based on Individual CYP2B6 Polymorphisms in Chinese Patients Positive for HIV.
Topics: Adult; Alkynes; Benzoxazines; Computer Simulation; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Dosage Calculations; Female; HIV Infections; Humans; Male; Middle Aged; Nonlinear Dynamics; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Precision Medicine; Retrospective Studies; Reverse Transcriptase Inhibitors | 2016 |
First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nevirapine; Time Factors; Treatment Failure; Uganda | 2016 |
HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Coinfection; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; Ethiopia; Female; Genetic Variation; Genome, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Immune Evasion; Lamivudine; Male; Mutation; Stavudine; Viral Load; Zidovudine | 2017 |
Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option B+ programme in Malawi.
Topics: Adult; Alkaline Phosphatase; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; Bone Resorption; Breast Feeding; Collagen Type I; Cyclopropanes; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Malawi; Male; Peptides; Pregnancy; Tenofovir; Young Adult | 2016 |
Efavirenz biotransformation as an up-stream event of mood changes in HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Anxiety; Benzoxazines; Biomarkers, Pharmacological; Biotransformation; Blood-Brain Barrier; Case-Control Studies; CD4 Lymphocyte Count; Cyclopropanes; Drug Monitoring; Drug Therapy, Combination; Feasibility Studies; Glucuronides; HIV Infections; Humans; Male; Metabolic Detoxication, Phase II; Middle Aged; Mood Disorders; Neurotoxicity Syndromes; Prevalence; Reverse Transcriptase Inhibitors | 2016 |
Prevalence and risk factors for efavirenz-based antiretroviral treatment-associated severe vitamin D deficiency: A prospective cohort study.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; Cholesterol; Cohort Studies; Cyclopropanes; Ethiopia; Female; HIV Infections; Humans; Male; Prevalence; Prospective Studies; Rifampin; Risk Factors; Treatment Outcome; Tuberculosis, Pulmonary; Vitamin D; Vitamin D Deficiency | 2016 |
Rollout of efavirenz-based regimens in option B+ in the prevention of mother-to-child transmission programs: challenges and lessons learned from a postexposure prophylaxis experience.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Female; Hallucinations; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Post-Exposure Prophylaxis; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors | 2016 |
Interchangeability between first-line generic antiretroviral products prequalified by WHO using adjusted indirect comparisons.
Topics: Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Biological Availability; Cyclopropanes; Drug Combinations; Drugs, Generic; Emtricitabine; HIV Infections; Humans; Lamivudine; Models, Statistical; Tenofovir; Therapeutic Equivalency; World Health Organization | 2017 |
Immune reconstitution inflammatory syndrome associated with dermatophytoses in two HIV-1 positive patients in rural Tanzania: a case report.
Topics: Adenine; Adult; Africa; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Deoxycytidine; Female; HIV Infections; HIV-1; Humans; Immune Reconstitution Inflammatory Syndrome; Male; Organophosphonates; Tanzania; Tinea | 2016 |
Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients.
Topics: Aged; AIDS Dementia Complex; Alkynes; Anxiety; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Cytochrome P-450 CYP2B6; Depression; Female; HIV Infections; Humans; Male; Middle Aged; Neuropsychological Tests; Pharmacogenetics; Plasma; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; Sleep Wake Disorders | 2017 |
Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Viral; Federal Government; Female; Follow-Up Studies; High-Throughput Nucleotide Sequencing; HIV Infections; HIV-1; Humans; Male; Mexico; Reverse Transcriptase Inhibitors; RNA, Viral; Surveys and Questionnaires; Viral Load; World Health Organization; Young Adult | 2016 |
Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD8-Positive T-Lymphocytes; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; RNA, Viral; Sustained Virologic Response; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2016 |
Gene-gene interactions between DRD3, MRP4 and CYP2B6 polymorphisms and its influence on the pharmacokinetic parameters of efavirenz in HIV infected patients.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; Humans; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Polymorphism, Single Nucleotide; Receptors, Dopamine D3; Young Adult | 2016 |
Adverse drug reactions associated with antiretroviral therapy in South Africa.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dizziness; Exanthema; Female; Gynecomastia; HIV Infections; Humans; Lipodystrophy; Male; Middle Aged; Nevirapine; Peripheral Nervous System Diseases; Renal Insufficiency; Retrospective Studies; South Africa; Stavudine; Tenofovir; Zidovudine | 2016 |
Precision Medicine 2.0: The Next Wave of Science.
Topics: Africa South of the Sahara; Alkynes; Anemia, Sickle Cell; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Pharmacogenetics; Precision Medicine | 2016 |
Improved Adherence to Antiretroviral Therapy Observed Among HIV-Infected Children Whose Caregivers had Positive Beliefs in Medicine in Sub-Saharan Africa.
Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Attitude to Health; Benzoxazines; Caregivers; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; Humans; Infant; Lamivudine; Linear Models; Logistic Models; Male; Medication Adherence; Multivariate Analysis; Nevirapine; Randomized Controlled Trials as Topic; Stavudine; Surveys and Questionnaires; Uganda; Zambia; Zidovudine | 2017 |
Virological failure reduced with HIV-serostatus disclosure, extra baseline weight and rising CD4 cells among HIV-positive adults in Northwestern Uganda.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Weight; CD4-Positive T-Lymphocytes; Cohort Studies; Cyclopropanes; Disclosure; Female; HIV Infections; HIV Seropositivity; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Nevirapine; Retrospective Studies; Tenofovir; Treatment Outcome; Uganda | 2016 |
Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Models, Theoretical; Young Adult | 2017 |
Survival Outcomes in a Pediatric Antiretroviral Treatment Cohort in Southern Malawi.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Dideoxynucleotides; Female; HIV Infections; HIV Wasting Syndrome; Humans; Infant; Lamivudine; Malawi; Male; Proportional Hazards Models; Retrospective Studies; Rural Population; Stavudine; Survival Analysis; Tuberculosis, Pulmonary; Zidovudine | 2016 |
Development of a Qualitative Quantitative Polymerase Chain Reaction Test to Identify Patients Failing First-Line Therapy to Non-Nucleotide Reverse Transcriptase Inhibitor.
Topics: Alkynes; Benzoxazines; Costs and Cost Analysis; Cyclopropanes; Drug Monitoring; Drug Resistance, Viral; Genotyping Techniques; HIV Infections; Humans; Mutation, Missense; Nevirapine; Point Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Treatment Failure | 2017 |
Cases of antiretroviral-associated gynaecomastia reported to the National HIV & Tuberculosis Health Care Worker Hotline in South Africa.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Cyclopropanes; Gynecomastia; Health Personnel; HIV Infections; Hotlines; Humans; Male; Middle Aged; South Africa; Testosterone; Treatment Outcome | 2016 |
Protein expression from unintegrated HIV-1 DNA introduces bias in primary in vitro post-integration latency models.
Topics: Alkynes; Benzoxazines; CD4-Positive T-Lymphocytes; Cyclopropanes; DNA, Viral; Genes, Reporter; Green Fluorescent Proteins; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lymphocyte Activation; Models, Biological; Nevirapine; Primary Cell Culture; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Viral Proteins; Virus Integration; Virus Latency; Virus Replication | 2016 |
Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.
Topics: Adult; Africa South of the Sahara; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load | 2017 |
Triple Drug Combination of Zidovudine, Efavirenz and Lamivudine Loaded Lactoferrin Nanoparticles: an Effective Nano First-Line Regimen for HIV Therapy.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Benzoxazines; Cell Line, Tumor; Cyclopropanes; Drug Combinations; Female; Half-Life; HIV Infections; HIV-1; Humans; Lactoferrin; Lamivudine; Male; Nanoparticles; Rats; Rats, Wistar; Tissue Distribution; Zidovudine | 2017 |
Factors associated with seminal impairment in HIV-infected men under antiretroviral therapy.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Male; Prospective Studies; Semen Analysis; Sperm Count; Sperm Motility; Spermatozoa; Viral Load | 2017 |
Antiretroviral Treatment with Efavirenz Disrupts the Blood-Brain Barrier Integrity and Increases Stroke Severity.
Topics: Alkynes; Animals; Benzoxazines; Blood-Brain Barrier; Cell Line; Cyclopropanes; HIV Infections; Humans; Male; Mice; Severity of Illness Index; Stroke | 2016 |
Can voluntary pooled procurement reduce the price of antiretroviral drugs? a case study of Efavirenz.
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Costs and Cost Analysis; Cyclopropanes; Developing Countries; Drug Costs; Global Health; HIV Infections; Humans; Organizational Case Studies | 2017 |
Early virological failure and HIV drug resistance in Ugandan adults co-infected with tuberculosis.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Treatment Outcome; Tuberculosis; Uganda; Viral Load | 2017 |
Tolerability of central nervous system symptoms among HIV-1 infected efavirenz users: analysis of patient electronic medical record data.
Topics: Adult; Alkynes; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Electronic Health Records; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Young Adult | 2017 |
Confirmation of factors that influence antiretroviral regimen change and the subsequent patient outcomes at a Regional Hospital in rural KwaZulu-Natal.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; Hospitals; Humans; Lamivudine; Lipodystrophy; Male; Middle Aged; Retrospective Studies; Rural Population; South Africa; Stavudine; Tenofovir; Treatment Outcome; Tuberculosis; Viral Load; Young Adult | 2016 |
Impact of Antiretroviral Therapy on Liver Fibrosis Among Human Immunodeficiency Virus-Infected Adults With and Without HBV Coinfection in Zambia.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Coinfection; Cyclopropanes; Elasticity Imaging Techniques; Emtricitabine; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Liver; Liver Cirrhosis; Logistic Models; Male; Prospective Studies; Viral Load; Zambia | 2017 |
First-line antiretroviral drug discontinuations in children.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Follow-Up Studies; HIV; HIV Infections; Humans; Infant; Kaplan-Meier Estimate; Lopinavir; Outcome Assessment, Health Care; Proportional Hazards Models; Ritonavir; South Africa; Stavudine; Withholding Treatment; Zidovudine | 2017 |
Acute Kidney Injury After Efavirenz/Tenofovir Disoproxil Fumarate/Emtricitabine (Atripla) Overdose.
Topics: Acute Kidney Injury; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Tenofovir | 2017 |
Association of IL10, IL4, IFNG, and CTLA4 Gene Polymorphisms with Efavirenz Hypersensitivity Reaction in Patients Infected with Human Immunodeficiency Virus.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Case-Control Studies; CTLA-4 Antigen; Cyclopropanes; Drug Hypersensitivity; Female; Genetic Predisposition to Disease; HIV Infections; Humans; Immunologic Factors; Interferon-gamma; Interleukin-10; Interleukin-4; Male; Middle Aged; Polymorphism, Single Nucleotide; Young Adult | 2017 |
Sepsis Mimicker in an Human Immunodeficiency Virus-Infected Patient.
Topics: Alkynes; Anti-Bacterial Agents; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Drug Hypersensitivity Syndrome; Exanthema; Fever; HIV Infections; HIV-1; Humans; Male; Reverse Transcriptase Inhibitors; Tenofovir; Thrombocytopenia; Young Adult | 2017 |
Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Tolerance; Female; HIV Infections; HIV-1; Humans; Logistic Models; Male; Nevirapine; Patient Selection; Poisson Distribution; Proportional Hazards Models; Reverse Transcriptase Inhibitors; Senegal; Time Factors; Treatment Outcome; Viral Load | 2008 |
[Evaluation of antiretroviral therapy in HIV-infected adults in the Department of Haematology, University Hospital of Brazzavllle, Congo].
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Congo; Cyclopropanes; Didanosine; Drug Evaluation; Drug Therapy, Combination; Female; Hematology; HIV Infections; Hospital Departments; Hospitals, University; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Retrospective Studies; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cambodia; Cyclopropanes; Exanthema; Female; Hepatitis; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Retrospective Studies; Stevens-Johnson Syndrome; Young Adult | 2008 |
Human immunodeficiency virus-induced uveitis: intraocular and plasma human immunodeficiency virus-1 RNA loads.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Aqueous Humor; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Eye Infections, Viral; HIV Antibodies; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Polymerase Chain Reaction; RNA, Viral; Tenofovir; Uveitis, Anterior; Viral Load | 2008 |
FDA notifications. FDA grants tentative approval of generic efavirenz tablets.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drugs, Generic; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Tablets; United States; United States Food and Drug Administration | 2008 |
Pharmacy-refill measure of adherence to efavirenz can predict maintenance of HIV viral suppression.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Medical Records Systems, Computerized; Medication Adherence; Pharmacy Service, Hospital; Retrospective Studies; Reverse Transcriptase Inhibitors; Viral Load | 2008 |
Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy.
Topics: Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Dyslipidemias; Female; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Retrospective Studies; Simvastatin; Viral Load | 2008 |
Efavirenz in human breast milk, mothers', and newborns' plasma.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Feasibility Studies; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Milk, Human; Plasma; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies | 2008 |
Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Prednisolone; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir | 2008 |
Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Mutation, Missense; Nevirapine; Nitriles; Pyridazines; Pyrimidines | 2008 |
Status epilepticus resulting from severe efavirenz toxicity in an HIV-infected patient.
Topics: Alkynes; Benzoxazines; Blood Chemical Analysis; Cyclopropanes; Female; HIV Infections; Humans; Liver Cirrhosis; Middle Aged; Status Epilepticus | 2008 |
Efavirenz concentrations in HIV-infected patients with and without viral hepatitis.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Benzoxazines; Case-Control Studies; CD4 Lymphocyte Count; Cyclopropanes; Disease Progression; Dose-Response Relationship, Drug; Drug Monitoring; Female; Follow-Up Studies; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Liver Diseases; Male; Pilot Projects; Reverse Transcriptase Inhibitors; Severity of Illness Index; Treatment Outcome; Viral Load | 2008 |
Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Male; Nevirapine; Rifampin; South Africa; Treatment Failure; Treatment Outcome; Tuberculosis; Viral Load | 2008 |
Hepatotoxicity in patients prescribed efavirenz or nevirapine.
Topics: Adult; Alkynes; Benzoxazines; CD4-Positive T-Lymphocytes; Chemical and Drug Induced Liver Injury; Cyclopropanes; Female; Hepacivirus; Hepatitis B virus; HIV Infections; Humans; Liver; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Risk Factors | 2008 |
Severe psoriasis due to cessation of antiretroviral therapy in a patient with human immunodeficiency virus.
Topics: Alkynes; Anti-HIV Agents; Anti-Inflammatory Agents; Anti-Retroviral Agents; Antiviral Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Male; Middle Aged; Mometasone Furoate; Pregnadienediols; Psoriasis; Risk Factors; Treatment Refusal | 2008 |
Initial treatment of HIV-1 infection.
Topics: Alkynes; Benzoxazines; Cause of Death; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir | 2008 |
A case of human bite by an 11-year old HIV positive girl in a paediatrics ward.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Bites, Human; Child; Cyclopropanes; Female; HIV Infections; Humans; Inpatients; Lamivudine; Male; Zidovudine | 2008 |
Initial treatment of HIV-1 infection.
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lopinavir; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Failure | 2008 |
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Black People; Body Weight; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Viral Load; White People | 2008 |
The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Kidney Failure, Chronic; Lopinavir; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Pyrimidinones; Renal Dialysis; Reverse Transcriptase Inhibitors; Ritonavir | 2008 |
Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the CYP2B6 516 TT polymorphism.
Topics: Alkynes; Amino Acid Substitution; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Middle Aged; Mutation, Missense; Oxidoreductases, N-Demethylating; Polymorphism, Genetic; Sequence Analysis, DNA; Viral Load | 2008 |
Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.
Topics: Adult; Africa, Southern; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Evaluation; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Patient Compliance; Reverse Transcriptase Inhibitors; Treatment Failure; Treatment Outcome; Viral Load | 2008 |
Clinical manifestations and antiretroviral management of HIV/AIDS patients with tuberculosis co-infection in Kramat 128 Hospital.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Female; HIV Infections; Humans; Indonesia; Male; Middle Aged; Nevirapine; Outpatient Clinics, Hospital; Outpatients; Risk Factors; Treatment Outcome; Tuberculosis, Pulmonary | 2008 |
A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations.
Topics: Administration, Oral; Adolescent; Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Body Weight; Child; Child, Preschool; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Infant; Male; Oxidoreductases, N-Demethylating; Pharmacogenetics; Polymorphism, Genetic; Practice Guidelines as Topic | 2008 |
Slow efavirenz metabolism genotype is common in Botswana.
Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; Haplotypes; HIV Infections; Humans; Male; Middle Aged; Oxidoreductases, N-Demethylating | 2008 |
Efavirenz-rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients.
Topics: Adult; Alkynes; Antibiotics, Antitubercular; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Monitoring; Female; HIV Infections; Humans; Male; Middle Aged; Pharmacogenetics; Reverse Transcriptase Inhibitors; Rifampin; Treatment Outcome; Tuberculosis | 2008 |
Low trough levels of tipranavir in a combination antiretroviral therapy of tipranavir/ritonavir and tenofovir require therapeutic drug monitoring.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Monitoring; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; Humans; Organophosphonates; Peptide Fragments; Pyridines; Pyrones; Retrospective Studies; Ritonavir; Sulfonamides; Tenofovir | 2008 |
Raltegravir phase III study data released.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase III as Topic; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Multicenter Studies as Topic; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2008 |
Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nevirapine; Proviruses; Reverse Transcriptase Inhibitors; RNA, Viral | 2008 |
Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
Topics: Adenine; Alkynes; Alleles; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Mutation, Missense; Nevirapine; Organophosphonates; Plasma; Polymerase Chain Reaction; Selection, Genetic; Tenofovir; Treatment Failure | 2009 |
CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.
Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Therapy, Combination; Female; Geography; HIV Infections; HIV-1; Humans; India; Male; Middle Aged; Oxidoreductases, N-Demethylating; Polymorphism, Genetic; Rifampin; Tuberculosis | 2009 |
A prospective study evaluating clinical outcomes and costs of three NNRTI-based HAART regimens in Kerala, India.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; HIV-1; Hospitals, Teaching; Humans; India; Lamivudine; Male; Medication Adherence; Nevirapine; Prospective Studies; Stavudine; Treatment Outcome; Zidovudine | 2009 |
Head-to-head comparison of two first-line regimens and an NRTI-sparing regimen for initial therapy of HIV-1 infection: what should we start?
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Outcome | 2009 |
A paediatric case of acute liver failure associated with efavirenz-based highly active antiretroviral therapy and effective use of raltegravir in combination antiretroviral treatment after liver transplantation.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Cyclopropanes; HIV Infections; Humans; Liver Failure, Acute; Liver Transplantation; Pyrrolidinones; Raltegravir Potassium | 2009 |
Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C.
Topics: Adult; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Female; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Plasma; Severity of Illness Index | 2009 |
Successful genotype-tailored treatment with small-dose efavirenz.
Topics: Aged; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Administration Schedule; HIV Infections; Humans; Male; Oxidoreductases, N-Demethylating; Pharmacogenetics; Reverse Transcriptase Inhibitors | 2009 |
Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine.
Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Gene Frequency; HIV Infections; Humans; India; Male; Middle Aged; Nevirapine; Oxidoreductases, N-Demethylating; Plasma; Point Mutation; Polymorphism, Genetic; Young Adult | 2009 |
Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.
Topics: Adult; Aged; Alkynes; Alleles; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Body Weight; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Female; HIV Infections; Humans; Male; Middle Aged; Models, Biological; Nonlinear Dynamics; Oxidoreductases, N-Demethylating; Pharmacogenetics; Polymorphism, Genetic | 2009 |
Switch to Viramune safe for some who can't tolerate Sustiva.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Nevirapine; Reverse Transcriptase Inhibitors | 2008 |
Pregnancy among HIV-infected refugees in Rhode Island.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emigrants and Immigrants; Female; HIV Infections; Humans; Liberia; Middle Aged; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Refugees; Retrospective Studies; Rhode Island; Young Adult | 2009 |
[Atazanavir-induced nephrolithiasis].
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lopinavir; Male; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir | 2009 |
FDA notifications. Generic stavudine and efavirenz are tentatively approved by FDA.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Approval; Drugs, Generic; HIV Infections; Reverse Transcriptase Inhibitors; Stavudine; United States; United States Food and Drug Administration | 2008 |
The cost-effectiveness analysis of initiating HIV/AIDS treatment with efavirenz-based regimens compared with nevirapine-based regimens in Thailand.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cost-Benefit Analysis; Cyclopropanes; Female; HIV Infections; Humans; Male; Markov Chains; Middle Aged; Models, Economic; Nevirapine; Probability; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Thailand; Young Adult | 2008 |
Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Chi-Square Distribution; Cohort Studies; Cyclopropanes; Drug Hypersensitivity; Exanthema; Female; HIV Infections; Humans; Logistic Models; Male; Nevirapine; Retrospective Studies; Risk Factors; Statistics, Nonparametric; Viral Load | 2009 |
Report from the 2008 joint ICAAC/IDSA meeting. Raltegravir vs. efavirenz in treatment-naive patients.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; HIV Infections; HIV Integrase Inhibitors; Humans; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Viral Load | 2008 |
Report from the 2008 joint ICAAC/IDSA meeting. Maraviroc vs. efavirenz: a reanalysis of MERIT.
Topics: Alkynes; Benzoxazines; CCR5 Receptor Antagonists; Cyclohexanes; Cyclopropanes; HIV Infections; Humans; Maraviroc; Reverse Transcriptase Inhibitors; Triazoles | 2008 |
Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Botswana; CD4 Lymphocyte Count; Comorbidity; Cyclopropanes; Female; HIV; HIV Infections; Humans; Liver Function Tests; Male; Nevirapine; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Tuberculosis, Pulmonary | 2009 |
Proinflammatory cytokine changes in clinically stable, virologically suppressed, HIV-infected patients switching from protease inhibitors to abacavir.
Topics: Adiponectin; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; HIV Infections; Humans; Nevirapine; Receptors, Tumor Necrosis Factor, Type II | 2009 |
Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dizziness; Europe; Female; Headache; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Risk Factors; Sleep Initiation and Maintenance Disorders | 2009 |
The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Ethnicity; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine | 2009 |
CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
Topics: Adult; Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Gene Expression; HIV Infections; Humans; Male; Middle Aged; Oxidoreductases, N-Demethylating; Pilot Projects; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; Treatment Outcome; Young Adult | 2009 |
Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women.
Topics: Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Cohort Studies; Cyclopropanes; Dose-Response Relationship, Drug; Female; HIV Infections; Humans; Linear Models; Middle Aged; Multivariate Analysis; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Time Factors; Young Adult | 2009 |
Opsoclonus-myoclonus syndrome and HIV-infection.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Autoimmune Diseases of the Nervous System; Bell Palsy; Benzoxazines; Brain Stem; CD4-CD8 Ratio; Cerebellum; Cyclopropanes; Female; HIV Infections; Humans; Middle Aged; Opsoclonus-Myoclonus Syndrome; Paranoid Disorders; Prednisone; Psychoses, Substance-Induced; Puerperal Disorders; Recurrence; Tuberculosis, Meningeal; Tuberculosis, Pulmonary; Weight Loss | 2009 |
Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients.
Topics: Adenine; Alkynes; Amino Acid Substitution; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Genetic Variation; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Ribonuclease H, Human Immunodeficiency Virus; Stavudine; Tenofovir | 2009 |
Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Thymidine; Treatment Failure; Uganda | 2009 |
Efavirenz treatment and false-positive results in benzodiazepine screening tests.
Topics: Alkynes; Anti-HIV Agents; Benzodiazepines; Benzoxazines; Cyclopropanes; False Positive Reactions; HIV Infections; Humans; Substance Abuse Detection; Substance-Related Disorders; Urine | 2009 |
Efavirenz and nevirapine interactions with rifampicin: resolving the dilemmas?
Topics: Alkynes; Anti-Bacterial Agents; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; HIV Infections; Humans; Nevirapine; Rifampin; Tuberculosis | 2009 |
Interaction of Ginkgo biloba with efavirenz.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Interactions; Ginkgo biloba; HIV Infections; HIV-1; Humans; Male; Middle Aged; Plant Extracts | 2009 |
Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children.
Topics: Adolescent; Alkynes; Anti-Infective Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Gene Frequency; Genotype; HIV Infections; Humans; Male; Oxidoreductases, N-Demethylating; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; Thailand | 2009 |
The relationships of ABCB1 3435C>T and CYP2B6 516G>T with high-density lipoprotein cholesterol in HIV-infected patients receiving Efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; Cholesterol, HDL; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; Humans; Male; Middle Aged; Multivariate Analysis; Oxidoreductases, N-Demethylating; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors; Sex Factors; Time Factors | 2009 |
CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation.
Topics: Adult; Aged; Aged, 80 and over; Alkynes; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Black People; Cohort Studies; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Gene Frequency; Genotype; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Oxidoreductases, N-Demethylating; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors; United Kingdom; White People; Young Adult | 2009 |
Pharmacokinetics of plasma efavirenz and CYP2B6 polymorphism in southern Chinese.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; China; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Leukocytes, Mononuclear; Male; Oxidoreductases, N-Demethylating; Polymorphism, Genetic; Prescriptions | 2009 |
Comparison of side effects with 2 doses of the HIV drug efavirenz.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Mental Disorders; Middle Aged; Sample Size; Sleep Wake Disorders; Viral Load | 2009 |
Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis.
Topics: Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Cytokines; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Follow-Up Studies; HIV Infections; Humans; Immunization; Lamivudine; Longitudinal Studies; Male; Middle Aged; Mycobacterium tuberculosis; Nevirapine; Stavudine; T-Lymphocytes; Tuberculosis | 2009 |
Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Approval; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Europe; HIV Infections; Humans; Organophosphonates; Oxazines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2009 |
Raltegravir: a new choice in HIV and new chances for research.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Approval; Drug Evaluation; HIV Infections; Humans; Life Expectancy; Patient Selection; Prognosis; Pyrrolidinones; Raltegravir Potassium | 2009 |
CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti.
Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Base Sequence; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Haiti; Haplotypes; HIV Infections; Humans; Linkage Disequilibrium; Male; Oxidoreductases, N-Demethylating; Polymorphism, Genetic | 2009 |
Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin.
Topics: Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Body Weight; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Multivariate Analysis; Rifampin; Tuberculosis | 2009 |
[Regimen simplification: lopinavir/ritonavir with or without efavirenz].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Pyrimidinones; Ritonavir; Treatment Outcome; Viral Load; Viremia | 2009 |
Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Case-Control Studies; Central Nervous System Diseases; Cyclopropanes; Drug Administration Schedule; Drug Monitoring; HIV Infections; Humans; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Sleep Initiation and Maintenance Disorders | 2009 |
Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; Treatment Failure; Viral Load | 2009 |
CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.
Topics: Adult; Alkynes; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Black People; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Dose-Response Relationship, Drug; Female; Genotype; Ghana; Glucuronosyltransferase; HIV Infections; Humans; Male; Oxidoreductases, N-Demethylating; Polymorphism, Single Nucleotide; Predictive Value of Tests; Reverse Transcriptase Inhibitors | 2009 |
Application of an allele-specific PCR to clinical HIV genotyping samples detects additional K103N mutations in both therapy naïve and experienced patients.
Topics: Alkynes; Alleles; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genetic Variation; HIV; HIV Infections; Humans; Male; Molecular Diagnostic Techniques; Mutation, Missense; Polymerase Chain Reaction; RNA, Viral; Sensitivity and Specificity; Viral Load | 2009 |
Birth defects following exposure to efavirenz-based antiretroviral therapy during pregnancy: a study at a regional South African hospital.
Topics: Abnormalities, Drug-Induced; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Infant; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimesters; Prenatal Exposure Delayed Effects; Prevalence; Prospective Studies; South Africa; Ultrasonography, Prenatal | 2010 |
Hyperhidrosis in association with efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Hyperhidrosis; Male; Reverse Transcriptase Inhibitors; Treatment Outcome | 2009 |
Factors influencing lopinavir and atazanavir plasma concentration.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Body Weight; Cyclopropanes; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Plasma; Pyridines; Pyrimidinones; Rifabutin; United Kingdom | 2010 |
Satisfactory cross-cultural validity of the ACTG symptom distress module in HIV-1-infected antiretroviral-naive patients.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cultural Competency; Cyclohexanes; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Language; Male; Maraviroc; Middle Aged; Multicenter Studies as Topic; Psychometrics; Randomized Controlled Trials as Topic; Reproducibility of Results; Stress, Psychological; Surveys and Questionnaires; Triazoles; Zidovudine | 2009 |
NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cell Survival; Cells, Cultured; Cyclopropanes; HIV Core Protein p24; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Macrophages; Microscopy, Atomic Force; Monocytes; Nanoparticles; Ritonavir | 2009 |
Development of an allele-specific PCR for detection of the K65R resistance mutation in patients infected with subtype C human immunodeficiency virus type 1.
Topics: Alkynes; Alleles; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Nevirapine; Polymerase Chain Reaction; Zidovudine | 2010 |
Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Aryldialkylphosphatase; Benzoxazines; Black People; Cyclopropanes; Female; HIV Infections; Humans; Lipoproteins, HDL; Male; Middle Aged; Statistics as Topic; White People | 2009 |
Combination antiretroviral drugs in PLGA nanoparticle for HIV-1.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Carriers; Drug Combinations; Drug Compounding; HIV Infections; Humans; Lactic Acid; Lopinavir; Macrophages; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrimidinones; Ritonavir | 2009 |
Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability [corrected].
Topics: Administration, Oral; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Biological Availability; Child; Cyclopropanes; HIV Infections; Humans; Male; Micelles; Polyethylene Glycols; Polymers; Propylene Glycols; Rats; Rats, Wistar; Solubility | 2010 |
FDA notifications. Generic efavirenz/emtricitabine/fenofovir has tentative approval.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Approval; Drug Combinations; Drugs, Generic; Emtricitabine; HIV Infections; Humans; Organophosphonates; Tenofovir; United States; United States Food and Drug Administration | 2009 |
FDA notifications. Generic efavirenz capsules tentatively approved by FDA.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Approval; Drugs, Generic; HIV Infections; Humans; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 2009 |
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Proportional Hazards Models; Prospective Studies; Pyridines; Pyrimidinones; Risk Factors; Switzerland; Tenofovir; Zidovudine | 2010 |
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.
Topics: Adult; Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Case-Control Studies; Cohort Studies; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Mutation, Missense; Polymerase Chain Reaction; Randomized Controlled Trials as Topic; Treatment Failure | 2010 |
Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Genetic Variation; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation, Missense; Plasma; Polymerase Chain Reaction; Selection, Genetic; Sequence Analysis, DNA; Treatment Failure | 2010 |
A highly concentrated and taste-improved aqueous formulation of efavirenz for a more appropriate pediatric management of the anti-HIV therapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Dosage Forms; Drug Stability; Drug Storage; HIV Infections; Humans; Taste | 2010 |
HIV type 1 antiretroviral resistance mutations in subtypes B, C, and F in the City of São Paulo, Brazil.
Topics: Alkynes; Benzoxazines; Brazil; Cohort Studies; Cyclopropanes; Darunavir; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Nevirapine; Nitriles; Pyridazines; Pyridines; Pyrimidines; Pyrones; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Failure; Viral Load | 2010 |
Antiretroviral therapy and bone mineral measurements in HIV-infected youths.
Topics: Adolescent; Alkaline Phosphatase; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Density; Child; Child, Preschool; Cross-Sectional Studies; Cyclopropanes; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Reverse Transcriptase Inhibitors; Young Adult | 2010 |
Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; CD4 Antigens; CD4 Lymphocyte Count; Child; Child, Preschool; Cross-Sectional Studies; Cyclopropanes; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Male; Nevirapine; Predictive Value of Tests; Recurrence; RNA, Viral; Severity of Illness Index; Tanzania; Treatment Failure | 2010 |
Elvucitabine data released at CROI.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Cyclopropanes; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load; Zalcitabine | 2010 |
Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cells, Cultured; Cyclopropanes; Delayed-Action Preparations; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Immunohistochemistry; Macrophages; Microscopy, Confocal; Microscopy, Electron, Transmission; Nanoconjugates; Nanotechnology; Oligopeptides; Pyridines; Ritonavir | 2010 |
Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.
Topics: Adolescent; Adult; Aged; Alkynes; Atazanavir Sulfate; Atovaquone; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Proguanil; Pyridines; Pyrimidinones; Ritonavir; Young Adult | 2010 |
Analysis of RT sequences of subtype C HIV-type 1 isolates from indian patients at failure of a first-line treatment according to clinical and/or immunological WHO guidelines.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; India; Lamivudine; Molecular Sequence Data; Nevirapine; Polymorphism, Single Nucleotide; Stavudine; Treatment Failure; Zidovudine | 2010 |
Better health-related quality of life after switching from a virologically effective regimen to a regimen containing efavirenz or nevirapine.
Topics: Adult; Aged; Alkynes; Anxiety; Benzoxazines; Cyclopropanes; Depression; Female; France; Health Status; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Prospective Studies; Quality of Life; Reverse Transcriptase Inhibitors; Surveys and Questionnaires; Treatment Outcome; Viral Load; Young Adult | 2010 |
The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cells, Cultured; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutagenesis, Site-Directed; Mutation, Missense; RNA, Viral; Sequence Analysis, DNA; Virus Replication | 2010 |
Acute psychosis under efavirenz in a HIV patient.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Male; Psychotic Disorders; Reverse Transcriptase Inhibitors | 2010 |
Pharmacokinetics of the treatment switch from efavirenz to nevirapine.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Nevirapine | 2010 |
Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV.
Topics: Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Dose-Response Relationship, Drug; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Oxidoreductases, N-Demethylating; Polymorphism, Genetic; Time Factors; White People | 2010 |
Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
Topics: Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA Mutational Analysis; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mutation, Missense; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors | 2010 |
Human immunodeficiency virus-infection induces major changes in high-density lipoprotein particle size distribution and composition: the effect of antiretroviral treatment and disease severity.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4-Positive T-Lymphocytes; Chromatography, Gel; Cyclopropanes; Disease Progression; Female; HIV Infections; Humans; Lipoproteins, HDL; Male; Middle Aged; Particle Size | 2010 |
Breast enlargement in an HIV-infected man on combined antiretroviral therapy: what if it was carcinoma?
Topics: Alkynes; Benzoxazines; Breast Neoplasms, Male; Carcinoma, Intraductal, Noninfiltrating; Cyclopropanes; Didanosine; Drug Therapy, Combination; Gynecomastia; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors | 2010 |
Efavirenz plasma concentrations at 1, 3, and 6 months post-antiretroviral therapy initiation in HIV type 1-infected South African children.
Topics: Adolescent; Alkynes; Ambulatory Care; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Chromatography, Liquid; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Plasma; South Africa; Tandem Mass Spectrometry; Time Factors | 2010 |
Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Treatment Failure | 2010 |
[Protease inhibitor or non-nucleoside reverse transcriptase inhibitor. ACTG study 5202 in focus].
Topics: Adenine; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Lamivudine; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Randomized Controlled Trials as Topic; Tenofovir | 2010 |
[HIV-therapy-associated immune reconstitution syndrome presenting as immunogenic hyperthyroidism].
Topics: Adenine; Alkynes; Anti-HIV Agents; Autoantibodies; Benzoxazines; Cyclopropanes; Deoxycytidine; Diagnosis, Differential; Drug Therapy, Combination; Emtricitabine; Graves Disease; HIV Infections; HIV-1; Humans; Immune Reconstitution Inflammatory Syndrome; Long-Term Care; Male; Middle Aged; Organophosphonates; Tenofovir; Thyroid Gland; Thyroiditis, Autoimmune | 2010 |
Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Outcome; Vitamin D; Vitamin D Deficiency; Young Adult | 2010 |
FDA notifications. FDA tentatively approves efavirenz cross-scored tablets.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Approval; HIV Infections; Humans; Reverse Transcriptase Inhibitors; Tablets; United States; United States Food and Drug Administration | 2010 |
Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA.
Topics: Abnormalities, Drug-Induced; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Life Expectancy; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Risk Assessment; Risk Factors; Teratogens; United States | 2011 |
Recent FDA approvals and changes.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Capsules; Cyclopropanes; Dideoxynucleosides; Drug Approval; Drug Labeling; Drugs, Generic; HIV Infections; HIV Protease Inhibitors; Humans; Reverse Transcriptase Inhibitors; Tablets; United States; United States Food and Drug Administration; Zidovudine | 2010 |
Switching from efavirenz to nevirapine.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Nevirapine; Time Factors; Treatment Failure | 2010 |
Theoretical studies on the molecular basis of HIV-1RT/NNRTIs interactions.
Topics: Alkynes; Amino Acids; Benzoxazines; Binding Sites; Cyclopropanes; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Biological; Molecular Dynamics Simulation; Mutation; Nevirapine; Nitriles; Protein Binding; Protein Conformation; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Thermodynamics; Uracil; Water | 2011 |
Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase.
Topics: Adult; Alkaline Phosphatase; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Bone Remodeling; CD4 Lymphocyte Count; Cross-Sectional Studies; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; London; Male; Reverse Transcriptase Inhibitors; Vitamin D Deficiency | 2010 |
CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients.
Topics: Adult; Aged; Alkynes; Aryl Hydrocarbon Hydroxylases; Asian People; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; China; Chromatography, High Pressure Liquid; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Female; Gene Frequency; Genotype; HIV Infections; Humans; Male; Mass Spectrometry; Middle Aged; Nevirapine; Oxidoreductases, N-Demethylating; Polymorphism, Genetic; Reverse Transcriptase Inhibitors | 2010 |
Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Chile; Chromatography, Liquid; Cyclopropanes; Cytochrome P-450 CYP2B6; Haplotypes; HIV Infections; Humans; Mass Spectrometry; Middle Aged; Oxidoreductases, N-Demethylating; Plasma; Polymorphism, Single Nucleotide; Young Adult | 2010 |
No changes in efavirenz plasma concentrations in HIV-infected patients who switch from Stocrin to Atripla.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Organophosphonates; Oxazines; Plasma | 2010 |
The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Monitoring; Female; Genotype; HIV Infections; Humans; Male; Middle Aged; Oxidoreductases, N-Demethylating; Polymorphism, Genetic | 2010 |
Deleterious pharmacokinetic interaction between bexarotene and efavirenz.
Topics: Aged; Alkynes; Benzoxazines; Cyclopropanes; Drug Interactions; HIV Infections; Humans; Male; Mycosis Fungoides; Skin Neoplasms | 2010 |
FDA notifications. FDA approves efavirenz insert revisions.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Labeling; HIV Infections; Humans; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 2010 |
A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.
Topics: Alkynes; Argentina; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Europe; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Israel; Lopinavir; Male; Nevirapine; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2011 |
Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study.
Topics: Adult; Aged; Alkynes; Anti-Retroviral Agents; Benzoxazines; Case-Control Studies; Chromatography, High Pressure Liquid; Cross-Sectional Studies; Cyclopropanes; Dideoxynucleosides; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Lopinavir; Male; Middle Aged; Plasma; Pyrimidinones | 2010 |
[Two cases of Fanconi's syndrome induced by tenofovir in the Ivory Coast].
Topics: Adenine; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cote d'Ivoire; Cyclopropanes; Drug Therapy, Combination; Enterobacter aerogenes; Enterobacteriaceae Infections; Fanconi Syndrome; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Malaria; Male; Middle Aged; Organophosphonates; Pyelonephritis; Pyrimidinones; Ritonavir; Tenofovir | 2011 |
Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms.
Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Hispanic or Latino; HIV Infections; HIV Reverse Transcriptase; Humans; Male; Middle Aged; Oxidoreductases, N-Demethylating; Pilot Projects; Polymorphism, Genetic; Prospective Studies; Reverse Transcriptase Inhibitors; White People | 2010 |
Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.
Topics: Adult; Alkynes; Alleles; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Female; Gene Frequency; Genotype; Glucuronosyltransferase; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Male; Oxidoreductases, N-Demethylating; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Regression Analysis; Reverse Transcriptase Inhibitors | 2010 |
Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Multivariate Analysis; Nevirapine; Prospective Studies; Risk Factors; Sex Factors; Stavudine; Uganda; Zidovudine | 2011 |
Determination of salivary efavirenz by liquid chromatography coupled with tandem mass spectrometry.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Stability; HIV Infections; Humans; Linear Models; Reproducibility of Results; Reverse Transcriptase Inhibitors; Saliva; Sensitivity and Specificity; Tandem Mass Spectrometry | 2010 |
Evaluating patients for second-line antiretroviral therapy in India: the role of targeted viral load testing.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV; HIV Infections; Humans; India; Lamivudine; Male; Middle Aged; Nevirapine; RNA, Viral; Stavudine; Treatment Failure; Viral Load; Zidovudine | 2010 |
Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection.
Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Black People; Cyclopropanes; Cytochrome P-450 CYP2B6; Dose-Response Relationship, Drug; Female; Haplotypes; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxidoreductases, N-Demethylating; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors; Uganda; United Kingdom; Zimbabwe | 2010 |
A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Ill-Housed Persons; Male; Middle Aged; Organophosphonates; Patient Compliance; Tenofovir; Viral Load | 2010 |
Plasma efavirenz in HIV infected children treated with generic antiretroviral drugs in India.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Drugs, Generic; Female; HIV Infections; Humans; India; Male; Reverse Transcriptase Inhibitors | 2010 |
[Immune reconstitution inflammatory syndrome associated with eosinophilic pustular folliculitis in an HIV-infected patient].
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Diagnosis, Differential; Emtricitabine; Eosinophilia; Folliculitis; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Organophosphonates; Rosacea; Skin Diseases, Infectious; Tenofovir | 2011 |
Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire.
Topics: Abortion, Induced; Abortion, Spontaneous; Adult; Africa, Western; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Infant, Low Birth Weight; Infant, Newborn; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Retrospective Studies; Risk Assessment; Stillbirth | 2011 |
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Brain; Chromatography, High Pressure Liquid; Cyclopropanes; Female; HIV Infections; Humans; Inhibitory Concentration 50; Male; Middle Aged; Nervous System Diseases; Random Allocation; Viral Load | 2011 |
Easier said than done: World Health Organization recommendations for prevention of mother-to-child transmission of HIV-areas of concern.
Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Benzoxazines; Breast Feeding; CD4 Lymphocyte Count; Child; Cyclopropanes; Female; Flow Cytometry; Global Health; HIV; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Nevirapine; Policy; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious; Public Health | 2011 |
A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Neuropsychological Tests; Nitriles; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult | 2011 |
Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Retrospective Studies; Viral Load; Viremia | 2011 |
Adherence to HIV therapeutic drug monitoring guidelines in The Netherlands.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Guideline Adherence; HIV Infections; Humans; Lopinavir; Netherlands; Nevirapine; Pregnancy; Pyrimidinones; Randomized Controlled Trials as Topic | 2011 |
Aminotransferase serum levels decrease after initiating antiretroviral treatment in HIV infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Lopinavir; Male; Pyrimidinones; Ritonavir; Serum; Transaminases; Zidovudine | 2011 |
Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an Efavirenz-based regimen.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; Cyclopropanes; Female; HIV; HIV Infections; Humans; Male; Tuberculosis; Viral Load; Viremia | 2011 |
Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Clinical Trials, Phase II as Topic; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lopinavir; Nevirapine; Pyrimidinones; Randomized Controlled Trials as Topic; Retrospective Studies; Ritonavir; RNA, Viral; South Africa; Young Adult | 2011 |
[Study of meta-trajectories of CD4 cells count from taxonomy in the antiretroviral response of efavirenz-based regimen with naive symptomatic patients in Abidjan].
Topics: Adult; Algorithms; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Classification; Cote d'Ivoire; Cyclopropanes; Female; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Outcome | 2011 |
Minimum effective plasma concentration of efavirenz in treatment-naïve Chinese HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; China; Cyclopropanes; Female; HIV Infections; Humans; Male; Middle Aged; Plasma; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
[HIV infected women with intense bone and muscular pain and general weakness].
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Fanconi Syndrome; Female; Hepatitis, Viral, Human; HIV Infections; Humans; Hypophosphatemia; Middle Aged; Muscle Weakness; Musculoskeletal Diseases; Organophosphonates; Osteomalacia; Pain; Radionuclide Imaging; Radiopharmaceuticals; Substance Abuse, Intravenous; Technetium Tc 99m Medronate; Tenofovir | 2011 |
Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation, Missense; Nucleosides; RNA, Viral; Sequence Analysis, DNA | 2011 |
Efavirenz-based combination antiretroviral therapy after peripartum single-dose nevirapine.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Middle Aged; Nevirapine; Peripartum Period; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Treatment Outcome; Viral Load | 2011 |
In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.
Topics: Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Body Weight; Computer Simulation; Cyclopropanes; Cytochrome P-450 CYP2B6; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Forecasting; HIV Infections; Humans; Models, Theoretical; Oxidoreductases, N-Demethylating; Phenotype; Rifampin; Tuberculosis | 2011 |
Vitamin D deficiency in HIV-infected patients: associated with non-nucleoside reverse transcriptase inhibitor or efavirenz use?
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Reverse Transcriptase Inhibitors; Vitamin D Deficiency | 2011 |
Do nevirapine and efavirenz affect vitamin D homeostasis similarly?
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Nevirapine; Vitamin D | 2011 |
Is lower serum 25-hydroxy vitamin D associated with efavirenz or the non-nucleoside reverse transcriptase inhibitor class?
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Reverse Transcriptase Inhibitors; Vitamin D Deficiency | 2011 |
Interaction between antiretroviral drugs and acenocoumarol.
Topics: Acenocoumarol; Alkynes; Anti-HIV Agents; Anticoagulants; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Venous Thrombosis | 2011 |
Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Topics: Acute Disease; Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2011 |
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients.
Topics: Activities of Daily Living; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Case-Control Studies; Chi-Square Distribution; Cognition Disorders; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Male; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Retrospective Studies; Young Adult | 2011 |
Serum Nevirapine and Efavirenz concentrations and effect of concomitant rifampicin in HIV infected children on antiretroviral therapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cross-Sectional Studies; Cyclopropanes; Drug Interactions; Drug Monitoring; Female; HIV Infections; Humans; Male; Nevirapine; Rifampin | 2011 |
Targeted maximum likelihood estimation of effect modification parameters in survival analysis.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Female; HIV Infections; Humans; Likelihood Functions; Male; Nevirapine; Proportional Hazards Models; Sex Factors; Survival Analysis | 2011 |
[Efavirenz in fixed combination with tenofovir and emtricitabine. Long-term effectiveness verified in new studies].
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Medication Adherence; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2011 |
[Long-term therapy strategy with raltegravir. Appropriate in all illness phases].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Long-Term Care; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic | 2011 |
[Persistence in focus. Atazanavir proves itself anew in long-term therapy].
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; Humans; Long-Term Care; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic | 2011 |
Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages.
Topics: Alkynes; Benzoxazines; CD4-Positive T-Lymphocytes; Cells, Cultured; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Macrophages; Mutation; Pyrrolidinones; Raltegravir Potassium; Zidovudine | 2011 |
AIDS diarrhea and antiretroviral drug concentrations: a matched-pair cohort study in Port au Prince, Haiti.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Diarrhea; Female; Haiti; HIV Infections; HIV-1; Humans; Male; Matched-Pair Analysis; Prospective Studies; RNA, Viral; Viral Load | 2011 |
Absence seizures associated with efavirenz initiation.
Topics: Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Child, Preschool; Cyclopropanes; Cytochrome P-450 CYP2B6; Epilepsy, Absence; Female; Genetic Predisposition to Disease; Genotype; HIV; HIV Infections; Homozygote; Humans; Oxidoreductases, N-Demethylating; Polymorphism, Genetic; South Africa; Viral Load | 2011 |
The male genital tract is not a pharmacological sanctuary from efavirenz.
Topics: Adolescent; Adult; Albumins; Algorithms; Alkynes; Anti-HIV Agents; Benzoxazines; Centrifugation; Chromatography, High Pressure Liquid; Cyclopropanes; Dialysis; Genitalia, Male; HIV Infections; HIV-1; Humans; Male; Protein Binding; Reverse Transcriptase Inhibitors; Semen; Tandem Mass Spectrometry; Ultrafiltration; Young Adult | 2011 |
Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; Fertilization; HIV Infections; Humans; Middle Aged; Pregnancy; Pregnancy Complications, Infectious; Risk Factors; United Kingdom; Viral Load; Young Adult | 2011 |
Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Didanosine; Female; Hepatitis C; HIV Infections; Humans; Insulin Resistance; Lipodystrophy; Liver Cirrhosis; Male; Middle Aged; Mitochondria; Sex Factors; Stavudine | 2011 |
Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Cohort Studies; Cyclopropanes; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nephrolithiasis; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Ritonavir; Sulfonamides | 2011 |
Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Coinfection; Cyclopropanes; Female; Follow-Up Studies; HIV; HIV Infections; Hospitals, Public; Humans; Infant; Lopinavir; Male; Mycobacterium tuberculosis; Recurrence; Ritonavir; South Africa; Survival Analysis; Tuberculosis, Pulmonary; Viral Load | 2011 |
UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues.
Topics: Alkynes; Animal Structures; Animals; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; HIV Infections; Humans; Indinavir; Male; Mice; Mice, Inbred BALB C; Oligopeptides; Pyridines; Ritonavir; Tandem Mass Spectrometry | 2011 |
HIV/AIDS and the road to Rome.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Congresses as Topic; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Seropositivity; Humans; Malawi; Male; Nitriles; Pregnancy; Pregnancy Complications, Infectious; Primary Prevention; Public Health; Pyrimidines; Randomized Controlled Trials as Topic; Rilpivirine; Sexual Behavior; Sexual Partners; South Africa; Stereotyping; Treatment Outcome | 2011 |
Rilpivirine: a step forward in tailored HIV treatment.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase III as Topic; Cyclopropanes; Delavirdine; Deoxycytidine; Drug Design; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Multicenter Studies as Topic; Mutation; Nevirapine; Nitriles; Organophosphonates; Pyrimidines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Viral Load | 2011 |
Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Child; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Patient Satisfaction; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2012 |
Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation, Missense; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Virus Replication | 2011 |
Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; South Africa; Treatment Failure; Viral Load; Zidovudine | 2011 |
Simultaneous determination of efavirenz, rifampicin and its metabolite desacetyl rifampicin levels in human plasma.
Topics: Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Monitoring; Drug Stability; HIV Infections; Humans; Reference Standards; Reproducibility of Results; Rifampin; Sensitivity and Specificity; Tuberculosis | 2011 |
A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Middle Aged; Models, Molecular; Mutation; Nevirapine; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Risk Factors; Treatment Failure; Viral Load | 2011 |
Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Cytochrome P-450 CYP2B6; Enzyme Induction; Female; Genotype; Glucuronosyltransferase; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Male; Oxidoreductases, N-Demethylating; Sex Factors | 2011 |
The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA Mutational Analysis; Drug Resistance, Viral; Female; HIV Infections; Humans; Male; Middle Aged; Mutation; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Viral Load; Young Adult | 2012 |
Prevalence of etravirine-associated mutations in clinical samples with genotypic resistance to nevirapine and efavirenz in Brazilian clinics.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Brazil; Cyclopropanes; Drug Resistance, Viral; HIV; HIV Infections; Humans; Mutation, Missense; Nevirapine; Nitriles; Prevalence; Pyridazines; Pyrimidines | 2011 |
High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; Chemical and Drug Induced Liver Injury; Cohort Studies; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Female; Genotype; HIV Infections; Humans; Male; Oxidoreductases, N-Demethylating; Proportional Hazards Models; Prospective Studies | 2012 |
Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals.
Topics: Adult; Aged; Aging; Alkynes; Anti-HIV Agents; Benzoxazines; Body Weight; CD4 Lymphocyte Count; Cyclopropanes; Drug Monitoring; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Viral Load | 2011 |
Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Ritonavir; Transaminases | 2011 |
Oropharyngeal yeast colonization in HIV-infected outpatients in southern Taiwan: CD4 count, efavirenz therapy and intravenous drug use matter.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antifungal Agents; Benzoxazines; Candida; Candidiasis, Oral; CD4 Lymphocyte Count; Cross-Sectional Studies; Cyclopropanes; Female; Fluconazole; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oropharynx; Outpatients; Prospective Studies; Reverse Transcriptase Inhibitors; Substance Abuse, Intravenous; Taiwan; Young Adult | 2012 |
Multiple sclerosis typical clinical and MRI findings in a patient with HIV infection.
Topics: Adult; Age of Onset; Alkynes; Benzoxazines; Brain; CD4 Lymphocyte Count; Cyclopropanes; HIV Infections; Humans; Lamivudine; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Neuroimaging; Stavudine; Treatment Outcome; Viral Load | 2011 |
Neither proteinuria nor albuminuria is associated with endothelial dysfunction in HIV-infected patients without diabetes or hypertension.
Topics: Adenine; Adult; Albuminuria; Alkynes; Anti-HIV Agents; Benzoxazines; Brachial Artery; Chi-Square Distribution; Creatinine; Cyclopropanes; Dideoxynucleosides; Endothelium, Vascular; Female; Glomerular Filtration Rate; HIV Infections; Humans; Linear Models; Male; Middle Aged; Organophosphonates; Proteinuria; Tenofovir; Ultrasonography; Vasodilation | 2011 |
HAART induced adverse drug reactions: a retrospective analysis at a tertiary referral health care center in India.
Topics: Alkynes; Anemia; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Exanthema; Female; Gastritis; HIV Infections; Humans; India; Lamivudine; Male; Nevirapine; Peripheral Nervous System Diseases; Pharmacovigilance; Retrospective Studies; Severity of Illness Index; Sjogren's Syndrome; Stavudine | 2011 |
Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Condoms; Contraceptive Agents, Female; Cyclopropanes; Desogestrel; Drug Interactions; Female; HIV Infections; Humans; Pregnancy; Pregnancy, Unplanned | 2012 |
Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans.
Topics: Adult; Alkynes; Area Under Curve; Benzoxazines; Cyclopropanes; Female; Half-Life; HIV Infections; Humans; Male; Metabolic Clearance Rate; Middle Aged; Reverse Transcriptase Inhibitors; Uganda; Young Adult | 2012 |
Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bayes Theorem; Benzoxazines; Cluster Analysis; Cyclopropanes; Demography; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Models, Genetic; Molecular Sequence Data; Mutation; Nevirapine; Odds Ratio; Reverse Transcriptase Inhibitors; Treatment Failure | 2011 |
Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Coinfection; Cyclopropanes; Female; Hepatitis C; HIV Infections; Humans; Liver; Liver Cirrhosis; Male; Middle Aged | 2012 |
Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Biomarkers, Tumor; Case-Control Studies; Comorbidity; Cyclopropanes; Female; Genotype; HIV Infections; Humans; Liver; Male; Middle Aged; Pharmacogenetics; Prospective Studies; Rifampin; Time Factors; Tuberculosis | 2011 |
Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Viral Load | 2011 |
Costs and benefits of multidrug, multidose antiretroviral therapy for prevention of mother-to-child transmission of HIV in the Dominican Republic.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cost-Benefit Analysis; Cyclopropanes; Dominican Republic; Drug Administration Schedule; Drug Costs; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Zidovudine | 2012 |
Treatment challenges in co-infected HIV and TB children.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Nevirapine; Rifampin | 2011 |
Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Molecular Typing; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Failure; Viral Load | 2012 |
Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; South Africa; Stavudine; Viral Load | 2012 |
Risk factors for mortality among HIV-positive patients with and without active tuberculosis in Dar es Salaam, Tanzania.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Candidiasis, Oral; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; Coinfection; Cyclopropanes; Female; HIV Infections; Humans; Karnofsky Performance Status; Leukocyte Count; Male; Middle Aged; Risk Factors; Sarcoma, Kaposi; Tanzania; Tuberculosis | 2012 |
Prevalence of MDR1 C3435T and CYP2B6 G516T polymorphisms among HIV-1 infected South African patients.
Topics: Adolescent; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; CD4-Positive T-Lymphocytes; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Gene Frequency; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Oxidoreductases, N-Demethylating; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; South Africa; Stavudine; Viral Load; Young Adult | 2012 |
Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Blood Chemical Analysis; Cyclopropanes; Desiccation; Drug Monitoring; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Plasma; Specimen Handling | 2012 |
Prevalence of etravirine resistance associated mutations in HIV-1 strains isolated from infected individuals failing efavirenz: comparison between subtype B and non-B genetic variants.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Genotype; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Mutant Proteins; Mutation, Missense; Nitriles; Portugal; Prevalence; Pyridazines; Pyrimidines; Retrospective Studies; Treatment Failure | 2012 |
Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.
Topics: Adult; Alkynes; Alleles; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Monitoring; Female; Genotype; Haplotypes; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide | 2012 |
Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Exanthema; Female; HIV Infections; Humans; Incidence; Lamivudine; Male; Middle Aged; Nevirapine; Nigeria; Organophosphonates; Pain; Retrospective Studies; Risk Factors; Stavudine; Tenofovir; Zidovudine | 2012 |
Efavirenz dose reduction in HIV-infected patients.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Italy; Male; Middle Aged; Reverse Transcriptase Inhibitors | 2012 |
Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age.
Topics: Abnormalities, Drug-Induced; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Computer Simulation; Cote d'Ivoire; Cyclopropanes; Female; HIV Infections; Humans; Nevirapine; Prognosis; Risk Assessment; Survival Rate | 2012 |
Safety and effectiveness of efavirenz versus nevirapine-based regimens in resource-limited settings: evidence, clinical practice and modelling projections.
Topics: Abnormalities, Drug-Induced; Alkynes; Anti-HIV Agents; Benzoxazines; Computer Simulation; Cyclopropanes; Female; HIV Infections; Humans; Nevirapine | 2012 |
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.
Topics: Adenine; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2012 |
Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genetic Markers; Genotype; HIV Infections; Humans; Male; Middle Aged; Oxidoreductases, N-Demethylating; Pharmacogenetics; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Retrospective Studies; Thailand; Young Adult | 2012 |
Mid-dosing interval efavirenz plasma concentrations in HIV-1-infected children in Rwanda: treatment efficacy, tolerability, adherence, and the influence of CYP2B6 polymorphisms.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Gene Frequency; HIV Infections; HIV-1; Humans; Male; Oxidoreductases, N-Demethylating; Plasma; Polymorphism, Genetic; Rwanda; Treatment Outcome; Viral Load | 2012 |
Severe efavirenz-induced vacuolar axonopathy complicated by fatal aspiration pneumonia.
Topics: Adult; Alkynes; Anti-HIV Agents; Axons; Benzoxazines; Cyclopropanes; Disorders of Excessive Somnolence; Dose-Response Relationship, Drug; Fatal Outcome; HIV Infections; Humans; Male; Pneumonia, Aspiration; South Africa; Zimbabwe | 2012 |
Susceptibility to etravirine of HIV type 1 subtype C isolates from nevirapine/efavirenz-experienced patients: comparative interpretation of ANRS and STANFORD algorithms.
Topics: Alkynes; Amino Acid Sequence; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; HIV Infections; HIV Integrase; HIV-1; Humans; Molecular Sequence Data; Mozambique; Nevirapine; Nitriles; Proviruses; Pyridazines; Pyrimidines; Sequence Analysis, DNA | 2012 |
Assessing the effectiveness of antiretroviral regimens in cohort studies involving HIV-positive injection drug users.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Substance Abuse, Intravenous; Treatment Outcome; Viral Load | 2012 |
High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Cross-Sectional Studies; Cyclopropanes; Female; France; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Vitamin D Deficiency | 2012 |
Case report of cytomegalovirus retinitis in an HIV-positive patient with a CD4-count nadir of 254 cells per μl.
Topics: Adenine; Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Aqueous Humor; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Cytomegalovirus; Cytomegalovirus Retinitis; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Male; Organophosphonates; Polymerase Chain Reaction; Tenofovir; Visual Acuity | 2012 |
Patient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovir.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cross-Sectional Studies; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Health Status; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Quality of Life; Severity of Illness Index; Tenofovir; Treatment Outcome; Veterans | 2012 |
Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naive HIV patients.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir | 2012 |
Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cloning, Molecular; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine | 2012 |
Immunological characterisation of an unmasking TB-IRIS case.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Cytokines; Female; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Male; Opportunistic Infections; Stavudine; Thymic Factor, Circulating; Tuberculosis, Pulmonary | 2012 |
Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval.
Topics: Alkynes; Anti-HIV Agents; Antifungal Agents; Area Under Curve; Benzoxazines; Chromatography, High Pressure Liquid; Coinfection; Cryptococcus neoformans; Cyclopropanes; Half-Life; HIV; HIV Infections; Humans; Male; Meningitis, Cryptococcal; Middle Aged; Tandem Mass Spectrometry | 2012 |
Response to valacyclovir in an HIV-infected girl with Epstein Barr infection.
Topics: Acyclovir; Alkynes; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; Child; Cyclopropanes; Epstein-Barr Virus Infections; Female; HIV Infections; Humans; Lamivudine; Valacyclovir; Valine; Zidovudine | 2012 |
Efavirenz-induced exfoliative dermatitis.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dermatitis, Exfoliative; HIV Infections; Humans; Male | 2013 |
Efavirenz and psychosis: is there a link?
Topics: Adenine; Adult; Alkynes; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Male; Organophosphonates; Oxazines; Psychoses, Substance-Induced; Reverse Transcriptase Inhibitors | 2012 |
Efavirenz conceptions and regimen management in a prospective cohort of women on antiretroviral therapy.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Substitution; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Pregnancy; Pregnancy Rate; Pregnancy Trimester, First; Prospective Studies; South Africa; Young Adult | 2012 |
Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Caco-2 Cells; Cohort Studies; Cyclopropanes; Dose-Response Relationship, Drug; Female; HIV Infections; Humans; Male; Middle Aged; Models, Chemical; Young Adult | 2012 |
Nevirapine- and efavirenz-associated hepatotoxicity under programmatic conditions in Kenya and Mozambique.
Topics: Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Clinical Protocols; Cyclopropanes; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Kenya; Male; Mozambique; Nevirapine; Odds Ratio; Retrospective Studies; Risk Factors | 2012 |
Virological evidence supporting the use of raltegravir in HIV post-exposure prophylaxis regimens.
Topics: Alkynes; Benzoxazines; CD4-Positive T-Lymphocytes; Cyclopropanes; Gene Expression Regulation, Viral; Genes, Reporter; Genes, Viral; HIV; HIV Infections; HIV Integrase Inhibitors; Humans; Luciferases; Macrophages; Microbial Sensitivity Tests; Post-Exposure Prophylaxis; Pyrrolidinones; Raltegravir Potassium; Time Factors | 2012 |
Connection domain mutations during antiretroviral treatment failure in Mali: frequencies and impact on reverse transcriptase inhibitor activity.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Binding Sites; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mali; Mutation; Nevirapine; Phenotype; Treatment Failure | 2012 |
[A single tablet against HIV: new combination preparation improves therapy].
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Cobicistat; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Glomerular Filtration Rate; HIV Infections; Humans; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Randomized Controlled Trials as Topic; Ritonavir; Tenofovir; Thiazoles; Viral Load | 2012 |
Efavirenz in an obese HIV-infected patient--a report and an in vitro-in vivo extrapolation model indicate risk of underdosing.
Topics: Alkynes; Benzoxazines; Body Mass Index; Computer Simulation; Cyclopropanes; Drug Dosage Calculations; Drug Monitoring; HIV; HIV Infections; Humans; Male; Middle Aged; Obesity; Reverse Transcriptase Inhibitors; Risk Factors; RNA, Viral; Viral Load | 2012 |
HIV-1 RNA may decline more slowly in semen than in blood following initiation of efavirenz-based antiretroviral therapy.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Gene Expression Regulation, Viral; HIV Infections; HIV-1; Humans; Kenya; Male; Models, Genetic; RNA, Viral; Semen; Statistics, Nonparametric | 2012 |
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Italy; Longitudinal Studies; Lopinavir; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Retrospective Studies; Ritonavir; Tenofovir; Time Factors | 2013 |
[The pillars of modern HIV therapy: effectiveness, tolerance, compatibility].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; Humans; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome | 2012 |
A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women.
Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Hair; HIV Infections; Humans; Middle Aged; Oxidoreductases, N-Demethylating; Plasma; Polymorphism, Single Nucleotide; Young Adult | 2012 |
Correlation of CYP2B6-516G > T Polymorphism with Plasma Efavirenz Concentration and Depression in HIV-Infected Adults in Northern Thailand.
Topics: Adult; Alkynes; Alleles; Analysis of Variance; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Cytochrome P-450 CYP2B6; Depression; Female; Genotype; HIV Infections; Humans; Male; Middle Aged; Oxidoreductases, N-Demethylating; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors; Thailand | 2012 |
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
Topics: Adenine; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; Glomerular Filtration Rate; Glycosuria; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Proteinuria; Pyridines; Retrospective Studies; Ritonavir; Tenofovir | 2013 |
Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cerebrospinal Fluid; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Plasma; Pyridines; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study.
Topics: Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Endothelium, Vascular; Female; Fibroblast Growth Factor-23; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Reverse Transcriptase Inhibitors; Viral Load | 2012 |
Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Carriers; Drug Evaluation, Preclinical; Gels; HeLa Cells; HIV Infections; HIV-1; Humans; Lactic Acid; Microbial Sensitivity Tests; Nanoparticles; Phagocytosis; Poloxamer; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrrolidinones; Raltegravir Potassium; Temperature; Time Factors | 2012 |
Effect of efavirenz versus nevirapine in antiretroviral-naive individuals in the HIV-CAUSAL Collaboration Cohort.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Hepatitis C; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors | 2012 |
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.
Topics: Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Clinical Protocols; Cyclopropanes; Cytochrome P-450 CYP2B6; Genetic Association Studies; Genetic Variation; Genome-Wide Association Study; Genome, Human; HIV Infections; Humans; Oxidoreductases, N-Demethylating; Polymorphism, Genetic | 2012 |
Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP3A; Enzyme Induction; Female; HIV Infections; Humans; Male; Prospective Studies; Reverse Transcriptase Inhibitors | 2013 |
Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Retrospective Studies; Risk Factors; South Africa; Stavudine; Time Factors | 2013 |
Intranasal administration of antiretroviral-loaded micelles for anatomical targeting to the brain in HIV.
Topics: Administration, Intranasal; Alkynes; Animals; Benzoxazines; Cyclopropanes; HIV Infections; Male; Micelles; Polyethylenes; Polypropylenes; Rats; Rats, Wistar; Reverse Transcriptase Inhibitors | 2013 |
PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alkynes; Benzoxazines; Black People; Constitutive Androstane Receptor; Cyclopropanes; Gene Frequency; Haplotypes; HIV Infections; Humans; Middle Aged; Polymorphism, Single Nucleotide; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid | 2012 |
The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Monitoring; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nevirapine; Oligopeptides; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors | 2013 |
Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-Retroviral Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Coinfection; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Nevirapine; Nigeria; Organophosphorus Compounds; RNA, Viral; Stavudine; Zidovudine | 2013 |
Rilpivirine. First-line treatment of HIV infection: efavirenz is better documented.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Resistance, Viral; HIV Infections; Humans; Nitriles; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Viral Load | 2012 |
Plasma concentrations of efavirenz with a 600 mg standard dose in Cambodian HIV-infected adults treated for tuberculosis with a body weight above 50 kg.
Topics: Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Body Weight; Coinfection; Cyclopropanes; HIV Infections; Humans; Tuberculosis; Viral Load | 2013 |
[Efficacy and tolerance of tenofovir-lamivudine-efavirenz combination in HIV-1 patients in Fann Teaching Hospital in Dakar].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Hospitals, Teaching; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Senegal; Tenofovir; Treatment Outcome | 2013 |
Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Ethambutol; Female; Genotype; HIV Infections; Humans; Isoniazid; Lamivudine; Male; Middle Aged; Organophosphonates; Oxidoreductases, N-Demethylating; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrazinamide; Reverse Transcriptase Inhibitors; Rifampin; Tenofovir; Tuberculosis; Young Adult | 2013 |
Pharmacological assessment of efavirenz weight-band dosing recommendations in HIV-infected Thai children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Body Weight; Child; Child, Preschool; Cyclopropanes; Female; HIV Infections; Humans; Male; Thailand | 2013 |
Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Gene Dosage; Genotype; HIV Infections; HIV-1; Humans; Male; Multivariate Analysis; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; Treatment Failure | 2013 |
Tenofovir, emtricitabine intracellular and plasma, and efavirenz plasma concentration decay following drug intake cessation: implications for HIV treatment and prevention.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Female; Half-Life; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Organophosphonates; Tandem Mass Spectrometry; Tenofovir; Young Adult | 2013 |
Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4-Positive T-Lymphocytes; Cell Line; Cell Survival; Cyclopropanes; Drug Therapy, Combination; HeLa Cells; HIV Infections; HIV-1; Humans; Lactic Acid; Lopinavir; Microscopy, Confocal; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Subcellular Fractions; U937 Cells | 2013 |
Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Kinetics; Predictive Value of Tests; Protein Binding; Semen; Serum Albumin | 2013 |
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cost-Benefit Analysis; Cyclopropanes; Deoxycytidine; Drug Combinations; Drugs, Generic; Emtricitabine; Female; HIV Infections; Humans; Male; Models, Theoretical; Organophosphonates; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Tenofovir; United States | 2013 |
Effectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Coinfection; Cyclopropanes; Female; HIV Infections; Humans; Male; Treatment Failure; Treatment Outcome; Tuberculosis; Viral Load | 2013 |
Cost-effectiveness of efavirenz vs rilpivirine in HIV patients initiating first-line combination antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; HIV Infections; Humans; Life Expectancy; Markov Chains; Models, Economic; Nitriles; Pyrimidines; Reproducibility of Results; Reverse Transcriptase Inhibitors; Rilpivirine | 2013 |
High plasma efavirenz concentration and CYP2B6 polymorphisms in Thai HIV-1 infections.
Topics: Adult; Alkynes; Aryl Hydrocarbon Hydroxylases; Asian People; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; HIV Infections; Humans; Polymorphism, Single Nucleotide; Thailand | 2013 |
Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Disease Susceptibility; Ethnicity; Exanthema; Female; HIV Infections; Humans; Male; Oxazines; Reverse Transcriptase Inhibitors; Sex Characteristics; Treatment Outcome | 2002 |
NNRTIs compared in switch group.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Nevirapine; Oxazines; Randomized Controlled Trials as Topic; Treatment Outcome; Viral Load | 2002 |
Extent and importance of cross-resistance to efavirenz after nevirapine failure.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; Humans; Male; Nevirapine; Oxazines; Prospective Studies; Treatment Failure | 2002 |
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Mutation; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral | 2002 |
Efavirenz-associated severe hyperlipidemia.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Hyperlipidemias; Male; Oxazines | 2002 |
HIV and refractory anemia with excess blasts (RAEB).
Topics: Adult; Alkynes; Anemia, Refractory, with Excess of Blasts; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Lamivudine; Male; Oxazines; Pancytopenia; Pneumonia; Stavudine; Treatment Outcome | 2002 |
Efavirenz-induced catatonia.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Catatonia; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors | 2002 |
Simultaneous determination of rifampicin and efavirenz in plasma.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; HIV Infections; Humans; Male; Middle Aged; Oxazines; Rifampin; Tuberculosis | 2002 |
Intravenous drug users risk group should also benefit from simpler highly active antiretroviral therapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Case-Control Studies; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Substance Abuse, Intravenous | 2002 |
Development of drug resistance in HIV-1 patients receiving a combination of stavudine, lamivudine and efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Genes, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Oxazines; RNA, Viral; Stavudine; Viral Load; Viremia | 2002 |
Virologic outcomes of complex drug regimens for human immunodeficiency virus.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Treatment Failure; Viral Load | 2002 |
Therapeutic responses to AZT + 3TC + EFV in advanced antiretroviral naive HIV type 1-infected Ugandan patients.
Topics: Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Patient Compliance; Reverse Transcriptase Inhibitors; Uganda; Viral Load; Zidovudine | 2002 |
Straight talk from DuPont on Sustiva.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Industry; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; Suicide; United States; United States Food and Drug Administration | 2000 |
Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Anxiety Disorders; Benzoxazines; Cognition Disorders; Cyclopropanes; Depressive Disorder; Female; Follow-Up Studies; HIV Infections; Humans; Male; Mental Disorders; Middle Aged; Mood Disorders; Oxazines; Quality of Life; Sleep Wake Disorders; Surveys and Questionnaires | 2003 |
Efavirenz effects worse than reported, study says.
Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors | 2003 |
Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Bayes Theorem; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; Treatment Failure | 2003 |
Efavirenz-induced psychosis leading to involuntary detention.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Commitment of Mentally Ill; Cyclopropanes; HIV Infections; Humans; Male; Oxazines; Psychoses, Substance-Induced | 2003 |
Chronic cough induced by abacavir apart from a context of hypersensitivity.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chronic Disease; Cough; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Middle Aged; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Rhinitis; Sputum; Stavudine; Trimethoprim, Sulfamethoxazole Drug Combination | 2002 |
[Simple, safe and effective. New protease inhibitor means progress].
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Oxazines; Pyridines | 2002 |
Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antidepressive Agents, Second-Generation; Benzoxazines; Bupropion; Cyclopropanes; Drug Therapy, Combination; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Oxazines; Retrospective Studies; Ritonavir; Seizures | 2003 |
Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
Topics: Age Factors; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cholesterol, HDL; Cholesterol, LDL; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Treatment Outcome; Triglycerides | 2003 |
Hypersensitivity to efavirenz treated with corticosteroids in a 6-year-old child.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; Humans; Hypersensitivity; Oxazines; Prednisone; Reverse Transcriptase Inhibitors | 2003 |
[Highly effective and tolerable protease inhibitor. New trump card against HIV].
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Oxazines; Pyridines; Treatment Outcome; Viral Load | 2003 |
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.
Topics: Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Biotransformation; Catalysis; Cyclopropanes; Cytochrome P-450 CYP2B6; HIV; HIV Infections; Humans; Microsomes, Liver; Oxazines; Oxidoreductases, N-Demethylating; Recombinant Proteins | 2003 |
Swiss study switching to efavirenz.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; Switzerland; Viral Load | 2002 |
Comparing liver toxicity between efavirenz and nevirapine.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; Humans; Male; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Viral Load | 2002 |
[Efficacy of efavirenz in a mixed population of patients. Identification of drop-out causes].
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Eruptions; Drug Evaluation; Female; HIV Infections; Humans; Male; Mental Disorders; Middle Aged; Oxazines; Patient Dropouts; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2002 |
Report from the Tenth Retrovirus Conference. Comparing efavirenz and nevirapine: the 2NN study.
Topics: Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; HIV Infections; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 2003 |
Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nevirapine; Oxazines; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome | 2003 |
[Measuring the HIV viral load with LCx (Abbott): importance for the therapeutic follow-up of 3 patients infected by type O HIV].
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Oxazines; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Viral Load; Viremia; Zidovudine | 2003 |
[Decrease of HIV-1 virus load by nevirapin/efavirenz].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Nevirapine; Oxazines; Treatment Outcome; Viral Load | 2003 |
[ACTG-study 5095: superiority of efavirenz containing drug scheme].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; HIV Infections; Humans; Oxazines; Treatment Outcome | 2003 |
Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load | 2003 |
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 2003 |
Photodermatitis in a patient with HIV infection.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Eruptions; Female; HIV Infections; Humans; Oxazines; Photosensitivity Disorders | 2003 |
Recurrence of post-traumatic stress disorder symptoms after initiation of antiretrovirals including efavirenz: a report of two cases.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Male; Middle Aged; Oxazines; Recurrence; Refugees; Reverse Transcriptase Inhibitors; Stress Disorders, Post-Traumatic; Zidovudine | 2003 |
Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography.
Topics: Alkynes; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; HIV Infections; HIV-1; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 2003 |
Experience with efavirenz in end-stage renal disease.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Kidney Failure, Chronic; Oxazines; Peritoneal Dialysis, Continuous Ambulatory | 2003 |
Nucleoside-free regimen tested.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Oxazines; Ritonavir; Thailand; Viral Load | 2003 |
Factors associated with maintenance of long-term plasma human immunodeficiency virus RNA suppression.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Case-Control Studies; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Male; Outpatients; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load | 2003 |
NIAID comments on AACTG Study A5095.
Topics: Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; HIV Infections; Humans; National Institutes of Health (U.S.); Oxazines; Reverse Transcriptase Inhibitors; United States | 2003 |
[Use of antiretroviral drugs in HIV infected children in a tropical area: a real benefit].
Topics: Adolescent; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cohort Studies; Comorbidity; Cote d'Ivoire; Cyclopropanes; Developing Countries; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Male; Malnutrition; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Treatment Outcome | 2003 |
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Female; Hepatitis B; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Liver; Liver Diseases; Male; Nevirapine; Oxazines; Prevalence; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Risk Factors; Thailand | 2003 |
Efavirenz-containing highly active antiretroviral therapy in an HIV-infected patient with myasthenia gravis.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Male; Myasthenia Gravis; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral | 2003 |
Treating advanced HIV infection.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Male; Oxazines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load | 2003 |
Does prior short-course nevirapine reduce the effectiveness of subsequent combination treatment with efavirenz?
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Longitudinal Studies; Male; Middle Aged; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 2003 |
Triple combinations regimens for HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Organophosphonates; Organophosphorus Compounds; Oxazines; Randomized Controlled Trials as Topic; Tenofovir; Treatment Failure | 2003 |
Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients.
Topics: Adult; Alanine Transaminase; Alcoholism; Alkynes; Anti-HIV Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C Antibodies; Hepatitis C, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Liver Diseases; Male; Multivariate Analysis; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Risk; Risk Factors; Transaminases | 2003 |
Genotypic resistance profile in treatment-experienced HIV-infected individuals after abacavir and efavirenz salvage regimen.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; Genotype; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Oxazines; Salvage Therapy; Time Factors | 2004 |
Substitution for protease inhibitors in HIV therapy.
Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; Humans; Nevirapine; Oxazines; Patient Dropouts; Reverse Transcriptase Inhibitors; Substance Abuse, Intravenous | 2003 |
Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Delavirdine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nevirapine; Oxazines; Prejudice; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome | 2003 |
Atazanavir sulphate.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Oxazines; Pyridines; Randomized Controlled Trials as Topic; Structure-Activity Relationship | 2003 |
No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; Cyclopropanes; Female; Genotype; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oxazines; Polymorphism, Genetic; Pyrimidinones; Retrospective Studies | 2003 |
Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Didanosine; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine; Oxazines; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome | 2003 |
Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Electroencephalography; Female; HIV Infections; Humans; Male; Oxazines; Reverse Transcriptase Inhibitors; Sleep Initiation and Maintenance Disorders; Sleep Stages; Sleep Wake Disorders | 2004 |
Treatment of primary HIV-1 infection with nonnucleoside reverse transcriptase inhibitor-based therapy is effective and well tolerated.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4-CD8 Ratio; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Flow Cytometry; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Activation; Lymphocyte Subsets; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2004 |
A case-control study of gynecomastia in HIV-1-infected patients receiving HAART.
Topics: Adult; Aged; Alkynes; Analysis of Variance; Antiretroviral Therapy, Highly Active; Benzoxazines; Case-Control Studies; CD4 Lymphocyte Count; Cyclopropanes; Gynecomastia; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Logistic Models; Male; Middle Aged; New York City; Oxazines; Risk Factors; Testosterone; Time Factors; Treatment Outcome | 2004 |
Experience with efavirenz in end-stage renal disease.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; Humans; Kidney Failure, Chronic; Male; Oxazines; Reverse Transcriptase Inhibitors; Viral Load | 2004 |
[A "once daily" drug that with proven effectiveness. Efavirenz has successful outcome also in direct comparisons].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; HIV Infections; Humans; Nevirapine; Oxazines; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
[Highly effective drug without modifying the lipid profile. Atazanavir, the protease inhibitor for "once daily" administration].
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Lipids; Nelfinavir; Oligopeptides; Oxazines; Pyridines | 2003 |
Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection.
Topics: Adolescent; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Male; Nevirapine; Oxazines; Retrospective Studies; Treatment Failure; Treatment Outcome | 2004 |
Virological and immunological outcomes in HIV-1-infected Chinese patients treated with a combination of Efavirenz and Indinavir for 48 weeks.
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Adult; Aged; Alkynes; Anti-HIV Agents; Antigens, CD; Benzoxazines; CD4-CD8 Ratio; Chronic Disease; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; HLA-DR Antigens; Humans; Indinavir; Male; Membrane Glycoproteins; Middle Aged; Oxazines; Viral Load | 2004 |
Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genetic Variation; HIV Infections; HIV-1; Humans; Male; Mutation; Nevirapine; Nucleosides; Oxazines; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; RNA, Viral | 2004 |
Tenofovir-related nephrotoxicity in HIV-infected patients.
Topics: Acute Kidney Injury; Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Oxazines; Tenofovir | 2004 |
Safe substitution for efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; HIV Infections; Humans; Hyperlipidemias; Nevirapine; Oxazines; Patient Selection; Retrospective Studies; Treatment Outcome; Viral Load | 2004 |
Antiretroviral therapy for previously untreated HIV-1-infected adults: 2NN, or just one?
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 2004 |
Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oxazines; Retrospective Studies; Reverse Transcriptase Inhibitors | 2004 |
Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Forecasting; Guideline Adherence; HIV; HIV Infections; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Nevirapine; Oxazines; Treatment Failure; Viral Load | 2004 |
Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.
Topics: Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Gene Frequency; Genotype; HIV Infections; HIV-1; Oxazines; Oxidoreductases, N-Demethylating; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; Statistics as Topic | 2004 |
Genes, ethnicity, and efavirenz response: clinical pharmacology update from the 11th CROI.
Topics: Alkynes; Area Under Curve; Benzoxazines; Body Weight; Cyclopropanes; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Ethnicity; Female; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oxazines; Pharmacogenetics; Reverse Transcriptase Inhibitors; Sex Factors | 2004 |
Factors associated with efavirenz discontinuation in a large community-based sample of patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cross-Sectional Studies; Cyclopropanes; Depression; Female; France; HIV Infections; Humans; Logistic Models; Male; Odds Ratio; Oxazines; Patient Acceptance of Health Care; Surveys and Questionnaires; Treatment Refusal | 2004 |
HIV/AIDS news: comparable anti-HIV antiviral efficacy of Viramune and Efavirenz--the Lancet publishes first large-scale comparison study.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Multicenter Studies as Topic; Nevirapine; Oxazines; Randomized Controlled Trials as Topic; Research Design; Reverse Transcriptase Inhibitors; Treatment Outcome | 2004 |
Triple-nucleoside regimens versus efavirenz.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Oxazines; Research Design; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2004 |
Triple-nucleoside regimens versus efavirenz.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Oxazines; Patient Compliance; Reverse Transcriptase Inhibitors; Zidovudine | 2004 |
Genetic correlates of efavirenz hypersusceptibility.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Genotype; HIV Infections; Humans; Mutation; Oxazines; Phenotype; Reverse Transcriptase Inhibitors; Risk Factors; Virus Replication | 2004 |
Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; Humans; Male; Nelfinavir; Nevirapine; Oxazines; Prospective Studies; Viral Load | 2004 |
Photosensitive drug eruption induced by efavirenz in a patient with HIV infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dermatitis, Photoallergic; Drug Eruptions; Follow-Up Studies; HIV Infections; Humans; Japan; Male; Middle Aged; Oxazines; Risk Assessment | 2004 |
The first case of efavirenz-induced photosensitivity in a Japanese patient with HIV infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dermatitis, Photoallergic; Drug Eruptions; Follow-Up Studies; HIV Infections; Humans; Japan; Male; Middle Aged; Oxazines; Photosensitivity Disorders; Risk Assessment; Severity of Illness Index | 2004 |
Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Blood-Testis Barrier; Cyclopropanes; Enfuvirtide; Genitalia, Male; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Oxazines; Peptide Fragments; Tenofovir | 2004 |
[Protease inhibitor sparing standard. Once daily efavirenz continues to be effective].
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; HIV-1; Oxazines; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2004 |
[3 years' data of tenofovir. Confirmed as a valuable building block].
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; Humans; Lamivudine; Organophosphonates; Oxazines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
[Valuable combination partner. Great benefit for therapy naive patients].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Multicenter Studies as Topic; Oxazines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Viral Load | 2004 |
[CROI--presentation of new study results. In a comparison of NNRTI nevirapine is equally effective].
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; HIV Infections; HIV-1; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2004 |
[5 years' data are convincing. Lopinavir as primary therapy is effective and safe in the long term].
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Drug Synergism; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Long-Term Care; Lopinavir; Organophosphonates; Oxazines; Pyrimidinones; Ritonavir; Tenofovir; Viral Load | 2004 |
Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis.
Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Oxazines; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary | 2004 |
Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults.
Topics: Adult; Alkynes; Anti-HIV Agents; Anticonvulsants; Area Under Curve; Benzoxazines; Cognition Disorders; Cyclopropanes; Drug Interactions; Female; Half-Life; HIV Infections; Humans; Lopinavir; Male; Oxazines; Pyrimidinones; Reverse Transcriptase Inhibitors; Valproic Acid | 2004 |
Mutations associated with hypersusceptibility...and with good adherence.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Mutation; Oxazines; Reverse Transcriptase Inhibitors | 2004 |
First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Oxazines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load | 2004 |
Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Mutation; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Treatment Failure; Viral Load | 2004 |
Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Hepatitis; HIV Infections; Humans; Indinavir; Liver Function Tests; Lopinavir; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Zidovudine | 2005 |
Warning on two specific 3-drug regimens: Viread + Didanosine + either Sustiva or Viramune.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Organophosphonates; Oxazines; Tenofovir; United States; United States Food and Drug Administration | 2004 |
Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhib
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Kinetics; Microbial Sensitivity Tests; Models, Molecular; Mutation; Nucleotides; Oxazines; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2005 |
In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results.
Topics: Alkynes; Amino Acid Substitution; Base Sequence; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Delavirdine; DNA, Complementary; Drug Resistance, Viral; HIV; HIV Infections; HIV Reverse Transcriptase; Humans; Mutation; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Selection, Genetic; Viremia | 2004 |
Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine.
Topics: Adenine; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir | 2005 |
Efavirenz intoxication due to slow hepatic metabolism.
Topics: Adult; Alkynes; Alleles; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Dose-Response Relationship, Drug; Female; Genetic Predisposition to Disease; HIV Infections; Homozygote; Humans; Liver; Oxazines; Oxidoreductases, N-Demethylating; Psychoses, Substance-Induced | 2005 |
An extremely different dysmetabolic profile between the two available nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Blood Glucose; Cross-Sectional Studies; Cyclopropanes; HIV Infections; Humans; Lipids; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 2005 |
Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Liver Diseases; Male; Middle Aged; Nevirapine; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Severity of Illness Index | 2005 |
The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cholesterol, HDL; Cyclopropanes; Female; Follow-Up Studies; Genes, MDR; Genetic Predisposition to Disease; HIV Infections; Humans; Hypercholesterolemia; Male; Middle Aged; Oxazines; Polymorphism, Genetic; Reverse Transcriptase Inhibitors | 2005 |
Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; DNA, Viral; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Oxazines; RNA, Viral; Stavudine; Tenofovir; Viremia | 2005 |
Efavirenz reclassified as FDA pregnancy category D.
Topics: Abnormalities, Drug-Induced; Alkynes; Benzoxazines; Cyclopropanes; Female; Fetus; HIV Infections; Humans; Oxazines; Pregnancy; Reverse Transcriptase Inhibitors | 2005 |
Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevi
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Calibration; Carbamates; Chromatography, Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Specimen Handling; Spectrophotometry, Ultraviolet; Sulfonamides | 2005 |
Rapid viral load suppression following generic highly active antiretroviral therapy in Southern Indian HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drugs, Generic; Female; HIV Infections; HIV-1; Humans; India; Lamivudine; Male; Middle Aged; Oxazines; Prospective Studies; Tablets; Treatment Outcome; Viral Load; Zidovudine | 2005 |
Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Cytochrome P-450 Enzyme System; Female; Genotype; Heterozygote; HIV Infections; Homozygote; Humans; Isoenzymes; Male; Middle Aged; Oxazines; Polymorphism, Single Nucleotide | 2005 |
The non-nukes. Sustiva. Viramune. The two major players.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 2005 |
Evaluation of a low cost reverse transcriptase assay for plasma HIV-1 viral load monitoring.
Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Oxazines; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Viral Load | 2005 |
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.
Topics: Adult; Alkynes; Alleles; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; HIV Seropositivity; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Nevirapine; Odds Ratio; Oxazines; Oxidoreductases, N-Demethylating; Pharmacogenetics; Polymorphism, Genetic; Protein Isoforms; Regression Analysis; Time Factors | 2005 |
Rare one and two amino acid inserts adjacent to codon 103 of the HIV-1 reverse transcriptase (RT) affect susceptibility to non-nucleoside RT inhibitors.
Topics: Alkynes; Benzoxazines; Cell Line; Codon; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Models, Molecular; Mutation; Nevirapine; Nucleosides; Oxazines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase | 2005 |
Recurrence of post-traumatic stress disorder and antiretrovirals.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4-Positive T-Lymphocytes; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Recurrence; RNA, Viral; Stress Disorders, Post-Traumatic; Viral Load; Zidovudine | 2005 |
A long-term survival case of small cell lung cancer in an HIV-infected patient.
Topics: Alkynes; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Benzoxazines; Camptothecin; Carbamates; Carboplatin; Carcinoma, Small Cell; Cisplatin; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Administration Schedule; Furans; HIV Infections; HIV Long-Term Survivors; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Oxazines; Ritonavir; Sulfonamides; Tomography, X-Ray Computed | 2005 |
Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Drug Therapy, Combination; Female; Health Services Accessibility; HIV Infections; HIV-1; Humans; Male; National Health Programs; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Thailand; Treatment Outcome; Viral Load | 2005 |
[Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China].
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Nevirapine; Oxazines; Stavudine; Viral Load | 2005 |
HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; HIV Reverse Transcriptase; Humans; Male; Middle Aged; Nevirapine; Oxazines; Retrospective Studies; Reverse Transcriptase Inhibitors; Viral Load; Viremia | 2005 |
Pregnancy category change for efavirenz.
Topics: Abnormalities, Drug-Induced; Alkynes; Benzoxazines; Cyclopropanes; Dandy-Walker Syndrome; Female; Fetal Monitoring; Follow-Up Studies; HIV Infections; Humans; Infant, Newborn; Meningomyelocele; Monitoring, Physiologic; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, First; Retrospective Studies | 2005 |
[Efavirenz].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Monitoring; HIV Infections; Humans; Nurse's Role; Oxazines; Patient Education as Topic; Patient Selection; Reverse Transcriptase Inhibitors | 2005 |
Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure.
Topics: Acute Kidney Injury; Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Hypersensitivity; Ghana; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Mycobacterium tuberculosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Tuberculosis | 2006 |
Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Hepatitis C; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Middle Aged; Mood Disorders; Mutation; Oxazines | 2005 |
Are adverse events of nevirapine and efavirenz related to plasma concentrations?
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Chemical and Drug Induced Liver Injury; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Exanthema; Female; HIV Infections; Humans; Male; Mental Disorders; Middle Aged; Nevirapine; Odds Ratio; Oxazines | 2005 |
Genital HIV-1 viral load is correlated with blood plasma HIV-1 viral load in Brazilian women and is reduced by antiretroviral therapy.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Brazil; Cervix Uteri; Cross-Sectional Studies; Cyclopropanes; Female; Genitalia, Female; HIV Infections; HIV-1; Humans; Lamivudine; Longitudinal Studies; Nelfinavir; Prevalence; Time Factors; Vagina; Viral Load; Zidovudine | 2006 |
Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinations.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Monitoring; Female; Half-Life; HIV Infections; Humans; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors | 2005 |
Determination of nevirapine and efavirenz in plasma using GC/MS in selected ion monitoring mode.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Calibration; Cyclopropanes; Dose-Response Relationship, Drug; Drug Monitoring; Gas Chromatography-Mass Spectrometry; HIV Infections; Humans; Ions; Lamivudine; Molecular Structure; Nevirapine; Oxazines; Reproducibility of Results | 2005 |
A K103N resistance mutation is not an absolute contraindication to adding efavirenz to a salvage regimen: a case report.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Contraindications; Cyclopropanes; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Middle Aged; Mutation; Oxazines; Salvage Therapy; Viral Load | 2005 |
Use of amitriptyline to offset sleep disturbances caused by efavirenz.
Topics: Alkynes; Amitriptyline; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Oxazines; Risk Assessment; Sleep Wake Disorders; Treatment Outcome | 2005 |
Recreational substance use and tolerance of efavirenz in HIV-1 infected patients.
Topics: Adult; Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Retrospective Studies; Substance-Related Disorders | 2005 |
Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals.
Topics: Adult; Alkynes; Anti-HIV Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Oxazines | 2005 |
Antiretroviral therapy in HIV-1 infected children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; India; Male; Nevirapine | 2005 |
Low density lipoprotein apolipoprotein B metabolism in treatment-naive HIV patients and patients on antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Apolipoproteins B; Benzoxazines; Body Composition; Cholesterol, LDL; Cross-Sectional Studies; Cyclopropanes; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oxazines; Reverse Transcriptase Inhibitors; Treatment Outcome | 2005 |
Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Oxazines; Reverse Transcriptase Inhibitors | 2005 |
Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis.
Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Male; Middle Aged; Oxazines; Rifabutin; Tuberculosis | 2005 |
Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Failure; Treatment Outcome; Viral Load; Zidovudine | 2005 |
Meeting notes from the 3rd IAS Conference. Old drugs, new data.
Topics: Alkynes; Anti-HIV Agents; Atenolol; Benzoxazines; Brazil; Congresses as Topic; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Oxazines; Pyrimidinones; Ritonavir | 2005 |
Assessment of adherence to highly active antiretroviral therapy in a cohort of African HIV-infected children in Abidjan, Côte d'Ivoire.
Topics: Adolescent; Age Factors; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cohort Studies; Cote d'Ivoire; Cross-Sectional Studies; Cyclopropanes; Female; HIV Infections; Humans; Male; Oxazines; Patient Compliance; Treatment Refusal; Viral Load | 2005 |
Summaries for patients. Neuropsychological side effects of efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Female; HIV Infections; Humans; Male; Middle Aged; Mood Disorders; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Sleep Wake Disorders | 2005 |
Neuropsychiatric effects of efavirenz: delayed onset.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Mental Disorders; Oxazines; Reverse Transcriptase Inhibitors; Time Factors | 2005 |
Economic impact of antiretroviral therapy prescription decisions in the context of rapid scaling-up of access to treatment: lessons from Mexico.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; Drug Prescriptions; Health Care Costs; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; Humans; Mexico; Oxazines; Patient Compliance; Practice Guidelines as Topic; Saquinavir; Zidovudine | 2006 |
Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients.
Topics: Adenine; Administration, Oral; Alkynes; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nevirapine; Organophosphonates; Oxazines; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Antiretroviral treatment in the Northern Cape.
Topics: Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; HIV Infections; Humans; Infant; Lamivudine; Lopinavir; Nevirapine; Oxazines; Pyrimidinones; Ritonavir; South Africa; Stavudine; Viral Load | 2005 |
[Severe psychosis in an African woman due to the antiretroviral agent efavirenz].
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Black People; Cyclopropanes; Female; Ghana; HIV Infections; Humans; Metabolic Clearance Rate; Netherlands; Oxazines; Psychotic Disorders | 2005 |
[Efavirenz--comprehensive status of studies].
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; Humans; Lopinavir; Nevirapine; Oxazines; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2005 |
[Didanosine--stability as backbone drug].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Oxazines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2005 |
Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance.
Topics: Alkynes; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Resistance, Viral; Genotype; HIV Infections; Humans; Oxazines; Oxidoreductases, N-Demethylating; Phenotype; Polymorphism, Genetic | 2006 |
HIV-1 reverse transcriptase gene 103K/N and 184M/V combinations in tandem: detection and quantification of HIV-1 populations in the CD45RO+ T-cell compartment by a double-ARMS real-time PCR assay.
Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Genes, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Immunologic Memory; Lamivudine; Leukocyte Common Antigens; Male; Middle Aged; Mutation; Nevirapine; Oxazines; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; T-Lymphocytes; Viral Load | 2006 |
HIV-related neutropaenia exacerbated by efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Liver; Male; Middle Aged; Neutropenia; Oxazines; Reverse Transcriptase Inhibitors | 2006 |
Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.
Topics: Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; HIV Infections; HIV-1; Humans; Oxazines; Oxidoreductases, N-Demethylating; Polymorphism, Genetic | 2006 |
Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.
Topics: Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nevirapine; Oxazines; Patient Compliance; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; RNA, Viral; ROC Curve; Stavudine | 2006 |
Study of efavirenz over 96 weeks shows durability, efficacious regimen. Results from 48-96 weeks essentially same.
Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load | 2006 |
A mutagenetic tree hidden Markov model for longitudinal clonal HIV sequence data.
Topics: Alkynes; Benzoxazines; Clone Cells; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; HIV; HIV Infections; Humans; Longitudinal Studies; Markov Chains; Models, Genetic; Oxazines; Point Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA | 2007 |
Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Oxazines; Ritonavir; Treatment Outcome; Tuberculosis, Pulmonary | 2006 |
The effects of the Roche AMPLICOR HIV-1 MONITOR UltraSensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and the inappropriateness of cross-study comparisons.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Blood Specimen Collection; Cyclopropanes; DNA Primers; Drug Therapy, Combination; Edetic Acid; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Internationality; Nucleic Acid Amplification Techniques; Oligopeptides; Oxazines; Pyridines; Randomized Controlled Trials as Topic; Reagent Kits, Diagnostic; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load | 2006 |
[Severe psychosis in an African woman due to the antiretroviral agent efavirenz].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Black People; Cyclopropanes; Diagnosis, Differential; Emergency Services, Psychiatric; HIV Infections; Humans; Oxazines; Psychotic Disorders | 2006 |
[Severe psychosis in an African woman due to the antiretroviral agent efavirenz].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Diagnosis, Differential; Emergency Services, Psychiatric; HIV Infections; Humans; Oxazines; Psychotic Disorders | 2006 |
Changes in sleep quality and brain wave patterns following initiation of an efavirenz-containing triple antiretroviral regimen.
Topics: Alkynes; Benzoxazines; Brain; Cyclopropanes; Dreams; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Male; Oxazines; Pilot Projects; Prospective Studies; Quality of Life; Reverse Transcriptase Inhibitors; RNA, Viral; Sleep; Sleep Stages | 2006 |
Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors.
Topics: Adult; Aged; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Male; Middle Aged; Oxazines; Pyrimidinones; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Triglycerides; Viral Load | 2006 |
Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in HIV-infected patients.
Topics: Adult; Alkynes; Benzoxazines; Cholesterol; Cholesterol, HDL; Cyclopropanes; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glycoproteins; HIV Infections; HIV-1; Humans; Male; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome | 2006 |
Potency and vulnerability: troubled 'selves' in the context of antiretroviral therapy.
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Culture; Cyclopropanes; HIV Infections; Humans; Immunity; Internal-External Control; Oxazines; Politics; Self Concept; Sick Role; Sleep | 2006 |
Report from the 13th retrovirus conference. Vicriviroc less effective than efavirenz in treatment-naive patients.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Oxazines; Viral Load | 2006 |
Concurrent use of efavirenz and oxcarbazepine may not affect efavirenz plasma concentrations.
Topics: Adult; Alkynes; Anti-HIV Agents; Anticonvulsants; Benzoxazines; Bipolar Disorder; Carbamazepine; Cyclopropanes; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Monitoring; HIV Infections; Humans; Male; Mental Disorders; Nervous System Diseases; Oxazines; Oxcarbazepine; Treatment Failure; Viral Load | 2006 |
Depressive symptoms predict increased incidence of neuropsychiatric side effects in patients treated with efavirenz.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Depression; HIV Infections; Humans; Oxazines; Psychoses, Substance-Induced; Reverse Transcriptase Inhibitors | 2006 |
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Oligopeptides; Organophosphonates; Oxazines; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir | 2006 |
Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Drug Resistance, Viral; Genes, Viral; HIV Infections; HIV-1; Humans; Mutation; Oxazines; RNA-Directed DNA Polymerase; Virus Replication | 2006 |
Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Oxazines; Reverse Transcriptase Inhibitors; Risk Factors | 2006 |
The implications of a high allelic frequency of CYP2B6 G516T in ethnic Chinese persons.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; Asian People; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Gene Frequency; HIV Infections; Humans; Oxazines; Oxidoreductases, N-Demethylating | 2006 |
Genotyping of CYP2B6 and therapeutic drug monitoring in an HIV-infected patient with high efavirenz plasma concentrations and severe CNS side-effects.
Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Monitoring; Genotype; HIV; HIV Infections; Humans; Lopinavir; Male; Oxazines; Oxidoreductases, N-Demethylating; Pyrimidinones | 2006 |
Reduced valproate plasma levels possible after introduction of efavirenz in a bipolar patient.
Topics: Adult; Alkynes; Anti-HIV Agents; Anticonvulsants; Benzoxazines; Bipolar Disorder; Cyclopropanes; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Male; Oxazines; Substance-Related Disorders; Valproic Acid | 2006 |
Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Dyslipidemias; Female; HIV Infections; Humans; Lipids; Male; Mental Disorders; Middle Aged; Nevirapine; Oxazines; Retrospective Studies; Reverse Transcriptase Inhibitors | 2006 |
Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cholesterol; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lipids; Lipoproteins; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Stavudine; Triglycerides | 2006 |
Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Exanthema; Female; HIV Infections; Humans; Incidence; Male; Middle Aged; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Risk Factors | 2006 |
Urinary NO3 excretion and renal failure in indinavir-treated patients.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Creatinine; Cyclopropanes; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Kidney Function Tests; Male; Middle Aged; Nitrates; Nitrites; Oxazines; Prospective Studies; Renal Insufficiency; Reverse Transcriptase Inhibitors; Risk Factors | 2006 |
Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet.
Topics: Adenine; Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; Humans; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2006 |
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity.
Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Case-Control Studies; Chemical and Drug Induced Liver Injury; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Genes, MDR; Genetic Variation; Genotype; HIV Infections; HIV-1; Humans; Liver; Liver Diseases; Male; Nevirapine; Oxazines; Oxidoreductases, N-Demethylating; Reverse Transcriptase Inhibitors | 2006 |
Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study).
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral | 2006 |
Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Controlled Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Hypersensitivity; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Incidence; Lamivudine; Male; Oxazines; Prospective Studies; Time Factors; Treatment Outcome; Zidovudine | 2006 |
Severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59 degrees N.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 Enzyme Inhibitors; HIV Infections; Humans; Male; Oxazines; Vitamin D Deficiency | 2006 |
Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison.
Topics: Adult; Aged; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypertriglyceridemia; Italy; Lopinavir; Male; Middle Aged; Nucleosides; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure; Viral Load | 2006 |
One pill, once daily: now an option for HIV patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Combinations; HIV Infections; Humans; Organophosphonates; Oxazines; Tenofovir | 2006 |
A once-daily combination tablet (Atripla) for HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Interactions; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; HIV Infections; Humans; Organophosphonates; Oxazines; Tenofovir | 2006 |
Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.
Topics: Adult; Alkynes; Benzoxazines; Cohort Studies; Cyclopropanes; Female; Genetic Variation; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Male; Middle Aged; Nelfinavir; Orosomucoid; Oxazines; Phenotype; Pyrimidinones; Ritonavir; Switzerland | 2006 |
Once-daily dosing and the treatment of HIV disease.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Emtricitabine; HIV Infections; Humans; Organophosphonates; Oxazines; Tenofovir | 2006 |
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.
Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; CD4 Lymphocyte Count; Chromatography, High Pressure Liquid; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Oxazines; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary; Viral Load | 2006 |
Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nevirapine; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Treatment Outcome; Viral Load | 2006 |
No increase in CNS defects.
Topics: Alkynes; Anti-HIV Agents; Baltimore; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Dandy-Walker Syndrome; Female; HIV Infections; Humans; Infant, Newborn; Medical Staff, Hospital; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors | 2006 |
Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells/microl.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cyclopropanes; Female; HIV Infections; Humans; Male; Nevirapine | 2006 |
Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Dose-Response Relationship, Drug; Drug Monitoring; Female; HIV Infections; HIV-1; Humans; International Agencies; Male; Oxazines; Practice Guidelines as Topic | 2006 |
Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study.
Topics: Adult; Alkynes; Australia; Behavioral Symptoms; Benzoxazines; Case-Control Studies; Cross-Sectional Studies; Cyclopropanes; Dreams; Female; HIV Infections; Humans; Male; Mental Disorders; Neuropsychological Tests; Prevalence; Reverse Transcriptase Inhibitors; Self Disclosure; Stress, Psychological | 2006 |
Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine.
Topics: Adult; Alkynes; Area Under Curve; Benzoxazines; Buprenorphine; Case-Control Studies; Cohort Studies; Cyclopropanes; Delavirdine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; HIV Infections; Humans; Male; Narcotic Antagonists; Opioid-Related Disorders; Oxazines; Probability; Prognosis; Reference Values; Reverse Transcriptase Inhibitors; Risk Assessment; Statistics, Nonparametric; Treatment Outcome | 2006 |
Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens.
Topics: Adolescent; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Cohort Studies; Cote d'Ivoire; Cyclopropanes; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Male; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2006 |
[Effects of traditional Chinese medicine on CD4 + T cell counts and HIV viral loads during structured treatment interruption in highly active antiretroviral therapy].
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Phytotherapy; Time Factors; Treatment Outcome; Viral Load; Zidovudine | 2006 |
Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine; Oxazines; Protease Inhibitors; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Virus Replication | 2007 |
Role of antiretroviral treatment in prolonging QTc interval in HIV-positive patients.
Topics: Aged; Alkynes; Benzoxazines; Case-Control Studies; Cyclopropanes; Electrocardiography; Female; HIV Infections; Humans; Male; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors; Risk Factors; Zidovudine | 2007 |
Report from the XVI International AIDS Conference. Efavirenz for high viral load and low CD4--a secondary analysis of ACTG 5095.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Oxazines; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2006 |
Efavirenz-associated podocyte damage.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Kidney Diseases; Kidney Glomerulus; Male; Middle Aged; Oxazines; Podocytes | 2007 |
Meeting report. Report from ICAAC.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Cyclopropanes; Furans; HIV Infections; Humans; Oligopeptides; Organic Chemicals; Organophosphates; Oxazines; Patient Compliance; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Viral Load | 2006 |
Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.
Topics: Adult; Alkynes; Alleles; Animals; Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Blotting, Western; Chlorocebus aethiops; COS Cells; Cyclopropanes; Cytochrome P-450 CYP2B6; Exons; Female; Genotype; HIV Infections; Humans; Male; Oxazines; Oxidoreductases, N-Demethylating; Plasmids; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prospective Studies; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2007 |
Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; Drug Hypersensitivity; HIV Infections; Humans; Lamivudine; Male; Oxazines; RNA, Viral | 2007 |
Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cyclopropanes; Exanthema; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Nevirapine; Pancreatitis; Peripheral Nervous System Diseases; Proportional Hazards Models; Rural Health; Stavudine; Survival Analysis; Uganda | 2007 |
Thailand and the compulsory licensing of efavirenz.
Topics: Alkynes; Benzoxazines; Brazil; Cyclopropanes; Developing Countries; Drug Costs; Drug Industry; Drugs, Essential; Drugs, Generic; HIV Infections; Humans; Legislation, Drug; Licensure; Oxazines; Reverse Transcriptase Inhibitors; Thailand | 2007 |
Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child Development; Child, Preschool; Cholesterol; Cohort Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Oxazines; Patient Compliance; Prospective Studies; Treatment Outcome | 2007 |
Transitory severe CNS adverse effects after accidental efavirenz overdose during post-exposure HIV prophylaxis.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Brain; Cyclopropanes; Drug Overdose; Female; HIV Infections; Humans; Medication Errors; Middle Aged; Needlestick Injuries; Occupational Diseases; Oxazines | 2007 |
Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Monitoring; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Lopinavir; Male; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Ritonavir; Severity of Illness Index | 2007 |
Nevirapine versus efavirenz based antiretroviral treatment in naive Indian patients: comparison of effectiveness in clinical cohort.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; India; Male; Nevirapine; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors | 2006 |
Quality of life and depression among HIV-infected patients receiving efavirenz- or protease inhibitor-based therapy in Senegal.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Depression; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Quality of Life; Senegal; Sex Distribution; Sleep Wake Disorders | 2007 |
No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Alleles; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Black or African American; Cyclopropanes; Cytochrome P-450 CYP2B6; Genotype; Haplotypes; HIV Infections; Humans; Oxidoreductases, N-Demethylating; Papua New Guinea; Polymorphism, Single Nucleotide; Population Groups; United States | 2007 |
Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Biological Assay; Buprenorphine; Calibration; Chromatography, Liquid; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mass Spectrometry; Molecular Structure; Narcotic Antagonists; Oligopeptides; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Substance-Related Disorders; Tandem Mass Spectrometry | 2007 |
Anti-HIV agents. New drugs, new hope, old lessons.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Cyclopropanes; HIV Infections; HIV Integrase Inhibitors; Humans; Lipodystrophy; Maraviroc; Organic Chemicals; Pyrrolidinones; Raltegravir Potassium; Triazoles; Viral Load | 2007 |
Anti-HIV agents. A second study confirms fat loss issues with efavirenz.
Topics: Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lipodystrophy; Male; Reverse Transcriptase Inhibitors; Viral Load | 2007 |
Anti-HIV agents. Efavirenz and fat wasting--what might be happening?
Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Lipodystrophy; Reverse Transcriptase Inhibitors | 2007 |
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black People; Cholesterol; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Fasting; Female; Hispanic or Latino; HIV Infections; HIV Protease Inhibitors; HIV Seronegativity; HIV Seropositivity; HIV-1; Humans; Indinavir; Lamivudine; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Multivariate Analysis; Nelfinavir; Nevirapine; Organophosphonates; Ritonavir; Stavudine; Tenofovir; Triglycerides; United States; White People | 2007 |
Genetic variability of CYP2B6 polymorphisms in four southern Chinese populations.
Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Asian People; Benzoxazines; China; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Gene Frequency; Genetic Variation; Genotype; Heroin Dependence; HIV Infections; Humans; Male; Oxidoreductases, N-Demethylating; Polymorphism, Genetic | 2007 |
NNRTI data in naive patients.
Topics: Alkynes; Benzoxazines; Clinical Trials, Phase II as Topic; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nitriles; Pyrimidines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Rilpivirine | 2007 |
Does tenofovir influence efavirenz pharmacokinetics?
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Drug Therapy, Combination; Female; Genotype; HIV Infections; Humans; Liver; Longitudinal Studies; Male; Middle Aged; Models, Biological; Organophosphonates; Oxidoreductases, N-Demethylating; Phenotype; Reverse Transcriptase Inhibitors; Switzerland; Tenofovir | 2007 |
Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Biological Availability; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Male; Prospective Studies; Rifampin; Tuberculosis | 2007 |
Discontinuation of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy due to nucleoside analogue reverse transcriptase inhibitor-related metabolic toxicity.
Topics: Adolescent; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; United Kingdom | 2007 |
Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Feasibility Studies; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; India; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Molecular Sequence Data; Mutation; Nevirapine; Polymerase Chain Reaction; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors | 2007 |
Dynamics of 103K/N and 184M/V HIV-1 drug resistant populations: relative comparison in plasma virus RNA versus CD45RO+T cell proviral DNA.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Leukocyte Common Antigens; Mutation; Nevirapine; Nucleic Acid Amplification Techniques; Proviruses; Reverse Transcriptase Inhibitors; RNA, Viral; T-Lymphocytes; Viremia | 2007 |
Efavirenz: innocent bystander or direct nephrotoxin?
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Kidney Diseases | 2007 |
FDA notifications. FDA tentatively approves generic efavirenz.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Approval; Drugs, Generic; HIV Infections; Humans; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 2007 |
New package inserts for efavirenz and T-20.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Information Services; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; Humans; Peptide Fragments | 2007 |
Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Patient Compliance; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Veterans; Viral Load | 2007 |
[Efficacy and tolerance of non nucleosidic reverse transcriptase inhibitors containing tritherapy in HIV-1 infection].
Topics: Adolescent; Adult; Aged; Alkynes; Benzoxazines; Cyclopropanes; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Retrospective Studies; Reverse Transcriptase Inhibitors | 2005 |
Comparison of the effectiveness of initial combined antiretroviral therapy with nelfinavir or efavirenz at a university-based outpatient service in Brazil.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Clinical Protocols; Cohort Studies; Cyclopropanes; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Retrospective Studies; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2007 |
Hair loss induced by lopinavir-ritonavir.
Topics: Adult; Alkynes; Alopecia; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Probability; Pyrimidinones; Ritonavir | 2007 |
[Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir].
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Metabolic Syndrome; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Time Factors | 2007 |
Efavirenz-induced neurological symptoms in rare homozygote CYP2B6 *2/*2 (C64T).
Topics: Alkynes; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; HIV Infections; Humans; Male; Middle Aged; Oxidoreductases, N-Demethylating; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors | 2007 |
Prednisolone mediated suppression of HIV-1 viral load strongly correlates with C-C chemokine CCL2: In vivo and in vitro findings.
Topics: Alkynes; Anti-HIV Agents; Anti-Inflammatory Agents; Benzoxazines; Chemokine CCL2; Cyclopropanes; Drug Resistance, Viral; Flow Cytometry; Gene Expression; HIV Infections; HIV-1; Humans; In Vitro Techniques; Interleukin-8; Lamivudine; Male; Prednisolone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Necrosis Factor-alpha; Uveitis; Viral Load; Viremia; Zidovudine | 2007 |
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
Topics: Adenine; Administration, Oral; Adult; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Genitalia, Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2007 |
No observable correlation between central nervous system side effects and EFV plasma concentrations in Japanese HIV type 1-infected patients treated with EFV containing HAART.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Central Nervous System; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Japan; Male; Middle Aged; Viral Load | 2007 |
Treatment of an atazanivir associated grade 4 hyperbilirubinaemia with efavirenz.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Middle Aged; Oligopeptides; Pyridines | 2007 |
Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy.
Topics: Adolescent; Age Factors; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Mass Index; Body Weight; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; DNA, Mitochondrial; DNA, Viral; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Lipids; Longitudinal Studies; Mitochondria; Nelfinavir; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA, Viral | 2007 |
Genotypic resistance in HIV-infected naive patients receiving abacavir plus lamivudine and efavirenz.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Spain; Species Specificity; Treatment Failure; Viral Load | 2007 |
Effect of anticoagulants on plasma nevirapine and efavirenz concentrations.
Topics: Adult; Alkynes; Anti-HIV Agents; Anticoagulants; Benzoxazines; Cyclopropanes; Drug Monitoring; Edetic Acid; Female; Heparin; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Specimen Handling | 2007 |
The validation of plasma darunavir concentrations determined by the HPLC method for protease inhibitors.
Topics: Alkynes; Benzoxazines; Calibration; Chromatography, High Pressure Liquid; Cyclopropanes; Darunavir; Drug Monitoring; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Reference Standards; Reproducibility of Results; Solutions; Sulfonamides | 2007 |
Maraviroc reduces viral load in naive patients at 48 weeks.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclohexanes; Cyclopropanes; HIV Infections; HIV-1; Humans; Maraviroc; Triazoles; Viral Load | 2007 |
Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Administration Schedule; Female; Food; HIV; HIV Infections; Humans; Lamivudine; Male; Spain; Viral Load | 2007 |
Psychosis in a 12-year-old HIV-positive girl with an increased serum concentration of efavirenz.
Topics: Alkynes; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Child; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Heterozygote; HIV Infections; Humans; Oxidoreductases, N-Demethylating; Point Mutation; Psychoses, Substance-Induced; Reverse Transcriptase Inhibitors | 2007 |
Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Aspartate Aminotransferases; Benzoxazines; CD4-Positive T-Lymphocytes; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis C; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Linear Models; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Risk Factors; Stavudine; Zidovudine | 2007 |
Pharmacogenetics of efavirenz: adherence and virologic outcomes.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black People; Cyclopropanes; HIV Infections; HIV-1; Humans; Patient Compliance; Pharmacogenetics; Reverse Transcriptase Inhibitors | 2007 |
High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe.
Topics: Acquired Immunodeficiency Syndrome; Adult; Algorithms; Alkynes; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Gene Frequency; Genetic Variation; Genotype; HIV Infections; Humans; Male; Models, Statistical; Oxidoreductases, N-Demethylating; Population; Reverse Transcriptase Inhibitors; Sex Factors; Zimbabwe | 2008 |
Intracellular efavirenz levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected individuals.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chromatography, Gas; Cyclopropanes; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Reverse Transcriptase Inhibitors; Tandem Mass Spectrometry | 2008 |
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; CD4 Lymphocyte Count; Child, Preschool; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Gene Frequency; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Multivariate Analysis; Nevirapine; Oxidoreductases, N-Demethylating; Polymorphism, Genetic; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome | 2007 |
Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cambodia; CD4 Lymphocyte Count; Cross-Sectional Studies; Cyclopropanes; Developing Countries; Feasibility Studies; Female; HIV Infections; HIV-1; Humans; Lamivudine; Logistic Models; Male; Prospective Studies; RNA, Viral; Stavudine; Treatment Outcome; Viral Load | 2007 |
Clinical interaction between efavirenz and phenytoin.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Monitoring; HIV Infections; Humans; Male; Phenytoin; Seizures | 2008 |
Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Disease Progression; Female; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver Cirrhosis; Male; Nevirapine; Protease Inhibitors; Retrospective Studies; Reverse Transcriptase Inhibitors; Ribavirin; Viral Load | 2008 |
Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Resistance, Viral; Europe; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Nevirapine; Proportional Hazards Models; Reverse Transcriptase Inhibitors; Treatment Failure; Treatment Outcome | 2008 |
Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Nevirapine; Outpatient Clinics, Hospital; Patient Compliance; Practice Guidelines as Topic; Practice Patterns, Physicians'; Protease Inhibitors; Reverse Transcriptase Inhibitors; Time Factors; United Kingdom | 2008 |
Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of therapy.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Monitoring; Female; HIV Infections; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors | 2008 |
Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Topics: Adolescent; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Hyperglycemia; Hypertriglyceridemia; Lamivudine; Lipodystrophy; Male; Nevirapine; Prevalence; Reverse Transcriptase Inhibitors; Stavudine; Thailand | 2007 |
Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen.
Topics: Adipose Tissue; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Composition; Body Fat Distribution; Body Mass Index; Cholesterol; Cholesterol, HDL; Cyclopropanes; Extremities; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Indinavir; Intra-Abdominal Fat; Male; Reverse Transcriptase Inhibitors; Ritonavir; Thailand; Triglycerides | 2007 |
Quantifying antiretroviral risk in pregnancy.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cesarean Section; Cyclopropanes; Female; HIV Infections; Humans; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome | 2007 |
Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Bayes Theorem; Benzoxazines; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; France; Furans; HIV Infections; Humans; Male; Models, Biological; Nevirapine; Organophosphates; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides | 2008 |
Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.
Topics: Adult; Alkynes; Benzoxazines; Case-Control Studies; Cohort Studies; Cyclopropanes; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Reverse Transcriptase Inhibitors; Treatment Failure | 2008 |
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alkynes; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Black People; Body Mass Index; Chromatography, High Pressure Liquid; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Gene Frequency; HIV Infections; Humans; Male; Middle Aged; Multivariate Analysis; Nevirapine; Oxidoreductases, N-Demethylating; Polymerase Chain Reaction; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; White People | 2008 |
HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Eruptions; Female; HIV Infections; HLA-DR Antigens; HLA-DRB1 Chains; Humans; Male; Middle Aged; Nevirapine; Prospective Studies | 2008 |
Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cost-Benefit Analysis; Cyclopropanes; Decision Trees; Deoxycytidine; Drug Costs; Emtricitabine; Health Care Costs; Health Resources; HIV Infections; HIV-1; Humans; Lamivudine; Models, Economic; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Zidovudine | 2008 |
Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children.
Topics: Adolescent; Age Factors; Alkynes; Anti-HIV Agents; Attention; Benzoxazines; Child; Child, Preschool; Chromatography, High Pressure Liquid; Cyclopropanes; Dyssomnias; HIV Infections; HIV-1; Humans; Metabolic Clearance Rate; Plasma; Psychotic Disorders; Seizures; Treatment Outcome; Treatment Refusal; Viral Load | 2008 |
Association of antiretroviral therapy with fibrinogen levels in HIV-infection.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Case-Control Studies; Cyclopropanes; Female; Fibrinogen; HIV Infections; Humans; Indinavir; Linear Models; Male; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir | 2008 |
Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Antitubercular Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine; Retrospective Studies; Reverse Transcriptase Inhibitors; Rifampin; Treatment Outcome; Tuberculosis; Viral Load | 2008 |
FDA notifications. FDA grants tentative approval of efavirenz.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Approval; Drugs, Generic; HIV Infections; Humans; United States; United States Food and Drug Administration | 2007 |
[Polyneuropathies in patients treated with HAART in Bobo-Dioulasso hospital, Burkina Faso].
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Burkina Faso; CD4 Lymphocyte Count; Cyclopropanes; Female; Follow-Up Studies; Foot Diseases; HIV Infections; Humans; Hypesthesia; Lamivudine; Male; Middle Aged; Nevirapine; Pain; Paresthesia; Polyneuropathies; Reflex, Abnormal; Sensory Thresholds; Stavudine; Vibration | 2008 |
European Commission approves Atripla.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Approval; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; European Union; HIV Infections; Humans; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Does tenofovir increase efavirenz hepatotoxicity?
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Tenofovir | 2008 |
Initial treatment for HIV infection--an embarrassment of riches.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir | 2008 |
Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cell Survival; Cells, Cultured; Cyclopropanes; Dendrimers; Drug Delivery Systems; HIV Infections; Humans; Macrophages; Magnetic Resonance Spectroscopy; Monocytes; Phagocytosis; Polypropylenes; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tetrazolium Salts; Thiazoles; Tuftsin | 2008 |
Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection: case report and review of the literature.
Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Monitoring; HIV Infections; Humans; Male; Oxidoreductases, N-Demethylating; Polymorphism, Genetic | 2008 |
Switch to efavirenz (EFV) after protease-inhibitor (PI)-failure: explorative analysis of outcome by baseline viral VS tolerability failure.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Databases, Factual; Female; Follow-Up Studies; HIV Infections; Humans; Male; Pilot Projects; Protease Inhibitors; Retrospective Studies; Treatment Failure; Treatment Outcome; Viral Load | 2008 |
Population dynamics studies of wild-type and drug-resistant mutant HIV in mixed infections.
Topics: Alkynes; Azepines; Benzoxazines; Cyclopropanes; Drug Resistance, Microbial; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Microbial Sensitivity Tests; Oxazines; Population Dynamics; Reverse Transcriptase Inhibitors; Time Factors; Urea; Viral Plaque Assay | 1997 |
[HIV infection: DuPont Pharma presents the results of its antiretroviral agent].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Evaluation; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Lamivudine; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viremia; Zidovudine | 1998 |
Treatment for AIDS.
Topics: Abnormalities, Drug-Induced; Acquired Immunodeficiency Syndrome; Adult; Alkynes; Benzoxazines; Child; Child, Preschool; Clinical Trials as Topic; Cyclopropanes; Drug Approval; Female; HIV Infections; Humans; Infant, Newborn; Male; Oxazines; Pregnancy; Reverse Transcriptase Inhibitors; United States | 1998 |
[FDA approval of the first HIV anti-retroviral from DuPont-Pharma: SUSTIVA (efavirenz). SUSTIVA should be associated with other anti-retrovirals and could be considered a new alternative first line treatment].
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Clinical Trials as Topic; Contraindications; Cyclopropanes; Drug Approval; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Oxazines; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration; Viral Load | 1998 |
Once-daily nonnucleoside reverse-transcriptase inhibitor approved.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Approval; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 1998 |
Three new drugs for HIV infection.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; Dideoxynucleosides; Dizziness; Drug Therapy, Combination; Headache; HIV Infections; Humans; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors | 1998 |
Once-daily drug for persons with HIV.
Topics: Administration, Oral; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors | 1998 |
[DuPont-Pharma Laboratories. Sustiva].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Brain; Cerebrospinal Fluid; Cyclopropanes; HIV; HIV Infections; Humans; Oxazines; RNA, Viral | 1998 |
Hope for HIV patients. News from the 12th International Conference on HIV and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Antigens; Cyclopropanes; Diet Therapy; HIV Infections; Humans; Hyperlipidemias; Oxazines | 1999 |
[HIV infections: mortality reduced only in developed countries].
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Developed Countries; Developing Countries; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors | 1999 |
Reply to Gonzalez and Everall: Lest we forget: neuropsychiatry and the new generation anti-HIV drugs.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors | 1999 |
High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Liver Diseases; Male; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Stavudine | 1999 |
Reply. Lest we forget: neuropsychiatry and the new generation anti-HIV drugs.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Nervous System Diseases; Oxazines; Reverse Transcriptase Inhibitors | 1999 |
Choosing the best initial therapy for HIV-1 infection.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral | 1999 |
Hypersensitivity syndrome associated with efavirenz therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Hypersensitivity; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Oxazines; Reverse Transcriptase Inhibitors; Syndrome | 2000 |
Four-drug salvage antiretroviral treatment including nelfinavir and efavirenz in highly treated children with congenital HIV disease.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Cyclopropanes; Drug Therapy, Combination; HIV Infections; Humans; Male; Nelfinavir; Oxazines; Salvage Therapy | 2000 |
[The 39th ICAAC (San Francisco) and the 7th European Conference on Clinical Aspects and Treatment of HIV-infection (Lisbon). HIV infection: antiretroviral agents in the development and trial stage].
Topics: Alkynes; Animals; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Quinoxalines; Reverse Transcriptase Inhibitors; Time Factors; Uracil; Viral Load | 2000 |
Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.
Topics: Adult; Alkynes; Benzoxazines; Cohort Studies; Cyclopropanes; Delavirdine; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Hospitals, University; Humans; Male; Middle Aged; Mutation; Nevirapine; Oxazines; Protease Inhibitors; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Viral Load | 2000 |
Pharmacokinetics of efavirenz in a patient on maintenance haemodialysis.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Monitoring; HIV Infections; HIV-1; Humans; Kidney Failure, Chronic; Male; Oxazines; Renal Dialysis | 2000 |
Phenotypic resistance to protease inhibitors in patients who fail on highly active antiretroviral therapy predicts the outcome at 48 weeks of a five-drug combination including ritonavir, saquinavir and efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Phenotype; Ritonavir; Saquinavir; Treatment Failure | 2000 |
Efavirenz in HIV infection.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Oxazines; Research Design; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 2000 |
Efavirenz interference in estradiol ELISA assay.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Enzyme-Linked Immunosorbent Assay; Estradiol; False Positive Reactions; HIV Infections; Humans; Luminescent Measurements; Oxazines; Radioimmunoassay; Reverse Transcriptase Inhibitors | 2000 |
Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction.
Topics: Alkynes; Benzoxazines; Calibration; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Oxazines; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides | 2000 |
Sustiva granted full FDA approval.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Approval; Drug Therapy, Combination; HIV Infections; Humans; Oxazines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 2000 |
Efavirenz approved in Europe.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child, Preschool; Cyclopropanes; Drug Approval; Europe; HIV Infections; Humans; Oxazines | 1999 |
Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Codon; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; HIV Infections; Humans; Logistic Models; Male; Middle Aged; Mutation; Organophosphonates; Oxazines; Protease Inhibitors; Retrospective Studies; Reverse Transcriptase Inhibitors; Salvage Therapy; Treatment Outcome; Viral Load | 2000 |
Efavirenz dosing in patients receiving continuous ambulatory peritoneal dialysis.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Kidney Failure, Chronic; Male; Middle Aged; Oxazines; Peritoneal Dialysis, Continuous Ambulatory; Reverse Transcriptase Inhibitors | 2000 |
48-week data released for combination treatment with efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Oxazines; Treatment Outcome | 1999 |
Can early failure with nevirapine be rescued with efavirenz?
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Treatment Failure | 2000 |
DuPont initiates Sustiva oral liquid expanded access program.
Topics: Administration, Oral; Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Clinical Trials as Topic; Cyclopropanes; Drug Industry; HIV Infections; Humans; Multicenter Studies as Topic; Oxazines; Reverse Transcriptase Inhibitors | 2000 |
[Long-term success in routine clinical practice. Effectiveness trial passed].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Family Practice; HIV Infections; Humans; Oxazines; Treatment Outcome | 2000 |
Efavirenz decreases methadone blood concentrations.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Lamivudine; Methadone; Oxazines; Reverse Transcriptase Inhibitors; Stavudine; Substance Withdrawal Syndrome | 2000 |
Methadone withdrawal symptoms with nevirapine and efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; HIV Infections; Humans; Male; Methadone; Narcotics; Nevirapine; Oxazines; Substance Withdrawal Syndrome | 2000 |
Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nevirapine; Oxazines; Retrospective Studies; Reverse Transcriptase Inhibitors; Salvage Therapy | 2000 |
Efficacy and safety of the combination of efavirenz and abacavir in HIV-infected patients failing antiretroviral therapy.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Oxazines; Safety; Salvage Therapy; Treatment Failure | 2000 |
Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Cyclopropanes; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Sequence Data; Mutation; Oxazines; Selection, Genetic; Treatment Failure | 2000 |
Photosensitivity reaction of efavirenz.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Male; Oxazines; Photosensitivity Disorders; Reverse Transcriptase Inhibitors | 2000 |
Preliminary experience of adverse drug reactions, tolerability, and efficacy of a once-daily regimen of antiretroviral combination therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hypercholesterolemia; Hypertriglyceridemia; Indinavir; Middle Aged; Nausea; Oxazines; Ritonavir | 2000 |
Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Eruptions; Exanthema; HIV Infections; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 2000 |
Pharmacokinetic interaction of amprenavir in combination with efavirenz or delavirdine in HIV-infected children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Child; Child, Preschool; Cyclopropanes; Delavirdine; Drug Interactions; Drug Therapy, Combination; Furans; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides; Time Factors | 2000 |
Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir.
Topics: Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Carbamates; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Drug Therapy, Combination; Furans; HIV Infections; Humans; Oxazines; Oxidoreductases, N-Demethylating; Ritonavir; Sulfonamides | 2000 |
Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Arteriosclerosis; Benzoxazines; Cholesterol; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Nevirapine; Oxazines; Risk Factors; Stavudine; Thymidine; Triglycerides; Zidovudine | 2000 |
The tolerability of efavirenz after nevirapine-related adverse events.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Anxiety Disorders; Benzoxazines; Cyclopropanes; Female; HIV; HIV Infections; Homosexuality; Humans; Male; Middle Aged; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 2000 |
Current issues in antiretroviral and psychiatric therapy for HIV-infected patients.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Mental Disorders; Oxazines; Pneumonia, Pneumocystis; Viremia | 2000 |
Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors | 2000 |
[Toxicity associated to efavirenz in HIV-infected persons enrolled in an expanded access program].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Oxazines | 2000 |
Four-drug regimens may be better.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Costs; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2000 |
Carbamazepine toxicity after starting combination antiretroviral therapy including ritonavir and efavirenz.
Topics: Alkynes; Anti-HIV Agents; Anticonvulsants; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamazepine; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Middle Aged; Mixed Function Oxygenases; Oxazines; Reverse Transcriptase Inhibitors; Ritonavir; Seizures | 2000 |
Raising levels of amprenavi.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Cyclopropanes; Drug Interactions; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Viral Load | 2000 |
SSRI safe with efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Interactions; Drug Monitoring; HIV Infections; Humans; Oxazines; Retrospective Studies; Reverse Transcriptase Inhibitors; Selective Serotonin Reuptake Inhibitors; Time Factors; Viral Load | 2000 |
Efavirenz-associated breast hypertrophy in HIV-infection patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Breast Diseases; Cyclopropanes; HIV Infections; Humans; Lipodystrophy; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors | 2001 |
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Predictive Value of Tests; Reverse Transcriptase Inhibitors; Treatment Failure; Viral Load | 2001 |
Tolerance of efavirenz in children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Cyclopropanes; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; Viral Load | 2001 |
Economic analysis of initial HIV treatment. Efavirenz- versus indinavir-containing triple therapy.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Disease Progression; Drug Costs; Drug Therapy, Combination; Health Care Costs; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Models, Economic; Oxazines; Reverse Transcriptase Inhibitors | 2001 |
Dynamics of seminal plasma HIV-1 decline after antiretroviral treatment.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; Cyclopropanes; Didanosine; Environmental Monitoring; HIV Infections; HIV-1; Humans; Hydroxyurea; Lamivudine; Male; Oxazines; Semen; Time Factors; Viral Load | 2001 |
Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Male; Oxazines; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Triglycerides | 2001 |
Smaller amounts of antiretroviral drugs are needed when combined with an active ribozyme against HIV-1.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cell Line; Cyclopropanes; Didanosine; Dose-Response Relationship, Drug; Enzyme Inhibitors; HIV Core Protein p24; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Oxazines; Protease Inhibitors; Reverse Transcriptase Inhibitors; RNA, Catalytic; T-Lymphocytes; Time Factors | 2001 |
Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Topics: Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Cells, Cultured; Clinical Trials, Phase II as Topic; Cohort Studies; Cyclopropanes; Delavirdine; Drug Resistance, Microbial; Drug Resistance, Multiple; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Leukocytes, Mononuclear; Microbial Sensitivity Tests; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Treatment Failure | 2001 |
DMP 266 and indinavir combination.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine | 1997 |
Criteria expanded for efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Drug Industry; HIV Infections; Hotlines; Humans; Oxazines; Patient Selection; United States | 1998 |
Dethroning AZT.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Lamivudine; Oxazines; Stavudine; Viral Load; Zidovudine | 1997 |
DMP 266 trials recruiting, many cities -- protease inhibitor naive.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Cyclopropanes; HIV Infections; Humans; Oxazines; Patient Selection; Reverse Transcriptase Inhibitors | 1997 |
Protease inhibitor failure trial: combination 1592, 141W94, and efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials, Phase II as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Male; Multicenter Studies as Topic; Oxazines; Patient Selection; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Failure | 1997 |
Expanded access programs.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Health Services Accessibility; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors | 1997 |
Efavirenz (Sustiva) expanded access now to 400 CD4.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Health Services Accessibility; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; United States | 1998 |
Efavirenz expanded access.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drugs, Investigational; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors | 1998 |
Broadened access to Sustiva.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Approval; Drug Therapy, Combination; Health Services Accessibility; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 1998 |
What's new and what's next.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-2; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides | 1998 |
Expanded access.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Ritonavir | 1997 |
Efavirenz expanded access broadened.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors | 1998 |
Selected highlights from the 5th Conference on Retroviruses and Opportunistic Infections.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Carbamates; Chicago; Clinical Trials as Topic; Congresses as Topic; Cyclopropanes; Dideoxynucleosides; Drug Hypersensitivity; Drug Interactions; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxyurea; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides | 1998 |
Safety alert issued on efavirenz (Sustiva).
Topics: Abnormalities, Drug-Induced; Alkynes; Anencephaly; Animals; Benzoxazines; Cleft Palate; Cyclopropanes; Eye; Haplorhini; HIV Infections; Oxazines; Pregnancy; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 1998 |
Update on antivirals.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dosage Forms; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 1997 |
Notice on efavirenz and pregnancy.
Topics: Abnormalities, Drug-Induced; Alkynes; Animals; Benzoxazines; Cyclopropanes; Drugs, Investigational; Female; Haplorhini; HIV Infections; Maternal-Fetal Exchange; Oxazines; Pregnancy; Reverse Transcriptase Inhibitors | 1998 |
Efavirenz pregnancy warning.
Topics: Abnormalities, Drug-Induced; Alkynes; Animals; Benzoxazines; Cyclopropanes; Female; Haplorhini; HIV Infections; Humans; Male; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors | 1998 |
Options when HIV treatments fail.
Topics: Adenine; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; Salvage Therapy | 1998 |
I want a new drug. An overview of three new anti-HIV drugs.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Approval; Drug Therapy, Combination; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 1998 |
Efavirenz (Sustiva) on fast-track for FDA accelerated approval. Food and Drug Administration.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Approval; Drug Therapy, Combination; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 1998 |
Efavirenz and Fortovase.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Gels; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Saquinavir | 1998 |
Efavirenz (Sustiva) may equal or exceed protease inhibitor in initial antiretroviral combination.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Drugs, Investigational; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; Viral Load | 1998 |
New drugs on the horizon.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides; United States; Zidovudine | 1998 |
New drug pricing consensus letter, sign-ons requested.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Economics, Pharmaceutical; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; United States | 1998 |
Sparing the protease for some spoils the price for all.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Industry; HIV Infections; Humans; Marketing of Health Services; Oxazines; Reverse Transcriptase Inhibitors | 1998 |
Another expensive drug for your cocktail.
Topics: Alkynes; Animals; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration; Viral Load | 1998 |
NNRTIs: a neglected class.
Topics: Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Delavirdine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 1998 |
New drugs in development.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Imidazoles; Kidney Diseases; Lopinavir; Oxazines; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Sulfonamides; Viral Load | 1998 |
Efavirenz (SUSTIVA) approved.
Topics: Adult; Alkynes; Benzoxazines; Child; Cyclopropanes; Drug Approval; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Oxazines; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 1998 |
Efavirenz approved in the U.S.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Approval; Drug Therapy, Combination; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 1998 |
Efavirenz use may cause false positive result for marijuana.
Topics: Alkynes; Benzoxazines; Cannabinoids; Chromatography, Gas; Cyclopropanes; Drug Therapy, Combination; False Positive Reactions; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors | 1998 |
Access to efavirenz and amprenavir.
Topics: Alkynes; Benzoxazines; Carbamates; Cyclopropanes; Furans; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides; United States | 1998 |
FDA approves Sustiva (efavirenz) capsules, first once-daily anti-HIV drug. Food and Drug Administration.
Topics: Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Approval; Drug Therapy, Combination; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 1998 |
New drug approved.
Topics: Adult; Alkynes; Benzoxazines; Child; Cyclopropanes; Drug Approval; Drug Therapy, Combination; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 1998 |
Efavirenz (Sustiva) available through patient assistance program.
Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Medical Assistance; Oxazines; Reverse Transcriptase Inhibitors; United States | 1998 |
First once-daily drug simplifies dosing, offers new options in HIV-1 treatment.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Oxazines; Patient Compliance; Reverse Transcriptase Inhibitors; Zidovudine | 1998 |
FDA approves efavirenz. Food and Drug Administration.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Approval; Drug Therapy, Combination; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 1998 |
A new approach to initial antiretroviral therapy: protease-sparing combination regimens.
Topics: Alkynes; Anti-HIV Agents; Antineoplastic Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Drugs, Investigational; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxyurea; Lamivudine; Lipodystrophy; Oxazines; Reverse Transcriptase Inhibitors; Time Factors; Zidovudine | 1998 |
Soaring prices, soaring sales.
Topics: Alkynes; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Packaging; Drug Therapy, Combination; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Interferon alpha-2; Interferon-alpha; Oxazines; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; United States | 1998 |
New drug pricing: progress on World AIDS Day?
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; United States | 1998 |
What's new, what's next?
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides | 1999 |
Antiretroviral therapy: rehashes, leftovers, and a pinch of new data.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Congresses as Topic; Cyclopropanes; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Salvage Therapy; Time Factors; Treatment Failure; Viral Load; Virus Replication | 1998 |
The high cost of fighting HIV.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Industry; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; United States | 1998 |
Report on HIV/AIDS from IDSA: news from the mile high city.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; Colorado; Cyclopropanes; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Interleukin-2; Oxazines; Pneumonia, Pneumocystis; Practice Patterns, Physicians'; Reverse Transcriptase Inhibitors; Tuberculosis; United States | 1999 |
The new drugs and how to use them.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Sulfonamides | 1999 |
Product information.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Oxazines; Pregnancy; Reverse Transcriptase Inhibitors | 1999 |
A new HAART on the horizon says the proof is in the potency.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Oxazines; Patient Compliance; Pregnancy; Reverse Transcriptase Inhibitors; Zidovudine | 1999 |
Treatment of the naive patient.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chicago; Clinical Trials as Topic; Congresses as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Drugs, Investigational; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors | 1999 |
Antiretroviral therapy in the experienced patient.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chicago; Clinical Trials as Topic; Congresses as Topic; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Drugs, Investigational; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Treatment Failure | 1999 |
Methadone and anti-HIV drugs.
Topics: Alkynes; Analgesics, Opioid; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; HIV Infections; Humans; Methadone; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Substance-Related Disorders | 1999 |
Switching drugs for lipodystophy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cholesterol; Cyclopropanes; Drug Administration Schedule; HIV Infections; Humans; Lipodystrophy; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Triglycerides | 1999 |
New study shows efavirenz effective with d4T and 3TC.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cerebrospinal Fluid; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Oxazines; Reverse Transcriptase Inhibitors; Stavudine; Vagina; Viral Load; Zidovudine | 1999 |
Efavirenz (Sustiva) receives FDA approval. Food and Drug Administration.
Topics: Adult; Alkynes; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Approval; Drug Interactions; Drug Therapy, Combination; Drugs, Investigational; Health Services Accessibility; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; United States Food and Drug Administration | 1998 |
Strategy update: protease-sparing regimens.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors | 1998 |
Antiretroviral update from the Interscience Conference on Antimicrobial Agents and Chemotherapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides | 1998 |
Dupont data supports earlier findings.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 1999 |
Novel approaches for the treatment of HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; Genetic Therapy; Heterocyclic Compounds; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Oxazines; Receptors, Chemokine; Reverse Transcriptase Inhibitors; Sulfonamides; Zinc Fingers | 1998 |
Fifth Conference on Retroviruses & Opportunistic Infections. Interview by Ron Baker.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Congresses as Topic; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Drugs, Investigational; Furans; Genetic Techniques; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxyurea; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides; Viral Load | 1998 |
CRIA clinical trials.
Topics: Adenine; Alkynes; Anabolic Agents; Anti-HIV Agents; Benzoxazines; Blood Glucose; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Male; Organophosphonates; Oxandrolone; Oxazines; Patient Selection; Reverse Transcriptase Inhibitors; Weight Loss | 1998 |
[Progress in HIV therapy. Effective and simple therapy with efavirenz].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Oxazines | 2001 |
[Positive change from protease inhibitor to non-nucleoside reverse transcriptase inhibitor efavirenz. Improved virus control thanks to protease inhibitor switch].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; HIV; HIV Infections; Humans; Oxazines | 2001 |
[Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; HIV; HIV Infections; Humans; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Treatment Outcome | 2001 |
Efavirenz-induced photoallergic dermatitis in HIV.
Topics: Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dermatitis, Photoallergic; HIV Infections; Humans; Male; Oxazines; Phenotype; Reverse Transcriptase Inhibitors | 2001 |
Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Mutagenesis; Nucleosides; Oxazines; Phenotype; Retrospective Studies; Reverse Transcriptase Inhibitors | 2001 |
Manic syndrome associated with efavirenz overdose.
Topics: Adult; Alkynes; Anti-HIV Agents; Antipsychotic Agents; Benzoxazines; Bipolar Disorder; Cyclopropanes; Drug Overdose; Female; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; Risperidone; Syndrome | 2001 |
Management of sudden psychiatric disorders related to efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Mental Disorders; Oxazines; Reverse Transcriptase Inhibitors | 2001 |
Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Educational Status; Female; HIV Infections; Humans; Male; Middle Aged; Neuropsychological Tests; Oxazines; Patient Dropouts; Prospective Studies; Reverse Transcriptase Inhibitors | 2001 |
In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; In Vitro Techniques; Inhibitory Concentration 50; Leukocytes, Mononuclear; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Virus Replication | 2001 |
Antiretroviral therapy for previously treated patients.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Failure | 2001 |
Gynecomastia without lipodystrophy syndrome in HIV-infected men treated with efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Gynecomastia; HIV Infections; Humans; Male; Oxazines; Reverse Transcriptase Inhibitors; Viral Load | 2001 |
Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Male; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Salvage Therapy; Treatment Outcome | 2001 |
Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oxazines; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Saquinavir; Urban Population | 2001 |
Antiretroviral rounds. When success is a pain.
Topics: Abdominal Pain; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2001 |
Switching from protease inhibitors to the non-nuke efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oxazines; Reverse Transcriptase Inhibitors; Viral Load | 2001 |
Efavirenz-induced psychosis.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Oxazines; Psychoses, Substance-Induced; Reverse Transcriptase Inhibitors | 2001 |
Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Failure | 2001 |
Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Male; Oxazines; Reverse Transcriptase Inhibitors; Semen; Viral Load | 2001 |
Efavirenz may have treatment advantage.
Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Oxazines; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Failure | 2001 |
Three-year durability for efavirenz.
Topics: Alkynes; Benzoxazines; Cohort Studies; Cyclopropanes; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors | 2001 |
Efavirenz switches may be beneficial.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Administration Schedule; HIV Infections; Humans; Oxazines; Patient Compliance; Reverse Transcriptase Inhibitors | 2001 |
Changes in metabolic parameters and body shape after replacement of protease inhibitor With efavirenz in virologically controlled HIV-1-positive persons: single-arm observational cohort.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Constitution; Body Weight; Cohort Studies; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors | 2001 |
Higher efavirenz plasma levels correlate with development of insomnia.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; Sleep Initiation and Maintenance Disorders | 2001 |
Efavirenz (Sustiva).
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Resistance, Microbial; HIV; HIV Infections; Humans; Oxazines; Practice Guidelines as Topic; Reverse Transcriptase Inhibitors | 2000 |
Drugs for HIV infection.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dose-Response Relationship, Drug; HIV Infections; HIV Protease Inhibitors; Humans; Nelfinavir; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Saquinavir; Stavudine; Zidovudine | 2001 |
A case of lipodystrophy after the initiation of zidovudine, lamivudine and efavirenz in an asymptomatic HIV-1-infected patient.
Topics: Abdomen; Adipose Tissue; Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Lipodystrophy; Male; Oxazines; Reverse Transcriptase Inhibitors; Tomography, X-Ray Computed; Zidovudine | 2000 |
Does efavirenz cause breast enlargement?
Topics: Alkynes; Benzoxazines; Cyclopropanes; Estradiol; Female; France; Gynecomastia; HIV Infections; Humans; Male; Oxazines; Reverse Transcriptase Inhibitors; Spain; Testosterone | 2001 |
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aspartate Aminotransferases; Benzoxazines; Bilirubin; Chemical and Drug Induced Liver Injury; Cyclopropanes; Female; Hepatitis B; Hepatitis C; HIV Infections; Humans; Liver Diseases; Male; Nevirapine; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Treatment Outcome | 2002 |
Antiretroviral rounds. A very discordant response.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Practice Patterns, Physicians'; Reverse Transcriptase Inhibitors; Stavudine; Viral Load | 2002 |
Myelomeningocele in a child with intrauterine exposure to efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Infant, Newborn; Lamivudine; Male; Maternal Exposure; Meningomyelocele; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Reverse Transcriptase Inhibitors; Stavudine | 2002 |
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.
Topics: Alkynes; Alleles; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Cytochrome P-450 Enzyme System; Female; Genes, MDR; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Male; Nelfinavir; Oxazines; Pharmacogenetics; Polymerase Chain Reaction; Prospective Studies; Treatment Outcome | 2002 |
Periconceptional exposure to efavirenz and neural tube defects.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; Follow-Up Studies; HIV Infections; Humans; Neural Tube Defects; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Risk Assessment | 2002 |
Efavirenz-induced leukocytoclastic vasculitis.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Biopsy, Needle; Cyclopropanes; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Oxazines; Prednisone; Risk Assessment; Severity of Illness Index; Skin; Stavudine; Treatment Outcome; Vasculitis, Leukocytoclastic, Cutaneous | 2002 |
Effect of antiretroviral combination therapies including efavirenz in heavily pretreated HIV-infected children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Viremia | 2002 |
Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort.
Topics: Adult; Alkynes; Benzoxazines; Case-Control Studies; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Tolerance; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Substance Abuse, Intravenous; Switzerland | 2002 |
Probable interaction between efavirenz and cyclosporine.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cyclosporine; Drug Interactions; HIV Infections; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Oxazines | 2002 |
Pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase efavirenz.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Interactions; HIV Infections; Humans; Methadone; Narcotics; Oxazines; Reverse Transcriptase Inhibitors | 2002 |
Skin eruption 8 days after a single dose of efavirenz-containing combination therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Eruptions; Female; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Spouses; Stavudine; Time Factors | 2001 |
Nevirapine + efavirenz based salvage therapy in heavily pretreated HIV infected patients.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Combinations; HIV Infections; Humans; Nevirapine; Oxazines; Retrospective Studies; Salvage Therapy | 2002 |
Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Prospective Studies; RNA, Viral | 2001 |
Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; HIV Infections; Humans; Kinetics; Methadone; Narcotics; Oxazines; Prospective Studies; Substance Withdrawal Syndrome; Time Factors | 2002 |
Efavirenz and retinal toxicity.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Oxazines; Retinal Diseases; Reverse Transcriptase Inhibitors; Vision Disorders | 2002 |
Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV-1; Humans; Mutation; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Treatment Failure; Viral Load | 2002 |
Efficacy and safety of abacavir plus efavirenz as a salvage regimen in HIV-infected individuals after 48 weeks.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Evaluation; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Oxazines; Patient Dropouts; Retrospective Studies; Reverse Transcriptase Inhibitors; Salvage Therapy; Treatment Failure; Treatment Outcome; Viral Load | 2002 |
FDA approves once-daily efavirenz formulation, revised labeling.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Approval; Drug Labeling; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 2002 |
High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma.
Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Monitoring; Furans; HIV Infections; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oxazines; Protease Inhibitors; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides | 2002 |
Efavirenz-associated QT prolongation and Torsade de Pointes arrhythmia.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardiac Pacing, Artificial; Cyclopropanes; Female; HIV Infections; Humans; Long QT Syndrome; Middle Aged; Oxazines; Time Factors; Torsades de Pointes | 2002 |
FDA notifications. Changes approved for Sustiva.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Dosage Forms; Drug Approval; HIV Infections; Humans; Oxazines; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 2002 |
Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using high-performance liquid chromatography with ultraviolet absorbance detection.
Topics: Alkynes; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Delavirdine; HIV Infections; HIV-1; Humans; Nevirapine; Oxazines; Reference Standards; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2002 |
Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Metabolic Syndrome; Middle Aged; Oxazines; Phenotype; Protease Inhibitors | 2002 |